Palladium organometallic compounds bearing N-Heterocyclic Carbene ligands as promising anticancer agents by Scattolin, Thomas
 
 
UNIVERSITÀ DEGLI STUDI DI TRIESTE 
e 
UNIVERSITÀ CA’ FOSCARI DI VENEZIA 
 
 
XXXI CICLO DEL DOTTORATO DI RICERCA IN 
CHIMICA 
                
 
PALLADIUM ORGANOMETALLIC COMPOUNDS 
BEARING N-HETEROCYCLIC CARBENE 
LIGANDS AS PROMISING ANTICANCER AGENTS 
 
 
Settore scientifico-disciplinare: CHIM/03 
 
DOTTORANDO 
THOMAS SCATTOLIN 
 
COORDINATORE 
PROF. BARBARA MILANI 
 
SUPERVISORE DI TESI 
PROF. FABIANO VISENTIN 
 
CO-SUPERVISORE DI TESI 
PROF. LUCIANO CANOVESE 
 
ANNO ACCADEMICO 2017/2018 
2 
 
 
  
3 
 
Table of Contents 
Abstract 9 
List of abbreviations 13 
1. GENERAL INTRODUCTION 
 
1.1. GENERAL ASPECTS ABOUT CANCER 18 
1.1.1. What is cancer? 18 
1.1.2. Incidence, mortality and risk factors 19 
1.1.3. Carcinogenesis 22 
1.1.4. An in-depth analysis of the cell cycle 24 
1.1.5. Apoptosis 25 
1.1.6. Ovarian cancer 26 
1.2. CANCER THERAPY  28 
1.2.1. Surgery 28 
1.2.2. Radiotherapy 29 
1.2.3. Photodynamic therapy (PDT) 29 
1.2.4. Immunotherapy 30 
1.2.5. Chemotherapy 31 
1.3. AN OVERVIEW OF ANTICANCER COMPOUNDS 33 
1.3.1. Origin and modern organic anticancer research  33 
1.3.2. Metal-based anticancer compounds 34 
1.3.3. Target for organometallic anticancer compounds 37 
1.3.4. Platinum: from cisplatin to the next generation drugs 38 
1.3.5. Ruthenium and gold complexes with antitumor activity 43 
1.3.6. Palladium compounds: recent investigations of promising anticancer agents 45 
1.4. N-HETEROCYCLIC CARBENES AS ANCILLARY LIGANDS 50 
1.5. PHOSPHINES, ARSINES AND ISOCYANIDES AS SPECTATOR LIGANDS 54 
1.6. ORGANOMETALLIC FRAGMENTS 55 
1.6.1. 3-allyl-Pd(II) fragment 55 
1.6.2. Palladacyclopentadienyl fragment 58 
1.6.3. 2-olefin-Pd(0) fragment 60 
1.7. REFERENCES 62 
4 
 
2. AIM OF THE PROJECT 69 
3. PURINE-BASED NHC COMPLEXES 
 
3.1. INTRODUCTION 72 
3.2. SYNTHESIS OF FUNCTIONALIZED XANTHINES  75 
3.3. PURINE-BASED IMIDAZOLIUM SALTS 77 
3.4. SILVER (I) PURINE-BASED NHC COMPLEXES 82 
3.5. PALLADIUM 3-ALLYL COMPLEXES BEARING PURINE-BASED NHCs 89 
3.5.1. Mixed NHC/PPh3 3-allyl complexes 89 
3.5.2. Mixed NHC/TPPTS and NHC/PTA 3-allyl complexes 93 
3.5.3. Mixed NHC/DIC 3-allyl complexes 98 
3.5.4. Bis(NHC) 3-allyl complexes 101 
3.6. PALLADACYCLOPENTADIENYL COMPLEXES BEARING PURINE-BASED             
NHCs 
103
 
3.6.1. Mixed NHC/PPh3 palladacyclopentadienyl complexes 103 
3.6.2. Mixed NHC/PTA palladacyclopentadienyl complexes 106 
3.6.3. Mixed NHC/DIC palladacyclopentadienyl complexes 108 
3.6.4. Bis(NHC) palladacyclopentadienyl complexes 110 
3.7. PALLADIUM (0) 2-OLEFIN COMPLEXES BEARING PURINE-BASED NHCs 113 
3.7.1. Mixed NHC/PPh3 and NHC/AsPh3 complexes 116 
3.7.2. Bis(NHC) complexes 122 
3.7.3. Bis(PTA) complexes 125 
3.8. ANTIPROLIFERATIVE AND PROAPOPTOTIC ANALYSIS 129 
3.8.1. Activity of Pd(II) 3-allyl complexes bearing purine-based NHCs toward 
ovarian cancer cell lines 
129 
 
3.8.2. Activity of palladacyclopentadienyl complexes bearing purine-based NHCs  
toward ovarian cancer cell lines 
136 
3.8.3. Activity of Pd(0) olefin complexes bearing purine-based NHCs toward ovarian  
cancer cell lines 
140 
 
3.9. CONCLUSIONS 144 
3.10. REFERENCES 145 
  
5 
 
4. PALLADIUM COMPLEXES WITH “CLASSICAL” NHCs AND 
BRIDGED BISNHCs 
 
4.1. INTRODUCTION 148 
4.2. SYNTHESIS OF THE IMIDAZOLIUM AND BISIMIDAZOLIUM SALTS  150 
4.3. SYNTHESIS OF THE SILVER-NHC COMPLEXES 152 
4.4. SYNTHESIS OF PALLADACYCLOPENTADIENYL COMPLEXES 154 
4.4.1. Palladacyclopentadienyl complexes bearing bidentate bisNHCs  155 
4.4.2. Palladacyclopentadienyl complexes bearing two monodentate NHCs 162 
4.4.3. Palladacyclopentadienyl complexes with chelating NHC-thioether or 166 
NHC-pyridine ligands  
4.4.4. Mixed NHC/PPh3 palladacyclopentadienyl complexes  171 
4.4.5. Mixed NHC/DIC palladacyclopentadienyl complexes 176 
4.4.6. Palladacyclopentadienyl complexes bearing chelating N-S and N-P ligands 180 
4.5. ANTIPROLIFERATIVE ACTIVITY AND BIOLOGIAL ASSAYS ON      
PALLADACYCLOPENTADIENYL COMPLEXES 
181 
4.5.1. Antiproliferative activity of palladacyclopentadienyl compounds on different  
cancer cell lines and fibroblasts 
182 
 
4.5.2. Reactivity of complexes with reduced L-glutathione (GSH) 186 
4.5.3. Uptake analysis 188 
4.5.4. Biological tests for the determination of the biological target 188 
4.6. SYNTHESIS OF 3-ALLYL PALLADIUM COMPLEXES 193 
4.6.1. 3-allyl palladium complexes bearing bidentate bisNHCs   194 
4.6.1.1. Complexes with R= methyl or benzyl 195 
4.6.1.2. Complexes with R= mesityl 196 
4.6.2. 3-allyl palladium complexes bearing two monodentate NHCs 204 
4.6.3. 3-allyl palladium complexes bearing chelating NHC-thioether or  
NHC-pyridine ligands 
207 
 
4.6.4. Mixed NHC/PPh3, NHC/PTA, NHC/DIC and PPh3/DIC 3-allyl palladium  
complexes 
210 
 
4.6.4.1. Mixed NHC/PPh3 complexes 210 
4.6.4.2. Mixed NHC/PTA complexes 213 
4.6.4.3. Mixed NHC/DIC and  PPh3/DIC complexes 215 
6 
 
4.6.5. 3-allyl palladium complexes bearing chelating phosphino-carbene ligands 216 
4.6.6. 3-allyl palladium complexes bearing chelating N-P and N-S ligands 217 
4.7. ANTIPROLIFERATIVE ACTIVITY OF ALLYL PALLADIUM COMPLEXES 218 
4.8. CONCLUSIONS  220 
4.9. REFERENCES 221 
5. CARBOHYDRATE BASED NHC COMPLEXES 
 
5.1. INTRODUCTION 226 
5.1.1. Carbohydrates: general aspects 226 
5.1.2. Anomeric effect and anomerization 228 
5.1.2.1. Mutarotation 229 
5.1.2.2. Anomerization 230 
5.1.3. Metal-based compounds with glycosidic groups and Warburg effect  231 
5.2. SYNTHESIS OF 2,3,4,6-TETRA-O-ACETYL--D-GLUCOPYRANOSYL  234 
BROMIDE  
5.3. SYNTHESIS OF 1-(2,3,4,6-TETRA-O-ACETYL--D-GLUCOPYRANOSYL)  236 
IMIDAZOLE  
5.4. SYNTHESIS OF IMIDAZOLIUM SALTS 237 
5.5. SYNTHESIS OF SILVER(I) COMPLEXES 242 
5.6. SYNTHESIS OF 3-ALLYL PALLADIUM COMPLEXES 244 
5.6.1. Neutral 3-allyl Pd(II) complexes 244 
5.6.2. Mixed NHC/PPh3 3-allyl Pd(II) complexes 250 
5.7. MIXED NHC/PPh3 PALLADACYCLOPENTADIENYL COMPLEXES 253 
5.8. ANTIPROLIFERATIVE ACTIVITY: PRELIMINARY RESULTS 256 
5.9. CONCLUSIONS 256 
5.10. REFERENCES 257 
  
7 
 
6. Pd(II) COMPLEXES BEARING N-TRIFLUOROMETHYL NHCs 
 
6.1. INTRODUCTION 260 
6.1.1. Trifluoromethyl and polyfluorinated groups in medicinal chemistry 260 
6.1.2. Synthetic methodologies for the introduction of the trifluoromethyl group 262 
6.1.3. N-Trifluoromethyl NHC ligands 265 
6.2. N-TRIFLUOROMETHYL BENZIMIDAZOLIUM SALTS 268 
6.3. Pd (II) 3-ALLYL COMPLEXES BEARING N-TRIFLUOROMETHYL NHCs 271 
6.3.1. Mixed NHC/PPh3 complexes 272 
6.3.2. Mixed NHC/PTA complexes 275 
6.4. ANTIPROLIFERATIVE ACTIVITY AND BIOLOGIAL ASSAYS 278 
6.5. CONCLUSIONS 282 
6.6. REFERENCES 283 
7. CONCLUSIONS AND FUTURE PERSPECTIVES 285 
8. PUBLICATIONS AND COMUNICATIONS AT CONFERENCES 289 
9. EXPERIMENTAL SECTION 293 
10. SUPPLEMENTARY MATERIALS 399 
 
 
8 
 
  
 
  
9 
 
Abstract 
 
Since the discovery of the antitumor properties of cisplatin and its approval by the FDA in 1978 (40 
years ago), inorganic compounds have been considered for the first time as anticancer agents. 
Cisplatin, however, has some limitations due to side effects on kidneys, liver and brain and the 
resistance, intrinsic or acquired over time, by some types of neoplasia. 
Despite the appearance in the market of platinum compounds with minor side effects (i.e. carboplatin 
and oxaliplatin), they did not solve the ineffectiveness on some types of tumors, having the same 
mechanism of action proposed for cisplatin (DNA platination). 
For this reason, many research groups have focused their attention on the synthesis and determination 
of the anticancer properties of compounds with metals different from platinum. 
Among the most investigated metals there are certainly ruthenium and gold and, only recently, 
palladium. 
The latter, despite belonging to the same group of platinum, has some rather different features: 
• Better water solubility of its complexes. 
• Structure-activity relationships and mechanisms of action generally different from platinum 
compounds.  
However, the fast dissociation pattern of palladium complexes compared to platinum represents a 
problem since the speciation, which heavily affects the biological activity and the pharmacokinetic 
properties, could be increased. To remedy this contraindication the most direct option is the 
introduction of ligands firmly anchored to the metal such as N-Heterocylic Carbenes (NHCs), which 
are known to give strong -bonds with most of the transition metals.  
Moreover, several NHC-palladium complexes have already exhibited an interesting cytotoxic activity 
in vitro and tumour growth suppression even in vivo. 
In this PhD thesis, the synthesis and characterization of new palladium compounds stabilized by 
different types of N-Heterocyclic Carbenes and important organometallic fragments such as 3-allyl-
Pd(II), palladacyclopentadienyl and 2-olefin-Pd(0) will be exposed (see Fig. A.1). 
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Fig. A1 
The reactivity and the importance in many catalytic processes of the fragments reported in Fig. A1 
are well known, on the contrary, their biological activity is almost unexplored. 
Starting from these premises, it was decided to test the synthesized compounds toward different tumor 
lines, particularly on ovarian carcinoma, and human fibroblasts (healthy cells). 
From the antiproliferative activity data collected for about one hundred compounds, emerges that, 
regardless of the nature of the selected carbene ligand, the most active compounds bear the allyl 
fragment. 
The allyl derivatives are generally much more active than cisplatin in the tumor lines taken into 
consideration (IC50 <1 M) and some of these, reported in Figure A2, are poorly cytotoxic on healthy 
cells (selective cytotoxic activity). 
 
Fig. A2 
For these species the evaluation of their activity in vivo and experiments aimed at identify the primary 
biological target, in order to propose the possible mechanism of action, are planned. 
A class of compounds generally slightly less active than that containing the allyl residue is represented 
by the palladacyclopentadienyl complexes and their derivatives. Nevertheless, for some of the 
synthesized compounds (see Fig. A3), an excellent antiproliferative and proapoptotic activity has 
been shown on ovarian cancer cell lines (CisPt sensitive and CisPt resistance), accompanied by a poor 
activity against normal cells. 
11 
 
 
Fig. A3 
For the compound 40a a thorough investigation on the main biological target, which was found to be 
DNA, and on the degree of uptake in tumor cells was also carried out. 
Due to the high stability imparted by the palladaciclopentadienyl fragment and the chelatig biscarbene 
ligand, this compound does not undergo substitution reactions when  reacted with reduced glutathione 
(GSH), which is a potential coordinating species present in abundance in the biological environment. 
It is therefore reasonable to suppose that the interaction with the DNA occurs through non-covalent 
interactions with the polynucleotide chain. 
Finally, the class of compounds decidedly less active than those described so far is represented by the 
Pd (0) derivatives stabilized by olefinic ligands. For these complexes the antiproliferative and 
proapoptotic activity was evaluated only in ovarian carcinoma lines, observing only in very few cases 
IC50 values comparable to those of cisplatin. For instance, the unpublished complex bearing two PTA 
ligands, shown in figure A4, is characterized by IC50 values of 3 and 5 M on the CisPt-sensitive and 
CisPt-resistant line, respectively. 
 
Fig. A4 Ellipsoid representation of 26 crystal ASU contents (50% probability) 
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The figure proposed at the beginning of the chapter is related to this source: http://epicstudios.com/?p=4877 
1 
General Introduction 
 
 
This introductory chapter will illustrate the basic concepts about cancer. The main types of neoplasia, 
the incidence, the risk factors and the carcinogenesis process will be expounded. A deepening on the 
ovarian cancer, which represents the type of tumour most taken into consideration in this work will 
be developed. 
The core of this introduction will be dedicated to the cancer therapy and particular emphasis will be 
devoted on the metallodrugs as anticancer agents. Owing to the complexity of the subject, a brief 
overview of the coordination and organometallic compounds of platinum, ruthenium, gold and 
palladium will be presented.  
Finally, the stereoelectronic properties of the N-Heterocyclic Carbene ligands and the organometallic 
fragments used in this work will be discussed. 
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1.1. General aspects about cancer  
1.1.1. What is cancer? 
Cancer represents an extensive and heterogeneous class of pathologies caused by an uncontrolled 
cells reproduction with consequent formation of solid masses called tumours. 
The process that transforms a healthy cell into a cancerous one occurs in several stages and is often 
generated by an accumulation of genetic anomalies affecting the genes responsible for the control of 
DNA repair, death and cell division processes.  
The tumour in its initial stage is called primary tumour. Often it become dangerous for the life of the 
ill person since obstructs organs and/or blood vessels. In the case of malignancy, death is most 
commonly caused by the spread of the primary neoplasia to vital organs, in a process known as 
metastasis. This diffusion process occurs through the lymphatic system or the bloodstream. 
 
  
Fig. 1.1 Main differences between tumour and healthy cells [1]. 
 
Surgery is not very effective in the case of metastasis and therefore the pharmacological approach 
remains the main treatment.  
The classification of the disease based on the target organ or on the type of cancer cells, includes 
more than 200 categories of tumours [2]. However, it is noteworthy that this approach is simplistic, 
since many different tumours afflict the same organ, respond to the treatments differently and with 
different rates of progression. 
However, in the sake of simplification a very rough classification divides the tumours into six large 
classes (Tab. 1.1) [2]. 
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Principal type of 
cancer 
Origin of the tumour 
Frequency 
(estimation) 
Localisation 
Adenocarcinoma 
Epithelium (surface 
tissue of many glands) 85% of all 
cancers 
Breast, liver, kidney, prostate, pancreas, 
ovary, thyroid, colon, stomach, salivary 
glands, lungs. 
Squamous-cell 
carcinoma 
Squamous epithelial 
cells (epidermis) 
Skin, gastrointestinal tract, lung, 
uterus, pancreas 
Sarcoma 
Connective tissues 
(bones, muscles) 
2-4% of all 
cancers 
Bone, cartilage, lungs, 
fat tissue, blood vessels 
Hodgkin’s 
Lymphoma 
B and T lymphocyte 
(large atypical cells) 5-7% of all 
cancers 
Lymph nodes, spleen 
Non-Hodgkin’s 
Lymphoma 
B and T lymphocyte 
Lymph nodes, gastrointestinal tract, skin, 
brain, bones, reproductive organs, lungs 
Leukaemia 
Bone marrow cells 
(blast) 4-6% of all 
cancers 
Blood 
Myeloma 
Bone marrow cells 
(plasmocyte) 
Bone marrow 
Tab. 1.1 Classification by type of cancer [2]. 
The table shows that carcinoma constitutes about 85% of human tumours and affects the epithelium 
of internal organs, glands and cavities. This pathology is common in the breast, colon, lungs, prostate 
and ovaries. 
Despite chemotherapy and other focoused therapies, the cancer remains a pathology (or a set of 
pathologies) difficult to treat. This is essentially due to the enormous diversity between the various 
tumors, their resistance to pharmacologic therapy and the side effects of different treatments. For 
these reasons, the cancer remains the crucial challenge in the medical field of the 21st century. 
 
1.1.2. Incidence, mortality and risk factors 
Because of the long period that often occurs between exposure to a carcinogen and the diagnosis of 
the neoplasia (up to 20-30 years), the current incidence data reflect the environmental conditions and 
lifestyles of a few decades ago. In the USA, the American Cancer Society estimated that in 2015 
about 166,000 new cases of cancer were diagnosed [3]. The data on the diagnosed tumours, classified 
according to area of the body in which they are localised, are reported in Figure 1.2 and show that the 
reproductive tract cancers constitute the most recurring cases, regardless of the individual gender. 
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Fig. 1.2 Incidence of the main types of cancer in the USA in 2015 [3]. 
 
The same study found that the number of deaths attributable to cancer was about 590,000 (53% men 
and 47% women), and the tumors that produced the highest number of deaths are those related to the 
digestive and respiratory systems. 
Very similar results can be found in the investigations conducted by the IARC (International Agency 
for Research on Cancer) [3] (Fig. 1.3), which estimated about 13 million the number of new cancers 
diagnosed worldwide in 2008 whereas, the RTI (Registro Tumori Italiani), indicates about 365,000 
new cases diagnosed in Italy in the 2016 [4]. 
 
 
Fig. 1.3 Percentage rates of incidence and mortality worldwide related to the main types of cancer [3]. 
 
Generally, in the older people, an increase in the probability of the disease, mainly due to the decrease 
in the efficiency of the immune system and the greater probability of presenting genetic mutations, is 
observed [5]. Exceptions include breast cancer, which mainly affects younger women (40-65 years), 
specific types of leukemia and the childhood cancers. 
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Although in the last 50 years there has been a steady progress in prevention, treatment and 
improvement of the lifestyle of the population, from the data of the Center for Disease Control and 
Prevention emerges that cancer is still the second cause of death of the American population after 
cardiovascular diseases. However, a comforting fact is that since 2003 the number of deaths due to 
cancer has decreased compared to 1930, despite the increase in population and average life 
expectancy [2]. This result is due to the effectiveness of the therapies, a better strategy of prevention 
and the change of bad habits regarding exercise and diet. 
Among the risk factors for cancer onset there are:  
• ethnicity; 
• exposure to carcinogens (environmental risk); 
• type of diet; 
• exposure to the sun; 
• exposure or intake of hormones. 
Figure 1.4 shows how environmental parameters have the greatest influence on the birth and evolution 
of cancer [6]. 
 
Fig. 1.4 The role of genes and environmental in the development of cancer [6]. 
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1.1.3. Carcinogenesis 
Robert A. Weinberg [7] contributed in reinforcing the idea that many cancer cells are the result of 
important changes in the cell physiology, eventually leading to the proliferation of malignant tumours. 
According to his studies, all tumors have some common features that distinguish them from other 
diseases: 
• self-sufficiency in growth signals; 
• intensification of growth inhibition signals; 
• lack or reduction of programmed cell death (apoptosis); 
• limited potential for reproduction; 
• pronounced angiogenesis;  
• tissue invasion and metastasis. 
The genetic changes that induce the appearance of cancer occur at different levels and with different 
mechanisms. The most common are mutations, involving changes in the sequence of DNA 
nucleotides. These mutations, which alter the expression of some genes, can be caused by five main 
factors: 
1. Inheritance: some people inherit the predisposition for cancer development from their 
family members. One or more genes therefore have mutations already from birth. 
2. Viruses: if a virus infects a cell, it introduces genetic material that can sometimes contain 
oncogenes. Furthermore, they can deactivate some genes or activate cell proliferation genes. 
3. Mutagenic factors: some molecules present in the environment, in addition to UV, X-rays 
and in general all ionizing radiations, can produce DNA alterations. 
4. Copying errors: during the cell division, unrecognized errors in the copy of the DNA can 
generate carcinogenic mutations. 
5. Epigenetic: small molecules (i.e. methylating agents) can bind to a gene. The enzyme 
responsible for DNA reading, sometimes is not able to read the entire gene and therefore 
the presence of an altered gene. 
The transformation of a normal cell into a tumour cell occurs according to a series of chain processes 
caused by an error occured in the initial phase. These processes can be summarized in the following 
steps [2]: 
1. A healthy cell can regulate its division via proliferation gene or decide to have a rest via an 
antiproliferation gene. In the presence of appropriate signals, it can also undertake the 
programmed death via the apoptosis gene. 
23 
 
 
2. During cell division the DNA is duplicated and the daughter cell receives a copy from the 
mother cell, while the DNA repair gene continuously checks that the copy received is 
identical to the original one. 
3. If an error occurs in the phase described above, the proliferative gene is mutated at variance 
with the antiproliferative gene which fortunately remains intact. In this case the growth 
slowing or induction of programmed cell death via apoptosis can occur. 
4. When the proliferative gene undergoes mutation, such cell no longer responds to the signals 
of end proliferation or apoptosis: the cell becomes cancerous and therefore refuses to die 
and duplicates in an uncontrolled way. 
5. The protection systems collapse one after the other, the DNA repair genes are damaged and 
the cell accumulates over time many errors in the DNA. 
 
 
Fig. 1.5 Stages of the carcinogenesis process [8]. 
 
The cancer cells are therefore grouped into solid clusters called tumours and some of these may 
undergo further mutations that allow them to enter inside the blood vessels. These cells can be easily 
fed by the glucose present in the blood vessels and transported to the rest of the body via bloodstream. 
Through this metastasis process they can affect other organs and tissues, creating new tumour masses. 
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1.1.4. An in-depth analysis of the cell cycle 
The cell cycle can be subdivided into four phases: G1, S, G2 and M. In particular, the S and M phases 
represent the main steps of the whole process. The duplication of the genetic patrimony of the cell 
takes places during the S phase, whereas in the M phase mitosis occurs, with the consequent 
segregation of the chromosomes and cytokinesis (division of the cell into two daughter cells). 
Clearly, besides DNA replication, it is important that the cell could increase its size and double its 
protein and organelle mass. For this reason, the gap phases G1 and G2 appear within the cell cycle. 
The gap phases allow the cell to have the necessary time to grow and control the internal and external 
environment, verifying that the conditions for the progress of the cell cycle are suitable and that all 
the preparatory steps before the S and M phases are completed. If the extracellular conditions are 
unfavorable, the cells may delay the G1 process and enter in a state of rest (G0), in which they can 
spend few hours or many years as well, before resuming proliferation [9]. 
A complex network of regulatory proteins (control system) works inside the cell, monitoring the cycle 
progression and postponing the following event until the completion of the previous one. Moreover, 
the control system intervenes in the stimulation or blocking proliferation as a consequence of the 
signals arriving from outside the cell itself [9]. 
Therefore, there are control points that authorize the progress or the blocking of the cycle: 
• Restriction point: located in late G1, corresponds to the point where the cell is allowed to enter 
in the cell cycle and duplicate the chromosomes. 
• G2/M: located between phase G2 and M, corresponds to the point where the control system 
triggers early mitotic events. 
• Metaphase-anaphase transition: a point in which the control system stimulates the completion 
of mitosis and cytokinesis. 
If the control system detects problems inside or outside the cell, the progression of the cell cycle will 
be blocked in one of these points until new favorable conditions. 
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Fig. 1.6 Cell cycle control [9]. 
 
Many human cells present a restricted number of replication processes and in their absence, the cell 
cycle is permanently stopped and no replication processes are allowed anymore. This phenomenon is 
known as senescence and is related to the progressive consumption of chromosomal ends (or 
telomere). Over time, the telomeres become shorter and the proteic structures protecting them 
progressively deteriorate (the cell cycle arrest is similar to that caused by other types of alterations). 
However, cancer cells regain the ability to produce telomerase, the enzyme that intervenes in the 
replication processes of telomeres and promotes the synthesis of proteic structures to protect these 
sequences, and therefore are able to preserve the function of telomeres during proliferation and bypass 
the process of senescence [9]. 
 
1.1.5. Apoptosis 
Apoptosis is a process programming the cell death. The cell die in a controlled manner and is quickly 
eliminated without inflammatory responses [2]. The cell that undergoes this mechanism shows 
characteristic morphological changes i.e. it reduces and condenses its size, the cytoskeleton collapses, 
the chromatin condenses and breaks up. The cell surface often produces vesicles and it is divided into 
fragments enclosed within membranes called apoptotic bodies. Moreover, during the process, the 
plasma membrane undergoes chemical alterations. For example, the phosphatidylserine (a negatively 
charged phospholipid that normally is contained in the cytoplasm) is expelled from the cell. The 
expulsion of this protein triggers the phagocytosis of the cell by macrophages. 
An important role in the apoptotic process is played by the caspases which are proteolytic enzymes 
containing one cysteine in their active site. Caspases are able to cut on specific points a series of 
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intracellular proteins (target proteins) promoting the cell death. Caspases can be distinguished in 
initiator and effector; usually they are present as inactive precursors called procaspases. Once 
activated, the initiator caspases, through a proteolytic cut, give the effector caspases that acting on 
specific cytosolic proteins and nuclear laminae, lead the cell to a controlled death in accord with a 
chain mechanism called proteolytic cascade. 
Often, many cancerous cells regulate abnormally the apoptotic process, stimulating the expression of 
factors able to inhibit its function or alter the coding mechanism of the p53 protein, which is 
responsible for the activation of the protective mechanisms and promotes apoptosis in the case of 
DNA alterations. Mutations in the p53 gene are in fact observed in about 50% of tumors [9]. 
 
1.1.6. Ovarian cancer  
Ovarian cancer, which is the most investigated type of cancer in this work, is a malignant tumor that 
develops in the tissues of the ovaries, the woman reproductive organs in which the ova are formed 
and where the female hormones are produced. 
Depending on the cell type from which the neoplasia originates, it is possible to identify three 
categories of ovarian cancer [10]: 
• Epithelial cancer: originates from epithelial cells that superficially cover the ovaries. 
• Germine tumor: originates from germ cells (those secerning the ova). 
• Stromal tumor: originates from the gonadal stroma (ovary support tissue). 
Most of the malignant tumors affecting the ovaries are epithelial and represent a total of about 90% 
of the recorded cases [11]. Based on the new knowledge acquired over time, a new classification has 
been introduced [12], in which the ovarian carcinoma is subdivided into two different classes of 
tumors, according to its morphological and genetic-molecular characteristics: 
• Type I tumors: these tumors are confined on the ovary and are characterized by slow growth 
and rarely show mutation of the p53 gene. They are generally associated with mutations in 
specific genes. 
• Type II tumor: these tumors, usually detected in advanced stage, are aggressive and show a 
high frequency of mutation of the p53 gene and are genetically unstable. 
The 5-year overall survival of patients with malignant epithelial tumors of the ovary is around 50% 
and an important role, able to significantly affect life expectancy, is played by the stage in which the 
carcinoma is identified. Unfortunately, the non-specific and late symptomatology of the disease and 
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the lack of diagnostic procedures of adequate sensitivity and specificity, often allows the 
identification of the disease when it has reached advanced stages (stages III and IV, Fig. 1.7) [13]. 
 
 
Fig. 1.7 Stages of ovarian cancer [14]. 
Generally, the used tools for the diagnosis of epithelial tumors are the pelvic ultrasound and the 
determination of CA125, which is a protein produced by the uterus or by the Fallopian tubes. CA125 
is found in small quantities in the blood because of damage or inflammation of the tissues of the cited 
organs, but the effectiveness of these investigations is insufficient. Recently, another marker called 
HE4, which appears to be more specific and sensitive in diagnosis than CA125, has been individuated 
[15]. With respect to the treatment of the pathology, the initial surgical approach plays an important 
role both for diagnostic and therapeutic purposes, since it allows the histopathological assessment of 
the nature of the mass and the stage of the tumor. If the tumor is present at an initial stage, a radical 
surgery can be decisive and when necessary, the surgical remotion can be enforced by an adjuvant 
chemotherapy. If the disease is at an advanced stage, the surgeon tries to remove as much as possible 
the mass of the tumor, which  will be subsequently treated chemotherapeutically [2, 13]. 
The chemotherapy cycles are calibrated according to the stage of the tumor and the general clinical 
situation. Usually a combined therapy (multiple drugs) is used in order to minimize the possibility of 
resistance phenomena. The commonly used chemotherapeutic agents are compounds based on 
platinum (cisplatin or carboplatin) and taxanes, such as paclitaxel or docetaxel. In the last twenty 
years, no chemotherapy regimen has proved to be more effective than standard carboplatin/paclitaxel 
treatment. 
After this primary treatment, it is possible to activate secondary treatments with the aim of preventing 
or combating recurrence [2, 13]. In fact, about 70-80% of people with advanced ovarian malignancy 
have recurrence of the disease within the first two years from the initial treatment. At this point, a 
second line therapy has mainly palliative purposes, since it results curative in a narrow minority of 
patients. 
 
BEFORE 
OVARIAN CANCER STAGE I STAGE II STAGE III STAGE IV
Healthy ovaries Cancer is confined to one
or both ovaries
Cancer spreads within
The pelvic region
Average stage of diagnosis: 
Stage IIIC
Cancer spreads to other body parts
within the abdomen
Cancer spreads beyond 
abdomen 
to other body parts
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1.2. Cancer therapy  
The choice of the appropriate treatment after the diagnosis of a tumor, is probably one of the most 
critical problems. There are numerous factors that contributing to the choice of the best treatment i.e.: 
the type of cancer, its stage, the presence of metastasis, the age and the health conditions of the patient. 
The five traditional methods are surgery, radiotherapy, photodynamic therapy, immunotherapy and 
chemotherapy. Surgery, radiotherapy and photodynamic therapy are often used for the treatment of 
locally confined tumors, whereas chemotherapy and immunotherapy are systemic methods. A 
combination of these strategies is often possible.  
 
1.2.1. Surgery 
 
Surgery is a generally used approach in the case of tumor confined in a specific region. Such method 
may provide good chances of recovery especially in absence of metastasis. The amount of tissue that 
can be surgically removed depends on the size of the tumor and the presence of metastasis. 
If a person presents a predisposition to a specific form of cancer, it is possible to intervene in a 
preventive manner. For example, a genetic alteration of the BRACA/1 and BRACA/2 genes 
predisposes to the onset of ovarian carcinoma and therefore the removal of the ovaries represents a 
precautionary measure [2]. During diagnostic or staging surgery, tissue samples can also be removed 
to identify the benign or malignant nature of the tumor by biopsy. 
If it is not possible to remove the whole tumor, the first objective of the intervention is to remove as 
much tumor as possible, in order to make radio- or chemo-therapy treatments (adjuvant therapy) more 
effective. In some cases, it can also be used a reverse approach (neoadjuvant therapy). 
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1.2.2. Radiotherapy 
 
Radiotherapy uses ionizing radiation, usually X-rays, to destroy cancer cells by irradiating the mass 
of the cancerous tissue. The radiations used can be emitted by radioactive substances such as iodine 
or cobalt (131I or 60Co) or produced by specific devices (linear accelerators) [2]. Thanks to the high 
energy and the ability to cross cancer cells, X-rays can heavily damage the DNA. The goal of 
radiotherapy is the induction of severe alterations in the DNA of the cell, which will die since its 
functionality is compromised. During the therapy, some healthy cells can be affected by the radiation. 
However, since such cells are not affected by anomalies in repair mechanisms of the DNA or 
apoptosis, they have a better resistance toward any suffered damage. The duration and overall dose 
of treatment depend on the type, size and location of the tumour in the body. Once the appropriate 
overall therapeutic dose has been determined, the planning of the therapeutic treatment (through a 
single or repetitive fractions) will be established. 
 
1.2.3. Photodynamic therapy (PDT) 
 
Photodynamic therapy (PDT) has been used since the 1990s and utilize light irradiation to contrast 
the skin, lung, bladder, prostate, urinary tract, esophagus and ophthalmic neoplasms in the case of 
localized and not deep-rooted tumours [16]. The PDT utilizes photo-sensitizers, or molecules capable 
Light source
Tumor
Photosensitizer
1) Administration of photosensitizer 2) Radiation of Light 3) Induction of Apoptosis or Necrosis
ROS
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of absorbing visible light at an appropriate wavelength interval, to produce the cytotoxic ROS 
(Reactive Organic Species) which eventually lead the death of tumour cells by apoptosis and necrosis. 
This technique allows a precise spatio-temporal control of the treatment, which can also be repeated. 
The photo-sensitizer is activated only in the irradiated areas and theoretically induces the destruction 
of the diseased tissue without causing serious damage to healthy one. This technique also allows the 
treatment of the not surgically operable areas. 
The first FDA approved photosensitizer was Photofrin, consisting of a mixture of dimers and 
oligomers of porphyrin type units. Thereafter, a second and third generation compounds were 
developed and coupled with a variety of biological targeting vectors [16]. In the case of porphyrins, 
it is possible to exploit their fluorescent and phosphorescent emissions, to define the limit between 
the diseased and the healthy tissues. This technique is also useful for the tumor imaging and the so-
called "guided surgery". 
The biomedical research are now looking for a possible therapeutic use of the photochemistry 
mediated by metal complexes on the basis of two different points of view. In one case, starting from 
a coordinated saturated complex one or more coordination sites will be made vacant allowing the 
interaction of the metal centre with biomolecules. Alternatively, the biologically active fragment will 
be constituted by the released ligand. In any case, the irradiation with light will cause the 
transformation of the pro-drug (stable in the dark) in the active species [16]. 
 
1.2.4. Immunotherapy  
 
The goal of the biological therapy or immunotherapy is the increase of the body's ability to identify 
and destroy cancer cells and repair the cells damaged during the treatment [2]. 
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For this purpose, the following techniques are used: 
• Interferons and cytokines: molecules used by the cells of the immune system to communicate 
each other. Their use can stimulate in some types of cells their immune system and increase 
their activity level. 
• Monoclonal antibodies: proteins produced by some white blood cells that assist the immune 
system in identifying microbes or malignant cells and then destroying them. Several 
monoclonal antibodies could selectively bind some proteins present on the surface of tumor 
cells, marking them as foreign and making them easily identifiable and therefore attackable 
by the immune system. 
• Gene therapy: introduction into the cells of DNA fragments containing genes encoding 
specific functions. This introduction can be done for example in the cells of the immune 
system so that proteins can be coded to increase their performance or within the cancer cells 
for their identification and destruction. 
 
1.2.5. Chemotherapy 
 
Technically, chemotherapy defines any therapeutic treatment perpetrated by means the use of 
chemicals, but usually the term is associated with the use of drugs for the treatment of cancer [2]. 
Chemotherapy, unlike surgery or radiotherapy, is a systemic form of treatment because the drugs used 
can spread in the body, allowing the neutralization of cancer cells also not under the form of solid 
tumour (i.e. leukaemia or lymphoma) or metastatic repetitions. 
In the best of cases, chemotherapy can be used to eliminate all the cancer cells in the body, but it can 
also be used to minimize, after surgery, the possibility of regrowth of a tumour or to inhibit the future 
development of metastasis. If a cure for the disease is not available, you can resort to chemotherapy 
for palliative purposes or to extend the duration and quality of the life of a person.  
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The anticancer drugs can be distinguished on the basis of their biological action in: 
• Antimetabolites: they intervene by blocking a particular metabolic pathway or interfering with 
the functionality of specific enzymes. 
• Alkylating and coordinating agents: they modify the structure of the DNA bases by alkylating 
(or coordinating) them. After this kind of modification some important functions of the cell 
can be alterated and cause: 
o An excessive DNA fragmentation promoted by the enzymes responsible for the repair 
of the alterations caused by the alkylating (or coordinating) agent. 
o Incorrect coupling of DNA bases. 
o Formation of permanent cross-links between the two DNA strands preventing their 
separation in the replication process. 
• Inhibitors of topoisomerases: are a class of enzymes important for the regulation of DNA 
metabolism. 
• Mitotic inhibitors. 
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1.3. An overview of anticancer compounds 
1.3.1. Origin and modern organic anticancer research 
In the modern age, the study of organic compounds as anticancer agents can be traced back to the 
observation of the drastic reduction of the somatic cells proliferation, particularly the lymph nodes, 
showed by the victims of chemical weapons (i.e. mustard gas). 
As a consequence of that observation, the pharmacologists Philips, Goodman and Gilman treated 
mice affected by lymphomas with analogues of mustard gas, observing the suppression of the tumour. 
Subsequently they treated a human patient with mustine (a derivative of mustard gas), noting the 
reduction of the tumour mass already from the first day of treatment [17]. 
In the 1950s, Sydney Farber observed that folic acid (vitamin B9) stimulated the proliferation of acute 
lymphoblastic leukaemia. Treating these cells with folic acid antagonists, such as aminopterin and 
amethopterin, he observed tumour regression [18]. For this reason, Farber can be considered the 
"father of the anticancer chemotherapy" (Fig. 1.8).  
 
Fig. 1.8 Sidney Farber father of the modern anticancer chemotherapy 
and founder of the pediatric pathology [19]. 
 
Following his work, many natural organic metabolites and molecules were studied for their possible 
anticancer activity. For example, in 1954 important studies of the antitumor properties of 6-
mercaptopurine and 5-fluorouracil were reported [20, 21]. 
In 1966, Dara Richardson synthesized for the first time the tamoxifen (an estrogen receptor 
antagonist) that was studied against breast cancer and subsequently approved by the FDA [22, 23]. 
In the second half of the 20th century, people began to think about the so-called “targeted therapy”, 
where the drug interacted selectively with the vital processes of the cancer cells. For example, in the 
1990s, studies of the AbI-Bcr oncogene showed that it produced analogues of tyrosine kinase proteins 
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within the tumours. The selective inhibition of this protein was tested by screening a large number of 
molecules synthesised on the basis of a rational drug design. The use of some organic compounds as 
agents against different types of chronic leukaemia and other neoplasms represents the consequent 
extension of the previous described results. Figure 1.9 shows a selection of organic molecules with 
marked anti-tumour activity. 
 
Fig. 1.9 Important organic anticancer compounds. 
 
1.3.2. Metal-based anticancer compounds 
For many decades, the research was aimed at discovering anticancer drugs able to block the essential 
functions of cells. The interactions of the drugs with the physiological environment are numerous i.e. 
they can interfere with microtubules (Taxol) [24], modify the DNA (cisplatin) [25], influence the 
synthesis of metabolites (Methotrexate) [26] or have effects on chromosome topology (Rinotecan) 
[27]. Some exceptions are represented by the estrogen receptor modulators in anti-hormonal therapy 
(i.e. Tamoxifen) [28] and epidermal growth factor receptor tyrosine kinase inhibitors (i.e. Gefitinib) 
[29]. Among all of these, cisplatin [25] is one of the most important compounds in chemotherapy and 
was widely used against malignant solid tumors for more than 30 years. At the really beginning of 
chemotherapy the compounds containing metals were not considered as possible drugs because their 
toxicity and the well known poor stability. 
From the serendipitous discovery of the anticancer properties of cisplatin, which was approved by 
the FDA in 1978, researchers began to consider as candidate drugs against cancer also metal-based 
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compounds and in particular the organometallic compounds, which by definition present at least one 
metal-carbon bond. This type of bond is generally strong and contributes to the stability of the 
corresponding complexes. This quality is extremely useful since does not allow the presence in 
physiological environment of the free metal, which causes a general toxicity. 
The first organometallic compound whose antiproliferative activity was reported is ferrocene (Cp2Fe) 
[30], which was followed by ruthenium and osmium derivatives.  
Moving from the coenzyme B12 (natural organometallic compound discovered in 1961 [31]) to 
titanocene dichloride (the first non-platinum organometallic compound), which underwent clinical 
trials in 1998 [32]), the bioorganometallic chemistry developed very rapidly (Fig. 1.10). 
 
Fig. 1.10 Historically important metal complexes in the development of anticancer drugs. 
 
The basic research in the field of organometallic chemistry, concerning the synthesis of new 
compounds, the study of their reactivity, accompanied by mechanistic studies also supported by DFT 
calculations, certainly allowed an easiest investigation on their possible applications as 
chemotherapeutics [33, 34]. As described in the following paragraphs, cisplatin and analogues are 
used in about 70% of the chemotherapeutic regimens concerning solid tumors. Their collateral 
toxicity, their ineffectiveness against some types of tumors and drug resistance, which is sometimes 
developed by the treated cells [35-37], are the main reasons leading many research groups to look for 
new metal-based compounds that could solve, or partially solve, the problems related to platinum 
compounds. 
The great structural variability of the organometallic derivatives, due to the different stereoelectronic 
characteristics of the ligands available, represents an advantage with respect to the organic 
compounds. For example, several half-sandwich ruthenium (II) complexes may act as bio-catalysts 
[38], DNA modifiers [39] or protein kinase inhibitors [40], simply by varying the type of chelating 
N-N ligand. 
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The anticancer compounds can be classified according to their mechanism of action, in function of 
the damage they cause to DNA, the type of cellular process with which they interfere or the source 
from which they derive. 
Drugs containing metals can be divided into five broad categories [41]: 
• Functional compounds (pro-drugs): their main action mechanism is based on the direct 
coordination of the metal to one or more target biomolecules. Therefore, they must possess at 
least one free coordination site that is made available by the in vivo dissociation of labile 
ligands. Secondary non-coordinating interactions such as hydrogen bonds and hydrophobic 
interactions can also be important. In the case of total dissociation of the initial ligands, the 
"naked" metal could also replace an essential metal by interfering with the metabolism. The 
activation of the functional species is triggered by the chemical-physical environmental 
conditions of the diseased tissue (i.e. hypoxia and low pH) or is induced by external stimuli. 
• Structural compounds can perform their function keeping intact their initial form, interacting 
with target biomolecules through purely supramolecular interactions (among them we find 
the "intercalators" of DNA). These complexes must therefore have high kinetic and 
thermodynamic stability; therefore, they often contain multidentate chelating ligands and/or 
organometallic fragments. 
• Compounds in which the metal behaves as carrier toward the active ligand, possibly protecting 
it before the delivery. 
• Compounds in which the metal is a catalyst aimed at accelerating a process, for example the 
formation of ROS (Reactive Oxygen Species). 
• Compounds containing a photoactive metal that acts as a photosensitizer (with subsequent 
applications in the photodynamic therapy). 
In any case, a very important feature for a chemotherapeutic agent is the selectivity or the preferential 
absorption of the compound by the tissue/organ that has to be treated. 
In particular, the main mechanism of passive selectivity is represented by the Enhanced Permeability 
and Retention (EPR), which is based on the greater permeability of the blood vessels of the solid 
tumors toward macromolecules or nanoparticles and on their greater retention, due to deficiencies in 
drainage owing to the poor efficiency of their lymphatic system. 
The induced or active selectivity, is obtained by the functionalization of the active principle (or of the 
nanoparticle surface) with appropriate targeting vectors able to selectively recognize the 
overexpressed proteins on the tumor surface and thus guide the accumulation of the drug in the 
diseased tissues [16]. 
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1.3.3. Target for organometallic anticancer compounds 
The three most common targets for organometallic antitumor compounds are DNA, proteins and 
redox systems. In this section the three categories will be discussed in detail. 
1. DNA  
Organometallic compounds acting on DNA are rather promising since they often act 
differently from cisplatin, showing in some cases a significant reduction of the general 
toxicity and side effects. For example, some organometallic derivatives of ruthenium and 
osmium have as main target topoisomerase (Fig. 1.11, complex A) [42], special DNA 
sequences [43] or G-quadruplex (Fig. 1.11, complex B) [44]. 
 
 
Fig. 1.11 Example of organometallic complexes acting on DNA. 
2. Essential proteins for proliferation 
Several types of promising protein targeting agents for the treatment of neoplasms have 
recently been studied. These include aurora-kinase inhibitors, epidermal growth factor 
receptor (EGFR) inhibitors and cyclin-dependent-kinase (CDK) inhibitors. For example, the 
ferrocene carboxaldehyde exhibits good anticancer activity in vitro and has been shown to be 
an EGFR inhibitor [45].  
Ruthenium (II) arene RAPTA derivatives undergo hydrolysis of the two chloride ligands and 
hence they interact with the DNA [46]. However, studies carried out by Messori demonstrate 
that these compounds simultaneously inhibit two enzymes such as cathepsin B and 
thioredoxin reductase (Trx) [47]. Some research groups have adopted as their strategy the 
synthesis of organometallic compounds that have the shape and chemical characteristics 
capable of interact with certain proteins involved in the proliferation of tumor cells [48]. 
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Although this idea is valid, it is not easy to prepare a complex that shows selectivity for a 
given protein without a concomitant interaction with other bio-targets. 
3. Redox systems 
Within the cells, the redox hierarchy can be expressed by the following order on going from 
the most reducing to the most oxidizing environment: mitochondria > nucleus > cytoplasm > 
endoplasmic reticulum > extracellular space [49]. Thus, the oxidizing species can 
preferentially damage the mitochondria membrane, altering the level of thiols such as 
glutathione (GSH). 
As a matter of fact, the amount of glutathione in tumour tissues is one of the factors 
influencing resistance to chemotherapy in certain neoplasms [50]. In addition to the 
thiol/disulphide pair, another important redox pair is NADH/NAD +. Some ruthenium arene 
complexes are able to selectively reduce NAD + to NADH under physiological conditions [51]. 
In any case, the redox activity and the correlation of redox activity/antitumor activity are 
certainly less clear and explored than that of compounds acting on DNA and/or on some 
proteins overexpressed in tumour tissues. 
 
1.3.4. Platinum: from cisplatin to the next generation drugs 
Cisplatin [(cis-diamino-dichloroplatin (II)], which is a yellow solid with a square planar geometry, 
was the first inorganic drug to be used in the clinical setting, individually or in combination with other 
drugs, for the treatment of various neoplasms including those of the lungs, ovaries, testicles, prostate 
and neck. However, despite the appearance of second and third generation analogues that have 
overtime replaced its use, it remains a standard compound with which to compare new potentials 
inorganic antitumor species [52]. Despite its effectiveness, especially for testicular cancer, where 
success of the cure spans between 90 and 100%, its clinical use is limited by dose-dependent side 
effects on the brain, liver and kidneys and by intrinsic or acquired resistance by malignant cells [53]. 
Cisplatin is administered intravenously into the bloodstream and due to the high concentration of 
chlorides present (about 100 mM), remains in the neutral form without giving rise to ligands 
dissociation. When the complex permeates the cell membrane, the lower concentration of chlorides 
(about 4-20 mM) promotes the slow release of one or both of the coordinated chlorides, with 
consequent formation of mono- and di-aqua cationic species. The entry into the cell occurs mainly 
by passive transport because of the neutral nature of the complex. Once inside the cellular 
environment, the aquaction process and the consequent formation of cationic species, prevents the 
expulsion of the drug. Unfortunately, a similar mechanism probably contributes to the high 
cytotoxicity of the compound.  
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On the other hand, it has been discovered that cellular uptake can also occur according to active 
transport mechanisms. The trans-membrane protein CRT1 and in general the proteins involved in 
copper transport seem to play an important role in controlling the accumulation and the expulsion of 
substances from the cell [16, 53]. The cationic mono- and di-aquo species formed inside the cell are 
very electrophilic and can react with the numerous biological ligands present in the cellular 
environment. The soft nature of Pt (II) allows the interaction of its complexes mainly with the -SH 
groups present in metallothioneins and cysteines, although their primary target seems to be DNA. 
The nucleophilicity of N7 nitrogen of adenine and guanine present in the DNA, form with cisplatin 
monoadducts or bifunctional adducts, mainly by intrastrand bonds with two contiguous guanines, a 
guanine and an adjacent adenine or with two guanines spaced from a third intermediate base. 
Remarkably, these interactions are not possible with transplatin for geometric reasons. In addition, 
interstrand bonds are possible with two bases belonging to different filaments and between DNA and 
proteins (Fig. 1.12). 
 
Fig. 1.12 Adducts between DNA and platinated agents. 
The DNA platination, in the case of the formation of the bifunctional adduct between the two adjacent 
guanine, induces a distortion of the dihedral angle between the two bases, a bending and a partial 
unwinding of the double helix near the involved sites [16]. Conformational modifications can be 
recognized by specific proteins capable of triggering a series of events aimed at repairing the damage 
or, hopefully promoting the cell death. As mentioned earlier, an important limitation in the use of 
cisplatin is the intrinsic or acquired resistance manifested by the malignant cells.  
A series of mechanisms responsible for this characteristic have been identified [16, 54]:  
• Decreased cisplatin level within the cell caused by a minor uptake and a greater efflux of the 
complex which is regulated by the trans-membrane proteins and by the specific proteins 
related to copper leakage (ATP7A and ATP7B). 
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• Increased concentration of glutathione (GSH) and metallothioneins with consequent increase 
their competitiveness toward DNA. The electrophilic character of the cationic complexes 
formed by the cisplatin inside the cell and the soft nature of Pt (II), promote an interaction 
between the metal and the thiol groups of these species. Specific pumps are then able to expel 
the complexes formed. 
• Increased DNA repair capacity, which is mainly due the efficiency of the NER (Nucleotides 
Excision Repair), a system able to recognize, cut, remove and synthesize the altered site. An 
inefficient NER system is thought to cause the effectiveness of cisplatin in the treatment of 
testicular tumours. 
• Increased tolerance of damaged DNA due to deficiencies in the MMR (Mismatch Repair), 
which is a system involving various proteins and enzymes responsible for DNA damage 
repair. 
• Bypass of apoptotic responses through changes in signal chains and activation of survival 
pathways.  
Probably is a combination of these mechanisms that reduces the therapeutic efficacy of the drug [16, 
54]. 
 
 
Fig. 1.13 Cisplatin mechanism of action [55]. 
 
Over the years, numerous platinum-based compounds have been synthesized, with the aim of 
obtaining new therapeutic agents characterized by less toxicity and less resistance developed by 
malignant cells. Despite the efforts, only carboplatin and oxaliplatin are currently used in the 
therapeutic field for the treatment of different types of cancer all over the world. However, it is 
noteworthy that nedaplatin and lobaplatin have been approved for clinical use in Japan, China and 
Korea, respectively [56]. 
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Fig. 1.14 Cisplatin and commercial analogues [16]. 
 
Carboplatin differs from cisplatin for the presence of the 1,1-cyclobutandicarboxylate group, which 
is hydrolyzed more slowly than chlorides. It is used against the same type of neoplasia treated with 
cisplatin but, owing to its reduced cytotoxicity, it requires a higher dosage (about four times higher) 
[16, 57]. 
Oxaliplatin has the oxalate as the displaceable group and the 1R,2R-diaminocyclohexane (DACH) as 
spectator ligand. This compound forms adducts with DNA analogous to those observed in the case 
of cisplatin and carboplatin, but the presence of a non-labile ligand more bulky and hydrophobic than 
ammonia, contrasts the action of the proteins involved in the repair of DNA and the altered site. These 
considerations confirm the hypothesis that structural modifications of the inert ligand may affect the 
activity of the compound [16]. 
Pt (IV) octahedral complexes have also been tested. These complexes show some advantages 
compared to square planar Pt (II) derivatives since they are inert toward substitution reactions 
therefore allowing the minimization of the collateral interactions with biological agents before 
reaching DNA [16]. The activation of these complexes inside the cell occurs as a consequence of the 
reduction of Pt (IV) to Pt (II) by reducing agents such as glutathione. Moreover, the presence of two 
further coordination sites renders more easy the modulation of their reactivity and activity, 
intervening on properties such as redox potential, kinetic stability, lipophilicity and selectivity toward 
specific sites. 
In this respect, Dyson and coworkers have proposed that the intracellular reduction of the pro-drug 
of Pt (IV), leads to the formation of cisplatin and promotes the release of two equivalents of ethacrynic 
acid, an inhibitor of glutathione S-transferase, enzyme responsible for drug resistance in some cancers 
(Figure 1.15)  [41, 58]. 
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Fig. 1.15 Schematic approach of target delivery [41]. 
 
The numerous derivatives of Pt (II) and Pt (IV) tested over the years as possible anti-tumour agents, 
allowed the identification of correlations between the structure of the complexes and their activity 
[16]:  
• The square planar complexes of Pt (II) must exchange only some of their ligands and the 
activation occurs as a result of the hydrolysis of the anionic leaving groups. The leaving 
groups must also be cis each other, since the trans isomers are in fact generally inactive. 
• The rate of hydrolysis must be moderate, to avoid the indiscriminate interaction of the 
complex with the biological components before reaching the tumour cells. However, the rate 
of hydrolysis cannot be too low otherwise the complex will be inert and therefore almost 
ineffective. 
• The ligand trans to the leaving groups must be firmly coordinated to the metal. The presence 
of hydrogen atoms in these groups can promote the formation of hydrogen bonds with the 
target molecule and influence the nature of the adducts between the complex and the DNA. 
• The complexes, although the active form may be charged as a consequence of the solvolysis, 
should initially be neutral. 
• In the case of Pt (IV) complexes, the two additional ligands in axial position may confer 
particular properties to the compound or act as targeting ligands once released as a 
consequence of the reduction of the metal.  
As previously reported, cisplatin and its currently used analogues present a series of limitations in 
their clinical utilization owing to their toxicity and the intrinsic or induced mechanisms of resistance 
of some tumour cells. Furthermore, the applicability of a limited type of tumours and the cytotoxicity 
extended to healthy cells, encuoraged the researchers to turn their attention also toward metal 
derivatives different from those of platinum. Their different nature and reactivity might open new and 
interesting perspectives in the therapeutic field. 
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1.3.5. Ruthenium and gold complexes with antitumor activity 
The first investigated ruthenium compounds were the octahedral Ru (III) chloro-complexes which 
were activated in vivo by reduction to Ru (II) and subsequent dissociation of chlorides [16]. 
At the end of the 1980s the [ImH][trans-RuCl4(dmso-S)(Im)], known as NAMI-A, a water-soluble 
imidazolium salt, was investigated (Fig. 16). 
Experimental evidence indicates that the NAMI-A binds less effectively DNA, which apparently does 
not represent the main target. At variance, NAMI-A interacts very quickly with some plasma proteins, 
such as albumin and transferrin, which may also have an active role in its transport within the tumor 
tissue, explaining the marked antimetastatic activity shown in preliminary in vivo tests. 
However, despite the high expectations, this compound did not overcome the clinical phase 2 because 
of its side effects and other problems related to its use [52]. 
In the same period, the complex Na[trans-RuCl4(Ind)2] ((N)KP1339) was also tested. Its high 
cytotoxicity toward a cisplatin-resistant colorectal tumor type suggests a totally different mechanism 
of action, probably involving an alteration of the mitochondrial function (Fig. 1.16). 
                
Fig. 1.16 NAMI-A and (N)KP1339 structures  
Recently, some researchers have been focused their attention on Ru (II) half-sandwich complexes. 
As a matteter of fact the presence of the arene, firmly bound to the metal center, confers a lipophilic 
character to the molecule and furthermore favors its intercalation toward the DNA [16 and Refs. 
therein]. By varying the type of ligands on the other three available sites, a number of complexes 
have been synthesized; one of the most representative is RM175 reported in Fig. 1.17. 
 
Fig. 1.17 RM175 structure 
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In RM175 there is only one labile ligand (Cl-) whose dissociation allows the formation of 
monofunctional adducts with DNA, which are stabilized by hydrogen interactions promoted by the 
ethylenediamine. The coordination of the PTA (1,3,5-triaza-7-phosphoadamantane), confers to the 
neutral RAPTA (Ruthenium Arene PTA) complexes a water-soluble character. There are some 
evidences that seem to identify the proteins of chromatin histones as the target of this type of 
compounds (Fig. 1.18). 
 
 
Fig. 1.18 Examples of RAPTA complexes. 
 
Since the end of the last century it has been considered the possibility of using Au (I) compounds in 
the biomedical field and in particular in the preparation of drugs against arthritis, antibacterial and 
finally of chemotherapeutic agents in substitution or coupled with cisplatin or organic compounds 
(i.e. Taxol). 
For the treatment of rheumatoid arthritis, the most active compounds were Aurothiomalate, 
Aurothioglucose and above all Auranofin [59]. The latter has been approved by the FDA and is 
commonly used successfully with these types of arthritis. 
In 1985 prof. Mirabelli and collaborators studied the antitumor properties of Auranofin [60], opening 
the way to the synthesis of gold compounds as possible chemotherapeutic agents. Although the 
mechanisms of action are still debated, the main target seems to be Thioredoxine reductase (Trx), a 
key enzyme overexpressed by tumor cells. The Au (I) complexes selectively and covalently bind  
selenium present in selenocysteine inhibiting such an enzyme [61].  
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Since 2008, interesting studies have been reported on Au (I) complexes stabilized by NHC ligands 
[62]. In vitro and in vivo studies on Au (I) complexes, and recently on Au (III) derivatives (i.e. Au 
(III) porphyrins and Au (III) dithiocarbamates), are of great interest in the case of different types of 
tumors and leukemia (Fig. 1.19). 
 
Fig. 1.19 Gold complexes with anticancer activity [62]. 
 
1.3.6. Palladium compounds: recent investigations of promising anticancer agents 
On the basis of the chemical similarities with platinum, palladium has recently awaked remarkable 
interest as anticancer agents. This metal, whose catalytic activity is well known and widely exploited 
[63], has been marginally explored for biological purposes especially if compared with platinum.   
Thus, recently interesting studies have been carried out and some palladium complexes have shown 
promising cytotoxic activity in vitro and in vivo for different types of tumor lines [64, 65]. 
Curiously, at variance with platinum, palladium trans isomers with the generic formula L2PdCl2 show 
an high cytotoxic activity [66]. Thus, many Pd (II) compounds of this class were prepared and their 
electronic properties, solubility and selective uptake capacity were carefully modulated by the 
introduction of suitable ligands including substituted pyridines [67], water-soluble phosphines and 
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glucopyranosidic groups [68]. In some cases, encouraging results in in vitro tests for several tumor 
lines have been obtained (Fig. 1.20). 
           
           
Fig. 1.20 Pd(II) complexes of which is known the in vitro anticancer activity. 
 
For example, Pd (II) complexes containing PTA ligands (Fig. 1.21) show IC50 value comparable to 
that of cisplatin in the case of A2780 tumour cells (sensitive cisplatin ovarian carcinoma) and, at the 
same time, a high cytotoxicity toward the A2780-R line (cisplatin resistant) [69]. 
 
 Fig. 1.21 Example of complexes containing PTA and tested in A2780 and A2780-R cell lines. 
Despite the similar electronic and structural characteristics, the Pd (II) complexes, when compared 
with their Pt (II) homologues, show a better water solubility and generally a greater reactivity in the 
substitution reactions (104-105 times higher) [65, 70]. 
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The greater lability of the coordinated ligands renders the hydrolysis processes easy in biological 
environment. Sometimes the sequestration of the metal by numerous soft bio-ligands, principally    
proteins, is also observed. This sort of reactivity reduces the possibility for the palladium compound 
to reach selectively the bio-target thereby increasing its general toxicity [71]. It should be emphasized 
that the bio-target may be not DNA; it has been experimentally demonstrated in fact, that some Pd 
(II) compounds stabilized by organic phosphines interact with the thiols present in proteins of the 
mitochondrial membrane [72]. 
All these critical points suggest that a careful choice of the ligands coordinating the metal play a key 
role in the design of Pd (II) complexes to be tested as chemotherapeutics. In particular, the most 
promising strategy seems to be to use polydentate ligands and/or organometallic structures in which 
the strong carbon-palladium bond prevents or slows down the hydrolysis processes. 
Recently, numerous mono- and poli-nuclear cyclopalladates containing strong σ Pd-N, Pd-C, Pd-S 
and Pd-P bonds have been synthesized, using ligands such as bipyridine, phenanthroline, modified 
ethylenediamines, dithiocarbamates and diphosphines (Fig. 1.22) [73]. 
 
 Fig. 1.22 Example of mononuclear cyclopalladated complexes containing σ Pd-N, Pd-C, Pd-S e 
Pd-P bonds. 
Another class of strong and generally bulky ligands recently employed in biomedical field are the N-
Heterocyclic Carbenes (NHCs), which have been coordinated to metal centres of Au, Ru, Ag, Cu, Pt, 
Ni and Pd [74] (Fig. 1.23). A recent study has shown that complexes of the type 
[(NHC)Pd(pyridine)Cl2] and [(NHC)2PdCl2], reported in Figure 1.23, show a good anti-tumour 
activity and are able to trigger apoptotic processes in cancer cells [75]. 
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Fig. 1.23 Examples of tested Pd (II) complexes containing N-Heterocyclic Carbene ligands.  
 
In another work, some cyclometallated Pd (II) complexes bearing NHC ligands (Fig. 1.24)  have been 
shown a high stability in the presence of biological thiols such as glutathione and a considerable 
cytotoxic activity toward different tumor lines, combined with a less invasiveness toward healthy 
cells (fibroblasts). 
These compounds seem to induce alterations at the mitochondrial level (inhibition of the respiratory 
chain) leading to death of cells by apoptosis. These promising results in vitro have also been 
preliminarily confirmed in vivo [76]. 
 
 
Fig. 1.24 Examples of cyclopalladated complexes with high stability in the presence of bio-thiols. 
 
On the contrary, the cytotoxic activity of the Pd (0) complexes is poorly investigated and one of the 
few examples so far reported in the literature, concerns the complex [Pd2(dba)3]·CHCl3 (dba = E,E-
dibenzylideneacetone). For this derivative (Fig. 1.25), two isomers are known. The main isomer 
presents three s-cis, s-trans bridged dba molecules, whereas the minor isomer shows one dba 
molecule in s-trans, s-trans configuration [77]. 
49 
 
 
 
Fig. 1.25 [Pd2(dba)3]·CHCl3 structure and dba configurations [64] 
 
The compound proved to be active against murine and human melanoma cells and was able to inhibit 
numerous pathways necessary for carcinogenesis [64, 78]. Its use in the treatment of pancreatic 
carcinoma and its ability to induce apoptosis in cells of chronic lymphocytic leukaemia seems also 
promising [79, 80]. 
  
50 
 
1.4. N-Heterocyclic Carbenes as ancillary ligands 
In the last 20 years, N-Heterocyclic Carbenes have become one of the most important ligands in 
organometallic chemistry and in catalysis [81, 82]. In most cases, they are characterized by the 
presence of an imidazole ring bearing two nitrogen atoms adjacent to the carbenic carbon (Fig. 1.26). 
 
Fig. 1.26 General structure of NHCs derived from imidazole ring. 
The first stable carbene of this type was isolated by Arduengo and co-workers in 1991 [83]. These 
ligands represent a subcategory of the Fisher carbenes that, showing a strong -donor capability, have 
in some cases replaced the classic aminic and phosphinic ligands.   
The presence in the alpha position of two nitrogen atoms is a key factor for the stability of these 
ligands for the following two reasons: 
1. Inductive effect: this effect is due to the difference in electronegativity between nitrogen and  
carbon rending the nitrogen -acceptor. 
2. Mesomeric effect: this effect is due to the presence in the nitrogen atoms of filled orbitals and 
empty orbitals of the same symmetry of those of the carbenic carbon. In this case, the nitrogen 
atoms act as excellent -donors. 
The combination of these two factors allows the stabilization of the  orbital of the carbene (increases 
its s-character) and the increasing of the energy of the unoccupied p orbital. The -p gap is then 
increased and the singlet state is by far the favored one (Fig. 1.27). 
 
Fig. 1.27 Representation of the mesomeric and inductive effect stabilizing NHCs (left); qualitative 
MO diagram of the N-C-N fragment (right). 
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It is also possible to obtain more stable complexes using polydentate N-Heterocyclic Carbene ligands 
(polyNHCs). In this case, there is an increase in the -donation to the metal center (the metal itself is 
more electron-rich and polarizable) and an increased stability toward decomposition due to the 
chelating effect [84]. Moreover, NHCs ligands can be easily functionalizated and this possibility 
permits to modulate their stereo-electronic features. NHCs porperties depends by: 
• Nature of the nitrogenous heterocyclic ring: in addition to imidazole, the pyrazole, triazole, 
tetrazole and benzimidazole derivatives can be considered as potential precursors of NHCs. 
There are also examples of NHCs based on six- and seven-membered rings (Fig. 1.28) [84].  
 
Fig. 1.28 NHCs based on different heterocycles. 
 
• Nature of the groups linked to the nitrogens adjacent to the carbenic carbon: these groups may 
be more or less bulky and present a further donor atom allowing to obtain chelating or bridging 
ligands. 
Typically, the N-Heterocyclic Carbenes synthetic protocol involves the deprotonation of the 
corresponding imidazolium salts by a strong base (i.e. t-BuOK). This strategy is not applicable if 
other functional groups susceptible of modification are present [83]. 
In some cases, it is possible to bypass the problem using silver oxide, which allows the deprotonation 
of the starting imidazolium salt and, at the same time, the stabilization of the resulting carbene as 
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silver derivative [85]. This protocol allows the synthesis of several complexes by transmetallation in 
which the carbenic fragment is transferred to other metals. The precipitation of the silver halide 
represent the driving force of the whole process (Scheme 1.1). 
 
Scheme 1.1 Deprotonation of the imidazolium salt and the transmetallation process. 
 
The advantages in the use of NHCs in homogeneous catalysis are the following: 
• High thermal stability toward hydrolysis owing to the exceptional strength of the M-C bond. 
• Their synthesis are generally easy and with high yields. 
• At variance with phosphines is not necessary to use an excess of the ligand.  
The best-known example of the application of NHCs is represented by the second-generation catalysts 
for olefinic metathesis processes described by Grubbs [86]. 
 
 
Fig. 1.29 Second generation Grubb’s Catalysts. 
Another very important example is given by the highly performing catalysts (Fig. 1.30) empolyed in 
Heck cross-coupling reactions [87]. 
53 
 
 
 
Fig. 1.30 Pd(II) NHCs catalysts for Heck type reactions. 
The high stability of the NHC complexes and the possibility of a fine tuning of their stereo-electronic 
properties, allow their applications not only in catalysis but also in the biomedical field, in 
supramolecular chemistry and in materials science. 
In the biomedical field there are examples of Ag (I) carbene complexes with excellent antimicrobial 
properties due to the gradual release of Ag+ ions [88]. 
 
Fig. 1.31 Examples of Ag(I) NHC complexes as antimicrobial agents. 
Furthermore, as previously reported, the anticancer activity carried out by metal complexes 
containing N-Heterocyclic Carbene ligands  has recently been studied [89, 90]. Some of these have 
shown a comparable or even better activity than cisplatin, in several cancer lines. 
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1.5. Phosphines, arsines and isocyanide as spectator ligands 
In organometallic chemistry the spectator ligands are very important since, although they do not 
undergo modifications and do not play an active role in the reactions involving the complex, are able 
to influence significantly the course of the processes, modulating the properties of the metal centre. 
Tertiary phosphines (PR3) represent an important and extremely versatile class of ancillary ligands 
since an appropriate variation of the substituents R directly bound to the phosphorus allows the 
modification of  their electronic and steric properties [91], promoting their use in many applications 
in the fields of organometallic chemistry and homogeneous catalysis [92].  
Alkyl phosphines are strong -donor, whereas the introduction of aryl, dialkylamino or alkoxide 
substituents implies an increasing π-acidity, which can even be compared to that of CO in the case of 
PF3 owing to the π-backdonation of the metal electrons to the  * orbitals of PR [91].  
The phosphines used in this work were triphenylphosphine, TPPTS (sodium 3,3′,3″-
phosphinetriyltribenzenesulfonate) and PTA (1,3,5-triaza-7-phosphoadamantane).  
The solubility in water of such compounds (TPPTS and PTA) is generally transferred to the 
complexes with different metal centres, facilitating their use in the biological environment (Fig. 1.32). 
Arsines are ligands similar to phosphines but show a reduced -donation for the increased s-character 
of the lone pair of the arsenic and the consequent decrease of the bond overlapping. The minor 
electronegativity of the arsenic as acceptor atom and its wide orbitals, also contribute in reducing the 
metal backdonation [93]. 
 
Fig. 1.32 Chemical structures of PTA, PPh3 and AsPh3. 
Another type of common ancillary ligands are the isocyanides (CN-R), whose structure is 
exhaustively described by the two resonance formulas reported in Scheme 1.2. 
 
 
Scheme 1.2 Resonance structures of a general isocyanide. 
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Isocyanides are isoelectronic with CO and hence they show an electron-withdrawing character as a 
consequence of π-backdonation prevailing on their σ-donation nature. However, this feature can be 
modulated to some extent by a focused selection of the substituent R [91]. 
 
1.6. Organometallic fragments  
As mentioned previously (Section 1.3.6.), one of the problems of  palladium compounds is their rapid 
hydrolysis if compared to platinum homologues. This feature might permit the coordination of many 
potential ligands present in the biological environment (i.e. glutathione) and/or the formation of 
palladium nanoparticles, enhancing its collateral toxicity.  
To overcome this contoindication, a posssible option is prepare complexes with ligands firmly 
tethered to the metal. Among them, organometallic palladium derivatives could be particularly 
suibtable because of the strength of the Pd-C bond. 
In this chapter we will give a brief description of the organometallic fragment used in this work. 
1.6.1. 3-allyl-Pd(II) fragment 
The synthesis, the properties and the applications of complexes containing this organometallic 
fragment have been studied since the 1960s. The allyl group in homogeneous catalysis represents a 
reactive actor ligand and as demonstrated in numerous studies, usually undergoes nucleophilic attack 
[94]. Among the best-known processes there is the Tsuji-Trost reaction [91, 95], involving the use of 
an allyl acetate as starting reagent and, through the cycle shown below, yields the introduction of a 
group at the terminal allylic position. The rate-determining step is often represented by the 
nucleophilic attack at the intermediate allyl complex (Fig. 1.33).  
  
Fig. 1.33 Tsuji-Trost allylation mechanism (X = OAc). 
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In the original procedure, proposed by Tsuji in 1965, the nucleophile (Nu) was diethyl malonate, 
whereas amines, carbanions, isocyanates and carbamates were subsequently used [96]. 
The allyl fragment coordinates in two different ways:  
• 3 hapticity: the allyl fragment acts as a bidentate ligand. Such a coordination mode represents 
by far the most observed one. 
• 1 hapticity: the allyl fragment acts as a monodentate ligand. The related complexes are rare 
but they are observed mainly when no two free coordination sites are available [97].   
The first example of 3-allyl-palladium complex was reported by Smidt and Hafner in 1959 [98]. 
They prepared the dimeric complex [Pd(-Cl)(3-C3H5)]2 starting from PdCl2 and allyl alcohol.  
The labile bridge formed by the chloride ligands allows the easily introduction of a monodentate 
ligand or, after dehalogenation, the introduction of two monodentate or one chelating ligand (Scheme 
1.3). 
 
Scheme 1.3 General synthesis of Pd(II) 3-allyl complexes  with mono- and bidentate ancillary 
ligands. 
The following two resonance forms (Scheme 1.4) are used for describing the structure of 3-allyl-
palladium bond: 
 
Scheme 1.4 
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In this configuration, the allyl group is symmetrical, with C-C bond lengths of about 1,35 Å and 
oriented side-on with respect to the metal. The plane identified by the three carbon atoms, is slightly 
inclined with an angle Ө = 5-10° with respect to the perpendicular at the main coordination plane of 
the complex [91, 99]. This inclination allows a better overlapping between the orbital dπx,z of the 
metal and the πn of the allyl (Fig. 1.34). 
 
Fig. 1.34 
The four allyl protons are called syn and anti, on the basis of their position toward the central allyl 
proton. They do not lie perfectly in the plane defined by the three carbon atoms due to a slight rotation 
of the CH2 groups around the C-C axis. H-syns are therefore found to be significantly closer to the 
metal than H-antis (Fig. 1.35). 
 
Fig. 1.35 
H-syns and H-antis can sometimes exchange positions for example through 3-1-3 rearrangements 
in solution. A possible mechanism for this process is illustrated in the following diagram (Scheme 
1.5). 
  
Scheme 1.5 
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Our research group has published many works on the synthesis and reactivity of allyl palladium 
complexes [100]. 
1.6.2. Palladacyclopentadienyl fragment 
The first example of palladacyclopentadienyl polymeric compound [PdC4(COOCH3)4]n was 
described by Maitlis in the 1970s by oxidative coupling between Pd2(dba)3·CHCl3 (dba = 
dibenzylideneacetone) and dimethylacetylenedicarboxylate (DMA), carried out in different solvents 
[101]. Subsequently, it was noted that the lability of the bridges between the monomeric units could 
be exploited to synthesize a wide range of palladium mononuclear complexes by reaction of the 
Maitlis polymer with mono- or bi-dentate ligands (Scheme 1.6). 
 
Scheme 1.6 Synthesis of the [PdC4(COOCH3)4]n precursor and reactions with mono- or bi-dentate 
ligands. 
Subsequent studies have shown that  the PdC4(COOCH3)4 unit may behave as an actor ligand and to 
be attacked by halogens or alkyl/aryl halides to give the corresponding Pd(II) butadienyl complexes, 
in a process consisting in an oxidative addition and subsequent stereospecific reductive elimination, 
yielding the Z/Z geometry isomer. The butadienyl fragment can then be released from the metal centre 
by a further oxidative addition and consecutive reductive elimination (Scheme 1.7) [102]. 
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Scheme 1.7 Addition of halogens to palladacyclopentadienyl complexes (E = COOCH3). 
The group with I worked as PhD student has recently studied the reactivity of the 
palladacyclopentadienyl complexes stabilized by a wide range of spectator ligands, including N-
Heterocyclic Carbenes. The achievement of different types of products, some of which definitely 
unusual, have been obtained [103]. 
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1.6.3.  2-olefin-Pd(0) fragment 
The first example of a 2-olefin complex was obtained by William Zeise in 1827, by reacting K2PtCl4 
with EtOH, but only in the 50s of the last century the real nature of this product was understood. The 
complex can be described by the formula K2[PtCl3(2-C2H4)]·H2O, suggesting that the ethanol 
dehydration yields ethylene which eventually acts as a π-ligand [91]. 
 
Fig.1.36 Chemical structure of the Zeise’s salt. 
Generally, the metal-olefin bond is described by means of two limit models, respectively known as 
the Dewar-Chatt-Duncanson and the metal-cyclopropane models, described below (Fig. 1.37). 
 
Fig. 1.37 a) Dewar-Chatt-Duncanson model b) Metal-cyclopropane model. 
The metal-olefin bond involves the donation of C=C electrons to an empty orbital of the metal and 
the back-donation of two d-electrons of the metal to the C=C * anti-bonding orbital of the alkene 
(Fig. 1.38). 
  
Fig. 1.38 Representation of the metal-olefin bond [104]. 
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It has been possible to demonstrate that an adequate -backdonation from the metal makes the bond 
and therefore also the complex stable. On the contrary, in the case of poor -backdonation, the bond 
becomes labile and the release/substitution of the olefin is facilitated. In order to favor -backdonation 
it is convenient to choose spectator ligands with good -donating capability, so that the electronic 
density on the metal increases, and olefins with electron-withdrawing substituents [91]. 
Numerous studies have been carried out on olefinic exchange reactions in Pd complexes of the type 
L2Pd(2-olefin), which allowed to define the following order of stability for the metal-alkene bond, 
valid independently of the type of spectator ligands L [105]: 
 
Fig. 1.38 Stability order of the Pd-alkene bond, related to the equilibrium constant in a process 
of olefin exchange [(L-L)Pd(2-olefin1)]+olefin2  [(L-L)Pd(2-olefin2)] + olefin1. 
 
The synthesis of Pd(0) and Pt(0) 2-olefin complexes and the study of their reactivity, particularly 
with respect to oxidative addition and olefinic exchange processes, have been widely studied by our 
research group [106].  
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The figure proposed at the beginning of the chapter is related to this source: https://www.marketingbinder.com 
2 
Aim of the project 
 
The primary goal of this thesis is the synthesis and characterization of new organometallic palladium 
complexes bearing N-Heterocyclic Carbenes as spectator ligands.  
In this respect, the six types of NHC ligands which have been taken into consideration are (Fig. 2.1): 
1. Carbenes deriving from functionalized purine bases. 
2. Alkyl and/or aryl imidazole derivatives. 
3. Chelating biscarbenes with a methylene or ethylene bridge. 
4. Bidentate carbenes derived from imidazoles having a linked pyridine or thioether group.  
5. Carbenes with a glucopyranosidic group. 
6. Carbenes derived from trifluoromethylbenzimidazole. 
  
Fig. 2.1
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As mentioned in the introductory section, the novelty of this work is represented by the first attempt 
to study the anticancer activity of palladium compounds stabilized by organometallic fragments (3-
allyl-Pd(II), palladacyclopentadienyl and 2-olefin-Pd(0)) and NHCs (spectator ligands). 
Remarkably, the application in catalysis and the reactivity of these species have been widely studied, 
whereas their biological activity is substantially unexplored.  
The use of organometallic fragments (Fig. 2.2), combined with the presence of carbene ligands should 
render our compounds more resistant to hydrolysis in vivo and thus reduce the general problem of 
collateral toxicity.  
 
Fig. 2.2 
 
A systematic study of their biological activity as potential antitumor agents against ovarian carcinoma 
and other tumor lines (colon and lung cancer and malignant melanoma), will be proposed. For a small 
class of compounds, a study on their toxicity toward healthy cells (fibroblasts) will also be presented 
and, by means of cellular uptake analyses, stability studies and specific biological tests, some 
hypotheses about their possible mechanism of action will be advanced. 
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The figure proposed at the beginning of the chapter is related to this source: H. Valdes et al., J. Organomet. Chem., 2018, 867, 51. 
3 
Purine-based NHC complexes 
 
 
The first class of compounds, whose cytotoxic activity was evaluated, is represented by the palladium 
complexes stabilized by N-Heterocyclic Carbene ligands derived from the functionalization of natural 
purine bases. Such a choice was based on the hope that the natural origin of these molecules could 
render the final complexes more compatible with the biological matrix. This kind of strategy has 
already given interesting results and, in the most favourable cases, the ligand has represented a real 
targeting vector for its metal derivatives [1].  
In this chapter the synthesis of palladium 3-allyl, palladacyclopentadienyl and palladium (0) 2-
olefin complexes stabilized by these carbenes will be illustrated in detail. 
In order to modulate the stereoelectronic features of the examined complexes, it will also be presented 
cases where the carbenic ligand is combined with an other different spectator ligand such as 
phosphines (PPh3, TPPTS and PTA) and isocyanides (i.e. DIC). In the final part of the following 
chapter the results of the antiproliferative and proapoptotic activity of these compounds versus 
cisplatin-sensitive and cisplatin-resistant ovarian cancer lines will be highlighted.
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3.1. Introduction 
Purine bases are a class of organic compounds whose chemical structure derives from purine, a 
molecule consisting in a condensed pyrimidine and imidazole ring. 
Many purine derivatives, especially those of adenine, are involved in several metabolic processes [2]. 
For example, the 5-triphosphate adenosine (ATP) is an important energy resource for the body, while 
NAD (nicotinamide adenine dinucleotide) and FAD (flavin adenine dinucleotide) are coenzymes 
involved in redox cellular processes. Together with pyrimidines, purines are important building 
blocks of DNA and RNA [3]. 
In nature the purine bases can be distinguished in two main categories (Fig. 3.1): 
• Purine bases of nucleic acids (adenine and guanine). 
• Purine bases deriving from xanthine (caffeine, theobromine and theophylline). 
 
 
 
 
Fig. 3.1 Chemical structure of the most important purine bases. 
 
Xanthine bases are commercial compounds of natural origin extracted respectively from the seeds of 
Coffee Arabica (caffeine), the leaves of Sinensis Thea (theophylline) and the seeds of Cacao 
(theobromine). Caffeine and theobromine have stimulating properties [4] while theophylline is an 
antiasthmatic [5]. 
Generally, the synthetic derivatives of xanthine are prepared starting from theophylline or 
theobromine, which have an NH group in position 7 and 1, respectively. Such a group can be easily 
functionalized by generic alkylating agents (R-X), in the presence of a base [6] (Scheme 3.1). 
73 
 
 
 
 
Scheme 3.1 Theophylline and Theobromine functionalization- 
 
The functionalization of N-9 is unfortunately limited to the introduction of methyl [7], ethyl [8] or 
benzyl [9] groups. Furthermore, this process requires drastic experimental conditions with 
unsatisfactory yields as reported in Scheme 3.2, in the case of some alkylation reactions of the 
caffeine. 
 
Scheme 3.2 Experimental conditions for the caffeine functionalization. 
The imidazolium salts obtained by the exhaustive functionalization can be considered precursors of 
the N-Heterocyclic Carbene ligands. 
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As a matter of fact, many examples of complexes of Ir [10], Rh [10, 11], Ru [12], Ag [13, 14], Cu 
[15], Pt [16] and Au [17] have been synthesized and in some cases their antiproliferative activity has 
been studied (Fig. 3.2). 
 
Fig. 3.2 Examples of late transition metal complexes bearing purine based-NHC. 
 
As for palladium, despite of the number of derivatives described in the literature, there are very few 
examples of complexes with purine-based NHCs and their  antiproliferative activity is not reported 
(Fig. 3.3) [9, 17]. 
             
Fig. 3.3 Examples of Pd(II) complexes with purine-based NHC ligands.  
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3.2. Synthesis of Functionalized Xanthines  
A number of theophylline and theobromine derivatives can be quite easily prepared by alkylation, 
under mild conditions, of the NH groups in positions 7 and 1, respectively. In this work we have 
synthesized, and used in subsequent synthetic steps, the benzyl and phenylpropargyl derivatives of 
theophylline and theobromine (Scheme 3.3). 
 
 
Scheme 3.3 Synthesis of functionalized xanthines 1b-d. 
Preliminary tests have demonstrated that benzyl and phenylpropargyl substituents were the most 
suitable alkylating agent owing the good yields and purity of the obtained derivatives. As reported in 
the above scheme, theophylline and theobromine were reacted in DMF at RT overnight, with benzyl 
bromide or phenylpropargyl chloride, in the presence of K2CO3 as base. This process represents a 
slightly modified version of the methodology reported by Groundwater and co-workers in 2012 [6]. 
The final products were easily precipitate by addition of water to the final reaction mixture. The 
success of the process is proved by 1H-NMR spectra, in which the disappearance of the peak related 
to the NH group (broad signal within 11-13 ppm)  and the simultaneous appearance of the signals of 
the benzyl or phenylpropargyl group (NCH2 protons resonate as a singlet within 5-6 ppm and the 
aromatic ones within 7.2-7.6 ppm) are observed. The slight shift related to the other signals (NCH3 
and NCHN groups) with respect to that of the starting purines is also apparent (Fig. 3.4). 
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Fig. 3.4 1H-NMR spectra of theophylline and 1b derivative (T=298K, CDCl3). 
 
The 13C{1H}-NMR spectra (Fig. 3.5) show the following signals: 
• NCH3 and NCH2 in the 28 - 50 ppm interval. 
• Alkyne carbons (for the compound 1c) within 80 and 88 ppm. 
• C5 and C4 at about 107 and 149 ppm, respectively. 
• Aromatic carbons within 121-137 ppm. 
• Imidazole carbon (NCHN) at about 141 ppm. 
• Two carbonyl carbons within 151-156 ppm. 
 
 
Fig. 3.5 13C{1H}-NMR spectrum of 1b (T=298K, CDCl3).  
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3.3. Purine-based imidazolium salts 
The previously described xanthine derivatives (1b-d) and the commercially available caffeine (1a) 
contain a sp2 nitrogen in position 9 that must be functionalized in order to obtain the corresponding 
imidazolium salts. This functionalization, as already stated, is restricted to the introduction of methyl 
[7], ethyl [8] or benzyl [9] substituents under very drastic conditions and often with low yields. In the 
present work the methylation of the alkylated xanthines 1 was obtained by a new protocol based on 
the modified conditions proposed by Hermann [7b] and Casini [16]. Such a protocol implies the 
reaction in acetonitrile at RT of a slight excess of Me3OF4 as methylating agent (Meerwein’s salt), in 
the presence of sodium carbonate as inorganic base (Scheme 3.4). 
 
Scheme 3.4  
In particular, the advantages of this protocol are: 
• Me3OBF4 is easier to handle and a less dangerous methylating agent if compared to methyl 
iodide or dimethylsulfate. Moreover, its use in slight excess reduces the problems of the waste 
dispersion in the environment. 
• The use of a polar solvent such as acetonitrile renders the rate of the nucleophilic substitution 
higher than that promoted by the chlorinated solvents. 
• The reaction is carried out at RT, in the air and with very short reaction times. 
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• The use of the easily removable by filtration inorganic base Na2CO3, contributes to the 
achievement in an almost quantitative yields (>90%) of the wanted fully alkylated species. As 
a matter of fact, the sodium carbonate deprotonates the by-product formed in the reaction of 
the starting xanthines 1 with HBF4, which is produced in small quantities when  Me3OBF4 
reacts with traces of H2O. Therefore, the  restored species 1 can undergo an exhaustive 
methylation (Scheme 3.5). 
 
Scheme 3.5  
 
The successful result of the methylation is evident from the analysis of 1H-NMR spectra. The reaction 
products show the signal of the N-CH3 group at lower fields if compared to the other pre-existing 
methyl groups. Moreover, the imidazolic proton (NCHN)  of the methylated species shifts at lower 
field (ca. 1 ppm) than that of the compounds 1 (Fig. 3.6). 
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Fig. 3.6 1H-NMR spectra of 1b and 2b (T = 298K, CD3CN). 
 
The 13C{1H}-NMR (Fig. 3.7) and ESI-MS spectra confirm the structure of the obtained products. 
 
 
Fig. 3.7 13C{1H }-NMR spectrum of  2b (T = 298K, CD3CN). 
The synthesis of Pd (0) and some Pd (II) complexes is easily feasible when Ag (I) carbene precursors 
obtained from imidazolium hydrochlorides are used as starting compounds. Thus, the imidazolium 
hydrochlorides have been synthesized in water by reacting the imidazolium tetrafluoroborates with 
AsPh4Cl (Scheme 3.6) [18]. Any traces of arsenic salts are completely removed in the subsequent 
steps, exploiting their different solubility with respect to the Ag (I) intermediate compounds and to 
the final palladium complexes.  
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Scheme 3.6 Synthesis of the imidazolium salts 3a-c. 
 
Another efficient method, although less rapid, is based on the exchanging anions by treating in 
methanol the imidazolium salts 2a,b and 2d for 24 hours with the ion exchange resin DOWEX-
21KCl. Regardless of the chosen synthetic path, it is possible to verify the nature of the obtained 
product by NMR, ESI-MS and elemental analysis.  
From the comparison of the 1H-NMR spectrum of the imidazolium salt 3a with that of 2a (Fig. 3.8), 
it is possible to see how the substitution of the initial BF4
- counterion with Cl- slightly affects the 
chemical shifts of the related protons. This influence is particularly remarkable in the case of the 
methyl groups of the imidazole system resonating between 3.4 and 4.2 ppm, since the splitting of two 
peaks that previously appeared overlapped becomes apparent. Moreover, although the position of the 
signal of the imidazole proton is not particularly diagnostic owing to its acidity, in the case of the 
hydrochloride derivative a significant downfield shift (Δδ ≈ 1.5 ppm) is observed. 
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Fig. 3.8 1H-NMR spectra of 3a and 2a (T = 298K, CD3CN). 
 
 
Fig. 3.9 13C{1H}-NMR spectrum of 3a (T = 298K, CD3CN). 
 
Considerations similar to those made for product 3a can be extended to compounds 3b and 3d. 
In the case of compound 3c, traces of decomposition can be detected in the NMR spectra and for this 
reason, such a  compound was not used in the synthesis of Pd (0) and Pd (II) neutral complexes.  
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3.4. Silver (I) purine-based NHC complexes  
The synthesis of the Ag (I) complexes was carried out by reacting the imidazolium salts 2-3 with 0.5 
equivalents of silver oxide. Starting from the imidazolium salts 2a-d, the addition of Ag2O, carried 
out in acetonitrile for 28 hours, led to the formation of equimolar mixtures of the biscarbene 
complexes 4a-d and AgBF4 (Scheme 3.7). 
 
Scheme 3.7 Synthesis of the 4a-d/AgBF4 mixtures. 
This result is confirmed by NMR, ESI-MS (Fig. 3.10), elemental analysis and, in the case of complex 
4b, by the solid state structure obtained by single crystal X-ray diffraction (Fig. 3.11). 
 
Fig. 3.10 ESI-MS spectrum of 4b/AgBF4 ([NHC-Ag-NHC]
+ as molecular ion peak). 
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Fig. 3.11 Ellipsoid representation of 4b crystal ASU contents (50% probability). 
The 1H-NMR spectra are characterized by the slight displacement of the signals with respect to those 
of the starting imidazolium salts and by the absence of the peak of the imidazole proton NCHN (Fig. 
3.12). 
 
 
Fig. 3.12 1H-NMR spectra of 2b and 4b (400 MHz, T=298K, CD3CN). 
The marked downfield shift of the imidazole carbon NCN in the 13C{1H}-NMR spectra from about 
140 ppm of the starting compound to 180-190 ppm, which is the typical resonance of the coordinated 
carbenic carbon, represents a further evidence confirming  the coordination process (Fig. 3.13).  
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Fig. 3.13 13C{1H}-NMR spectrum of 4b (T=298K, CD3CN). 
The attribution of the proton and carbon signals was carried out by bidimensional HMQC and HMBC 
spectra (Figs. 3.14 and 3.15). 
 
Fig. 3.14 HMQC spectrum of 4b (T=298K, CD3CN). 
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Fig. 3.15 HMBC spectrum of 4b (T=298K, CD3CN). 
 
Beside the formation of the complex [NHC-Ag-NHC]BF4, the presence of AgBF4 in a 1:1 ratio is 
noticed  as suggested by the darkening of the precipitate within 1-2 days. However, as will be seen 
later, the presence of AgBF4 does not represent a problem for the transmetallation process but rather 
an advantage. 
Similar approach has been used in the synthesis of type 5 complexes, which were obtained from the 
reaction between the imidazolium salts 3 and silver oxide. 
The reactions were carried out in acetonitrile, where the progressive dissolution of the silver oxide 
and the simultaneous precipitation of the products as white solids were observed. The final complexes 
were separated by filtration, subsequently dissolved in dichloromethane and finally filtered off on 
millipore apparatus in order to eliminate the residual Ag2O. From the resulting solutions, the products 
5a-b and 5d were obtained in pure form by precipitation with diethylether (Scheme 3.8). 
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Scheme 3.8 Synthesis of 5a-b and 5d. 
 
As an example, the 1H-NMR spectra of complex 5b shows the signals of the alkyl and aryl groups 
slightly displaced with respect to those of the corresponding imidazolium salt 3b as a consequence of 
the coordination of the metal (Fig. 3.16). The disappearance, in the 1H-NMR spectrum of the complex 
5b, of the signal related to the imidazole proton NCHN is also particularly diagnostic. 
 
Fig. 3.16 1H-NMR spectra of 3b e 5b (T = 298K, CD2Cl2 and CD3CN). 
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Fig. 3.17 13C {1H}-NMR spectrum of 5b (T = 298K, CDCl3). 
The simple formula [(NHC)-Ag-Cl] was initially hypothesized for the Ag (I) complexes prepared. 
However, the ESI-MS spectrum (Fig. 3.18), indicates the presence of the molecular ion [NHC-Ag-
NHC]+, therefore we propose a structure of the type [NHC-Ag-NHC][AgCl2]. 
 
 
Fig. 3.18 ESI-MS spectrum of 5b. 
This assumption is supported by literature data describing cationic complexes of Ag (I) containing 
the species [AgCl2]
- as a counterion (Fig. 3.19) [19, 20]. 
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Fig. 3.19 Structure of the complex [(IMes)2Ag][AgCl2] (ball and stick model) [19]  
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3.5. Palladium (II) 3-allyl complexes bearing purine-based NHCs 
The synthesis of cationic Pd(II) 3-allyl complexes, (see section 1.6.1.), is generally carried out by 
reacting the dimeric precursor [Pd(-Cl)(3-allyl)]2, with two monodentate or one bidentate ligands 
(Scheme 3.9).  
 
 
Scheme 3.9 General synthesis of Pd(II) 3-allyl complexes  with mono- and bidentate ancillary 
ligands. 
A dechlorinating agent (i.e. NaClO4 or AgBF4) is often necessary to ensure the coordination of both 
the spectator ligands since in aprotic solvent a competitive coordination between the ligands and the 
free chloride might established. In this paragraph the synthesis of 3-allyl complexes bearing two 
purine-based carbene ligands (biscarbene compounds) and complexes bearing one purine-based 
carbene and one different ligand such as a phosphine or an isocyanide (mixed NHC/L complexes), 
will be discussed. The presence of a different spectator ligand was taken into consideration since it 
allows the modulation of the stereoelectronic characteristics and the solubility of the mixed 
complexes. In our case, the dechlorinating agent is not necessary since the AgBF4 present as 
companion of  the Ag (I) carbene precursors reacts with the free chloride to give the insoluble AgCl 
which can be easily removed by filtration.  
 
3.5.1. Mixed NHC/PPh3 3-allyl complexes (6) 
The first class of 3-allyl compounds we have synthesized was stabilized by one purine-based carbene 
and one triphenylphosphine as spectator ligands. These compounds were obtained by addition of the 
Ag (I) carbene complex (4a-d/AgBF4 mixtures) and a stoichiometric amount of triphenylphosphine, 
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dissolved in acetonitrile, to an acetonitrile solution of the dimeric precursor [Pd(-Cl)(3-allyl)]2 
(Scheme 3.10). 
 
Scheme 3.10 Synthesis of complexes 6a-d. 
 
The precipitation of AgCl, which is subsequently removed by filtration on millipore (or Celite), is a 
clear indication of the reaction progress. The products were isolated by precipitation induced by 
addition of diethylether to the concentrated solution. The reactions lead in all cases to the exclusive 
formation of the mixed NHC/PPh3 derivatives, whereas the presence of the species with two carbene 
ligands (biscarbenes) and two phosphinic ligands was never observed. The selective formation of 
mixed derivatives will be discussed in detail in paragraph 4.6.4. 
The mixed NHC/PPh3 complexes 6a-d were characterized by IR, NMR and elemental analysis. 
The NMR spectra of the products 6a-d confirm their nature and suggest some important structural 
characteristics: 
1. Since the involved carbene ligands are not symmetric and their rotation around the Pd-C bond 
is prevented, the ensuing complexes are present in solution as a pair of atropoisomers 
according to the different position of the allyl fragment with respect to the carbene fragment 
(Fig. 3.20). 
 
 
Fig. 3.20 Representation of the two atropoisomers for the complex 6a (DFT calculations). 
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This fact is confirmed by the doubling of all signals in the 1H-NMR, 31P{1H}-NMR and  
13C{1H}-NMR spectra. As expected, the concentration of the two isomers is practically equal. 
 
2. The presence of the coordinated phosphine is attested by the position of the 31P{1H}-NMR 
signals at about 25-26 ppm ( ≈ 30 ppm compared to the free triphenylphosphine). 
 
Fig. 3.20 31P{H1} NMR spectrum of complex 6a in CDCl3 at 298K. 
 
3. The five different signals for each isomer traceable back to the allyl protons are listed below 
and indicate the coordination of both phosphine and carbene with the consequent induced 
dissymmetry of the allyl fragment: 
a) H anti, trans to carbene; doublet with J = 13-14 Hz at 2.9-3.3 ppm. 
b) H anti, trans to PPh3; multiplet between 2.4 and 3.8 ppm. 
c) H syn, trans to carbene; doublet with J = 6-8 Hz at 4.0-4.3 ppm. 
d) H syn, trans to PPh3; multiplet or doublet of doublet (JH-H = JH-P = 6-8 Hz) between 3.6 and 
4.7 ppm. 
e) H central; multiplet between 5 and 6 ppm. 
Owing to the well differentiated resonances of the four terminal allyl protons, no fluxionality 
of the allyl systems (syn-syn/anti-anti, or 3-1 isomerization) was detected by 1H NMR 
experiment at RT.  
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Fig 3.21 1H NMR spectrum of complex 6a in CDCl3 at 298K. 
4. In the 13C{1H}-NMR spectra, the chemical shifts of the two terminal allyl carbons are very 
close (at about 70 ppm), confirming that the trans-influence of carbene ligands and 
triphenylphosphine is comparable. Both carbons resonate as a doublet due to the coupling with 
phosphorus (J = 27-28 Hz for the carbon trans to phosphine and J = 1-2 Hz for that trans to 
carbene). The doublets (JC-P = 18-20 Hz) related to the carbene carbons are detected between 
186 and 188 ppm.  
 
 
Fig 3.22 13C{H1} NMR spectrum of complex 6a in CDCl3 at 298K. 
5. The presence of the carbene ligand is also confirmed by the signals detected in both the 1H-
NMR and 13C{1H}-NMR, traceable back to the NCH3 present in the purine structure and, for 
compounds 6b-d, by the resonances of the benzyl or phenylpropargyl groups. In the case of 
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the 1H-NMR spectra of the complexes 6b and 6d, the CH2Ph protons are observed as an AB 
system (one for each isomer, J = 14-18 Hz)  due to the diastereotopicity induced by the hindered 
rotation.  
The IR spectra show the presence of the characteristic stretching of BF4
- (ṽB-F = 1055 cm-1) and signals 
related to the C=O groups (ṽC=O = 1660-1710 cm-1). The solid state structure of complex 6a was 
resolved by X-ray single crystal diffraction (Figure 3.23). 
 
Figure 3.23 Ellipsoid representation of 6a crystal ASU contents (50% probability). 
 
3.5.2. Mixed NHC/TPPTS and NHC/PTA 3-allyl complexes (7-8) 
In order to evaluate whether water-soluble complexes might have comparable or different activity 
than that of the previously discussed species, it was decided to synthesize mixed complexes bearing 
the phosphines TPPTS and PTA. As a matter of fact, the water-soluble PTA ensures good solubility 
in both polar and less polar solvents to its derivatives and has been widely used for the synthesis of 
complexes with antitumor properties (See in paragraph 1.3.5 of the introductory part the 
characteristics of the ruthenium compounds RAPTA). 
Therefore, we have synthesized the complexes 7 and 8 by reacting the precursor [Pd(-Cl)(3-allyl)]2, 
the water-soluble phosphine (PTA or TPPTS) and the mixture of the silver precursors 4 and AgBF4, 
in stoichiometric amount (Scheme 3.11). 
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Scheme 3.11 Synthesis of complexes 7 and 8. 
The reactions were carried out at room temperature for 15' in CH3CN in the case of the PTA 
complexes 8 or in CH3CN : H2O (6 : 1 vv) for the TPPTS derivatives 7. As usual, the almost 
instantaneous precipitation of AgCl testified the reaction progress. 
From the NMR spectra it is possible to state that: 
1. All the reported complexes (7-8) were present in solution as a pair of atropoisomers. This fact 
is confirmed by the two peaks (different or coincident) present in the 31P{1H}-NMR spectra 
and by the doubling of all the signals in the 1H-NMR and 13C{1H}-NMR spectra.  
2. The TPPTS coordination is confirm by the marked downfield shift of the signals in the 
31P{1H}-NMR (Fig. 3.24) compared to those of the uncoordinated TPPTS ( ≈ 34 ppm). 
 
 
Fig. 3.24 31P{1H}-NMR spectrum of  7a (T=298K, D2O). 
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3. The five different signals of the allyl protons, present for each isomer, are listed below: 
a) H anti, trans to carbene; doublet with J = 13-14 Hz at 3-3.4 ppm. 
b) H anti, trans to TPPTS; multiplet at about 3.5 ppm. 
c) H syn, trans to carbene; doublet with J = 7-8 Hz at 4.3-4.5 ppm. 
d) H syn, trans to TPPTS; multiplet at about 4.6 ppm. 
e) H central, multiplet at 5.7-5.9 ppm. 
 
Fig. 3.25 1H-NMR spectrum of 7a (T=298K, D2O). 
 
4. Owing to the comparable trans-influence of the carbene and TPPTS, in the 13C{1H}-NMR 
spectra (Fig. 3.26) the two terminal ally carbons resonate at ca. 69 ppm. The signal of the 
carbon trans to the phosphine (present as doublet due to the phosphorus coupling) resonates 
to a slightly higher field ( ≈ 1 ppm) than that trans to carbene.  
 
Fig. 3.26 13C{1H}-NMR spectrum of  7a (T=298K, D2O). 
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5. The signals of the carbene carbons are detected between 185 and 187 ppm as doublets owing 
to the J2 coupling with the TPPTS phosphorus (JC-P = 19-20 Hz). 
6. The presence of the carbene ligand is also confirmed by high-field signals, in both the 1H- and 
13C{1H}-NMR spectra, of the NCH3 groups of the purine structure and, in the case of 
compounds 7b and 7d, by the resonance of the benzyl substituent (-CH2Ph). In these last two 
cases, the -CH2Ph protons are observed in 
1H-NMR spectra as AB system (one for each 
isomer) due to the diastereotopicity induced by the hindered rotation (Fig. 3.27). 
 
 
Fig. 3.27 1H-NMR spectrum of 7d (T=298K, D2O). 
 
As for the mixed NHC/PTA complexes, it is possible to observe for each atropoisomer that: 
1. the presence of the coordinated PTA is indicated by the position of the signals in the 
31P{1H}-NMR spectra at fields significantly lower than those of the free ligand ( ≈ 45 
ppm). 
 
Fig. 3.28 31P{1H}-NMR spectrum of 8b (T=298K, D2O). 
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In the 1H-NMR spectra, the NCH2P protons are present as two singlets (one for each isomer) 
practically coincident at about 4.2 ppm whereas the NCH2N protons are detected as a 
multiplet at about 4.5 ppm. 
In the 13C{1H}-NMR spectra, the NCH2N systems are found as singlets at about 70-71 ppm 
and the NCH2Ps as doublets (with J = 13-14 Hz) at about 50-51 ppm. 
 
Fig. 3.29 1H-NMR spectrum of 8a (T=298K, D2O). 
 
2. The coordination of the allyl fragment is confirmed by the presence in the 1H-NMR spectra 
of five different signals: 
a) H anti, trans to carbene; doublet with J = 13-14 Hz at about 2.7 ppm. 
b) H anti, trans to the PTA; a multiplet at about 3 ppm. 
c) H syn, trans to carbene; a doublet with J = 6-7 Hz at about 2.7 ppm. 
d) H syn, trans to the PTA; multiplet at about 4.4 ppm. 
e) H central, multiplet at about 5.4 ppm. 
3. In the 13C{1H}-NMR spectra the two terminal allyls carbons resonate at quite different 
chemical shifts (at about 63 ppm for that trans to carbene and at 69 ppm for that trans to 
PTA). 
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Fig. 3.30 13C{1H}-NMR spectrum of 8a (T=298K, D2O). 
Owing to the coupling with the PTA phosphorus, the signals ascribable to carbene carbons 
are observed between 184 and 186 ppm as doublets (JC-P = 19-20 Hz). 
 
3.5.3. Mixed NHC/DIC 3-allyl complexes (9) 
After the synthesis of the mixed NHC/phosphine complexes 6, 7 and 8, we taken in account the 
possibility of isolate novel mixed NHC/isocyanide complexes. Due to their -acid character, 
isocyanides impart to their complexes remarkable differences with respect to that observed in  alkyl 
or aryl phosphines derivatives. In our case the best synthetic results were obtained with the 2,6-
dimethylphenyl isocyanide (DIC). The NHC/DIC complexes were synthesized according to the 
following Scheme 3.12. 
 
Scheme 3.12 Synthesis of complexes 9a-d. 
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From the NMR spectra of the final products 9 it is possible to infer some important structural features:  
1. At variance with the NHC/phosphine complexes described so far, the presence of 
atropoisomeric species is not observed at 298 K. 
2. The presence of the coordinated isocyanide is deduced from the downfield shift of the 
signals related to the methyl substituents (at about 2.3 ppm).  
 
Fig. 3.31 1H-NMR spectrum of 9a in CDCl3 at 298K. 
In the 13C{1H}-NMR spectra the DIC methyl groups are observed as singlets at ca. 19 
ppm and the CN carbon as a broad signal at ca. 151 ppm. 
 
 
Fig. 3.32 13C{1H}-NMR spectrum of 9a in CDCl3 at 298K. 
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3. The coordination of the allyl fragment is confirmed by the presence in the 1H-NMR 
spectra of complexes 9 of five different signals:  
a) H anti, trans to carbene; doublet with J = 13.5 Hz between 3.2 and 3.5 ppm. 
b) H anti, trans to isocyanide; doublet with J = 12.5 Hz between 3.4 and 3.5 ppm. 
c) H syn, trans to carbene; doublet with J = 6-7 Hz between 4.2 and 4.5 ppm. 
d) H syn, trans to isocyanide; doublet with J = c.a. 7.5 Hz between 4.6 and 4.8 ppm. 
e) H central; multiplet at about 5.7 ppm. 
4. In the 13C{1H}-NMR spectra the two terminal allyl carbons are observed within 65 and 
69 ppm, whereas the chemical shift of the central carbon resonates at ca. 122 ppm. 
5. The signal ascribable to the carbene carbon is detected as a singlet within 181 and 183 
ppm.  
The IR spectra show the CN stretching of the coordinated isocyanide at about 2175 cm-1, the BF4-  
peak (B-F = ca. 1055 cm-1) and those of the carbonyl groups (C=O = 1660-1710 cm-1). 
 
Fig. 3.33 IR spectrum of complex 9a in KBr. 
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3.5.4. Bis(NHC) 3-allyl complexes 
The Pd(II) 3-allyl complexes bearing two purine-based NHCs as spectator ligands were synthesized 
by reacting the stoichiometric mixture of the silver precursors 4 and AgBF4 with the palladium allyl 
dimer, in the presence of KI. The addition of potassium iodide is necessary to remove all the silver 
from the reaction mixture (Scheme 3.13). 
 
 
Scheme 3.13 Synthesis of complexes 10a-d. 
The 10a-d biscarbene complexes were characterized by IR, NMR and elemental analysis. 
The most significant conclusion that can be immediately noticed by NMR spectra of complexes 10 is 
the presence, of an only set of signals. This observation suggests that there is free rotation of the two 
N-Heterocyclic Carbene ligands about the Pd-C bond. 
The 1H-NMR spectra show three different signals for the allyl protons indicating the coordination of 
two equal carbene ligands. In particular: 
a) H anti; doublet with J = 13-14 Hz at about 3 ppm. 
b) H syn; doublet with J = 7-8 Hz at 4 ppm. 
c) H central; as multiplet between 5.5 and 6 ppm. 
 
Fig. 3.34 1H NMR spectrum of complex 10a in CD3CN at 298K. 
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In the 13C{1H}-NMR spectra, the two terminal allyl carbons resonate between 60 and 65 ppm, unlike 
the central allyl carbon which resonates at 120-122 ppm. The signal of carbene carbons are detected 
at ca. 185 ppm. 
 
 
Fig. 3.35 13C{H1} NMR spectra of complex 10a in CD3CN at 298K. 
 
In the case of the complex 10d it was possible to resolve its solid state structure by X-ray single 
crystal diffraction (Figure 3.36). 
 
  
Fig. 3.36 Ellipsoid representation of 10d crystal ASU contents (50% probability). 
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3.6. Palladacyclopentadienyl complexes bearing purine-based NHCs 
[PdC4(COOCH3)4]n was used for the synthesis of the palladacyclopentadienyl complexes. This 
precursor can be obtained by oxidative coupling of Pd2(DBA)3·CHCl3 with dimethylacetylene 
dicarboxylate (DMA) (Scheme 3.14). 
 
 
Scheme 3.14 Synthesis of the polymeric precursor [PdC4(COOCH3)4]n 
 
This polymer is an ideal precursor for the synthesis of our complexes since the presence of oxygen-
labile bridges allows an easy introduction of two monodentate spectator ligands or a bidentate one. 
 
3.6.1. Mixed NHC/PPh3 palladacyclopentadienyl complexes 
The palladacyclopentadienyl complexes containing a purine-based NHC and a triphenylphosphine 
(compounds 11a-b and 11d) were synthesized in good yields. The synthesis of these compounds was 
carried out by adding to a CH2Cl2 solution of the [PdC4(COOCH3)4]n precursor, a mixture of the 
silver carbene complex (5a-b or 5d) and triphenylphosphine. The process is relatively fast and takes 
about an hour to be complete (Scheme 3.15). 
 
Scheme 3.15 Synthesis of the mixed NHC/PPh3 complexes 11a-b and 11d. 
The final products were isolated, after separation of AgCl by filtration on millipore membrane and 
reduction of the solvent to small volume, by precipitation  with diethylether. 
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Complexes 11a-b and 11d were characterized by NMR and IR spectroscopy. The formation of a 
single species is inferred from the presence of a single peak at about 25-26 ppm in the 31P{1H}-NMR 
spectra (Δδ  30 ppm compared to the uncoordinated PPh3).  
 
Fig. 3.37  31P{1H}-NMR spectrum of the complex 11b (T = 298K, CDCl3). 
 
The nature of the obtained products was deduced on the basis of the 1H- and 13C{1H}-NMR spectra. 
In fact, owing to the presence of two different spectator ligands, four signals corresponding to the 
four magnetically non-equivalent ester groups (COOCH3) are observed. As for the carbene ligand, in 
addition to the signals of the NCH3 groups, for the compounds 11b and 11d it is possible to observe 
the signals due to two methylene protons NCH2 resonating as an AB system. In this case the magnetic 
non-equivalence is again due to the prevented rotation of the carbene ligand about the Pd-C bond 
(Fig. 3.38). 
 
Fig. 3.38 1H-NMR spectrum of the complex 11b (T = 298K, CDCl3). 
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In the 13C{1H}-NMR spectra (Fig. 3.39), the most important signal, for all the synthesized 
compounds, is detected at about 190 ppm and is ascribable to the doublet (JC-P ≈ 16 Hz) due to the 
coupling with the phosphorus of triphenylphosphine of the carbenic carbon. 
 
 
Fig. 3.39 13C{1H}-NMR spectrum of the complex 11b (T = 298K, CDCl3). 
 
As a further and definitive confirmation of the conclusions obtained by IR and NMR techniques, we 
report, for complex 11b, the solid state structure obtained by X-ray diffraction (Fig. 3.40). 
 
C8_4 C1_3 
 
Pd_1 
C4_3 
P_2 
 
Fig. 3.40 Ellipsoid representation of 11b crystal ASU contents (50% probability). 
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3.6.2. Mixed NHC/PTA palladacyclopentadienyl complexes 
The synthesis of the mixed NHC/PTA palladacyclopentadienyl complexes was carried out similarly 
to that previously described, in agreement with the scheme proposed below (Scheme 3.16). 
 
 
Scheme 3.16 Synthesis of the mixed NHC/PTA complexes 12a-b and 12d. 
 
The exclusive obtainment of the mixed derivatives is unequivocally confirmed by the 1H-NMR 
spectra (Figs 3.41 and 3.42), in which the signals related to the NCH3 (singlets) and NCH2 (AB 
systems within 5.3-6.2 ppm) groups of the carbene ligand, the four different ester groups of  the 
palladacycle, the methylene protons of the coordinated PTA (NCH2N; AB system within 4.3-4.5 ppm 
and NCH2P; doublet, JH-P ≈ 2 Hz, within 3.5 and 4 ppm) can be observed.  
 
Fig. 3.41 1H-NMR spectrum of the complex 12a. 
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Fig. 3.42 1H-NMR spectrum of the complex 12b (T = 298K, CDCl3). 
 
In the 13C{1H}-NMR spectra (Fig. 3.43) it is possible to observe at 180-190 ppm the signal of the 
carbene carbon which resonates as a doublet (JC-P ≈ 17-18 Hz). As for the coordinated PTA, the peaks 
of the NCH2P and NCH2N methylene carbons at about 50 ppm (doublet with JC-P ≈ 10 Hz) and 73 
ppm (doublet with JC-P ≈ 6 Hz) can be detected. 
These signals, together with all the others related to the spectator ligands and to the cyclometallated 
fragment, have been attributed on the basis of the interpretation of the bidimensional HSQC and 
HMBC spectra. 
 
Fig. 3.43 13C{1H}-NMR spectrum of the complex 12a (T = 298K, CDCl3). 
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Finally, the 31P{1H}-NMR spectra show the presence of a single peak. Its position at chemical shift 
higher than that of the free ligand (Δδ ≈ 45 ppm), confirms the coordination of the PTA. 
 
3.6.3. Mixed NHC/DIC, palladacyclopentadienyl complexes 
The success of the reactions with PTA and triphenylphosphine prompted us to use the same synthetic 
approach to obtain cyclometallated complexes with a purine-based NHC and an isocyanide (i.e. DIC) 
as spectator ligands. The synthesis of this class of compounds requires much longer times than that 
necessary in the case of mixed NHC/phosphines complexes. As a matter of fact, the addition of the 
DIC isocyanide and the silver carbene complex to the solution of the palladacyclic precursor, yields 
in few minutes a mixture containing the mixed product and the two bis-DIC and bis-NHC 
palladacyclopentadienyl species. However, in around 48 hours at room temperature it is possible to 
observe the progressive transformation of the two bis-DIC and bis-NHC palladacyclopentadienyl 
species into the mixed derivative. 
Therefore, it was possible to synthesize with good yields the compounds 13a-b and 13d, adopting the 
conditions shown in Scheme 3.17. 
 
Scheme 3.17 Synthesis of the mixed NHC/DIC complexes 13a-b and 13d. 
 
In the 1H-NMR spectra (Fig. 3.44), the signals of the two different spectator ligands (isocyanide and 
carbene) can be easily identified. The presence of the palladacyclic fragment is evidenced by the four 
different peaks that can be assigned to the OCH3 groups together to the singlet observed between 2 
and 2.5 ppm, which is attributable to the two methyl groups of the coordinated isocyanide.  
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Fig. 3.44 1H-NMR spectrum of the complex 13d (T = 298K, CDCl3). 
 
In the 13C{1H}-NMR spectra (Fig. 3.45), the weak signals ascribable to the CN group (149 ppm) and 
the coordinated carbenic carbon (180-190 ppm) are also identified. 
 
Fig. 3.45 13C{1H}-NMR spectrum of the complex 13d (T = 298K, CDCl3). 
Finally, in the IR spectra (Fig. 3.46) a medium intensity and the strong bands at 2175-2180 cm-1 and 
between 1670 and 1710 cm-1 have been assigned to the CN of the coordinated isocyanide and to the 
CO, respectively. 
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Fig. 3.46 IR spectrum (in KBr) of the complex 13d. 
 
3.6.4. Bis(NHC) palladacyclopentadienyl complexes 
The synthesis of the palladacyclopentadienyl complexes with two purine-based NHC ligands was 
successfully performed according to the following scheme (Scheme 3.18). 
 
Scheme 3.18 Synthesis of the bisNHCs palladacyclopentadienyl complexes 14a-b and 14d. 
 
All recorded spectra show the presence of two atropoisomeric species due to the asymmetry of the 
carbene ligand and the hindered rotation about the Pd-C bond (Fig. 3.47). 
Date: 21 /08 /201 7
4000,0 3000 2000 1500 1000 400,0
51,0
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84
85,2
cm-1
%T 
34 47
31 33
21 78
17 10
16 75
15 3314 31
14 00
13 11
12 05
11 65
10 66
10 00
88 0 78 6
75 7
74 6
70 1
53 9
111 
 
 
 
Fig. 3.47 Representation of the two atropoisomers related to the complex 14b, obtained by                             
DFT calculations (with E = CN instead of COOCH3). 
 
As can be seen in Figure 3.47, in the case of compound 14b the nature of the atropoisomers is 
determined by the mutual position of the two benzyl substituents with respect to the main coordination 
plane. The 1H-NMR spectra of the atropoisomers (Figs. 3.48 and 3.49) are characterized by: 
• The presence of the signals relating to the NCH3 groups of the purine base resonating at 
different chemical shifts with respect to those of the starting silver complex. 
• The presence of two signals ascribable to the two distinct pairs of OCH3 groups. 
• The presence, in the case of compounds 14b and 14d (Fig. 3.49), of an AB system related to 
the methylene protons of the benzyl groups, at about 5-6 ppm. 
 
Fig. 3.48 1H-NMR spectrum of the complex 14a (T = 298K, CD2Cl2). 
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Fig. 3.49 1H-NMR spectrum of the complex 14d (T = 298K, CDCl3). 
 
The 13C{1H}-NMR spectra (Fig. 3.50) of the atropoisomers show the signals ascribable to the 
different pairs of the COOCH3 and C(COOCH3) groups and those of the coordinated carbenic carbon 
at about 188 ppm. 
 
 
Fig. 3.50 13C{1H}-NMR spectrum of the complex 14a (T = 298K, CD2Cl2). 
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3.7. Palladium (0) 2-olefin complexes bearing purine-based NHCs 
As already stated (section 1.3.6), the cytotoxic activity of the Pd(0) complexes is almost unexplored. 
In this section, the synthesis and characterization of unpublished Pd(0) olefin complexes stabilized 
by xanthine-based NHC ligands will be dealt with. The adopted synthetic approach is based on a 
previous work published by our research group [21]. This approach is based on the preliminary 
synthesis of Pd (0) olefin complexes stabilized by bidentate N-S ligands (2-methyl-6-
(methylthiophenyl)pyridine (Me-PyCH2SPh) and 2-methyl-8-methyltoquinoline (TMQ-Me)), using 
the complex Pd2(dba)3·CHCl3 as precursor. Instead of N-S, the ligands COD (cyclooctadiene) or t-
BuDAB (1,4-diterbutyl-1,4-diaza-1,3-butadiene) were used by other authors [22], but in these cases 
they were able to obtain only complexes stabilized by the strongly deactivated olefin maleic 
anhydride. 
At variance with the former derivatives, the complexes containing the Me-PyCH2SPh  and TMQ-Me 
ligands show a remarkable versatility as precursors since their stabilization and consequent easily 
manipulation is obtained with a number of different olefins [23]. Although not commercially 
available, the N-S ligands can be easily synthesized [24] and the corresponding pallada-olefin 
complexes suddenly obtained by reacting simultaneously the Pd2(dba)3·CHCl3, the Me-PyCH2SPh  
(or TMQ-Me) ligand and the wanted olefin (Scheme 3.19). 
  
 
Scheme 3.19 Synthesis of the Pd(0) olefin precursors.  
 
The distortion of the chelated ring induced by the steric interference of the methyl substituent in the 
pyridine or quinolinic moiety [21], renders these ligands labile and consequently their derivatives 
good starting complexes for successive synthesis. Among the olefins taken into consideration, only 
dimethylfumarate (dmfu) is unable to stabilize the complexes with the Me-PyCH2SPh  ligand. Dmfu 
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is indeed the most labile among the olefins used (Fig. 3.51) and therefore the potentially most able in 
promoting oxidative additions [25].  
 
Fig. 3.51 Stability order of the Pd-alkene bond related to the equilibrium constant in a process 
of olefin exchange [(L-L)Pd(2-olefin1)]+olefin2  [(L-L)Pd(2-olefin2)] + olefin1. 
The starting complex bearing dmfu as stabilizing olefin was therefore synthesized using TMQ-Me  
as ancillary ligand, since its ensuing derivative is stable.  
A further synthetic step can be obtained by the displacement of the labile N-S ligand from the (Me-
PyCH2SPh)Pd(2-olefin) or (TMQ-Me)Pd(2-dmfu) complexes by one bidentate or two monodentate 
ligands (Scheme 3.20). 
 
 
Scheme 3.20 Reactions of (NS)Pd(2-olefin) precursors with mono- or bi-dentate ligands. 
 
By means of the described synthetic approach, a number of biscarbene and mixed NHC/L (L = PPh3 
or AsPh3) complexes have been isolated. Preliminary tests have shown that is not possible to obtain 
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selectively the mixed NHC/DIC and NHC/PTA derivatives. In fact, a mixture of the wanted product 
and of the two species bis-DIC or bis-PTA is obtained. In Figure 3.52, one test carried out with PTA, 
among all those preliminarily explored, is reported as an example. 
 
 
Figure 3.52 1H-NMR spectrum of the reaction between the silver complex 5a, PTA and the 
Pd(Me-PyCH2SPh)(2-tmetc) precursor. 
 
It was decided to synthesize complexes bearing different spectator ligands and olefins in order to 
verify whether the cytotoxicity might be somehow traceable back to the Pd-olefin bond strength 
according to the coordinative capability trend reported in Figure 3.51. 
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3.7.1. Mixed NHC/PPh3 and NHC/AsPh3 complexes 
The mixed NHC/PPh3 and NHC/AsPh3 complexes were synthesized by adding a mixture containing 
triphenylphosphine (or triphenylarsine) and the silver carbene complex (5a-b or 5d) to a 
dichloromethane solution of the olefinic precursor of interest (Scheme 3.21). The reaction proceeds 
for about one hour and is characterized by the progressive precipitation of AgCl. After the filtration 
of the reaction mixture by a Millipore apparatus, the products were isolated by precipitation from a 
dichloromethane/diethylether mixture (16a, 17a, 18a, 20a, 21a and 22a) or obtained by the removal 
of the solvent (15a-b, 15d, 19a-b and 19d). 
 
 
Scheme 3.21 Synthesis of the mixed NHC/PPh3 and NHC/AsPh3 complexes 15-22. 
The obtained complexes were characterized by NMR and IR spectroscopy and the relevant responses 
are reported below. 
All the 1H-NMR spectra show the presence of the signals ascribable to the NCH3 (singlets at 3-4 ppm) 
and NCH2 groups (AB systems or singlets at 5-6 ppm) of the carbene moiety. 
The same  groups resonate in the 13C-NMR between 25 and 50 ppm, whereas the signal of the  
coordinated carbenic carbon is observed as a singlet for the mixed NHC/AsPh3 complexes and as a 
doublet, due to the coupling with phosphorus (JC-P ≈ 15 Hz), for the mixed NHC/PPh3 complexes, 
between 195 and 200 ppm. 
Moreover, for complexes containing PPh3, it is possible to observe a single peak at 25-30 ppm in the 
31P-NMR spectra (Fig. 3.53), shifted downfield of about 30-35 ppm with respect to the uncoordinated 
triphenylphosphine. 
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Fig. 3.53 31P{1H}-NMR spectrum of the complex 15d (T = 298K, CDCl3). 
Complexes with tmetc 
In the 1H-NMR spectra of the complexes 15a-b and 15d (Fig. 3.54) it is possible to observe four 
signals ascribable to the OCH3 groups of the coordinated tmetc between 3.1 and 3.7 ppm. This 
differentiation is due to the presence of two different ancillary ligands and to the hindered rotation of 
the asymmetric carbene about the C-Pd bond. 
 
Fig. 3.54 1H-NMR spectrum of the complex 15d (T = 298K, CDCl3). 
Moreover, in the 13C{1H}-NMR spectra (Fig. 3.55) of the complexes 15a-b and 15d it is possible to 
observe the signals ascribable to the OCH3 groups between 51 and 53 ppm and those related to the 
olefinic carbons between 60 and 65 ppm. These latter resonate as singlets in the case of  NHC/AsPh3 
complexes and as doublets (JC-P ≈ 38 Hz) in the case of the NHC/PPh3 derivatives. The highfield shift 
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of the olefinic carbons with respect to the uncoordinated olefin ( ≈ 80 ppm), is a direct consequence 
of its coordination on the palladium center and of the high degree of back-donation, particularly 
marked in the presence of strongly electron-withdrawing olefins. 
 
 
Fig. 3.55 13C{1H}-NMR spectrum of the complex 15d (T = 298K, CDCl3). 
Complexes with fumaronitrile 
The 1H-NMR spectra (Fig. 3.56) of complexes 16a and 20a are characterized by the following signals:  
• one doublet of doublets ascribable to the olefin proton pseudo-trans to the phosphine (JH-H = 
9.4 Hz and JH-P = 3.4 Hz) at about 2.9 ppm and one doublet ascribable to the olefin proton 
pseudo-trans to the carbene (JH-H = 9.4 Hz) at about 3 ppm, in the case of complex 16a. 
• Two doublets related to the different olefin protons between 2.8 and 3.2 ppm, for complex 
20a. 
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Fig. 3.56 1H-NMR spectrum of the complex 16a (T = 298K, CDCl3). 
The 13C{1H}-NMR spectra (Fig. 3.57) of complexes 16a and 20a are characterized by the following 
signals:  
• One doublet ascribable to the olefin carbon pseudo-trans to the carbene (JC-P = 3 Hz) at about 
22.5 ppm and a doublet ascribable to the olefin carbon pseudo-trans to the phosphine (JC-P = 
38 Hz) at 22.9 ppm, for complex 16a. 
• The signals of the coordinated olefin at about 38 ppm in the case of complex 20a. 
• The signals of the CN carbons at about 123 ppm. 
 
 
Fig. 3.57 13C{1H}-NMR spectrum of the complex 20a (T = 298K, CDCl3). 
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The IR spectra show the typical band of the coordinated fumaronitrile at 2191 cm-1 and the signals of 
the carbonyl groups within 1665 and 1710 cm-1. 
 
Complexes with maleic anhydride 
The 1H-NMR spectra (Fig. 3.58) of complexes 17a and 21a are characterized by the following signals: 
• One doublet of doublets ascribable to the olefin proton pseudo-trans to the carbene at about 4 
ppm (JH-H = 3.9 Hz and JH-P = 2.9 Hz) and one doublet of doublets related to those pseudo-
trans  to the phosphine at about 4.2 ppm (JH-H = 3.9 Hz and JH-P = 9.8 Hz), for complex 17a. 
• Two doublets related to the coordinated olefin protons between 3.5 and 4.6 ppm, in the case 
of complex 21a. 
 
 
Fig. 3.58 1H-NMR spectrum of the complex 21a (T = 298K, CDCl3). 
 
The 13C{1H}-NMR spectra (Fig. 3.59) show the following signals: 
• One singlet ascribable to the olefin carbon pseudo-trans to the carbene at 45.6 ppm and one 
doublet related to the olefin carbon pseudo-trans to the phosphine (JC-P = 27.8 Hz) at about 
47.5 ppm, for complex 17a. 
• The signals of the coordinated olefin carbons between 43 and 47 ppm, for complex 21a. 
• A doublet ascribable to the carbonyl carbon of maleic anhydride pseudo-trans to the carbene 
(JC-P = 2 Hz) and a doublet ascribable to those pseudo-trans to the phosphine (JC-P = 6 Hz) at 
about 172 ppm, for complex 17a.  
• The signals of the carbonyl carbons at about 173 ppm, for complex 21a. 
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Fig. 3.59 13C{1H}-NMR spectrum of the complex 17a (T = 298K, CDCl3). 
Complexes with dimethylfumarate 
The 1H-NMR spectra (Fig. 3.60) of the complexes 18a and 22a show the following signals: 
• One broad singlet and two singlets ascribable to the OCH3 groups of the coordinated dimethyl 
fumarate (3.2-3.6 ppm) for complexes 18a and 22a, respectively. 
• One doublet of doublets ascribable to the olefin proton pseudo-trans to the carbene at about 
4.1 ppm (JH-H = 9.5 Hz) and one doublet of doublets for those pseudo-trans to the phosphine 
at about 4 ppm (JH-H = 9.5 Hz and JH-P = 2.6 Hz), for complex 18a. 
• Two singlets between 4 and 4.2 ppm related to the olefinic protons in the case of complex 
22a. 
 
Fig. 3.60 1H-NMR spectrum of the complex 18a (T = 298K, CDCl3). 
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The 13C{1H}-NMR spectra show two peaks at about 38 ppm ascribable to the OCH3 groups and the 
signals of the olefinic carbons between 45 and 48 ppm. 
 
3.7.2. Bis(NHC) complexes 
The Pd (0) biscarbene compounds were obtained by transmetallation between the Ag (I) complexes 
5a-b or 5d and the [(Me-PyCH2SPh)Pd(2-olefin)] precursor, according to the Scheme 3.22. 
 
Scheme 3.22 Synthesis of the biscarbene complexes 23-24. 
It was possible to obtain in good yields and purity the complexes with tetramethylethene-1,1,2,2-
tetracarboxylate (tmetc) (23a-b and 23d) and fumaronitrile (fn) (24a), only. The preliminary tests 
carried out with the maleic anhydride and dimethylfumarate have highlighted the formation of 
mixtures of products of difficult identification.  
All the 1H-NMR spectra show the presence of the signals ascribable to the NCH3 (singlets at 3-4 ppm) 
and NCH2 (singlets at 5-6 ppm) groups of the carbene moiety. 
The signals related to these groups are observed in the 13C-NMR between 25 and 50 ppm, whereas 
the signal of the coordinated carbenic carbon resonates as a singlet between 195 and 200 ppm. 
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Complexes with tmetc  
The 1H-NMR spectra (Fig. 3.61) of the complexes 23a-b and 23d show a singlet ascribable to the 
OCH3 groups of the coordinated olefin at about 3.6 ppm. 
 
Fig. 3.61 1H-NMR spectrum of the complex 23b (T = 298K, CDCl3). 
The 13C{1H}-NMR spectra (Fig. 3.62) of the complexes 23a-b and 23d show: 
• Signals related to the coordinated olefinic carbons at about 58 ppm. 
• Signals of the four OCH3 groups of the coordinated tmetc at about 52 ppm. 
• Signals ascribable to the carbonyl carbons at about 171 ppm. 
 
Fig. 3.62 13C{1H}-NMR spectrum of the complex 23b (T = 298K, CDCl3).  
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Complex with fumaronitrile 
The 1H-NMR spectrum of complex 24a (Fig. 3.63) shows a singlet ascribable to the olefinic protons 
of the coordinated fumaronitrile at about 2.6 ppm. 
 
 
Fig. 3.63 1H-NMR spectrum of the complex 24a (T = 298K, CDCl3). 
 
The 13C{1H}-NMR spectrum of complex 24a (Fig. 3.64) shows the signals related to the olefinic 
carbons and to the CN groups at 16 and 125 ppm, respectively. 
 
 
Fig. 3.64 13C{1H}-NMR spectrum of the complex 24a (T = 298K, CDCl3). 
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3.7.3. Bis(PTA) complexes 
Due to the capability of PTA of increasing the solubility in water of its complexes and the cytoxicity 
of many its derivatives toward several tumor lines [26], we decided to synthesize compounds 
containing two PTA fragments. This choice was also supported by the fact that in the literature no 
Pd(0) olefin complexes bearing this spectator ligand are reported. 
The synthesis of the bis-PTA complexes (Scheme 3.23) was carried out in dichloromethane by 
reacting the olefinic precursor [Pd(Me-PyCH2SPh)(2-olefin)] (olefin = maleic anhydride, 
fumaronitrile, tetracarboxymethylethylene) or [Pd (TMQ-Me)(2-dmfu)] and two equivalents of 
PTA.  
 
Scheme 3.23 Synthesis of the bis(PTA) complexes 25-28. 
 
The compounds were precipitated by addition of diethyl ether to the concentrated solutions and 
characterized by NMR and IR spectroscopy. 
The 1H-NMR spectra show for the PTA ligand the following signals: 
• One AB system (J = 10-15 Hz) ascribable to the NCH2P protons at about 4.1 ppm. 
• One AB system (J = 13-20 Hz) ascribable to the NCH2N protons at about 4.5 ppm. 
The signals of the olefinic protons are reported below: 
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• Tmetc: one singlet for the OCH3 groups at about 3.6 ppm. 
• Maleic anhydride: one singlet at about 4.2 ppm. 
• Fumaronitrile: one singlet at about 3 ppm. 
• Dimethylfumarate: one singlet related to the OCH3 protons at about 3.6 ppm.  
The 1H-NMR spectrum of compound 25 is reported in the following figure. 
 
 
Fig. 3.65 1H-NMR spectrum of the complex 25 (T = 298K, CDCl3). 
Depending on the coordinated olefin, the 31P{1H}-NMR spectra (Fig. 3.66) show one singlet between 
-61 and -64 ppm ( ≈ 50 ppm downfield of the uncoordinated PTA). 
 
Figure 3.66 31P{1H}-NMR spectrum of the complex 25 (T = 298K, CDCl3). 
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The 13C{1H}-NMR spectra show for the PTA ligand one doublet ascribable to the NCH2P system at 
53-54 ppm (JC-P = 8-9 Hz) and one doublet related to the NCH2N system at 73-74 ppm (JC-P = 6-7 
Hz). 
The signals of the olefin carbons are listed below: 
• Tmetc: one singlet for the OCH3 groups at 52 ppm, the signal of the olefinic carbons at 67 
ppm and that of the carbonyl carbons at 168 ppm. 
• Maleic anhydride: the signal of the olefin and carbonyl carbons at 51 and 171 ppm, 
respectively. 
• Fumaronitrile: the signal of the olefinic carbons and of the CN groups at 27 and 121 ppm, 
respectively. 
• Dimethylfumarate: signals of the olefinic carbons and of the carbonyl groups at 52 and 173 
ppm, respectively. 
 
As an example, the 13C{1H}-NMR spectrum of compound 25 is shown in the following figure. 
 
 
Fig. 3.67 13C{1H}-NMR spectrum of the complex 25 (T = 298K, CDCl3). 
In the case of the complex 26 it was possible to solve the crystal structure by means of the X-ray 
diffraction of the single crystal (Figure 3.68). 
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Fig. 3.68 Ellipsoid representation of 26 crystal ASU contents (50% probability). 
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3.8. Antiproliferative and proapoptotic analysis 
The cytotoxic activity of the Pd (0) and Pd (II) complexes containing purine-based NHC ligands 
toward human ovarian cancer cell lines, in collaboration with the molecular biology group of the 
University of Ferrara (coordinator: Prof. Roberto Gambari), has been evaluated. 
In particular, the following tumour lines were examined: 
• A2780 
• A2780-R 
• SKOV-3 
A2780 cells derive from a patient who has not undergone any therapy. These cells grow in adhesion 
to form a monolayer and from which, through chronic exposure to increasing amounts of cisplatin, 
the A2780-R line were obtained. A2780-R cells show also resistance to irradiation, melphalan 
(alkylating agent) and adriamycin (antineoplastic antibiotic) [27]. 
SKOV-3 line represents ovarian carcinoma cells growing in adhesion, extracted from the ascitic fluid 
of a 64-year-old Caucasian patient [27].  
The results of the antiproliferative and proapoptotic activity will be presented below, considering the 
different class of organometallic compounds. 
3.8.1. Activity of Pd (II) 3-allyl complexes bearing purine-based NHCs toward ovarian cancer 
cell lines 
With regard to the 3-allyl complexes (compounds 6-10), the antiproliferative activity was tested on 
A2780 (cisplatin-sensitive) and SKOV-3 (cisplatin-resistant) tumor lines. Stock solutions of each 
compound (25-50 mM) were prepared in DMSO; the working solutions were produced by diluition 
of the stock solution with water.  
Preliminarily, the stability of our complexes was checked in 1:1 dmso-d6/D2O solution (6, 9 and 10) 
or D2O (7 and 8): after 48 hours at room temperature no degradation and no ligand replacement was 
observed.  
In addition to the complexes of interest, also the antiproliferative activities of the [Pd(-Cl)(3-allyl)]2 
precursor, the imidazolium salts 2a-d and cisplatin were evaluated. The latter is nowadays used as a 
reference both to detect any anomalies in the analysis protocols (positive control) and to compare the 
activity of the tested compounds. The antiproliferative activity data are reported in Table 3.1 
expressed as IC50 (concentration of the complex that leads to the death of 50% of the cells inserted in 
the culture medium), with the exception of imidazolium salts 2a-d which were substantially inactive 
in both the lines (IC50> 100 M). 
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COMPLEX 
IC50 (M) 
A2780 SKOV-3 
Cisplatin 1.5 ± 0.2 5.94 ± 0.08 
[Pd(-Cl)(3-C3H5)]2 7.8 ± 0.2 10 ± 4 
6a 5 ± 2 5 ± 1 
6b 4 ± 2 3 ± 1 
6c 0.09 ± 0.02 4.02 ± 0.09 
6d 0.81 ± 0.08 1.7 ± 0.9 
7a 82 ± 9 66 ± 13 
7b 7 ± 1 40 ± 2 
7d 9.2 ± 0.8 57 ± 8 
8a 7 ± 2 5.20 ± 0.08 
8b 7.60 ± 0.07 6.5 ± 0.7 
8d 0.9 ± 0.2 50.5 ± 0.5 
9a 5 ± 2 4.0 ± 0.7 
9b 3.72 ± 0.06 5 ± 1 
9d 5 ± 1 3 ± 1 
10a 7 ± 2 7.7 ± 0.4 
10b 4 ± 1 61 ± 7 
10c 3.8 ± 0.5 60 ± 6 
10d 6.4 ± 0.7 39 ± 6 
 
Table 3.1 Effects of the Pd(II) allyl complexes on the proliferation of A2780 and SKOV-3 cells 
(72h). The inhibition of cell growth is represented as IC50. 
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Fig. 3.77 Pd(II) allyl complexes with IC50<10 M on A2780 cell line. 
 
 
Fig. 3.78 Pd(II) allyl complexes with IC50<8 M on SKOV-3 cell line. 
 
All of the assayed complexes, except for 7a, showed good antiproliferative activity on the cisplatin-
sensitive A2780 cell line. Compounds 6c-d (mixed NHC/PPh3) and 8d (mixed NHC/PTA) are more 
active than cisplatin showing 0.09 ± 0.02, 0.81 ± 0.08 and 0.9 ± 0.2 M IC50 values, respectively.  
As for the cisplatin-resistance SKOV-3 cells, the IC50 values are comparable to cisplatin one (IC50 = 
5.94 ± 0.08 M) or higher, as in the case of complexes 7a, 7b, 7d, 8d, 10b, 10c and 10d which have 
average values between 38 and 66 M. The mixed NHC/PPh3 complexes 6a-d are the most 
performing also in this tumour line, with average IC50 values ranging from 1.7 to 5 M (similar or 
better than cisplatin).  
Biscarbene (10a-d) and mixed NHC/TPPTS (7a-b and 7d) complexes are instead the species less 
active. 
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To test the selectivity of Pd-compounds versus cancer cells, normal human fibroblasts (MRC-5) were 
treated with four different complexes (6d, 8d, 9b and 10a)  representative of different subclasses with 
high activity on cancer cells. As shown in Table 3.2, the compounds are almost inactive on fibroblasts, 
suggesting a preferential activity on cancer cells. In particular, the compound 6d is more active than 
8d, 9b and 10a on A2780 and SKOV-3 cancer cell lines but with an IC50 > 100 M on fibroblasts. 
 
Complex IC50 (M) 
Cisplatin 14 ± 1 
6d >100 
8d 22 ± 6 
9b 17 ± 1 
10a >100 
Table 3.2 Effects of the Pd(II) allyl complexes on the proliferation of MRC-5 cells (72h). The 
inhibition of cell growth is represented as IC50. 
 
Pro-apoptotic effect  
To verify if the antiproliferative activity exerted by our complexes is associated with an apoptotic 
process, the proapoptotic effect was assessed for both the cell lines (A2780 and SKOV-3), using the 
Muse cytometer (Merck Millipore, Billerica, MA, USA) and the Muse® Annexin V and Dead Cell 
Assay Kit. 
The marker used is the Annexin V-PE, which allows to exploit on the one hand the ability of Annexin 
to bind to phosphatidylserine (a phospholipid exposed outside the cell membrane during apoptosis) 
and on the other the luminescent properties of PE (phycoerythrin) to identify cells. The use of 
Annexin V-PE in combination with the 7AAD cell death marker (7 aminoactinomycin D) allows to 
distinguish cells in early or late apoptosis from those dead by necrosis. 
The two concentrations used for each complex were close to the previously determined IC50 value. 
In Table 3.3, the percentage of total apoptosis was reported and each data was compared to the 
analysis of untreated cells (negative control, C-), in which the observed total apoptosis was less than 
5%.  
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Complex 
Total apoptosis 
(%) 
Dead cells 
(%) 
Total apoptosis 
(%) 
Dead cells (%) 
A2780 A2780 SKOV-3 SKOV-3 
C- 2.61 1.96 5.30 0.50 
Cisplatin 38.25 (2.5 M) 3.30 (2.5 M) 13.33 (5 M) 1.17 (5 M) 
[Pd(-Cl)(3-
C3H5)]2 
8.15 (1 M) 
29.40 (10 M) 
2.00 (1 M) 
1.00 (10 M) 
6.55 (1 M) 
7.10 (10 M) 
0.55 (1 M) 
2.20 (10 M) 
6a 
3.80 (1 M) 
12.35 (10 M) 
0.30 (1 M) 
0.25 (10 M) 
6.35 (1 M) 
12.71 (10 M) 
5.35 (1 M) 
4.86 (10 M) 
6b 
8.35 (1 M) 
10.66 (10 M) 
0.50 (1 M) 
0.33 (10 M) 
7.25 (1 M) 
44.31 (10 M) 
8.05 (1 M) 
1.12 (10 M) 
6c 
54.04 (0.1 M) 
98.35 (1 M) 
0.25 (0.1 M) 
0.24 (1 M) 
43.78 (1 M) 
84.04 (10 M) 
15.83 (0.1 M) 
3.16 (1 M) 
6d 
2.25 (1 M) 
21.00 (10 M) 
7.62 (1 M) 
1.45 (10 M) 
6.50 (0.5 M) 
52.35 (5 M) 
3.70 (1 M) 
0.57 (10 M) 
7a 
3.20 (50 M) 
2.21 (100 M) 
2.10 (50 M) 
1.31 (100 M) 
12.55 (50 M) 
44.96 (100 M) 
0.36 (50 M) 
0.29 (100 M) 
7b 
2.66 (1 M) 
1.60 (10 M) 
2.26 (1 M) 
1.30 (10 M) 
11.25 (25 M) 
53.01 (50 M) 
0.15 (1 M) 
0.25 (10 M) 
7d 
2.97 (1 M) 
5.65 (10 M) 
0.86 (1 M) 
0.96 (10 M) 
8.73 (50 M) 
36.37 (100 M) 
0.51 (1 M) 
0.34 (10 M) 
8a 
3.00 (1 M) 
15.25 (10 M) 
0.30 (1 M) 
0.00 (10 M) 
2.45 (1 M) 
3.10 (10 M) 
0.10 (1 M) 
0.65 (10 M) 
8b 
4.25 (1 M) 
7.05 (10 M) 
0.80 (1 M) 
0.15 (10 M) 
3.00 (1 M) 
3.65 (10 M) 
0.45 (1 M) 
0.65 (10 M) 
8d 
5.49 (1 M) 
5.76 (10 M) 
2.32 (1 M) 
1.43 (10 M) 
9.82 (50 M) 
27.49 (100 M) 
3.06 (1 M) 
1.71 (10 M) 
9a 
9.50 (1 M) 
9.20 (10 M) 
0.60 (1 M) 
0.15 (10 M) 
15.05 (1 M) 
34.55 (10 M) 
0.60 (1 M) 
0.15 (10 M) 
9b 
26.52 (1 M) 
61.18 (10 M) 
0.59 (1 M) 
0.18 (10 M) 
6.26 (1 M) 
69.10 (10 M) 
0.59 (1 M) 
0.18 (10 M) 
9d 
1.40 (1 M) 
79.45 (10 M) 
8.92 (1 M) 
0.34 (10 M) 
3.45 (1 M) 
52.95 (10 M) 
0.90 (1 M) 
0.15 (10 M) 
10a 
2.65 (1 M) 
3.50 (10 M) 
0.20 (1 M) 
0.25 (10 M) 
3.65 (1 M) 
30.89 (10 M) 
0.35 (1 M) 
0.46 (10 M) 
10b 
5.69 (1 M) 
43.03 (10 M) 
1.86 (1 M) 
0.34 (10 M) 
6.32 (50 M) 
56.60 (100 M) 
0.41 (1 M) 
0.44 (10 M) 
10c 
1.39 (1 M) 
23.66 (10 M) 
7.28 (1 M) 
3.09 (10 M) 
7.84 (50 M) 
52.01 (100 M) 
0.39 (1 M) 
0.38 (10 M) 
10d 
5.90 (1 M) 
61.17 (10 M) 
0.56 (1 M) 
0.00 (10 M) 
12.74 (25 M) 
79.32 (50 M) 
1.29 (1 M) 
3.18 (10 M) 
Table 3.3 Pro-apoptotic effects of the Pd-complexes on A2780 and SKOV-3 cell lines detected at 
two different concentrations. (C-: untreated cells). 
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The compounds that showed the highest pro-apoptotic activity on the A2780 cell line are 6c-d, 9b, 
9d and 10b-d, with a total pro-apoptotic effect between 21% (6d) and 98% (6c). Furthermore, 
compound 6c shows the greatest total pro-apoptotic activity even with the lowest tested concentration 
(0.1 M, total apoptosis = 54%). The remaining compounds are moderately active in inducing the 
apoptosis process. 
With regard to the SKOV-3 line (CisPt resistant), compounds 6b-d, 7a-b, 7d, 8d, 9a-b, 9d and 10a-
d were found to be particularly active, with a total pro-apoptotic effect between 28% (8d) and 84% 
(6c). As for the A2780 line, compound 6c is very active even at the lowest tested concentration (1 
M, total apoptosis = 44%). 
The proportion of dead cells, also reported in Table 3.3, suggest that apoptotic effects and 
antiproliferative activity are not associated with major cytotoxicity. 
 
 
Fig. 3.79 Representative apoptosis profile of A280 cells untreated (C-), treated with cisplatin (C+) 
and with complexes 6c, 9d and 10b (1-10 M) for 72 h.  
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Fig. 3.80 Representative apoptosis profile of SKOV-3 cells untreated (C-), treated with cisplatin (C+) 
and with complexes 6c, 9d and 10b (1-10 M) for 72 h. 
 
From the analysis of antiproliferative data, we can therefore conclude that the 3-allyl complexes 
display a good activity against A2780 and SKOV-3 ovarian cancer cell lines. In particular, the species 
coordinating a purine-based NHC ligand and PPh3 (mixed NHC/PPh3 complexes) are the most active. 
Moreover the most active compounds on cancer cells are almost inactive on normal cells, suggesting a 
marked cancer selectivity.  
Finally, it was proved that the antiproliferative activity of many of the synthesized complexes is 
associated with induction of apoptosis.  
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3.8.2. Activity of palladacyclopentadienyl complexes bearing purine-based NHCs toward 
ovarian cancer cell lines 
The antiproliferative activity of the palladacyclopentadienyl complexes (compounds 11-14) was 
tested on A2780 (cisplatin-sensitive) and A2780-R (cisplatin-resistant) tumour lines. A stock solution 
in DMSO (50 mM) was prepared for each compound and the working solutions were obtained by 
diluting the stock solution with ethanol. All complexes are stable for at least 48 hours at room 
temperature in dmso-d6. The antiproliferative activity data are reported in Table 3.4 , in which is also 
apparent the low activity of the [PdC4(COOCH3)4]n precursor in both the lines (IC50 > 100 M). 
 
COMPLEX 
IC50 (M) 
A2780 A2780-R 
Cisplatin 0.6 ± 0.1 6 ± 1 
[PdC4(COOCH3)4]n >100 >100 
11a 5.3 ± 0.7 6.7 ± 0.8 
11b 5.0 ± 0.2 5.25 ± 0.05 
11d 6.66 ± 0.03 16 ± 1 
12a 4.3 ± 0.7 0.6 ± 0.2 
12b 0.9 ± 0.1 1.0 ± 0.3 
12d 0.56 ± 0.08 0.64 ± 0.07 
13a 3.3 ± 0.6 2.1 ± 0.4 
13b 1.6 ± 0.3 1.8 ± 0.9 
13d 0.70 ± 0.05 0.87 ± 0.09 
14a 9.0 ± 0.7 9.0 ± 0.7 
14b 6.5 ± 0.5 6.5 ± 0.5 
14d 81 ± 4 81 ± 4 
 
Table 3.4 Effects of the palladacyclopentadienyl complexes on the proliferation of A2780 and 
A2780-R cells (72h). The inhibition of cell growth is represented as IC50. 
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Fig. 3.81 Palladacyclopentadienyl complexes with IC50<10 M on A2780 cell line. 
 
Fig. 3.82 Palladacyclopentadienyl complexes with IC50<8 M on A2780-R cell line. 
To test the selectivity of the palladacyclopentadienyl complexes versus cancer cells, normal human 
fibroblasts (MRC-5) were treated with two different complexes (11b and 12d). As shown in Table 
3.5, the compounds are poorly active (11b) or inactive (12d) on fibroblasts, suggesting a preferential 
activity on cancer cells.  
Complex IC50 (M) 
Cisplatin 14 ± 1 
11b 30 ± 15 
12d >100 
Table 3.5 Effects of the palladacyclopentadienyl complexes on the proliferation of MRC-5 cells. 
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With regard to the proapoptotic effect for some representative compounds (11b, 12d, 13d and 14b) 
the percentage of total apoptosis was reported in Table 3.6.  
 
COMPLEX 
Total apoptosis (%) 
A2780 A2780-R 
C- 6.0 11.3 
Cisplatin 
19.5 (0.6 M) 
16.9 (1.2 M) 
48.1 (6 M) 
68.0 (12 M) 
11b 
97.3 (5 M) 
95.8 (7.5 M) 
91.0 (5 M) 
92.0 (8 M) 
12d 
53.2 (0.6 M) 
87.2 (0.8 M) 
34.8 (0.6 M) 
52.3 (0.9 M) 
13d 
8.8 (0.7 M) 
19.25 (1 M) 
17.4 (0.9 M) 
15.4 (1.3 M) 
14b 
96.0 (6.5 M) 
95.8 (9 M) 
14.6 (5.5 M) 
23.7 (8.5 M) 
Table 3.6 Pro-apoptotic effects of palladacyclopentadienyl complexes (C-: untreated cells). 
 
The analysis of data shows that compounds 11b, 12d and 14b have an excellent pro-apoptotic activity 
at concentrations between 0.8 and 6.5 M on the A2780 line. In particular, the total apoptosis (early 
and late) stands at between 87 and 97%. Furthermore, compound 12d shows the greatest total pro-
apoptotic activity even with the lowest tested concentration (0.6 M, total apoptosis = 53%). 
In the case of the A2780-R cell line, complexes 11b and 12d are those with the greater percentages 
of total apoptosis; however, the value between 52 and 92% is smaller than that found for the cisplatin-
sensitive line. 
On the basis of the above results the following considerations can be proposed: 
1. The compounds with the best antiproliferative activity are the mixed NHC/DIC and 
NHC/PTA complexes. The latter compounds are particularly interesting since the only soluble 
in water among those texted. The less active complexes are the biscarbene derivatives. In 
detail, it was possible to observe the following activity trend: 
NHC/PTA, NHC/DIC > NHC/PPh3> Bis(NHC)  
2. For the same spectator ligand (PPh3, DIC or PTA), there is no general trend that correlates 
antiproliferative activity with the type of N-substituents present in the carbenic fragment. 
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3. For the same compound, the IC50 values regarding the two different cell lines are in many 
cases comparable. This fact seems to indicate that the mechanism of action of the 
palladacyclopentadienyl complexes might be different from that proposed for cisplatin.  
4. With regard to the cisplatin-sensitive A2780 cell line, compounds 12b and 12d (NHC/PTA) 
and 13d (NHC/DIC) have IC50 values comparable to cisplatin. 
5. As for the cisplatin-resistance A2780-R line, there are four compounds (11a-b and 14a-b) that 
have activity comparable to cisplatin and six (12a-b, 12d, 13a-b and 13d) which are more 
active. These values are very interesting if compared with the most active Pd complexes 
reported in the literature [28]. 
6. It was proved that the antiproliferative activity of many of the synthesized complexes is 
associated with induction of apoptosis.  
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3.8.3. Activity of Pd(0) olefin complexes with purine-based NHCs toward ovarian cancer lines 
The antiproliferative activity of Pd(0) olefin compounds was tested on A2780 (cisplatin-sensitive) 
and A2780-R (cisplatin-resistant) tumour lines. A stock solution in DMSO (50 mM) was prepared 
for each compound and the working solutions were obtained by diluting the stock solution with 
ethanol (complexes 15-24) or water (bis-PTA complexes 25-28).  
The stability of complexes was preliminarily checked in D2O (25-28) or dmso-d6 (15-24): after 48 
hours at room temperature no degradation and no ligand replacement was observed. The 
antiproliferative activity data are reported in Table 3.7, expressed as IC50. 
Complex 
IC50 (M) 
A2780 A2780-R 
Cisplatin 0.6 ± 0.1 6 ± 1 
15a 8 ± 3 34 ± 2 
15b 5.4 ± 0.8 5.4 ± 0.1 
15d 4.8 ± 0.7 6.1 ± 0.5 
16a 4.7 ± 0.4 4.7 ± 0.3 
17a 0.8 ± 0.2 4.8 ± 0.2 
19a 6.3 ± 0.8 48.4 ± 0.6 
19b 5.0 ± 0.7 38.7 ± 0.9 
19d 4.4 ± 0.9 6.7 ± 0.3 
20a 5.5 ± 0.2 3.8 ± 0.7 
21a 37 ± 3 23.9 ± 0.3 
23a 6.7 ± 0.2 51.3 ± 0.4 
23b 10 ± 0.2 49.4 ± 0.7 
23d 5.7 ± 0.4 43.9 ± 0.9 
24a 4.7 ± 0.6 1.1 ± 0.1 
25 31 ± 1 0.8 ± 0.2 
26 2.9 ± 0.5 5.4 ± 0.5 
27 31 ± 1 8.7 ± 0.1 
Table 3.7 Effects of Pd(0) olefin complexes on the proliferation of A2780 and A2780-R cells (72h). 
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Fig. 3.83 Pd(0) olefin complexes with IC50<6 M on A2780 cell line. 
 
 
Fig. 3.84 Pd(0) olefin complexes with IC50<8 M on A2780-R cell line. 
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From the analysis of IC50 values, we can propose the following general considerations: 
1. The compounds having a carbene and a triphenylphosphine ligand (mixed NHC/PPh3 
complexes) show the best antiproliferative activity on both cell lines. A similar result has been 
obtained with the Pd (II) allyl complexes (see paragraph 3.8.1). 
2. As for the A2780 line (cisPt sensitive) only one complex (17a) shows activity comparable to 
that of cisplatin, while for A2780-R line, the number of compounds able to equal its 
performance is higher (15b, 15d, 16a, 17a, 19d, 20a and 26); two of the synthesized 
complexes (24a and 25) are definitely better than cisplatin. The results of compound 25 appear 
particularly interesting for the water-solubility of the complex, an important feature for a  
potential biomedical agent. 
3. With regard to the A2780 line, the change of the cordinated olefin in complexes with the same 
spectator ligands does not influence the activity of the complex. Likewise, maintaining the 
same type of olefin (tmetc) and changing the type of carbene ligand, there are no substantial 
differences in terms of activity. 
4. With regard to the A2780-R line, for the same spectator ligands, the most efficient complexs 
are those coordinating fumaronitrile and maleic anhydride. On the other hand, complexes with 
tmetc are poorly active, with the sole exception of the bis-PTA complex. 
5. Comparing the IC50 values obtained in the two different lines, we can observe that compounds 
coordinating the fumaronitrile maintain their antiproliferative activity. A similar trend is 
found in the complexes with maleic anhydride. The analogous complexes with tmetc, except 
for 15b, 15d and 19d, instead reduce their activity passing from the cisplatin-sensitive line to 
the resistant one. 
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Pro-apoptotic effect  
In Table 3.8 the percentage of total apoptosis was reported for some representative compounds (15b, 
16a, 17a, 20a, 24a, 25 and 26) and each data was compared to the analysis of untreated cells (negative 
control, C-), in which the observed total apoptosis was less than 5%. 
 
COMPLEX 
Total apoptosis (%) 
A2780 A2780-R 
C- 3.7 10.9 
Cisplatin 
19.5 (0.6 M) 
16.9 (1.2 M) 
48.1 (6 M) 
68.0 (12 M) 
15b 
4.4 (6 M) 
6.7 (9 M) 
8.3 (5 M) 
10.0 (9 M) 
16a 
41.8 (5 M) 
88.2 (8 M) 
13.7 (5 M) 
35.3 (8 M) 
17a 
6.9 (0.8 M) 
10.0 (1.2 M) 
15.2 (5 M) 
22.5 (8 M) 
20a 
7.7 (6 M) 
14.8 (10 M) 
23.6 (4 M) 
13.2 (8 M) 
24a 
64.4 (5 M) 
98.8 (8 M) 
48.1 (6 M) 
68.0 (12 M) 
25 
7.2 (30 M) 
58.8 (70 M) 
10.8 (0.9 M) 
14.0 (1.4 M) 
26 
6.8 (3 M) 
62.9 (7 M) 
23.2 (3 M) 
33.8 (8 M) 
Table 3.8 Pro-apoptotic effects of Pd(0) olefin complexes (C-: untreated cells) 
 
The analysis of the results obtained for the A2780 line shows that compounds 16a, 24a and 26 have 
a good pro-apoptotic activity at concentrations between 5 and 8 M. In particular, the total apoptosis 
(early and late) remains between 63% and 99%.  
Also in the case of the A2780-R cell line, complexes 16a, 24a and 26 are those with the greater 
percentages of total apoptosis; however, the value between 30 and 35% is smaller than that found for 
the cisplatin-sensitive line. 
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3.9. Conclusions 
In this chapter we have presented the synthesis and characterization of palladium 3-allyl, 2-olefin 
and palladacyclopentadienyl complexes containing purine-based NHC ligands. These complexes, 
which are stable both in the solid state and in solution, were tested toward ovarian cancer cell lines 
both cisplatin-sensitive and cisplatin-resistant. The results of the antiproliferative activity have 
highlighted that 3-allyl palladium and palladacyclopentadienyl complexes are generally more active 
than 2-olefn palladium (0) derivatives. Among the most active species, 3-allyl complexes 
containing a NHC ligand and a triphenylphosphine and mixed NHC/PTA palladacyclopentadienyl 
compounds are especially promising. In fact, they display an excellent antiproliferative activity on 
the ovarian cancer lines and, at the same time, they are almost inactive on normal cells.  
Moreover, the analysis of the proapoptotic activity showed that the most active complexes are able 
to promote programmed cell death (apoptosis). This process, unlike necrosis, is preferred because the 
system can recycle the cellular material avoiding or reducing inflammatory processes.  
Encouraged by the results regarding the compounds with purine-based NHCs, we decided to extend 
our study also to 3-allyl-palladium and palladacyclopentadienyl complexes stabilized by other types 
of NHCs. The synthesis of these classes of compounds and their biological activity will be presented 
in the successive chapters. 
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 Pd complexes with “Classical” 
NHCs and Bridged BisNHCs  
       
 
In this chapter the synthesis and evaluation of the antitumor activity of complexes bearing imidazole 
derived NHC ligands and 3-allyl-Pd(II) or palladacyclopentadienyl organometallic fragments will 
be examined. As already stated, these classes of compounds, seem to be more promising than the Pd 
(0) olefin derivatives. In addition to the results related to their synthesis and biological activity, some 
connected kinetic and thermodynamic aspects will be discussed in detail.  
Their anticancer activity has been evaluated not only against ovarian carcinoma lines but also toward 
lung, colon cancer and malignant melanoma lines. Moreover, a possible correlation between their 
antiproliferative activity and structure will be hypothesized. 
Finally, the activity of the examined complexes toward healthy cell (fibroblasts) and some tests aimed 
at identifying the main bio-target and the probable mechanism of action of some particularly 
promising compounds, will be discussed. 
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4.1. Introduction 
As mentioned in paragraph 1.4, the most common ("classical") N-Heterocyclic Carbene ligands are 
obtained by functionalization of imidazole (Fig. 4.1). 
 
 
Fig. 4.1 General structure of NHC derived from the imidazole ring. 
It was also emphasized that the bulkiness of such ligands can be easily modified by the steric demand 
of the substituents R whereas their electronic characteristics are of difficult modulation, since R 
substituents are not directly linked to the carbenic carbon and summing up NHCs act basically as 
strong -donor ligands. However, the versatility of these ligands can be increased by the inclusion of 
R substituents bearing another coordinating function. Thus, the presence of one or more additional 
donor atoms renders these species potentially bi- or poly-dentate ligands. Moreover, from another 
point of view, additional donor atoms may act as free Lewis bases and interact with sites present in 
the biological environment. 
In this chapter, the classical alkyl and aryl imidazoles together with the NHC ligands characterized 
by thioethers (C-S ligands) or pyridine (C-N ligands) residue will be described (Fig. 4.2). 
 
Fig. 4.2 Structure of NHC and hemi-labile NHC-pyridine or NHC-thioether ligands. 
 
As a part of the whole work, the synthesis of complexes with bidentate biscarbene ligands will be 
dealt with (Fig. 4.3). In this respect, it is important to know that the nature of the bridging group Y is 
a crucial element in determining the coordination mode (chelate vs. bridging).  
Generally speaking, these compounds are good -donor ligands and moreover, thanks to the chelating 
effect, they bind very strongly the metal center.  
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Fig. 4.3 Structure of bidentate bisNHCs. 
 
In this regard, many examples of palladium and other transition metals derivatives stabilized by this 
class of ligands are well known [1]. The catalytic activity [2] and the optical properties (i.e. 
photoluminescence) of these species [3] have been extensively explored, whereas their biological 
activity has been remarkably less studied [4]. As an example, some compounds present in the 
literature and their applications are reported in Fig. 4.4. 
 
 
Fig. 4.4 Structure of bidentate bisNHC complexes with catalytic and optical proprieties [131-133]. 
 
In the following paragraphs the multi-step synthesis of complexes bearing imidazole derivatives will 
be discussed. 
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4.2. Synthesis of the imidazolium and bisimidazolium salts  
The imidazolium salts used as precursors of the NHC ligands described in this chapter can be divided 
into four categories (Fig. 4.5).  
 
 
Fig. 4.5 
 
The synthesis of compounds with one imidazole ring, apart from the commercially available IMesHCl 
(compound 31b), was carried out by reacting an imidazole derivative (Me-Imidazole, Mes-Imidazole 
[5] or TolCH2-Imidazole [6]) with a suitable alkylating agent (alkyl chlorides or bromides), under the 
experimental conditions shown in Scheme 4.1 [7]. 
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Scheme 4.1 
The bis-imidazolium salts (34a-d) were prepared starting from Methyl-Imidazole, Benzyl-Imidazole 
or Mesityl-Imidazole by reaction with dibromo-methane or dibromo-ethane as reported by Lee and 
co-workers, according to the Scheme 4.2 [8]. 
 
Scheme 4.2 
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4.3. Synthesis of the silver-NHC complexes 
The synthesis of the silver complexes bearing only one imidazole unit, was carried out according to 
the protocols reported in the literature [7d-e], by reacting the imidazolium salts 29a-b, 30a-d and 
31a-d with 0.5 equivalents of silver oxide under the experimental conditions shown in Scheme 4.3. 
 
 
Scheme 4.3 
 
The reaction progress is evidenced by the progressive dissolution of the silver oxide. From the 1H-
NMR spectra of the isolated complexes, it is possible to observe the disappearance of the peak at ca. 
9-11 ppm related to the NCHN proton (Fig. 4.6) whereas, in the 13C-NMR spectra, the appearance of 
the signal of the coordinated carbenic carbon at about 170-190 ppm, is detected. 
 
Fig. 4.6 1H-NMR spectra of the silver complex 37a and the imidazolium salt 31a (T=298K, CDCl3). 
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The synthesis of the complexes with two imidazole units (bidentate bisNHC silver complexes), was 
carried out following the protocol reported by Slaughter and Chen [9]. Thus, the bisimidazolium salts 
34a-f were  reacted with 1 equivalent of Ag2O in methanol, in the case of the compounds with the 
methyl or benzyl residue, or in dichloromethane for compounds with the mesityl as wingtip 
substituent (Scheme 4.4.). 
 
 
Scheme 4.4 
The 1H-NMR spectra show the disappearance of the central imidazole proton at ca. 9-11 ppm (see 
Fig. 4.7) and, in the 13C-NMR spectra, the simultaneous appearance of the coordinated carbenic 
carbon signal between 170 and 190 ppm, is observed.  
 
 
Fig. 4.7 1H-NMR spectra of the silver complex 39a and the imidazolium salt 34a (T=298K, d6-
DMSO). 
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It should be noted that the complexes with the mesityl group (34c-d) are present in solution as a 
mixture of oligomers, as pointed out in an article published by Slaughter and co-workers [9b]. 
4.4. Synthesis of palladacyclopentadienyl complexes 
As already reported in section 3.6, the palladacyclopentadienyl complexes are generally obtained by 
addition of a bidentate ligand or two monodentate ligands to the polymeric precursor 
[PdC4(COOCH3)4]n. In the following section we will describe in detail the synthesis and 
characteristics of the palladacyclopentadienyl complexes reported in Fig. 4.8. 
 
Fig. 4.8  
155 
 
 
4.4.1. Palladacyclopentadienyl complexes bearing bidentate bisNHCs 
The possibility of inserting a bidentate bis-NHC ligand into the palladacyclopentadienyl fragment 
was preliminarily assessed by tests carried out in NMR tube. The following scheme 4.5 summarizes 
the results. 
  
 
Scheme 4.5 
 
These tests suggest that the exclusive formation of a pure product is possible only in the case of the 
bis-carbene with a benzyl as wingtip substituent.  
The bis-carbene with the mesityl substituent, yields mixtures of products of difficult identification 
probably owing to its high steric bulkiness (Fig. 4.9). 
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Fig. 4.9 1H-NMR spectra of the reaction between [PdC4(COOCH3)4]n and the silver complex  
[(MesImCH2ImMes)Ag2Br2] in CD2Cl2 at T = 298 K. 
 
The tests carried out with substrates having the methyl group as wingtips, indicate that the desired 
product is initially formed, but subsequently one side-product and traces of decomposition products 
are detected in the NMR spectra. After 48 hours, an equilibrium between the two species in the ratio 
(product/main side-product) of about 40/60 is reached (Fig. 4.10).  
 
 
Fig. 4.10 1H-NMR spectra of the reaction between [PdC4(COOCH3)4]n and the silver complex  
[(CH3ImCH2ImCH3)Ag2Br2] in CD2Cl2 at T = 298 K. 
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From the analysis of the NMR spectra (Fig. 4.10), we can argue that the main side-product shows the 
same number of signals than that of the product of interest and it should therefore be a species with a 
high degree of symmetry. Our formulated hypothesis suggests the formation of a dimeric species, in 
which the bidentate bisNHC acts as a bridged ligand between the two palladacyclopentadienyl 
fragments. Two different structures are possible for this dimeric species (Fig 4.11) and, between the 
two, the compound B (Cs symmetry) is more stable than the sterically hindered complex A, as 
confirmed by DFT calculations (G° = 14.6 kcal/mol).  
 
Fig. 4.11 Representation of the two isomers of the dimeric species by means of DFT calculations 
(COOCH3 groups are not shown to simplify the figure). 
 
Complex B is also slightly more stable than the wanted monomeric species (G° = -0.9 kcal/mol). 
Such difference in energy justifies the coexistence of the monomer and the dimer observed by NMR 
spectroscopy (Scheme 4.6). 
 
 
Scheme 4.6  
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The synthesis of the substrates bearing the bidentate NHC ligand with the benzyl wingtip groups and 
the palladacyclopentadienyl fragment (complexes 40a-b), carried out under the conditions reported 
in Scheme 4.7, was successfully performed. 
 
 
Scheme 4.7 
 
The final compounds were isolated, after filtration of the AgBr, by precipitation from a CH2Cl2/ Et2O 
mixture and characterized by elemental analysis, NMR and IR spectroscopy. 
As for the compound 40a, in the 1H-NMR spectra (Fig. 4.12) we observe: 
• The presence, between 3 and 4 ppm, of two signals ascribable to the two distinct pairs of 
OCH3 groups. 
• The presence of two AB systems, one between 5 and 6 ppm (J = 15 Hz) related to the 
methylene protons of the terminal benzyl groups, the other, between 6 and 6.5 ppm (J = 13.6 
Hz), ascribable to the methylene bridged protons between the two carbenic fragments. 
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Fig. 4.12 1H-NMR spectrum of the complex 40a (T=298K, CDCl3). 
 
The 1H-NMR spectrum (Fig. 4.13) of the compound 40b shows the presence of the two distinct 
groups of OCH3 protons between 3 and 4 ppm (similarly to compound 40a), an AB system at about 
5.2 ppm (J = 15.4 Hz) related to the methylene protons of the lateral benzyl groups and two multiplets 
at about 4.3 and 5.3 ppm ascribable to the protons of the ethylene bridge. 
 
 
Fig. 4.13 1H-NMR spectrum of the complex 40b (T=298K, CDCl3). 
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In the 13C{1H}-NMR spectra (Figs. 4.14 and 4.15) it is possible to identify the signals ascribable to 
the two different pairs of the COOCH3 and C(COOCH3) groups and that of the carbenic carbon at 
about 180 ppm. 
 
 
Fig. 4.14 13C{1H}-NMR spectrum of the complex 40a (T=298K, CDCl3). 
 
 
 
Fig. 4.15 13C{1H}-NMR spectrum of the complex 40b (T=298K, CDCl3). 
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The IR spectra show the presence of strong bands between 1730 and 1680 cm-1 (C = O) of the carbonyl 
groups of the cyclopalladate fragment. 
The structures inferred by the interpretation of the IR and NMR spectra, were confirmed in the case 
of complex 40a by single crystal X-ray diffraction (Fig. 4.16).  
 
 
Fig. 4.16 Ellipsoid representation of 40a crystal ASU contents (50% probability).  
  
162 
 
4.4.2. Palladacyclopentadienyl complexes bearing two monodentate NHCs 
Palladacyclopentadienyl derivatives stabilized by two monocoordinated carbene ligands represent a 
category of complexes similar to those previously described. Similarly to the complexes with 
chelating bisNHCs, the choice of the R substituents at the monocoordinated carbene is very important 
for the success of the reactions. In particular, it has been observed that in the case of carbene 
substituted by one benzyl group and one bulkier group (i.e. mesityl or 2,6-diisopropylphenyl), the 
synthesis of the biscarbene is impossible owing to high steric demand [10]. Conversely, this kind of 
reactions gives good results when carbenes bearing less bulky substituents are used. The addition of 
two equivalents of the silver complexes 35a, 36a or 37c to a solution of [PdC4(COOCH3)4]n in 
dichloromethane is sufficient to promote transmetallation, as can be deduced by the progressive 
precipitation of AgBr (Scheme 4.8). 
 
Scheme 4.8 
The characterization of the products by NMR spectroscopy reveals the presence of a pairs of 
atropoisomers (syn and anti) for each compound, caused by the hindered rotation of the carbene 
ligands about the Pd-C bond (Fig. 4.17). 
 
Fig. 4.17  
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The 1H-NMR spectra reveal the presence of two signals related to the two pairs of OCH3 groups of 
the palladacycle and AX or AB systems ascribable to the methylene protons NCH2, for each 
atropoisomer (Fig 4.18). 
 
Fig. 4.18 1H-NMR spectrum of the complex 41a (T=298K, CDCl3).  
In the 13C-NMR and in the bidimensional HMBC and HMQC spectra (see Fig. 4.19), the two carbenic 
carbons (one for each atropoisomer) are always well distinguishable at about 180 ppm. 
 
Fig. 4.19 HMBC spectrum of the complex 41a (T=298K, CDCl3).  
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The assignment of the peaks ascribable to the syn and anti isomers is based on the NOESY spectra 
(Fig. 4.20), where an intense cross-peak between the protons of the methyl substituent and one of the 
two methylene protons (anti isomer), was observed.  
 
Fig. 4.20 NOESY spectrum of the complex 41a (T=298K, CDCl3). 
 
At equilibrium, the ratio between the two isomers is summarized in table 4.1. 
 
COMPOUND anti/syn 
41 a 3.6 
41 b 2.0 
41 c 2.8 
Table 4.1 
 
In the case of compound 41a it was also possible to obtain its solid-state structure by single crystal  
X-ray diffraction (Fig. 4.21). 
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Fig. 4.21 Ellipsoid representation of 41a crystal ASU contents (50% probability).  
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4.4.3. Palladacyclopentadienyl complexes with chelating NHC-thioether or NHC-pyridine 
ligands 
Another class of ligands taken into consideration is represented by the hemi-labile NHC-thioether 
and NHC-pyridine ligands. 
The corresponding palladacyclopentadienyl complexes (42 and 43) were synthesized by reacting one 
equivalent of the silver compounds 35a-b and 36c with the polymeric precursor [PdC4(COOCH3)4]n, 
under the conditions indicated in Scheme 4.9. 
 
 
Scheme 4.9 
 
This class of compounds was synthesized with the purpose of verify whether the presence of a labile 
coordinative site (pyridine nitrogen or thioether sulphur) might affect the biological activity of the 
system. As a matter of fact, such complexes may interact with soft bio-ligands (i.e. glutathione) and 
form in vivo some species with enhanced or reduced activity if compared to that of the starting 
compounds. 
Species 42 and 43 were fully characterized by IR and NMR spectroscopic techniques and elemental 
analysis. 
The 1H-NMR and 13C-NMR spectra of the complex 42b (Figs. 4.22 and 4.23) confirming the 
hypothesized structure, are shown below. 
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Fig. 4.22 1H-NMR spectrum of the complex 42b (T=298K, CD2Cl2).  
 
 
Fig. 4.23 13C{1H}-NMR spectrum of the complex 42b (T=298K, CD2Cl2). 
 
For the compound 42a it was also possible to obtain its solid-state structure by single crystal  X-ray 
diffraction (Fig. 4.24). 
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Fig. 4.24 Ellipsoid representation of 42a crystal ASU contents (50% probability).  
In some articles of our research group, the reactivity of the palladacyclopentadienyl complexes 
toward halogens and interhalogens [10, 11] was studied and, in one case, the formation of an 
unprecedented compound was observed when the complexes 42a-b, bearing hemilabile NHC-
pyridine ligands, are reacted with one equivalent of iodine [11e]. 
In particular, it was firstly observed the formation of the expected -butadienyl product (oxidative 
addition of I2 followed by stereoselective reductive elimination) and subsequently, with different rate 
depending on the R substituent of the carbenic fragment, the exclusive formation of a zwitterionic 
species with a chelating ligand consisting in a 10-terms ring and two iodides coordinated in trans to 
the palladium (Scheme 4.10 and Fig. 4.25). 
 
Scheme 4.10 
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Fig. 4.25 1H-NMR spectrum of the complex 42b (T=298K, CD2Cl2). 
 
For this process a reaction mechanism was also proposed on the basis of  kinetic studies carried out 
by NMR spectroscopy and theoretical DFT calculations (Scheme 4.11). 
 
 
Scheme 4.10 Computed energies for the reaction between complex 42a and I2, starting from the 
related -butadienyl intermediate. 
 
The final species 47a-b were characterized by IR and NMR techniques, but it was the achievement 
of the X-ray structure for the complex 47b that defined its nature (Fig. 4.26). 
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Fig. 4.26 Ellipsoid representation of 47b crystal ASU contents (50% probability). 
 
These complexes, as will be reported in the following section 4.5, have been tested in vitro because 
they structurally belong to one of the classes of palladium compounds that have shown a good 
antitumor activity (see section 1.3.6). These are trans-PdX2L2 compounds, widely studied and 
summarized in the review published in 2014 by Fairlamb and Kapdi [12]. 
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4.4.4. Mixed NHC/PPh3 palladacyclopentadienyl complexes 
As already stated, it is possible to synthesize palladacyclopentadienyl complexes bearing one purine-
based NHCs  and one triphenylphosphine.  
Compounds 44a-b, bearing classical NHCs, were synthesized in good yields and purity following a 
similar protocol. In Scheme 4.11 the synthesized complexes are reported. 
 
Scheme 4.11  
 
The first mixed NHC/PPh3 compound synthesized was 44a, taking advantage of the easy 
displacement of the labile pyridine nitrogen  by the entering phosphine (Scheme 4.12). 
 
 
Scheme 4.12  
 
A more general approach, including complexes with carbene ligands without a second coordinating 
labile function, was subsequently developed [10]. 
In fact, the addition of one equivalent of PPh3 and one of the silver carbene complex to the polymeric 
precursor [PdC4(COOCH3)4]n, selectively leads to the formation of the NHC/PPh3 mixed complexes 
44a-b. 
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In principle, this procedure does not guarantee the exclusive formation of the mixed derivative since 
the "homoleptic" complexes containing two phosphine or two carbene ligands could also be produced 
at the same time. 
However, DFT theoretical calculations have shown that the exclusive formation of the mixed 
derivative is favourable from the thermodynamic point of view (Scheme 4.13) [10]. 
 
 
Scheme 4.13  Computed energies (G°) related to the “homoleptic” and mixed NHC/PPh3 
complexes. 
 
Nevertheless, the possibility that the reaction might be under kinetic control, requires that the 
operating conditions giving the selective obtainment of the mixed species have to be in any case 
experimentally verified. 
Preliminary tests suggest the following indications: 
1. The mixed derivatives are selectively obtained by adding to the solution of the 
[PdC4(COOCH3)4]n precursor a solution containing both triphenylphosphine and the silver 
carbene complex. 
2. An alternative is represented by the addition of the silver carbene complex and then of 
triphenylphosphine, but this approach firstly yields a mixture of the two “homoleptic” 
complexes and only after, very slowly and partially (decomposition processes cannot be easily 
controlled), gives  the mixed product. 
The effect of the two different protocols was interpreted and described according to Scheme 4.14. 
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Scheme 4.14 Possible competitive processes involving the polymer precursor, the phosphine and the 
carbene ligand present in the reaction environment. 
 
The four described reactions are all clearly possible, but we have to suppose that the processes (1) 
and (2) must be faster than the processes (3) and (4). 
In fact, the preliminary addition of triphenylphosphine only, or combined with the silver carbene 
complex, leads to the formation of the desired product according to the reactions (1) and (2), without 
the slower process (3) is simultaneously activated. 
Conversely, if we first add the silver carbene complex to the palladacyclic precursor, the biscarbene 
complex is obtained (reaction (3)); the subsequent addition of one equivalent of phosphine leads to 
the formation of the bis-phosphinic derivative by reaction with the unreacted palladacyclic precursor 
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(reaction (1)). The conversion of these two compounds into the mixed derivative is eventually 
gradually obtained by means of the slow reaction (4). 
Once defined the synthesis protocol, the mixed complexes 44a-b were obtained in one hour with good 
yields (Scheme 4.15).  
 
Scheme 4.15  
 
These products were characterized by NMR spectroscopy. In particular, the presence of only one 
species is well evidenced by the single peak observed in the 31P{1H}-NMR spectra, resonating at 
about 26-27 ppm. In the 1H-NMR (Fig. 4.27) and 13C{1H}-NMR (Fig. 4.28) spectra, owing to the 
presence of two different spectator ligands, four different signals ascribable to COOCH3 ester groups 
can be detected. 
 
Fig. 4.27 1H-NMR (a) and 31P{1H}-NMR (b) spectra of the complex 44a in CDCl3 at T = 298 K. 
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Moreover, the signal ascribable to the carbene carbon at about 180 ppm is present in all 13C{1H}- 
NMR spectra of all the synthesized derivatives and, due to the coupling with the phosphorus of the 
adjacent phosphine ligand, it appears as a doublet (JC-P ≈ 16 Hz) (Fig. 4.28). 
 
 
Fig. 4.28 13C{1H}-NMR spectra of the complex 44a in CDCl3 at T = 298 K. 
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4.4.5. Mixed NHC/DIC palladacyclopentadienyl complexes 
The same methodology was adopted for the synthesis of the mixed NHC/DIC 
palladacyclopentadienyl complexes.  
A test carried out in NMR tube, by adding to a solution of the [PdC4(COOCH3)4]n precursor another 
solution containing one equivalent of the silver complex 37d and one equivalent of DIC, indicated 
the formation after few minutes of a mixture of the mixed derivative and of the two “bis-DIC”  and 
“bis-NHC” complexes. However, it was observed the progressive transformation of the two 
compounds with the same spectator ligand into the mixed derivative in about 48 hours, without 
detecting perceptible decomposition (Fig. 4.29). 
 
 
Fig. 4.29 1H-NMR spectra of the reaction between [PdC4(COOCH3)4]n, DIC and the silver complex 
37d in CDCl3 at T = 298 K. 
On the basis of a reaction scheme similar to that reported in the former Scheme 4.14, it is apparent 
that in this case the processes (3) and (2) must be of comparable rate, whereas the process (4) probably 
remains significantly slower than the other three. This scheme explains the initial presence in solution 
of all the three possible palladacyclometallated species and the subsequent slow achievement of the 
mixed derivative (Scheme 4.15). 
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Scheme 4.15 Possible competitive processes involving the polymer precursor, DIC and the carbene 
ligand present in the reaction environment. 
 
It can be concluded that the synthesis of the mixed NHC/DIC complex, needs a considerably 
lengthening of the reaction times with respect to that necessary with phosphines. Once defined these 
experimental conditions, the complexes can be easily separated from the reaction mixture and 
selectively isolated in good yields (Scheme 4.16). 
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Scheme 4.16 
 
In the 1H-NMR spectra, the signals of the two different ligands (isocyanide and carbene) are clearly 
identifiable. The two benzyl protons resonate as a pair of doublets, again as a consequence of the 
hindered rotation about the Pd-carbenic carbon bond. Finally, the presence of the 
palladacyclopentadienyl fragment is confirmed by the four different peaks ascribable to the OCH3 
groups (Fig. 4.30).  
 
 
Fig. 4.30 1H-NMR spectrum of the complex 46b  in CD2Cl2 at T = 298 K. 
 
In the 13C{1H}-NMR spectra, it is possible to observe the weak signal of the isocyanide carbon atom 
(at about 150 ppm) and the coordinated carbene signal at about 178 ppm (Fig. 4.31). 
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Fig. 4.31 13C{1H}-NMR spectrum of the complex 46b  in CDCl3 at T = 298 K. 
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4.4.6. Palladacyclopentadienyl bearing chelating N-S and N-P ligands 
The last class of palladacyclopentadienyl compounds, synthesized by published protocols [11b, 11d, 
13], whose antiproliferative activity has been evaluated, are stabilized by bidentate N-S (pyridyl-
thioethers or thioquinolines) and N-P (phosphoquinolines) ligands. This category of complexes has 
been synthesized according to the conditions reported in the Scheme 4.17 and, it is worth noting that 
among all those described hitherto, they bear the most labile ancillary ligands. 
 
 
Scheme 4.17 
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4.5. Antiproliferative activity and biological assays on                      
palladacyclopentadienyl complexes 
In this paragraph the antiproliferative activity of the palladacyclopentadienyl compounds described 
in the previous section (see Fig 4.8), will be examined on different human tumor lines. 
These studies, as well as those reported in the next chapters, were carried out by the molecular biology 
research group of dr. Flavio Rizzolio at the "Centro di Riferimento Oncologico" (CRO) of Aviano. 
In particular, the following cancer lines have been considered: 
• A2780 and A2780-R: human ovarian carcinoma (sensitive and resistant to cisplatin), already 
studied in the case of compounds containing purine-based NHCs (paragraph 3.8) [14]. 
• OVCAR5: human ovarian carcinoma (Cisplatin sensitive) from a 67-year-old woman not 
previously treated with any pharmacological therapy [15]. 
• A549: human lung cancer (adenocarcinomic human alveolar basal epithelial cells) from a 58-
year-old Caucasian male [16]. 
• A375: human malignant melanoma, a solid tumor from a 54-year-old female [17]. 
• DLD1: human colon adenocarcinoma removed from a female subject [18]. 
In order to verify the selectivity of these palladium complexes versus cancer cells, normal human 
fibroblasts MRC-5 (derived from lung tissue of at 14-week-old aborted Caucasian male fetus) were 
also tested. 
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4.5.1. Antiproliferative activity of palladacyclopentadienyl compounds on different cancer cell 
lines and fibroblasts. 
The fibroblasts and the tumor lines were treated with DMSO solutions of the palladacyclopentadienyl 
compounds (10 mM stock solutions), suitably diluted in the culture medium; their antiproliferative 
activities are expressed as IC50 (M) and reported in table 4.2.  
Preliminarily, the stability of the examined palladacyclopentadienyl complexes was checked in 1:1 
dmso-d6/D2O solution (42, 43, 46 and D-F) or dmso-d6 (40, 41, 44 and 47) by NMR spectroscopy: 
after 48 hours at room temperature no degradation and no ligand replacement was observed.  
 
Class of 
compound 
Compound 
IC50 (M) 
A2780 A2780-R OVCAR5 A549 A375 DLD1 MRC-5 
Cisplatin Cisplatin 0.81±0.06 9±3 0.84±0.04 6±3 4.7±0.4 19±4 14±1 
Bidentate 
bisNHCs 
40a 0.039±0.006 2.8±0.6 0.30±0.07 >100 0.3±0.1 >100 >100 
40b 0.46±0.05 7±5 0.49±0.09 >100 2.5±0.7 >100 >100 
Monodentate 
bisNHCs 
41a 2.6±0.4 12±3 7±2 >100 9±5 7±1 >100 
41b 0.58±0.03 4.4±0.3 13±3 >100 10.2±0.1 34±15 >100 
41c 46±11 31±1 0.13±0.07 >100 19±16 0.10±0.09 >100 
NHC-CH2Py 42b 2.7±0.2 >100 52±26 >100 24±9 >100 >100 
NHC-CH2SR 43 3.7±0.2 4.4±0.9 1.79±0.06 >100 2±2 >100 >100 
Mixed 
NHC/PPh3 
44a 3.9±0.6 3.4±0.8 1±1 0.05±0.02 29±7 >100 >100 
44b 0.33±0.08 1.3±0.4 1.2±0.4 17±9 4.4±0.3 4.7±0.9 4.7±0.2 
Mixed 
NHC/DIC 
46a 2.6±0.4 3.9±0.6 13±2 0.24±0.09 4.9±0.9 7±2 >100 
46b 1.0±0.2 0.6±0.2 3.5±0.4 2.8±0.2 5.6±0.5 5.2±0.7 4.8±0.2 
Zwitterionic 
species 
47a 5.8±0.6 >100 6.8±0.6 >100 2±1 >100 >100 
47b 0.51±0.04 1.12±0.04 4.4±0.9 3.5±0.3 0.3±0.2 4.4±0.7 >100 
Chelating  
N-P and N-S 
D 98±49 >100 >100 >100 >100 >100 >100 
E 10±2 28±3 >100 >100 >100 >100 >100 
F 16±5 >100 >100 >100 37±3 >100 >100 
Table 4.2 In vitro antiproliferative IC50 values (M, 72 h) of the palladacyclopentadienyl complexes 
toward human cell lines of ovarian cancer (A2780 and OVCAR5), the cisplatin resistant clone 
(A2780-R), lung cancer (A549), malignant melanoma (A375), colon cancer (DLD1) and normal 
lung fibroblast (MRC-5). 
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Fig. 4.32 Palladacyclopentadienyl complexes with IC50<8 M on A2780 cell line. 
 
 
 
Fig. 4.33 Palladacyclopentadienyl complexes with IC50<18 M on A2780-R cell line. 
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Fig. 4.34 Palladacyclopentadienyl complexes with IC50<8 M on OVCAR5 cell line. 
 
 
Fig. 4.35 Palladacyclopentadienyl complexes with IC50<8 M on A549 cell line. 
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Fig. 4.36 Palladacyclopentadienyl complexes with IC50<6M on A375 cell line. 
 
 
Fig. 4.37 Palladacyclopentadienyl complexes with IC50<20 M on DLD1 cell line. 
 
From the analysis of IC50 values it is possible to propose the following considerations: 
• All the examined species, except for compounds 44b and 46b, are substantially inactive 
toward healthy cells (IC50> 100 M on fibroblasts). This feature, if accompanied by a good 
activity toward the tumor lines, is of fundamental importance. 
• For the cisplatin-sensitive ovarian cancer lines (A2780 and OVCAR5) the most active 
compounds are those bearing: i) chelating bisNHCs (40a-b) ligands, ii) two NHC ligands (41b 
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and 41c, respectively active in the A2780 and OVCAR5 lines), iii) mixed NHC/PPh3 (44b) 
and NHC/DIC (46b) ligands  and iv) the zwitterionic complex 47b. 
• For the cisplatin-resistant ovarian cancer line A2780-R, the active compounds are those 
bearing: i) chelating bisNHCs (40a-b), ii) the biscarbene complex 41b, iii) the complex with 
the pyridylcarbene ligand 43, iv) all the mixed NHC/PPh3 and NHC/DIC complexes (44a-b 
and 46a-b) and v) the zwitterionic compound 47b. 
• On the lung cancer line (A549), only the mixed NHC/PPh3 and NHC/DIC compounds (44a-
b and 46a-b) and the zwitterionic complex 47b are active. Particularly interesting is the 
compound 44a which shows an IC50 about 100 times lower than to cisplatin. 
• As for the malignant melanoma (A375 line) the most active compounds are those bearing:  i) 
chelating bisNHCs (40a-b), ii) mixed NHC/PPh3 and NHC/DIC ligands (44a-b and 46a-b) 
and iii) the zwitterionic complexes 47a- b. 
• For the colon adenocarcinoma (DLD1 line) the compounds that have a significant activity are 
those bearing: i) two carbene ligands (41a-c), ii) mixed NHC/PPh3 and NHC/DIC complexes 
(44b and 46b) and iii) the zwitterionic species 47b. 
• Complexes with chelating N-S and N-P ligands (D-F) are poorly active or inactive toward all 
the lines taken into consideration. 
 
4.5.2. Reactivity of complexes with reduced L-glutathione (GSH)  
In order to verify whether the different activity of the palladacyclopentadienyl complexes may be 
ascribed to the different lability of their ancillary ligands, some reactivity tests were performed with 
reduced glutathione (GSH). This tripeptide, as already mentioned in the introductory chapter, is one 
of the main potential soft bio-ligands present in the cellular environment and can potentially 
coordinate on the metal centre replacing one or more ligands present in the starting complex.  
The tests carried out by us, using 2 mM and 10 mM concentrations respectively of complex and 
glutathione, have shown that: 
 
1. The complexes bearing chelating or two monodentate carbene ligands (40-41) and the mixed 
NHC/DIC complexes (46) are stable for 48 h in the presence of reduced glutathione. 
2. The mixed NHC/PPh3 complexes (44) and that stabilized by the phosphinoquinoline ligand 
DPPQ (D), undergo substitution of PPh3 and of phosphinoquinoline moiety within 24 hours, 
respectively. It is noteworthy that in both cases the phosphine ligand is converted into the 
corresponding phosphine oxide. 
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3. After the addition of GSH, the complexes bearing  chelating carbene ligands (NHC-pyridine 
(42) and NHC-thioether (43)) undergo the fast displacement of the labile heteroatom arm. The 
system does not further evolve and the carbene group remains coordinated to the palladium 
centre.  
4. In the complexes with thioquinoline and pyridylthioether (TMQ and PyrCH2SCH3, complexes 
E-F), glutathione immediately replaces the bidentate ligands. 
5. In no case it is possible to observe any reaction between the palladacyclopentadienyl residue 
and glutathione. 
 
Fig. 4.38 H1-NMR spectra (298K) of complex 40a in DMSO-d6/D2O (1) and after the addition of 
GSH, recorded at  different time: t=0 (2), 24h (3), 48h (4). 
In summary, the mixed NHC/DIC complexes and those bearing two carbene ligands retain their 
structure (Fig. 4.38). On the contrary, the remaining complexes undergo partial or total ligand 
substitution by GSH.  
These reactivity tests allow us to make further considerations in relation to the biological data reported 
in Table 4.2. 
In particular, we can observe that generally the most active compounds have spectator ligands firmly 
anchored to the metal center (chelating bisNHCs, bisNHCs, mixed NHC/PPh3 or NHC/DIC), whereas 
species that do not contain at least one coordinated carbene (chelating N-S and N-P ligands) are poorly 
active or inactive. 
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In this regard, the most interesting compounds we have identified are: 
• Complex 40a, which is particularly active on ovarian cancer lines (A2780, OVCAR5 and 
A2780-R). 
• Complex 41c, which is particularly active on the OVCAR5 line (ovarian carcinoma) and 
above all DLD1 (colon adenocarcinoma). 
• Complexes 44a and 46a, which are very active on the A549 line (lung carcinoma). 
• The zwitterionic complex 47b, which displays a good/excellent activity in all the lines taken 
into consideration. 
Since this work is particularly focused on ovarian cancer, a more in-depth study on the activity of the 
promising complex 40a will be proposed below. 
In particular, the cellular uptake data and the results of specific biological tests, aimed at identify the 
main biological target of this compound, will be presented. 
 
4.5.3. Uptake analysis 
In order to verify whether the activity of the examined complexes may be influenced by the different 
cellular uptake, we have compared the uptake percentage of the efficient complex 40a and the 
virtually inactive complex E, on the A2780 cell line.  
The collected data showed that the greater activity of 40a (IC50 ≈ 0.04 M) with respect to E (IC50 ≈ 
98 M) is ascribable also to the higher uptake level (ca. 60% vs 0.6%), determined close to the IC50 
value. 
 
4.5.4. Biological tests for the determination of the biological target 
To better understand the main mechanism of action of compound 40a, all the cell-based experiments 
were performed following different time points.  
As reported in some recently published works, one of the possible main targets for palladium 
complexes is DNA [12, 19]. 
To test the interaction between this important biomolecule and compound 40a, as a sensitive marker 
for DNA double-strand breaks, the phosphorylation of Ser139 of Histone H2AX was evaluated. In 
fact, after DNA damage, the phosphorylation at Ser139 helps to recruit the DNA repair machine and 
apoptotic proteins to dispatch their function [20]. As shown in Figure 4.39, the complex is active 
already at 40 nM (IC50 value) and after only 3 hours the phosphorylation of Ser139-Histone H2AX 
starts to accumulate in the nucleus.   
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Fig. 4.39 Assay for DNA double-strand breaks. After incubation of A2780 cells with compound 40a 
(40nM, 80nM, 320nM), cisplatin (10µM) or control (non-treated) for 3h, 6h or 12h, they were 
stained with anti-phospho-histone H2AX antibody and detected with Alexa Fluor® 488-conjugated 
secondary antibody (green). A2780 cells were also stained with DAPI for visualization of nucleus 
(blue). White arrows are rapresentative foci formation (accumulation of phospho-histone H2AX in 
the nucleus) showing that compound 40a induces DNA double-strand breaks 3 hours after 
treatment compared to the untreated cells. 
 
Following the DNA damage, cells activate the apoptotic pathway by inducing the release of 
cytochrome C, a conserved electron-transport protein which is part of the respiratory chain of 
mitochondria. This early event was studied by immunofluorescence.  
After 6-12 hours, in the A2780 cells treated with compound 40a, the cytochrome C appears to be 
translocated from the mitochondria to the cytoplasm as a diffuse cytoplasmic staining pattern  (Fig. 
4.40). 
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Fig. 4.40 Assay for the release of cytochrome C. After incubation of A2780 cells with compound 
40a (40nM, 80nM, 320nM), cisplatin (10µM) or control (non-treated) for 3h, 6h or 12h, they were 
stained with anti-cytochrome c antibody detected with Alexa Fluor® 488-conjugated secondary 
antibody (green). A2780 cells were also stained with DAPI for visualization of nucleus (blue). 
White arrows indicate a selection of apoptotic cells showing that compound 40a, similar to 
cisplatin, induces the translocation of cytochrome c from mitochondria to cytoplasm (diffuse 
cytoplasmic staining pattern) 6-12 hours after treatment compared to the untreated cells showing a 
pointed or massive staining pattern. 
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After the release of cytochrome C, cells activate the caspase cascade to induce the apoptosis process. 
The induction of caspase 3/7 was assessed at different time points and concentration of compound 
40a.  Starting from 40 nM of such compound, cells displayed a high level of caspase 3/7 compared 
to untreated cells (Fig. 4.41).  
 
Fig. 4.41 Effect of compound 40a on caspase-3 and caspase-7 activities after incubation of A2780 
cells with compound 40a (40nM, 80nM, 320nM), cisplatin (10µM) or control (non-treated) for 3h, 
12h, 24h. After 24 hours of treatment with compound 40a, A2780 cells, similar to cisplatin effect, 
showed a high level of caspase-3 and caspase-7 activation compared to untreated cells. 
 
To confirm that the complex 40a acts mainly and effectively on the DNA, causing only afterwards 
damage in the other regions of the cell, a test aimed at indentify after how long the damage occurs on 
the mitochondrial membrane has been carried out. 
In this regard, the cyclopalladated compounds recently published by Fong and co-workers, mainly 
act against this membrane and only marginally cause DNA damage in the early hours of exposure to 
the drug by the cell [21]. 
The assay for mitochondrial membrane potential that we performed, showed that it is possible to see 
clear membrane damage only after 24 hours from the treatment of the A2780 cells with compound 
40a (Fig. 4.42). This evidence suggests that damage to the mitochondria occurs as a result of DNA 
damage (evident as early as 3 hours) and activation of apoptosis pathways. 
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Fig. 4.42 Assay for mitochondrial membrane potential. After incubation of A2780 cells with 
compound 40a (40nM, 80nM, 320nM), cisplatin (10µM) or control (non-treated) for 24h or 48h, 
they were stained with JC-1 dye. Untreated cells showing red J-aggregate fluorescence indicated 
hyperpolarized membrane potentials. Cells treated with cisplatin showing cytoplasmic diffusion of 
green monomer fluorescence indicated depolarized membrane potentials. Cells treated with 
compound 40a show a progressive loss of red J-aggregate fluorescence (hyperpolarized membrane 
potentials) and cytoplasmic diffusion of green monomer (depolarized membrane potentials) 24 
hours after treatment of A2780 cells compared to untreated cells. 
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4.6. Synthesis of 3-allyl palladium complexes 
Analogously to that described in the previous paragraphs about the palladacyclopentadienyl 
complexes, it was decided to test in vitro the cationic 3-allyl palladium complexes synthesized by 
our research group and summarized in Figure 4.43. 
 
 
Fig. 4.43 
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4.6.1. 3-allyl palladium complexes bearing bidentate bisNHCs 
The synthesis of cationic 3-allyl palladium compounds containing chelating biscarbene ligands was 
carried out following a synthetic strategy different from that proposed by Elsevier and co-workers, 
who synthesized the allyl derivatives by reacting the dimeric precursor [Pd(-Cl)(3-allyl)]2 with the 
silver carbene complexes 39a-f [22] (Scheme 4.18). 
 
Scheme 4.18 
 
In order to extend the synthesis to the complexes with two monodentate NHCs and obtain compounds 
with perchlorate as counterion, in uniformity with the other categories of allyl complexes that will be 
discussed, it was decided to synthesize allyl palladium precursors with a labile pyridyl-thioether 
ligand (Me-PyCH2SPh), and subsequently carry out the transmetallation with the silver complexes 
39a-f (Scheme 4.19). 
 
 
Scheme 4.19 
 
All these compounds were selectively obtained and isolated as solids, by precipitation from 
dichloromethane/diethyl ether mixture, and  exhaustively characterized by NMR, IR and elementary 
analysis techniques. 
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4.6.1.1. Complexes with R = methyl or benzyl 
Complexes 48a-b and 48g-h were obtained as single species, since the rearrangement of the 
methylene or ethylene spacer up and down to the main coordination plane is free and therefore no 
isomers are observed. Due to the symmetry of these species, in the 1H-NMR spectra (Fig. 4.44) we 
can notice the presence of: 
• The central allyl proton between 5.2 and 5.4 ppm as a multiplet. 
• The anti allyl protons, as one doublet, between 2.7 and 2.9 ppm (J ≈ 13 Hz). 
• The syn allyl protons, as one doublet, between 3.8 and 4.3 ppm (J ≈ 7-8 Hz). 
• The methylene bridge protons as an AB system between 6 and 7 ppm (J ≈ 13 Hz) in the case 
of complexes  48a and 48g. 
• The ethylene bridge protons as a multiplet between 4.5 and 5 ppm in the case of complexes 
48b and 48h. 
• The signals ascribable to the methyl substituents at about 3.7 ppm (singlet) in the case of  
complexes 48a-b or the methylene protons of the benzyl substituents between 5 and 5.3 ppm 
(singlet) in the case of compounds 48g-h. 
 
Fig. 4.44 1H-NMR spectrum of the complex 48a in CDCl3 at T = 298 K. 
As for the 13C-NMR spectra (Fig. 4.45), in addition to the signals related to the methyl or benzyl 
substituents and of the aromatic carbons, we can observe: 
• A single signal for the terminal allyl carbons at about 58-59 ppm. 
• The signal of the central allyl carbon at about 119 ppm. 
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• The signal of the methylene spacer carbon (NCH2N) at about 62-63 ppm in the case of species 
48a and 48g or the ethylene spacer carbon (NCH2CH2N) at about 48 ppm in the case of 
complexes 48b and 48h. 
 
Fig. 4.45 13C{1H}-NMR spectrum of the complex 48a in CD2Cl2 at T = 298 K. 
4.6.1.2. Complexes with R = mesityl 
The synthesized complexes bearing the mesityl as lateral substituent, unlike the previous ones, are all 
present as a pair of atropoisomers. In fact, the ensuing high steric hindrance prevents the free 
movement with respect to the main coordination plane of the spacer and favours the formation of the 
two possible atropoisomers exo and endo, as shown in Figure 4.46. 
  
Fig. 4.46 Representation of the two atropoisomers for complex 4c by means of DFT calculations. 
Consequently, the doubling of all the NMR signals is observed. In particular, for each atropoisomer, 
it is possible to notice the presence in 1H-NMR spectra (Fig. 4.47) of: 
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• A doublet (J ≈ 13 Hz) between 1.5 and 2 ppm related to the anti allyl protons. 
• A doublet (J ≈ 8 Hz) between 3 and 3.2 ppm for the syn allyl protons. 
• A multiplet between 4.5 and 5 ppm for the central allyl proton. 
• A multiplet at about 5 ppm for the ethylene spacer of the complex 48d or an AB system (J ≈ 
13 Hz) between 6 and 7 ppm ascribable to the methylene spacer (complex 48c). 
• Three different methyl signals ascribable to the mesityl substituent. 
 
Fig. 4.47 1H-NMR spectrum of the complex 48d in CDCl3 at T = 298 K. 
 
In the 13C-NMR spectra it is possible to observe the presence of two signals, one for each isomer, 
ascribable to the coordinated carbenic carbon at about 176 ppm. 
For analogues compounds with the chloride counterion, a single set of signals is present in the NMR 
spectra, as reported by Elsevier and co-workers [22]. This fact can be easily explained by previous 
experience, suggesting that the presence of nucleophiles in solution tends to promote the 3- 1-3 
isomerization process and thus the interconversion between the two atropoisomers [23].  
In the biological environment, in which chlorides and other nucleophiles are present, the allyl 
complexes present as a pair of atropoisomers, can easily interconvert throughout the 3- 1-3 
isomerization process. 
The marked tendency of the compounds 48c-d to precipitate as microcrystals of excellent purity 
prompted us to synthesize chelating biscarbene complexes bearing the 2-methylallyl or the 1,1-
dimethyl-allyl moieties and the carbene substituted by the mesityl fragment.  
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It is well known that the introduction of substituents (i.e. methyl or phenyl groups) on the allyl moiety 
heavily influences the reactivity of the derived compounds. This aspect could be exploited for the 
modulation of the reactivity of complexes in biological environment as can be deduced by the values 
of the kinetic constants related to the nucleophilic attack of amines on differently substituted allyl 
fragment, in complexes bearing the same spectator ligand (Scheme 4.20) [24].  
 
Scheme 4.20 
From the table of Scheme 4.20 it is possible to infer how the introduction of a methyl in the central 
or peripheral position of the allyl fragment considerably slows down the rate of the nucleophilic attack 
of the amines. Thus, complexes 48e-f were synthesized following a protocol similar to that previously 
used in the case of the derivatives bearing the unsubstituted allyl fragment (Scheme 4.21). 
 
Scheme 4.21 
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The 1H-NMR spectrum of compound 48e (Fig. 4.48) shows, for each atropoisomer, the presence of: 
• A singlet at about 2 ppm related to the anti allyl protons. 
• A singlet at about 2.5 ppm ascribable to the syn allyl protons. 
• A singlet between 1 and 1.5 ppm traceable back to the methyl substituent of the allyl fragment 
and an AB system (J ≈ 13 Hz) between 6.5 and 7 ppm related to the NCH2N spacer. 
• Three different methyl signals for the mesityl substituent between 1.5 and 2.5 ppm. 
  
Fig. 4.48 1H-NMR spectrum of the complex 48e in CDCl3 at T = 298 K. 
At variance with complexes 48a-d, the 13C-NMR spectra of complexes 48e-f show the signal of 
central allyl carbon at about 130 ppm ( ≈10 ppm downfield with respect to the complex 48c), 
whereas the coordinated carbenic carbon resonates at about 177 ppm. 
For the complex 48e it was also possible to obtain its solid-state structure by single crystal X-ray 
diffraction (Fig. 4.49). 
 
Fig. 4.49 Ellipsoid representation of 48e crystal ASU contents (50% probability). 
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In contrast to the previously cases, the reaction between the precursor [(Me-PyCH2SPh)Pd(1,1-
dimethyl-3-C3H3)]ClO4 and the silver complex 39c is not selective at room temperature nor at 233K 
(Scheme 4.22). 
 
Scheme 4.22 
As a matter of fact, a compound present in solution at 25% does not present signals traceable back to 
the allyl fragment in its NMR spectra. 
Such compound, that was separated from the starting mixture by selective precipitation (in a 1 : 2 
mixture of dichloromethane/diethylether, set at 5 °C for 24 h), is stable both in solid and in solution. 
According to the data obtained by X-ray diffraction, this side product (compound 87) is a dinuclear 
complex of Pd(I) containing a Pd-Pd bond and stabilized by two bridged bis-NHCs (Fig. 4.50). 
 
Fig. 4.50 Ellipsoid representation of 87 crystal ASU contents (50% probability). 
201 
 
 
Remarkably, palladium complexes in oxidation state +1 are quite rare and the most important 
examples are reported in figure 4.51. 
  
 
Fig. 4.51 
 
Among the described species, the neutral allyl Pd (I) complexes A, reported on the left of Fig. 4.46, 
were firstly observed as decomposition products of Pd (II) allyl complexes used in some catalytic 
processes [25]. Subsequently they were selectively obtained by means of a synthetic strategy 
developed by Hazari and co-workers [26]. The neutral Pd (I) species B have recently been 
successfully used as catalysts in cross-coupling reactions [27], whereas the complex reported on the 
right side of figure 4.51 (compound C) is very similar to that we synthesized [28]. However, at 
variance with our complex, is difficult to handle because its high instability as a solid (air sensitive) 
and in solution.  
The Pd(I) complex 87 was also fully characterized by NMR spectroscopy and elemental analysis. 
In the 1H-NMR spectrum (Fig. 4.52) it is possible to detect: 
• The methyl substituents of the mesityl groups within 1.2 and 2.4 ppm. 
• An AB system (J = 13.6 Hz) ascribable to the methylene bridges within 6.5 and 7.3 ppm. 
• The aromatic protons between 6.9 and 8 ppm. 
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Fig. 4.52 1H-NMR spectrum of the complex 87 in d6-DMSO at T = 298 K. 
In the 13C-NMR spectrum (Fig. 4.53) the presence of the signal ascribable to the coordinated carbenic 
carbon at about 183 ppm was observed. 
 
Fig. 4.53 13C{1H}-NMR spectrum of the complex 87 in d6-DMSO at T = 298 K. 
The expected allyl complex 48f, once separated from the dimeric species 87, is stable in solution 
and, for each atropoisomer, the 1H-NMR spectra show (Fig. 4.54): 
• A doublet of doublets at about 4.5 ppm related to the central allyl proton. 
• A doublet at about 1.5 ppm ascribable to the anti allyl proton (J ≈ 12 Hz) and a doublet at 
about 2.5 ppm traceable back to the syn allyl proton (J ≈ 6 Hz). 
• Two singlets between 0.5 and 1.5 ppm related to the terminal allyl methyl groups. 
• An AB system between 6 and 7 ppm ascribable to the NCH2N spacer. 
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Fig. 4.54 1H-NMR spectrum of the complex 48f in CDCl3 at T = 298 K. 
 
Finally, in the 13C-NMR spectra (Fig. 4.55) it is possible to observe, for each species, the signal of 
the carbenic carbon between 175 and 180 ppm and all the other signals related to the allyl fragment 
and biscarbene ligand. 
 
Fig. 4.55 13C{1H}-NMR spectrum of the complex 48f in CDCl3 at T = 298 K.  
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4.6.2. 3-allyl palladium complexes bearing two monodentate NHCs 
In analogy to what reported in the previous paragraph, some 3-allyl palladium species stabilized by 
two monodentate carbenes were also synthesized. In particular, starting from the [(Me-
PyCH2SPh)Pd(3-allyl)]ClO4 precursor and according to the following scheme, the compounds 49a-
d have been synthesized in good yields and purity (Scheme 4.23). 
 
Scheme 4.23 
The success of the reactions was confirmed by NMR spectroscopy. The use of symmetric or 
asymmetric carbenes allowed in all cases to observe in solution at RT a single species (no 
atropoisomers) owing to the free rotation about the Pd-carbene bond of the spectator ligands. 
In the 1H-NMR spectra (Fig. 4.56) it is possible to detect the presence of: 
• A doublet at about 2.4-2.6 ppm ascribable to the anti allyl protons. 
• A doublet at about 3.6-3.8 ppm ascribable to the syn allyl protons. 
• A multiplet between 5 and 5.5 ppm ascribable to the central allyl proton. 
 
Fig. 4.56 1H-NMR spectrum of the complex 49b in CDCl3 at T = 298 K. 
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In the 13C-NMR spectra (Fig. 4.57), in addition to the typical signals of the allyl fragment and of the 
NHC substituents, the peak of the coordinated carbenic carbon at about 177 ppm was detected. 
 
Fig. 4.57 13C{1H}-NMR spectrum of the complex 49b in CDCl3 at T = 298 K. 
In one case (complex 49d), the structure obtained by X-ray diffraction has been previously reported 
(Fig. 4.58) [29]. In the cited work, the synthesis of this class of compounds was carried out by 
transmetallation between the allyl complex containing the NHC-thioether bidentate ligand (complex 
55, see paragraph 4.6.3) and the silver complex 36b exploiting the displacement of the labile wing 
(thioether) with the consequent formation of the biscarbene complex 49d. 
 
Fig. 4.58 Ellipsoid representation of 49d crystal ASU contents (50% probability). 
In conclusion, it is important to underline how the success of the reactions is heavily influenced by 
the steric demand. In fact, the concomitant coordination of two carbene each containing two mesityl 
substituents was an unsuccessful (Scheme 4.24) and a number of by-products is formed; among them 
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it is possible to observe the linear Pd (0) complex stabilized by two carbenic fragments (the signals 
coincide with those reported in the spectra of the product isolated by Herrmann and co-workers [30]) 
and the neutral allyl complex [(IMes)Pd(Cl)(3-allyl)]. 
 
 
Scheme 4.24  
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4.6.3. 3-allyl palladium complexes with chelating NHC-thioether or NHC-pyridine ligands 
Another category of allyl complexes synthesized exhibits as bidentate ligand a carbene with a 
thioether or pyridine wing. 
According to Scheme 4.25, these complexes were prepared by reaction between the [Pd(-Cl)(3-
allyl)]2 precursor and the silver complexes 35b and 36b-d, in the presence of sodium perchlorate 
(dissolved in a 1/3 dichloromethane/methanol mixture) as dechlorinating agent. 
 
 
Scheme 4.25 
 
The success of the reactions is evidenced by the coherence among the NMR spectra and the 
elementary analyses with the wanted structures. 
In particular, owing to the asymmetry of the spectator ligand, the 1H-NMR spectra show five signals 
related to the allyl fragment, together with the signals ascribable to the carbene fragment (Fig. 4.59). 
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Fig. 4.59 1H-NMR spectrum of the complex 53 in CDCl3 at T = 298 K. 
 
Likewise, in the 13C-NMR spectra (Fig. 4.60), the signals of the three different allyl carbons and that 
of the coordinated carbenic carbon can be found. 
 
 
Fig. 4.60 13C{1H}-NMR spectrum of the complex 53 in CDCl3 at T = 298 K 
 
In the case of the carbenes with the pyridine wing, the complexes 51 and 52, bearing the 2-methylallyl 
and 1,1-dimethylallyl fragments, were synthesized (Scheme 4.26). 
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Scheme 4.26 
 
As can be seen in Fig. 4.61, the NMR spectra indicate the presence of only one species with the two 
methyl groups of the allyl fragment trans to the carbene (complex 52). Likewise, the synthesis of 
complex 51 was  successful and in both cases characterized by very high yield.  
 
Fig. 4.61 1H-NMR spectrum of the complex 52 in CDCl3 at T = 298 K. 
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4.6.4. Mixed NHC/PPh3, NHC/PTA, NHC/DIC and PPh3/DIC 3-allyl palladium complexes  
Similarly to the cases previously discussed (see paragraphs 3.5 and 4.4) related to the compounds 
containing purine-based NHCs and palladacyclopentadienyl complexes, respectively, it was decided 
to synthesize 3-allyl palladium complexes bearing two different types of spectator ligands. In 
particular, the synthesis of mixed NHC/PPh3, NHC/PTA, NHC/DIC and DIC/PPh3 complexes was 
carried out. 
At variance with the palladacyclopentadienyl mixed complexes described so far (section 4.4), the 
following reactions (vide infra) are characterized by a favourable thermodynamic and a short  reaction 
time (max 1 hour). 
4.6.4.1. Mixed NHC/PPh3 complexes 
The complexes bearing one carbene and one triphenylphosphine (59-68) were synthesized according 
to the conditions reported in the following scheme (Scheme 4.27). 
 
 
Scheme 4.27 
 
The complexes with symmetric NHC ligands were obtained as single species, characterized by a peak 
observed at about 23 ppm in the 31P-NMR spectra ( ≈ 30 ppm downfield compared to the 
uncoordinated triphenylphosphine). The 1H-NMR spectra (Fig. 4.62) show five distinct allylic 
signals, with the syn and anti protons trans to phosphine resonating as doublets of doublets (or 
multiplets), owing to their coupling with phosphorus. 
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Fig. 4.62 1H-NMR spectrum of the complex 62 in CDCl3 at T = 298 K. 
The 13C-NMR spectra (Fig. 4.63), show the doublet ascribable to the carbenic carbon at about 180 
ppm (JC-P = 15 Hz) and the two different terminal allyl carbons at very similar frequencies (similar 
trans influence between carbene and phosphine) with the carbon trans to phosphine resonating as a 
doublet (JC-P ≈ 30 Hz). 
 
 Fig. 4.63 13C{1H}-NMR spectrum of the complex 62 in CDCl3 at T = 298 K. 
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As for the complexes bearing an asymmetric NHC, the formation of pairs of atropoisomers due to the 
hindered rotation at RT about the Pd-C bond, and the consequent doubling of the signals in 1H-NMR 
and 13C-NMR spectra, as reported in figure 4.64 are observed. 
 
Fig. 4.64 1H-NMR spectrum of the complex 65 in CDCl3 at T = 298 K. 
 
In the case of the compound 60 it was also possible to obtain its solid-state structure by single crystal  
X-ray diffraction (Fig. 4.65). 
 
Fig. 4.65 Ellipsoid representation of 60 crystal ASU contents (50% probability).  
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4.6.4.2. Mixed NHC/PTA complexes 
The mixed NHC/PTA complexes can be distinguished into two categories: 
a) Complexes with NHCs without a side coordinating function. 
b) Complexes with NHCs with a side coordinating function. 
The first kind of derivatives were prepared by a similar protocol than that of the complexes with 
triphenylphosphine. Therefore, the allyl precursors [Pd(-Cl)(3-allyl)]2 or [Pd(-Cl)(3-2-Me-
allyl)]2 were reacted with the silver complex 37b, and subsequentely  treated with the dechlorinating 
agent NaClO4  and PTA (Scheme 4.28).  
 
Scheme 4.28 
The NMR spectra confirm the coordination of both PTA and carbene ligand (Fig. 4.66). 
 
Fig. 4.66 1H-NMR spectrum of the complex 76 in CDCl3 at T = 298 K. 
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The synthesis of mixed NHC/PTA complexes with carbenes bearing a pyridine or thioether wing, 
were carried out in two separated steps. The starting C-S or C-N chelated compounds were first 
prepared, according to  the synthesis reported in the previous paragraph 4.6.3, and subsequently the 
labile pyridine or thioether wing was displaced  by PTA. However, these reactions are not selective, 
and hence, only the complex 78 was obtained pure. 
 
 
Scheme 4.29 
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4.6.4.3. Mixed NHC/DIC and mixed PPh3/DIC complexes 
The synthesis of mixed NHC/DIC and PPh3/DIC complexes 85 and 86 was carried out following 
published protocol synthetically summarized in Scheme 4.30 [31]. 
 
 
Scheme 4.30 
 
In the NMR spectra of the products (see Rif. [31]), all the signals of the carbene (or 
triphenylphosphine) ligand and of the isocyanide ligand, are found.  
Remarkably, in the case of complex 85 it was possible in the past to collect its solid-state structure 
obtained by single crystal X-ray diffraction (Fig. 4.67). 
 
 
Fig. 4.67 Ellipsoid representation of 85 crystal ASU contents (50% probability). 
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4.6.5. 3-allyl palladium complexes bearing chelating phosphino-carbene ligands 
Another category of 3-allyl complexes described in this chapter is characterized by chelating 
phosphino-carbenes as ancillary ligands. This class of molecules, whose synthesis was reported by 
Togni and Visentin in 2007 [32] is synthetically depicted in scheme 4.31. The interest about such 
compounds  stems on the fact that they contain strong chelating C-P ligands and a residue deriving 
from the ferrocene, whose antitumor activity has been extensively studied as reported in the 
introductory section 1.3.2. 
 
 
Scheme 4.31 
 
These complexes with a chiral C-P ligand form pairs of atropoisomers (endo and exo) observable in 
the reaction mixture (Fig. 4.68). As reported in the original work, they were successfully 
characterized by NMR, IR and elemental analysis. 
 
 
Fig. 4.68 
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4.6.6. 3-allyl palladium complexes bearing chelating N-P and N-S ligands 
The last class of allyl compounds exposed, is characterized by bidentate N-S (pyridyl thioethers or 
thioquinolines) or N-P (phosphinoquinolines) as spectator ligands. 
The compounds taken into consideration are summarized in Scheme 4.32, together with the 
corresponding synthetic protocol so far reported [24, 33]. 
 
Scheme 4.32 
As stated in the previously cited papers, they have been exhaustively characterized by NMR and IR 
spectroscopic techniques, as well as by the solid-state structures obtained by single crystal X-ray 
diffraction (Fig. 4.69). 
 
Fig. 4.69 Ellipsoid representation of the complex F [(DPPQ)Pd(3-allyl)]ClO4) crystal ASU 
contents (50% probability). 
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4.7. Antiproliferative activity of allyl palladium complexes 
The antiproliferative activity of the allyl palladium complexes and the Pd(I) dimeric species was 
firstly tested on A2780 and A2780-R cancer lines and toward MRC-5 fibroblasts (Table 4.3).  
The preliminary stability tests in DMSO-d6 or DMSO-d6/D2O mixtures have shown that these 
molecules have a good stability in solution. 
Class of compound Compound 
IC50 (M) 
A2780 A2780-R MRC-5 
Cisplatin Cisplatin 0.81±0.06 9 ± 3 14 ± 1 
Bidentate bisNHCs 
48b 0.3 ±  0.1 0.4 ± 0.1 3.1 ± 0.1  
48c 0.16 ±0.02 0.08 ± 0.04 0.28 ± 0.03  
48f 0.09 ± 0.02 0.027 ± 0.03 0.27 ± 0.08 
Monodentate bisNHCs 
49b 0.08 ± 0.06 0.25 ± 0.07 2.4 ± 0.8  
49c 0.37 ± 0.08 4.8 ± 0.8 >100  
Hemilabile NHCs 
50 0.013 ± 0.002 0.030 ± 0.009 0.04 ± 0.01 
53 0.019 ± 0.001 0.12 ± 0.05 1.7 ± 0.4 
Mixed NHC/PPh3 
61 0.013 ± 0.003 0.12 ± 0.01 0.017 ± 0.001 
62 0.26 ± 0.02 0.4 ± 0.2 0.55 ± 0.12 
63 0.034 ± 0.007 0.42 ± 0.04 0.34 ± 0.04 
Mixed NHC/PTA 76 0.020 ± 0.005 0.033 ± 0.003 3.8 ± 0.3 
Mixed NHC/DIC 85 0.004 ± 0.001 0.021 ± 0.003 0.022 ± 0.001 
Mixed DIC/PPh3 86 0.24 ± 0.07 2.0 ± 0.4 >100 
Pd(I) dimer 87 0.031 ± 0.008 2.3 ± 0.3 >100 
Chelating NHC-P 
G 0.025 ± 0.007 0.31 ± 0.09 0.23 ± 0.01 
H 0.1 ± 0.1 0.40 ± 0.02 0.35 ± 0.09 
Chelating 
 N-P and N-S 
I 0.020 ± 0.003 0.08 ± 0.04 0.26 ± 0.05 
J 2.6 ± 0.3 2.4 ± 0.6 >100 
K 1.8 ± 0.2 4.1 ± 0.4 35 ± 8 
L 2.1 ± 0.6 4.5 ± 0.7 >100 
Table 4.3 
 
From the antiproliferative activity data, concerning most of the synthesized compounds (some data 
are not yet available), it is possible to make the following considerations: 
1. All tested compounds, except for those indicated with the abbreviations J, K and L, are 
significantly more active than cisplatin toward the A2780 and A2780-R lines. 
2. This high cytotoxicity seems quite indipendent of the nature of the spectator ligands and 
therefore it may be credited reasonably to the 3-allyl-Pd(II) fragment. 
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3. Unfortunately, most of these allyl compounds are cytotoxic even on healthy cells (MRC-5), 
with IC50 values often comparable to those obtained for the tumor lines. Important exceptions 
are the bis-NHC complex  49c (with two pyridil-nitrogen free), the mixed PPh3/DIC complex 
86 and the complexes with chelating N-S ligands (J, K and L). The allyl complex coordinating 
one carbene ligand (IMes) and one PTA molecule (compound 76) is also interesting since, 
despite its moderate cytotoxic toward healthy cells (IC50 ≈ 4 M), it is more active than 
cisplatin in both tumor lines of about two orders of magnitude. 
4. The Pd (I) dimeric species 87, even though not containing the allylic fragment, shows an high 
antiproliferative activity toward both cisplatin sensitive A2780 and cisplatin resistant A2780-
R cell lines. Its low toxicity to MRC-5 fibroblasts (IC50 >100 M) renders this compound 
particularly promising. 
As shown in Table 4.4, extending the analysis (for now only on some compounds) toward other tumor 
lines it is possible to notice how this class of compounds is generally very cytotoxic even on these 
types of neoplasms. 
Compound 
IC50 (M) 
OVCAR5 A549 A375 DLD1 
Cisplatin 0.84 ± 0.04 6 ± 3 4.7 ± 0.4 19 ± 4 
50 0.031 ± 0.008 0.06 ± 0.06 0.01 ± 0.009 0.33 ± 0.08 
53 0.38 ± 0.08 0.07 ± 0.02 0.022 ± 0.002 0.29 ± 0.02 
61 0.29 ± 0.06 0.36 ± 0.04 0.141 ± 0.009 0.40 ± 0.04 
63 0.034 ± 0.005 0.4 ± 0.2 0.36 ± 0.04 0.40 ± 0.08 
86 4 ± 1 1.32 ± 0.06 3.0 ± 0.5 4.2 ± 0.7 
G 0.23 ± 0.01 0.49 ± 0.03 0.20 ± 0.03 3.5 ± 0.2 
H 0.35 ± 0.09 0.17 ± 0.08 0.6 ± 0.1 3.26 ± 0.03 
I 0.27 ± 0.02 0.10 ± 0.03 0.023 ± 0.004 0.023 ± 0.002 
J 7 ± 2 5 ± 1 4.5 ± 0.7 >100 
K >100 3.2 ± 2 3 ± 1 >100 
L 8 ± 1 4 ± 2 4.5 ± 0.1 >100 
Table 4.4 In vitro antiproliferative IC50 values (M, 72 h) of the 3-allyl-Pd(II) complexes toward 
human cell lines of ovarian cancer (OVCAR5), lung cancer (A549), malignant melanoma (A375) 
and colon cancer (DLD1). 
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4.8. Conclusions 
In this chapter it was described the synthesis and characterization of allyl and palladacyclopentadienyl 
complexes (and their derivatives) stabilized by N-Heterocyclic Carbenes deriving from the 
functionalization of imidazole. 
For these compounds, the antiproliferative activity was studied toward different tumor lines (ovarian 
carcinoma, colon cancer, lung cancer and malignant melanoma), showing that the allyl compounds 
are generally much more active than those containing the palladacyclopentadienyl fragment. 
However, this greater activity often involves a greater cytotoxicity even on healthy cells. In any case, 
it was possible to identify some species with marked antitumor activity and low cytotoxicity on 
fibroblasts (Fig. 4.72). 
 
 
Fig. 4.72 
For one of these promising compounds (40a), some specific biological tests have allowed to identify 
DNA as the main bio-target. The high stability of the palladacyclopentadienyl fragment and the strong 
coordinating capability of the biscarbene ligand, (no substitution reaction was observed in presence 
of excess of glutathione) probably permit to this compound to remain intact in the biological 
environment; therefore it is reasonable to suppose that its binding with the DNA occurs through non-
covalent interactions with the polynucleotide chain (intercalation). 
Finally, compounds 47b and 87 (Fig. 4.72) are interesting both from the structural point of view and 
for their antiproliferative activity. In fact, from the preliminary results, they are very active against 
the investigated cancer lines and inactive toward healthy cells.  
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The figure proposed at the beginning of the chapter is related to this source:  
https://news.usc.edu/117042/from-mother-to-baby-secondhand-sugars-can-pass-through-breast-milk/ 
5 
Carbohydrate based                 
NHC complexes 
 
 
As seen in the previous chapter, complexes with carbene ligands deriving from alkyl imidazoles or 
bidentate biscarbene ligands, display an interesting activity toward different tumour lines but in many 
cases they are cytotoxic toward fibroblasts. The introduction of one or more glycosidic units could 
improve the selectivity of such compounds, on the basis of the well-known Warburg effect, which is 
for example the basis of the PET technique as will be explained in detail later. 
As a matter of fact, glucose and its derivatives tend to accumulate preferentially in tumour cells rather 
into the healthy ones. After a brief general introduction about carbohydrates, the following section 
will deal with the synthesis and antitumor activity of Pd (II) complexes stabilized by carbohydrate-
based NHC ligands. 
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5.1. Introduction [1,2] 
5.1.1. Carbohydrates: General aspects  
Carbohydrates are the most abundant class of organic molecules in nature and are one of the three 
main components of living cells, along with amino acids and lipids. Carbohydrates have numerous 
biological functions: they represent an important source of energy (through their oxidation, in non-
photosynthetic cells), an indispensable structural component of the cellulose and cartilage and also 
play a fundamental role in the immune and reproductive systems. 
They can be divided into three main classes: monosaccharides, oligosaccharides and polysaccharides. 
The simplest carbohydrates are called monosaccharides and are substantially polyhydroxy aldehydes 
or polyhydroxy ketones (or substances that generate such compounds by hydrolysis) having from 
four to nine carbon atoms in their chain (five or six for the most part). 
Apart dihydroxyacetone, all monosaccharides contain one or more asymmetric carbon atoms 
(stereogenic centers) and are therefore often present in nature in several optically active isomeric 
forms. A classic way to represent the structure and therefore the configuration of the monosaccharides 
is the use of the so-called "Fisher projections" [3]. For instance, the "Fisher projections" of the 
glyceraldehyde, the simplest aldose, display only one stereogenic center and therefore two optical 
isomers (enantiomers), called D- and L-glyceraldehyde (Fig. 5.1). 
 
 
Fig. 5.1 
Monosaccharides can be divided in two categories i.e. D- or L-isomers on the basis of the their 
stereogenic center furthest from the carbonyl group having the same configuration of that of the D- 
or L- glyceraldehyde, respectively. Most of the hexoses present in living organisms are D-isomers 
(Fig. 5.2). 
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Fig. 5.2.  The D-family of aldoses. 
 
In aqueous solution, the aldotetroses and all the other monosaccharides with five or more carbon 
atoms assume a cyclic form, due to the reaction between the carbonyl group and a hydroxyl group 
belonging to the chain. This reaction produces an additional stereogenic center which can assume two 
different configurations called  and   (Fig. 5.3). 
 
 
Fig. 5.3.  Structure of - and -D-glucose. 
 
These cyclic forms are also called hemiacetal or hemiketal, depending on their starting molecule 
which can be an aldehyde or a ketone. Their structures can be traced back to those of the pyran, if 
they form a six-term ring (pyranoses), or furan if they form a five-term ring (furanoses). The isomeric 
forms ( or ) differing only for the configuration of the hemiacetal (or hemiketal) carbon are called 
anomeric forms.   
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5.1.2. Anomeric effect and anomerization [2] 
In 1928 Pascu discovered that the -anomers of the acetylated and alkylated glucose anomerize in 
the presence of Brönsted acids (i.e. H2SO4) or Lewis acids (i.e. SnCl4 or BF3) to give mixtures of  
and  forms [4]. 
The effect leading to the reposition of an aglycone (substituent on the anomeric carbon) from the 
equatorial to the more crowded axial position, is called direct anomeric effect. According to Corey 
and Edward, this relocation can be traced back to the interaction between dipoles associated to the 
hemiacetalic oxygen atom with that bound to C-1 (Fig. 5.4). 
 
 
Fig. 5.4 
In the case of imidazolic aglycones it can be represented as follows (Scheme 5.1): 
 
 
Scheme 5.1 
The opposite phenomenon, observed in the case of an aglycone bound to the monosaccharide by an 
electron-withdrawing group or a positive atom, is called "reverse anomeric effect" and is typical of 
the imidazolium salts (Scheme 5.2). 
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Scheme 5.2 
Therefore, anomerization is the process that promotes the attainment of the thermodynamic 
equilibrium between anomers and obviously depends from the relative energy between the species 
under examination. This process is catalysed by Brönsted or Lewis acids and is more conspicuous in 
the presence of polar protic solvents. The mechanisms of anomerization can be approximately 
distinguished in two categories: mutarotation and anomerization in the strict sense of the term. 
 
5.1.2.1. Mutarotation   
The mutarotation is a process possible in the presence of water and favored by the presence of acids 
or bases. It involves the passage from the closed hemiacetal to the open form, rotation about the C1-
C2 bond and hemiacetal reclosing, as reported in Scheme 5.3. 
 
 
Scheme 5.3 
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5.1.2.2.  Anomerization 
The transformation from  to  anomer (or vice versa) without passing through the open form of the 
sugar is called anomerization in the strict sense. The difference with the mutarotation is that it can be 
promoted only by Brönsted or Lewis acids and does not necessarily require water or protic polar 
solvents. The mechanisms proposed for such a transformation are summarized in Scheme 5.4: 
 
Scheme 5.4 
In the case of the processes which will be described later, the most probable is mechanism 4, which 
is promoted by the interaction between the metal centers (Ag and/or Pd) and the hemiacetalic oxygen. 
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5.1.3. Metal-based compounds with glycosidic groups and Warburg effect 
Unlike the differentiated normal cells, which exploit the mitochondrial oxidative phosphorylation as 
their primary source of energy, most tumour cells prefer to acquire energy by a mechanism not very 
clear yet, which is based on the aerobic glycolysis, an inefficient process producing adenosine-5'-
triphosphate (ATP) [5].  
This phenomenon is called "Warburg effect", and its most important expression is the significant 
increase of the uptake and incorporation of nutrients in tumour cells if compared to the healthy ones. 
In important works by Warburg (1920) and others [5, 6], the remarkable uptake and consumption of 
glucose taking place in tumour cells have been highlighted and the increased acidity interpreted on 
the basis of the different way to metabolize the sugar with consequent production of lactic acid. 
These findings have subsequently led many research groups to employ glucose and its derivatives to 
identify tumour masses (i.e. PET) and/or to selectively damage them (by the introduction of 
glycosidic fragments into potential chemotherapeutic agents). 
In the field of diagnostics, PET (Positron Emission Tomography) allow to obtain maps of the 
functional processes occurring inside the body, at variance with the Computerized Tomography (CT) 
and the Magnetic Resonance Imaging (MRI) which provide only morphological information. 
Obviously, the three cited techniques are often complementary. 
PET technique exploits the great tendency of the tumor masses (up to 200 times compared to healthy 
tissues) to absorb the radiopharmaceutical 18F-fluoroglucose (18F-FDG), permitting us to acquire 
images in marked contrast with those of the areas not affected by cancer (Fig. 5.5) [7]. 
 
Fig. 5.5 The tumor (T) is readily visualized by FDG-PET/CT before therapy (left). After 4 weeks of 
therapy (right), the tumor shows no uptake of FDG despite persistent abnormalities on CT. Excess 
FDG is excreted in the urine, and therefore the kidneys (K) and bladder (B) are also visualized as 
labelled [5]. 
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In the last decades several transition metal complexes containing glycosidic units have been 
synthesized and some of their biological properties, such as the antiproliferative activity against 
different tumors, studied. 
The most important example is the [2,3,4,6-tetra-O-acetyl-1-(thio-κS)--D-glucopyranosato]-
(triethylphosphane)gold(I), usually called Auranofin (Fig. 5.6). 
 
Fig. 5.6. Chemical structure of Auranofin 
This compound was approved by the FDA in 1985 as a drug against rheumatoid arthritis [8] and in 
the same year, Mirabelli and co-workers studied its antitumor activity. The mechanisms of action are 
still debated, and the main target seems to be Thioredoxine reductase (TrxK), a key enzyme 
overexpressed by tumor cells. Auranofin reacts selectively with the selenium of the selenocysteine 
covalently bound to the TrxK, and in that way inhibits the enzyme [9]. This kind of inhibition induces 
the cell apoptosis through a "cascade" mechanism. 
In 2016, phase I and II of clinical trials for the treatment of chronic lymphocytic leukemia (CLL) with 
Auranofin were successfully completed [10]. 
In the case of palladium few compounds containing glycosidic units are known, but the results of  in 
vitro tests are encouraging (Fig. 5.7) [11]. 
        
Fig. 5.7 
233 
 
 
These facts prompt us to try the synthesis of new organometallic palladium compounds bearing NHC 
with glycosidic substituents. In particular, the interesting results described in the previous chapters 
induces us to focus our attention on palladacyclopentadienyl and 3-allyl complexes. Our hope is that 
the introduction of a glycosidic fragment could improve the selectivity of the modified complexes 
against tumour cells. 
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5.2. Synthesis of 2,3,4,6-tetra-O-acetyl--D-glucopyranosyl bromide 
The first step of the synthesis of the compounds which will be discussed in this chapter is the 
protection of the -D-glucose hydroxyl groups in positions 2, 3, 4 and 6 with acetyl groups 
(esterification reaction) and the simultaneous activation of the anomeric carbon (position 1) by 
bromination. This step was carried out by reacting at room temperature, -D-glucose, acetic 
anhydride and acetyl bromide in the presence of a small amount of HClO4 [12] (Scheme 5.5). 
 
Scheme 5.5 
The ensuing compound can be easily identified from its 1H-NMR spectrum (Fig. 5.8), showing: 
• Four different singlets ascribable to the OCH3 groups, within 2 and 2.1 ppm. 
• The CH and CH2 protons of the glycoside within 4.1 and 6.6 ppm. In particular, the proton in 
position 1, relative to the anomeric carbon, is present as a doublet at about 6.6 ppm and will 
be of fundamental importance for the interpretation of the spectra of the compounds which 
will be discussed later. 
 
Fig. 5.8.  1H-NMR spectrum of 2,3,4,6-tetra-O-acetyl--D-glucopyranosyl bromide (CDCl3). 
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In the 13C{1H}-NMR spectrum (Fig. 5.9), the following signals are observed: 
• Four OCH3 groups at about 20.5 ppm. 
• CH2 in position 6 at about 61 ppm. 
• Five glycosidic CH between 67 and 87 ppm. 
• Four carbonyl carbons at about 170 ppm. 
 
 
Fig. 5.9.  13C{1H}-NMR spectrum of 2,3,4,6-tetra-O-acetyl--D-glucopyranosyl bromide (CDCl3) 
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5.3. Synthesis of 1-(2,3,4,6-tetra-O-acetyl--D-glucopyranosyl) imidazole 
The nucleophilic substitution between the 2,3,4,6-tetra-O-acetyl--D-glucopyranosyl bromide and 
the imidazole is strategic for the final synthesis of the target complexes bearing N-Heterocyclic 
Carbenes. The reaction was carried out using imidazole in excess, following the conditions of Scheme 
5.6 [13]. 
 
Scheme 5.6 
The imidazole derivative can be easily precipitated by addition of water to the reaction mixture. Since 
the employed reaction is a SN2 nucleophilic substitution, it was possible to observe the inversion of 
the configuration of the anomeric carbon (from  to ). The final compound was characterized 
exhaustively by 1H-NMR spectroscopy. In particular, in the 1H-NMR spectrum (Fig. 5.10) it is 
possible to observe the presence of: 
• Four signals ascribable to the OCH3 groups within 1.9 and 2.1 ppm. 
• CH and CH2 glycosidic protons within 3.5 and 5.5 ppm. 
• The imidazolic proton (NCHN) at about 7.7 ppm. 
 
Fig. 5.10.  1H-NMR spectrum of 1-(2,3,4,6-tetra-O-acetyl--D-glucopyranosyl)imidazole.  
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5.4. Synthesis of imidazolium salts 
The corresponding imidazolium salts can be easily obtained by alkylation of the non-functionalized 
nitrogen (quaternization) of the above described compound. In particular, as highlighted in Scheme 
5.7, the reaction of the imidazole with n-butyl bromide or methyl iodide, yields the imidazolium salts 
33a and 33b, respectively [13]. 
 
 
Scheme 5.7 
 
The imidazolium salt 33a requires a purification on a chromatographic column whereas  compound 
33b was isolated by precipitation from a CH2Cl2/Et2O mixture. 
From the 1H-NMR spectra (Figs. 5.11 and 5.12) of the compounds, it is possible to observe the 
presence of: 
• The CH and CH2 glycosidic protons within 4 and 7 ppm. In particular, the proton in position 
1 resonates as doublet at about 6.5 ppm. 
• The imidazolium proton NCHN within 10.5 and 11 ppm ( ≈ 3 ppm with respect to the 
starting imidazole). 
• The butyl substituent signals within 1 and 2 ppm (CH22 ', CH23', CH34') and the CH2 directly 
bound to the imidazole nitrogen (CH2
1') at about 4 ppm, in the case of the imidazolium salt 
33a. 
• The NCH3 signal at 4.3 ppm in the case of compound 33b. 
238 
 
 
Fig. 5.11.  1H-NMR spectrum of the imidazolium salt 33a (T=298K, CDCl3). 
 
 
Fig. 5.12.  1H-NMR spectrum of the imidazolium salt 33b (T=298K, CDCl3). 
 
In the 13C{1H}-NMR spectra (Fig. 5.13), it is possible to observe: 
• The signals of the carbonyl carbons at about 170 ppm. 
• The NCHN imidazolic carbon signal at about 135-140 ppm. 
• The CH and CH2 glycosidic signals within 60 and 90 ppm. 
• The signals of the OCH3 groups at about 21 ppm. 
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Fig. 5.13.  13C{1H}-NMR spectrum of the imidazolium salt 33b (T=298K, CDCl3). 
 
The synthesis of the imidazolium salt bearing a mesityl substituent was carried out by direct reaction 
between the 2,3,4,6-tetra-O-acetyl--D-glucopyranosyl bromide, mesityl imidazole and silver triflate 
(Scheme 5.8). The reaction was carried out in reflux of acetonitrile for 16 hours [14]. 
 
 
Scheme 5.8 
 
The product was isolated by precipitation from a dichloromethane/diethylether mixture. In order to 
favour the successive synthetic steps, the triflate was replaced with chloride by the ion-exchange resin 
DOWEX-21KCl (Scheme 5.9). 
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Scheme 5.9 
At variance with its triflate precursor, the derivative 33c is present in solution as two anomers ( and 
), in ca. 60:40 ratio. The anomerization was most likely promoted by the interaction between the 
compound and the resin (interaction with acidic sites in a polar protic solvent). The co-presence of 
the two anomers is unequivocally attested by the duplication of all the signals in the 1H-NMR and 
13C-NMR spectra.  
In 1H-NMR spectra (Fig. 5.14) we can see in detail: 
• The imidazole protons at about 11 and 8.5 ppm. 
• The glycosidic proton in position 1 (one for each anomer) resonant as a doublet at 7.3 ppm. 
• The other CH glycosidic protons within 4.2 and 5.6 ppm. 
• The signals of the methyl groups of the acetyls and of the mesityl substituents within 2 and 
2.4 ppm. 
 
 
Fig. 5.14.  1H-NMR spectra of 33c and the starting imidazolium salt (T=298K, CDCl3)- 
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The 13C{1H}-NMR spectrum (Fig. 5.15) of compound 33c shows signals similar to those already 
recorded in the case of compounds 33a and 33b. In addition, those of the carbons of the methyl 
substituents of the mesityl group resonating within  17 and 21 ppm and the aromatic carbons at 130-
140 ppm are observed. 
 
 
Fig. 5.15.  13C{1H}-NMR spectrum of the imidazolium salt 33c (T=298K, CDCl3). 
 
Finally, in the IR spectra (Fig 5.16) the disappearance of the signals at 639 cm-1 (S=O bending) and 
at 1200-1300 cm-1 (S=O and C-F triflate stretchings) are observed.  
 
            
Fig. 5.16. IR spectra (in KBr) of 33c (right) and the starting imidazolium salt (left). 
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5.5. Synthesis of Silver(I) complexes 
The Ag(I) carbene complexes 38a-c were obtained by reacting the imidazolium salts 33a-c with silver 
oxide according to the conditions reported in Scheme 5.10. 
 
 
Scheme 5.10 
 
The reactions were carried out in anhydrous dichloromethane, under inert atmosphere (Ar), in the 
dark for a time ranging from 5 to 12 hours, as entailed by the R substituent. In all cases, the reaction 
advancement is revealed by the progressive dissolution of the silver oxide. The products were isolated 
in good yields by precipitation with diethyl ether from the reaction mixture. The novel compounds 
38a-c, in analogy with similar Ag (I) complexes reported in the literature [15], should be formulated 
as [Ag(NHC)2][AgX2]. All the investigated complexes have been characterized by NMR and IR 
spectroscopy and are present as a single isomer, independently of the presence of one or two anomers 
in the starting imidazolium salts.  
In the NMR spectra it is possible to observe: 
• The disappearance, in the 1H-NMR spectra (Fig. 5.17), of the peak ascribable to the imidazolic 
proton NCHN between 8 and 11 ppm.  
• The typical coordinated carbenic carbon signal between 180 and 190 ppm in the 13C{1H}-
NMR spectra (Fig. 5.18). 
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Fig. 5.17.  1H-NMR spectra of the silver complex 38b and the imidazolium salt 33b (T=298K, 
CDCl3). 
 
 
Fig. 5.18.  13C{1H}-NMR spectrum of the silver complex 38b (T=298K, CDCl3). 
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5.6. Synthesis of the 3-allyl Pd(II) complexes 
5.6.1. Neutral 3-allyl Pd(II) complexes  
The reaction between the precursor [Pd(-Cl)(3-allyl)]2 with the silver complexes 38a-c yields the 
neutral 3-allyl complexes 56a-c together with the precipitation of the corresponding silver halide, 
that  constitutes the real driving force of the entire process (Scheme 5.11). 
 
  
Scheme 5.11 
 
The final complexes were obtained in good yields by treatment of the reaction residue with a 
diethylether/n-hexane mixture. 
1H-NMR spectra at 298 K reveal that each product consists of two anomers. The anomerization is 
most likely promoted by the presence in the reaction mixture of the metal centers Pd (II) and Ag (I), 
which can act as Lewis acids (see section 5.1). 
The complexes under examination, having two different spectator ligands (Cl- and NHC), present 
five different proton signals (for each anomer) related to the 3-allyl fragment (Hsynt-Cl, Hsynt-C, Hantit-
Cl, H
anti
t -C and H
central), in addition to the typical signals of the carbenic moiety. 
Thus, for each anomer, in the 1H-NMR spectra (Figs. 5.19 and 5.20) it is possible to identify: 
• The acetyl OCH3 signals resonant as singlets within 2 and 2.1 ppm. 
• The Hantit-Cl and Hantit-C doublets (J ≈ 12-13 Hz) within 2.5 and 3.4 ppm, respectively. 
• The Hsynt-Cl and Hsynt-C doublets (J ≈ 5-7 Hz) within 3.5 and 4.4 ppm, respectively. 
• The Hcentral signal as a multiplet at about 5.5 ppm. 
• The CH and CH2 glycosidic signals within 4 and 6.3 ppm. In particular, the two doublets at 
about 6.2 ppm (2H1) is indicative of the two different anomeric species. 
• The signal of the methyl, n-butyl and mesityl substituents slightly displaced with respect to 
those of the starting Ag (I) complexes. 
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Fig.5.19.  1H-NMR spectrum of the complex 56b (T=298K, CDCl3). 
 
 
Fig. 5.20.  1H-NMR spectrum of the complex 56a (T=298K, CDCl3). 
 
The assignment of the proton signals was achieved by means of two-dimensional COSY technique 
(Fig. 5.21). 
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Fig. 5.21.  COSY spectrum of the complex 56a (T=298K, CDCl3) 
 
By means of the NOESY spectra (Fig. 5.23), using as reference the H1 protons, it was possible to 
attribute the proton signals to the two different anomeric species. In particular, as shown by DFT 
theoretical calculations, the spatial distance between the protons H1 and H2 (Fig. 5.22) is different in 
different anomers, being of about 2.9 Å and 2.3 Å for anomer  and , respectively. Therefore, it is 
possible to discriminate between anomers on the basis of the Nuclear Overhauser Effect (NOE), 
which is generally evident under 3 Å. Thus, the cross-peak less intense was assigned to  anomer. 
 
Fig. 5.22.  Representation of the two anomers of compound 56a (DFT calculations). 
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Fig. 5.23  Relevant part of the NOESY spectrum of the complex 56a (T=298K, CDCl3). 
 
By recording the 1H-NMR spectra at low temperature (193-233 K) it was possible to freeze the 
rotation about the Pd-carbene bond with the consequent visualization of the signals related to four 
different species, two atropoisomers (exo and endo) for each anomer ( e ) (Fig. 5.24). 
 
 
Fig. 5.24 1H-NMR spectrum of the complex 56a (T=193K, CD2Cl2). 
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The two atropoisomers are distinguishable as a consequence of the mutual position of the R 
substituent (i.e. n-butyl for the compound 56a) with respect to the central proton of the allyl group. 
As a matter of fact, the allyl central proton and the R group may be on the same or opposite side with 
respect of the main coordination plane which is identified by the palladium, the carbenic carbon and 
the chloride ligand. As can be seen in Fig. 5.25, atropoisomers exo are characterized by a reduced 
steric hindrance and therefore are the most abundant in solution. For instance, the ratio between the 
exo and endo species in complex 56a is exo:endo ≈ 80/20 as can be deduced from the spectra recorded 
at 193K (see Fig 5.24).  
 
 
Fig. 5.25 Representation of the four atropoisomers of  the complex 56a (DFT calculations). 
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The NMR characterization was completed by the analysis of the 13C{1H}-NMR spectra (Fig. 5.26) 
where, for each anomer, it is possible to observe: 
• The signal of the carbenic carbon at 180-185 ppm. 
• The signal of central allyl carbon at about 115 ppm. 
• The signal of the allyl carbon trans to carbene at about 73 ppm. 
• The signal of the allyl carbon trans to chloride at about 49 ppm. 
 
 
Fig. 5.26  13C{1H}-NMR spectrum of the complex 56b (T=298K, CDCl3). 
 
 
Fig. 5.27  HSQC spectrum of the complex 56b (T=298K, CDCl3). 
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5.6.2. Mixed NHC/PPh3 3-allyl Pd(II) complexes  
The high antiproliferative activity  exerted by the allyl complexes stabilized by classic NHC ligand 
and triphenylphosphine (paragraph 4.7), encouraged us to synthesize compounds bearing 
triphenylphosphine and carbohydrate-based carbenes. We hoped to maintain similar activity against 
the tumour lines but to decrease the cytotoxicity generally detected versus the fibroblasts lines 
(healthy cells). 
Therefore, the cationic complexes 69a-c were obtained by dehalogenation with NaClO4 and addition 
of triphenylphosphine [16] to the neutral 56a-c allyl complexes (Scheme 5.12). 
 
Scheme 5.12 
 
The reactions were carried out by adding to a solution in dichloromethane of the complexes 56a-c, 
one equivalent of PPh3 and subsequently an excess of NaClO4·H2O (dissolved separately in a 3:1 
mixture of dichloromethane/methanol). The precipitation of NaCl attests the progress of the reaction. 
After the removal of the solvent, the residue was dissolved in dichloromethane and the inorganic salts 
filtered off on Celite filter. The final products were then easily isolated by precipitation induced by 
the addition of diethyl ether and n-hexane. 
At variance with the neutral compounds 56a-c, the presence in solution of the four different isomers 
(two atropoisomers for each anomer) is observed already at room temperature, since the 
triphenylphosphine prevents the rotation about the Pd-C bond of the NHC fragment. Therefore, in the 
31P{1H}-NMR spectra (Fig. 5.28) the four signals, located in a range between 25 and 27 ppm (with a 
 ≈  ppm with respect to the uncoordinated PPh3) are always observed. From the 31P{1H}-NMR 
spectra, it is possible to notice that the abundance of the anomeric species is more or less the same, 
whereas the atropoisomers present different concentration. 
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Fig. 5.28  31P{1H}-NMR spectrum of the complex 69b (T=298K, CDCl3). 
 
In the 1H-NMR spectra (Fig. 5.29), for each species, we can identify: 
• The Hantit-C signal as doublet (J ≈ 12-13 Hz) at about 3.2 ppm. 
• The Hantit-P signal as multiplet at about 3.4-3.6 ppm. 
• The Hsynt-C signal as doublet (J ≈ 3-4 Hz) at 3.6-3.8 ppm. 
• The Hsynt-P signal as multiplet between 4.0 and 4.4 ppm. 
• The Hcentral signal as multiplet at about 5.8-6.0 ppm. 
 
 
Fig. 5.29  1H-NMR spectrum of the complex 69b (T=298K, CDCl3). 
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In the 13C{1H}-NMR spectra (Fig. 5.30), for each isomer, we can observe: 
• At about 180 ppm the signal ascribable to the carbenic carbon, resonating as a doublet (JCP ≈ 
20 Hz). 
• A doublet (JCP ≈ 25-30 Hz) at about 69 ppm related to the CH2 allyl trans to the phosphine.  
• A singlet at about 74 ppm related to the CH2 allyl trans to the carbene. 
• A singlet, at about 120-125 ppm, related to the central allyl carbon. 
 
 
Fig. 5.30  13C{1H}-NMR spectrum of the complex 69b (T=298K, CDCl3). 
In the IR spectra (Fig. 5.31), the C=O and C-O stretching at about 1750 and 1231 cm-1 are respectively 
observed, whereas the Cl-O stretching of the perchlorate counterion is detected at approximately 1100 
cm-1. 
 
Fig. 5.31  IR spectrum (in KBr) of the complex 69b. 
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5.7. Mixed NHC/PPh3 palladacyclopentadienyl complexes  
The mixed compounds 45a-c were synthesized in good yields by reacting, in dichloromethane at 
room temperature, the [PdC4(COOCH3)4]n precursor, one equivalent of PPh3 and one equivalent of 
the Ag (I) complexes 38a-c (Scheme 5.13). 
 
Scheme 5.13 
The products were isolated, after the removal of the silver halide, by  precipitation with diethylether 
and n-hexane. The ensuing complexes (45a-c), analyzed by NMR and IR spectroscopy, always 
formed a mixture of two different anomers ( and ). It is worth noting that, on the contrary of the 
mixed NHC/PPh3 allyl complexes, in this case a potential hindered rotation around the Pd-carbene 
bond should not  produce atropoisomers, being the palladacyclopentadienyl fragment symmetric with 
respect to the main coordination plane. 
Consistently, in the 31P{1H}-NMR spectra (Fig. 5.32) the presence of two singlets related to the 
triphenylphosphine coordinated to two different anomers, is detected. As can be seen, the mentioned 
singlets have a comparable intensity and resonate within the 24-26 ppm range. 
 
Fig. 5.32 31P{1H}-NMR spectrum of the complex 45b (T=298K, CDCl3). 
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In the 1H-NMR spectra (Fig. 5.33), beside the signals of the carbenic substituents (n-Bu, Me or 
Mesityl),  we observe for each anomer: 
• Four different OCH3 singlets at about 2 ppm ascribable to the acetyl groups present in the 
glycosidic substituent. 
• Four different singlets within 2.5 and 4 ppm assigned to the OCH3 of the 
palladacyclopentadienyl fragment. 
• The signals ascribable to the CH and CH2 of the glycosidic protons within 3 and 6.5 ppm. 
 
 
Fig. 5.33 1H-NMR spectrum of the complex 45b (T = 298 K, CDCl3). 
 
In the 13C{1H}-NMR spectra (Fig. 5.34), recorded at 243 K (owing to the partial decomposition of 
the complexes at RT), we observe: 
• The OCH3 signals of the glycosidic fragment at about 20 ppm. 
• The OCH3 signals of the palladacyclopentadienyl fragment at about 50 ppm. 
• The carbonyl signals, related to both the glycosidic fragment and palladacycle, at about 170 
ppm. 
• The typical signal of the coordinated carbene carbon at about 182 ppm, resonating as a doublet 
due to the J2 coupling with the phosphorus of the triphenylphosphine (JC-P ≈ 20 Hz).  
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Fig. 5.34  13C{1H}-NMR spectrum of the complex 45b (T=298K, CDCl3). 
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5.8. Antiproliferative activity: preliminary results 
The antiproliferative activity of the allyl compounds bearing a carbohydrate-based NHC and PPh3 
was preliminary analyzed on A2780 line and on MRC-5 fibroblasts. The results for compound 69c 
are reported in table 5.1 (the triplicated data are not yet available for the remaining compounds). 
 
COMPLEX 
IC50 (M) 
A2780 MRC-5 
Cisplatin 0.81 ± 0.06 14 ± 1 
69c 0.31 ± 0.03 3.9 ± 0.2 
Table 5.1 
 
As reported in Table 5.1, compound 69c is more active than cisplatin on the A2780 cancer line. 
Furthermore, a slight selectivity of action emerges analysing the data on fibroblasts. The IC50 value 
determined for healthy cells is one order of magnitude higher compared to the A2780 line.  
Anyway, in order to accurately evaluate the selectivity of these species and therefore the possible 
presence of the Warburg effect, as stressed in the numerous works concerning this phenomenon [5-
9], it will be necessary to await the results of the in vivo tests. 
 
5.9. Conclusions 
In this chapter a synthetic protocol for the synthesis of novel Pd (II) allyl and palladacyclopentadienyl 
complexes containing carbohydrate-based NHC ligands has been proposed.  
In particular, the stable cationic species 69a-c (mixed NHC/PPh3 complexes), were obtained from the 
neutral allyl complexes 56a-c. 
These compounds were synthesized as a mixture of four isomers, due to the anomerization (presence 
of alpha and beta isomers) and the hindered rotation around the Pd-carbene bond (formation of 
atropoisomers).  
The antiproliferative activity of these compounds toward the A2780 ovarian cancer line showed, in 
the preliminary results (compound 69c), a better activity compared to cisplatin. Furthermore, this 
species has a slight selectivity toward cancer cells compared to healthy cells. In order to better 
evaluate the degree of selectivity of this class of compounds, also based on the well-known Warburg 
effect, in vivo studies will be carried out in the future.  
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The figure proposed at the beginning of the chapter is related to this source: http://www.1zoom.me/en/wallpaper/455190/z6781/ 
6 
 Pd(II) complexes bearing           
N-Trifluoromethyl NHCs              
 
 
The last class of compounds which has been synthesized and studied under its antiproliferative 
activity, is constituted by 3-allyl palladium complexes stabilized by N-trifluoromethyl NHC ligands. 
The synthesis of such compounds was carried out during the Ph.D. period spent at the Polytechnic of 
Zurich (ETH Zurich) under the supervision of prof. Antonio Togni. 
CF3 is a very important group under pharmacological aspect and interesting from the electronic point 
of view owing to its strong electron-withdrawing nature, promoting remarkable -backdonation when 
present as a substituent in the NHC ligands. In this chapter we will discuss how to insert the CF3 
group into our molecules following a protocol recently developed by the group of prof. Togni. 
In particular, it was decided to synthesize the mixed NHC/PPh3 and NHC/PTA complexes, which 
have already given excellent biological results as shown in the previous chapters. 
 
 
  
260 
 
6.1. Introduction 
This section will give an overview on i) the importance of the CF3 in compounds of pharmaceutical 
interest, ii) the main processes of insertion of this group into the molecules of interest 
(trifluoromethylation reactions) and finally iii) the characteristics acquired by the carbene fragment 
bearing this kind of substituent. 
6.1.1. Trifluoromethyl and polyfluorinated groups in medicinal chemistry 
The importance of fluorine and polyfluorinated groups in medicinal chemistry is highlighted by a 
large number of published articles on this topic and also by commercially available drugs and 
biologically active compounds containing at least one fluorine atom [1, 2]. 
Although fluorine represents the most abundant halogen on earth, only a dozen fluorinated organic 
compounds have been identified in nature [3]. 
The introduction of fluorine-containing groups into organic molecules significantly changes the 
chemical, physical and biological properties of these species. For these reasons organofluorine 
structures have received much interest in medicinal, pharmaceutical, agricultural chemistry and 
material sciences [1b]. 
As an example, we report 8 drugs bearing the CF3 group, among the 200 most successful, available 
on the market (US, 2012) (Fig. 6.1). 
 
 
Fig. 6.1 
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Furthermore, the interest has also been focused on the OCF3 and SCF3 groups, which have very 
similar properties than CF3 [4]. 
The effect of fluorine on the lipophilicity of compounds mainly depends on the number of fluorine 
atoms inserted and on their position in the molecule. For instance, fluorination of aromatic rings 
considerably increases the lipophilicity of the derivatives [5].  
Table 6.1 shows the influence on the Hansch-Leo hydrophobic parameter , derived from the 
octanol/water partition coefficients PX and PH, of different groups on the generic C6F5X compound 
[6]. 
 
Hydrophobic parameter [X= log(PX/PH) (octanol/water)]  
for C6F5X compounds 
X X X X 
OH  -0.67 SCH3 0.61 
F 0.14 SCF3 1.44 
CH3 0.56 CH3CO 0.02 
CF3 0.88 CF3CO 0.55 
OCH3 -0.02 CH3SO2 -1.63 
OCF3 1.04 CF3SO2 0.55 
Table 6.1 [5] 
 
Moreover, the perfluorinated groups confer a remarkable stability to their derived systems, owing to 
the strength of the C-F bond. For instance, chloride or methyl groups can undergo metabolic oxidation 
whereas the CF3 group and analogues are stable toward this type of degradation and therefore used 
as valid alternative (bioisostere groups) [7]. 
Recently, thanks to the 19F-NMR spectroscopy it was possible to study the affinity of some libraries 
of fluorinated compounds toward particular regions of target receptors, eventually suggesting the  
drugs design  once the main receptor was individuated [8]. 
The interest toward the perfluorinated substituents and in particular for the CF3 group is also the result 
of numerous methods currently available for their introduction into the systems of interest as  will be 
illustrated in the following paragraph. 
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6.1.2. Synthetic methodologies for the introduction of the trifluoromethyl group 
The first method describing the insertion of a CF3 group into an organic molecule is attributed to 
Frédéric Swarts, that in 1892 published the reaction between trichlorophenylmethane and SbF3 
(subsequently replaced by HF in the 1930s) to give PhCF2Cl and PhCF3 [9]. The reaction between 
CF3I and iodobenzene in the presence of copper, was instead the first example reported in the 
literature of a stoichiometric coupling (McLoughlin-Thrower, 1968, see Scheme 6.1) [10]. 
 
Scheme 6.1 
Later, the first catalytic coupling between iodoarenes, trifluoroethylsilane, copper iodide (0.1 eq) and 
1.10-phenanthroline was published by Oishi and co-workers in 2009 (Scheme 6.2) [11]. 
 
Scheme 6.2 
The palladium-catalysed process in which aryl halides and (trifluoromethyl)triethylsilane were 
reacted in the presence of the dimeric species [Pd(-Cl)(3-allyl)]2 was later published [12]. 
It is now important to remind that the trifluoromethylation reactions can be divided into three broad 
categories: 
• Radical trifluoromethylations. 
• Nucleophilic trifluoromethylations. 
• Electrophilic trifluoromethylations. 
In the radical trifluoromethylations the formation of the free trifluoromethyl radical [13] is the key 
step and such a species is much more reactive than the methyl radical [14]. One typical reagent is 
represented by the CF3I/triethylborane combination (Scheme 6.3) [15]. 
263 
 
 
 
Scheme 6.3 
More recently, other processes have been developed for the production of radicals similar to CF3 as 
for instance OCF3 (trifluoromethoxylation reaction, see Scheme 6.4) [4b]. 
 
Scheme 6.4 
In the nucleophilic trifluoromethylation processes the active species is the CF3
- anion, which is a very 
reactive species, and hence this type of process can be often difficult. This anion was isolated with 
the [K(18-crown-6)]+ counterion from Prakash and co-workers [16]. An example of nucleophilic 
trifluoromethylation characterized by CF3Cu as intermediate is reported below (Scheme 6.5) [17]. 
 
Scheme 6.5 
In the electrophilic trifluoromethylations the key step is the extremely difficult production of the CF3
+ 
cation. 
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The first reagent used in this aim was the diaryl(trifluoromethyl)sulfonium salt [Ar2SCF3] [SbF6], and 
its application for the functionalization of thiophenolates was exposed in detail in 1984 (Fig. 6.2) 
[18]. Analogous reagents with the sulphur replaced by oxygen, selenium or tellurium are also 
available [19]. 
For this broad category of reagents anilines, pyridines and triphenylphosphine were examined as 
substrates. 
 
Fig. 6.2 
A second important category of trifluoromethyl donors is represented by hypervalent iodine (III)-CF3 
reagents, firstly published by Togni and co-workers [20]. This sort of reagents has been used with a 
huge number of substrates, among them thiols [20a], alcohols [20a], phosphines [20a], arenes and 
(hetero) arenes [21], unactivated olefins [22] and unsaturated carboxylic acids [23], are worthy of 
mention. 
 
Scheme 6.6 [20a] 
For both the electrophilic and nucleophilic trifluoromethylations, some examples of enantioselective 
processes are known. One of these processes proposed by Allen and co-workers is reported below 
(Scheme 6.7) [24]. 
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Scheme 6.7 [24e] 
 
6.1.3. N-Trifluoromethyl NHC ligands 
This last introductory section will show and discuss the main characteristics of N-Heterocyclic 
Carbenes functionalized with the CF3 group (N-trifluoromethyl NHCs). 
As reported in the introductory section concerning the N-Heterocyclic Carbene ligands (section 1.4), 
their success, in the field of catalysis, is due to their excellent -electron donating properties, which 
leads to the formation of very strong metal-carbene bonds, thereby increasing the stability and activity 
of the catalysts [25]. Recent works have however demonstrated the catalytic importance of the -
backdonation, which can be increased by using electron-withdrawing groups as substituent at the 
nitrogen [26]. For instance, a great -backdonation renders the metal more electron-deficient and 
makes processes such as -acid catalysed cyclizations easier [27]. 
An excellent example is the work by Alcarazo et al. where, by tuning the -acceptor properties of the 
NHCs, they were able to selectively modulate the result of three distinct gold (I)-catalysed processes 
[28].  
From a theoretical point of view, Gusev and co-workers were able to calculate by DFT simulations, 
the Tolman electronic parameter (TEP) related to different NHC ligands in the [Ni(CO)3(NHC)] 
complexes taken as a model [29]. The study also examined ligands not synthesized yet, such as N-
bistrifluoromethyl NHC ImN(CF3)2 (Fig 6.3). 
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Fig. 6.3 
These studies have shown that this ligand is a significantly weaker donor than the N-methyl analogue 
(ImN(Me)2). As a matter of fact, there is a partial donation of electron density from the lone pairs of 
the nitrogen atoms to the *C-F antibonding orbital, which decreases the -donation of the nitrogen 
atoms to the empty p orbital of the carbenic carbon. 
Togni and co-workers published in 2015 the first example of complexes with N-trifluoromethyl NHC 
ligands [30] obtained from trifluorobenzimidazole, which is synthesized on a large scale by 
electrophilic N-trifluoromethylation of benzimidazole [20a, 31]. The latter can be finally 
functionalized by alkyl or aryl groups, to give the corresponding imidazolium salts (Scheme 6.8) [30]. 
 
Scheme 6.8 
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These imidazolium salts react with metallic precursors (i.e. [Rh(COD)Cl]2, [RuCl2(=CHPh)(PCy3)2] 
or [Au(DMS)Cl]) in the presence of a base (i.e. K2CO3) to give the final carbene species, which are 
efficient catalysts in the metathesis of the olefins (Ru complexes [32]) or in the  hydroalkoxylation 
of olefins (Au (I) complexes (Scheme 6.9) [30]). 
 
 
Scheme 6.9 
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6.2. N-trifluoromethyl benzimidazolium salts 
As already mentioned in the previous paragraph (section 6.1.3), it is possible to synthesize the N-
trifluoromethyl benzimidazole by electrophilic trifluoromethylation, with the protocol developed by 
Togni and co-workers [20a, 31]. This neutral compound reacts with a suitable alkylating agent to give 
the corresponding imidazolium salt. 
In this work, for reasons which will be explained later, we have only synthesized imidazolium salts 
bearing tetrafluoroborate as counterion, following  the conditions shown in Scheme 6.10. 
 
Scheme 6.10 
In order to obtain the methylated derivative 32a, the trifluorobenzimidazole was reacted in 
dichloromethane with the Meerwein’s salt (Me3OBF4) under controlled atmosphere. 
Owing to the commercial  unavailability of the (iPr)3OBF4 species, the introduction of the isopropyl 
substituent was achieved by the synthesis of the iodide derivative according to the method already 
reported in the literature [30], first followed by the I-/BF4
- counterion-exchange using silver 
tetrafluoroborate as a dehalogenizing agent. After the filtration of AgI, the desired product was easily 
isolated. 
The successful result of the reactions is proved by the presence in the 1H-NMR spectra (Fig. 6.4) of 
all the signals of benzimidazole and those of the inserted methyl or isopropyl substituents. Moreover, 
in the 19F-NMR spectra are present  two sets of signals (Fig. 6.5). In more detail: 
• A singlet at ca. -59 ppm related to the CF3 group. 
• Two singlets at ca. -152 ppm ascribable to the tetrafluoroborate counterion (10BF4 and 11BF4). 
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Fig. 6.4 1H-NMR spectrum of the imidazolium salt 32b (T=298K, CD3CN). 
 
 
Fig. 6.5 19F{1H}-NMR spectrum of the imidazolium salt 32b (T=298K, CD3CN). 
 
Finally, the synthesis of the phenyl derivative 32c was carried out following the Ullmann method 
reported in literature and consisting in the coupling between the N-trifluoromethyl benzimidazole and 
(Ph2I)BF4 in the presence of Cu(OTf)2 as a catalyst (Scheme 6.11) [30]. 
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Scheme 6.11 
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6.3. Palladium (II) 3-allyl complexes bearing N-trifluoromethyl NHCs 
Owing to the promising antiproliferative activity against several tumor lines obtained in the case of 
the allyl complexes (paragraphs 3.8, 4.7 and 5.8), we decided to synthesize some palladium 
complexes bearing the allyl fragment and the N-trifluoromethyl NHC ligands. 
Preliminary tests have shown that silver compounds bearing these ligands are of not easy isolation. 
These species are in fact not very stable and of difficult manipulation. It was therefore decided to 
carry out one-pot reactions by reacting in acetonitrile for seven hours the starting imidazolium salt 
with 0.5 equivalents of silver oxide and subsequently, adding to the reaction mixture the palladium 
allyl precursor of interest. 
Further preliminary tests have highlighted the difficulty of the selective synthesis of 3-allyl 
complexes bearing two N-trifluoromethyl NHCs (biscarbene complexes). On the contrary, the 
synthesis of mixed palladium allyl derivatives bearing one N-trifluoromethyl carbene and one 
phosphine ligand (PPh3 or PTA) was successful achieved with high yields according to the 
experimental condition of  Scheme 6.12. 
 
Scheme 6.12  
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All the investigated complexes, owing to the hindered rotation about the Pd-carbene bond, are again 
present in solution as a pair of atropoisomers (Fig. 6.6). As a matter of fact, it is possible to observe 
in the NMR spectra the doubling of all the characteristic signals of these molecules. 
 
 
Fig. 6.6.  Representation of the two atropoisomers related to compound 74 (DFT calculations). 
 
6.3.1. Mixed NHC/PPh3 complexes 
The 1H-NMR spectra of the mixed NHC/PPh3 complexes, show the presence in solution of  two 
atropoisomer each complex (Fig. 6.7). In particular, the following peaks are observed: 
• The signals of the anti allyl proton trans to carbene within 2.5 and 3.5 ppm (doublet, with J 
≈ 13 Hz, in the case of  the complexes bearing  3-allyl fragment or a singlet for those with 
the 3-2-Me-allyl group). 
• The signals of the anti allyl proton trans to phosphorus within 3 and 4 ppm (doublet of 
doublets, with J1 ≈ 13 Hz and J2 ≈ 10 Hz, in the case of compounds bearing the 3-allyl 
fragment or a doublet, with  J ≈ 12 Hz, for those with the 3-2-Me-allyl group). 
• The signals of the syn allyl proton trans to carbene within 3.8 and 4.5 ppm (doublet, with J ≈ 
7 Hz, for the compounds bearing the 3-allyl fragment or a singlet for those with the 3-2-
Me-allyl group). 
• The signals of the syn allyl proton trans to phosphorus within 4.2 and 4.8 ppm (doublet of 
doublets, with J1 ≈ 7 Hz and J2 ≈ 7 Hz, for the compounds bearing the 3-allyl fragment or a 
broad doublet for those with the 3-2-Me-allyl fragment). 
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• The signals of the central allyl proton within 5.5 and 6.5 ppm for the compounds bearing the 
3-allyl fragment (multiplet) or a singlet at ca. 2 ppm of the central methyl group for those 
with the 3-2-Me-allyl fragment. 
 
Fig. 6.7  1H-NMR spectrum of the complex 70 (T=298K, CDCl3). 
 
The 31P{1H}-NMR (Fig. 6.8) spectra show two narrow quartets at about 25 ppm (one for each isomer), 
due to the coupling through the space between the phosphorus and the fluorine nuclei of the CF3 
group (JP-F=1-4 Hz). 
 
Figure 6.8 31P{1H}-NMR spectrum of the complex 70 (T=298K, CDCl3). 
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The 19F{1H}-NMR spectra (Fig. 6.9), show two narrow doublets (one for each isomer) at about -55 
ppm (JP-F = 1-4 Hz) related to the CF3 group and the tetrafluoroborate counterion signals at about         
-153 ppm. 
 
Fig. 6.9  19F{1H}-NMR spectrum of the complex 70 (T=298K, CDCl3). 
 
In the 13C-NMR spectra (Fig. 6.10), in addition to the typical signals of the allyl carbons, it is possible 
to see the signal of the coordinated carbene carbon at about 190 ppm resonating as a multiplet 
(coupling with the phosphorus and fluorine nuclei). 
 
 
Fig. 6.10.  39C{1H}-NMR spectrum of the complex 70 (T=298K, CDCl3). 
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Finally, in the case of the compound 74 it was possible to obtain the structure of the single crystal, 
by X-ray diffraction (Fig. 6.11).   
 
 
Fig. 6.11 Ellipsoid representation of 74 crystal ASU contents (50% probability). 
 
6.3.2. Mixed NHC/PTA complexes 
The 1H-NMR spectra of the mixed NHC/PTA complexes show the presence in solution of  two 
atropoisomer each complex (Fig. 6.12). In particular, the following signals are observed: 
• The signals of the anti allyl proton trans to carbene within 2.5 and 3.0 ppm (doublet, with J ≈ 
13 Hz, for the compounds bearing the 3-allyl fragment or a singlet for those with the 3-2-
Me-allyl fragment). 
• The signals of the anti allyl proton in trans to phosphorus within 3 and 3.5 ppm (multiplet for 
the compounds bearing the 3-allyl fragment or a doublet, with  J ≈ 9 Hz, for those with the 
3-2-Me-allyl fragment). 
• The signals of the syn allyl protons and the NCH2N/NCH2P systems within 4 and 5 ppm.  
• The signals at ca. 5.5 ppm of the central allyl proton for the compounds bearing the 3-allyl 
fragment (multiplet) or a singlet at ca. 1.8 ppm of the central methyl group for those with the 
3-2-Me-allyl fragment. 
276 
 
  
Fig. 6.12 1H-NMR spectrum of the complex 81 (T=298K, CD3CN). 
 
The 31P{1H}-NMR (Fig. 6.13) spectra show two superimposed quartets (one for each isomer) at about 
-58 ppm with a JP-F=1-5 Hz. 
 
 
Fig. 6.13 31P{1H}-NMR spectrum of the complex 81 (T=298K, CD3CN). 
 
The 19F{1H}-NMR spectra (Fig. 6.14) show two narrow doublets (one for each isomer) at about -56 
ppm (JP-F = 1-4 Hz) related to the CF3 group and that of the tetrafluoroborate counterion at about          
-152 ppm. 
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Fig. 6.14 19F{1H}-NMR spectrum of the complex 81 (T=298K, CD3CN). 
 
Finally, the 13C-NMR spectra (Fig. 6.15) show the typical signals of the allyl carbons and that of the 
coordinated carbene carbon at about 190 ppm resonating as a multiplet (coupling with the phosphorus 
and fluorine nuclei). 
 
Fig. 6.15 39C{1H}-NMR spectrum of the complex 81 (T=298K, CD3CN). 
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6.4. Antiproliferative activity and biological assays 
The antiproliferative activity of the allyl compounds described in this chapter was determined in vitro 
toward healthy cells (MRC-5 fibroblasts) and several tumor lines. The final results are summarized 
in table 6.2 and visualized in figures 6.16-6.21. 
COMPOUND 
IC50 (M) 
A2780 A2780-R OVCAR5 A549 A375 DLD1 MRC-5 
Cisplatin 0.81±0.06 9±3 0.84±0.04 6±3 4.7±0.4 19±4 14±1 
70 0.03±0.01 0.051±0.004 0.26±0.03 0.18±0.09 0.041±0.003 0.28±0.06 0.28±0.01 
71 0.14±0.03 0.08±0.02 0.30±0.05 0.14±0.06 0.083±0.009 0.31±0.04 1.8±0.6 
72 0.024±0.002 0.027±0.004 0.20±0.06 0.17±0.01 0.045±0.005 0.28±0.01 0.30±0.05 
73 0.18±0.05 0.12±0.02 0.5±0.1 0.32±0.05 0.24±0.02 0.50±0.09 1.5±0.3 
79 0.23±0.07 0.9±0.2 10±1 10±3 0.286±0.006 1.11±0.09 >100 
80 0.25±0.01 1.4±0.1 6±1 2.1±0.1 1.7±0.3 48±29 >100 
81 0.30±0.02 0.22±0.05 2.8±0.7 1.37±0.09 0.34±0.06 3±1 >100 
82 0.76±0.01 1.3±0.1 6.3±0.7 2.5±0.1 2.7±0.8 5.4±0.5 >100 
Table 6.2 In vitro antiproliferative IC50 values (M, 72 h) of complexes 70-82 toward human cell 
lines of ovarian cancer (A2780 and OVCAR5), the cisplatin resistant clone (A2780-R), lung cancer 
(A549), malignant melanoma (A375), colon cancer (DLD1) and normal lung fibroblast (MRC-5). 
 
Fig. 6.16 Antiproliferative activity on A2780 cell line. 
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Fig. 6.17 Antiproliferative activity on A2780-R cell line. 
 
 
Fig. 6.18 Antiproliferative activity on OVCAR5 cell line. 
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Fig. 6.19 Antiproliferative activity on A549 cell line. 
 
Fig. 6.20 Antiproliferative activity on A375cell line. 
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Fig. 6.21 Antiproliferative activity on DLD1 cell line (compound 80 has been omitted). 
 
On the basis of these results, we can propose the following considerations: 
1. These compounds, except for some rare cases, appears to be more active than cisplatin in all 
the tumor lines taken into consideration. 
2. The mixed NHC/PPh3 compounds (70-75) are in most cases more active than the mixed 
NHC/PTA homologues (79-84). 
3. For the same spectator ligands, the complexes with the 3-2-Me-allyl organometallic fragment 
are generally less active than those containing the 3-allyl fragment. 
4. Mixed NHC/PTA compounds, even if they show a slightly lower activity compared to 
NHC/PPh3 homologues, have the advantage of being almost inactive toward healthy cell lines 
(IC50> 100 M on fibroblasts). 
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6.5. Conclusions 
In this chapter the synthesis of cationic complexes of Pd (II), stabilized by N-trifluoromethyl NHC 
ligands and phosphines (PTA or PPh3) was described. 
The new compounds were completely characterized by spectroscopic techniques (IR and NMR), 
elemental analysis and X-ray diffraction (for compound 75). 
Their antiproliferative activity was assayed on several tumor lines, showing in most cases a higher 
effectiveness than cisplatin.  
In particular, the mixed NHC/PTA complexes are very interesting since, in addition to a good  
antiproliferative activity on the examined tumor lines, do not seem particularly cytotoxic on healthy 
cells (IC50> 100 M on MRC-5 fibroblasts). 
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Togni, J. Am. Chem. Soc., 2017, 139, 13117.
285 
 
The figure proposed at the beginning of the chapter is related to this source: https://de.fotolia.com/ 
7 
 Conclusions and                     
future perspectives              
    
 
This work reports the synthesis and characterization of about one hundred palladium compounds in 
three different oxidation states (0, +1 and +2), stabilized by six different types of N-Heterocyclic 
Carbenes and bearing three different organometallic fragments (Fig 7.1). 
 
 
Fig. 7.1 
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The synthetic strategies used and the features of products obtained have been discussed in detail both 
from the kinetic and thermodynamic point of view, sometimes with the support of DFT theoretical 
calculations.  
All compounds were subsequently tested in vitro on several tumor lines (mainly of ovarian 
carcinoma) and, in order to verify their selectivity toward cancer cells, also on lung fibroblast lines. 
From this screening it is possible to deduce that the antiproliferative activity promoted by these 
complexes is mainly dependent on the type of organometallic fragment involved. 
The nature of the organometallic function (3-allyl-Pd(II), palladacyclopentadienyl or 2-olefin-
Pd(0)) seems to play a fundamental role in the interactions of the palladium complexes with biological 
systems and consequently in the definition of their cytotoxicity. In particular, it has been observed 
that compounds containing the allyl residue are generally more active than the 
palladacyclopentadienyl complexes and much more active toward tumor cells than those coordinating 
an olefin. 
In any case, it was possible to verify that for the same organometallic fragment, the choice of the 
spectator ligands somehow allows a rough modulation of the antiproliferative activity of the complex 
and its selectivity toward cancer cells.  
Therefore, at the end of this systematic work we have been able to identify eight molecules (or sub-
categories of molecules) showing high antiproliferative activity against the examined cancer lines 
and, at the same time, low cytotoxicity toward healthy cells (Figs. 7.2 and 7.3). 
 
Fig. 7.2 
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Fig. 7.3 
 
Two of these compounds (47b and 87) do not contains any of the three organometallic fragments 
peculiar of this work, but are their derivatives or by-products and deserve attention even for their 
original structure.  
For one of the most promising complex, the biscarbene compound 40a, it was possible to identify the 
DNA as primary target and define the sequence of events that leads to the death of tumor cell for 
apoptosis. 
Our program for the future is extends the studies on mechanism of action also to the other complexes 
reported in figures 7.2-7.3 and finally tests their behaviour in vivo, in order to understand the real 
potential of this kind of molecules as new possible anticancer agents for chemotherapy. 
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 Experimental section 
 
 
In the experimental section the synthesis and characterization of all the compounds will be reported 
in detail. The synthesis of the final palladium complexes, the silver carbene precursors and the 
different imidazolium salts used, will be described. 
In this chapter the details related to the X-ray diffraction measurements, the functionals and basis sets 
used in the DFT theoretical calculations, the protocols followed in the biological tests about the 
antiproliferative and pro-apoptotic activity, and the tests aimed at determining the main biological 
target will be reported. 
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9.1. Solvents and reagents 
The solvents CH2Cl2 and CH3CN were distilled over CaH2, whereas acetone was refluxed over 4Å 
molecular sieves and distilled. Palladium precursors [PdC4(COOCH3)4]n [1], [Pd(Me-PyCH2SPh)(2-
olefin)] (2-olefin = ma, fn, tmetc), [Pd(TMQ-Me)(2-dmfu)] [2], [Pd(Me-PyCH2SPh)(3-C3H5)] 
ClO4, [Pd(Me-PyCH2SPh)(3-2-MeC3H4)]ClO4 and [Pd(Me-PyCH2SPh) (3-1,1-dimethylC3H3)] 
ClO4 [3] were prepared according to published procedures. All other solvents and chemicals were 
commercial grade products and used as purchased. 
 
9.2. Instruments 
• NMR spectra were recorded on a Bruker Avance 400 or 300 MHz spectrometer; chemical shifts 
() are reported in ppm related to the residual solvent signals.  
• IR spectra (KBr) were recorded on a Perkin−Elmer Spectrum One spectrophotometer. 
• IR spectra (neat) were recorded on a Thermo Fischer Scientific Nicolet 6700 FT-IR equipped 
with PIKE Technologies Gladi ATR or on a PerkinElmer BX II using ATR FT-IR technology. 
• ICP−MS measurements were carried out by a Nexion 350X mass spectrometer (Perkin−Elmer) 
interfaced with a plasma torch in KED (Kinetic Energy Discrimination) procedure with He as 
collision gas.  
• ESI−MS analysis were performed using a LCQ−Duo (Thermo−Finnigan) operating in positive 
ion mode. Instrumental parameters: capillary voltage 10 V, spray voltage 4.5 kV, capillary 
temperature 200 °C, mass scan range from 150 to 2000 amu, N2 was used as sheath gas and the 
He pressure inside the trap was kept constant. The pressure directly read by an ion gauge (in the 
absence of N2 stream) was 1.33 × 10−5 Torr. Sample solutions were prepared by dissolving the 
compounds in acetonitrile and directly infused into the ESI source by a syringe pump at 8 μL 
min−1 flow rate. 
• Elemental analysis was carried out using an Elemental CHN ‘CUBO Micro Vario’ analyzer. 
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9.3. Computational details 
The geometrical optimization of the complexes was carried out without symmetry constraints, using 
the hyper-GGA functional M06 [4, 5] in combination with polarized triple-ζ-quality basis sets 
(LAN2TZ(f )) [6, 7] and relativistic pseudopotential for the Pd atoms, a polarized double-ζ-quality 
basis set (LANL2DZdp)[8] with diffuse functions for the halogen atoms and a polarized double-ζ-
quality basis set (6-31G(d,p)) for the other elements.  
Solvent effects (dichloromethane, ε = 8.93) were included using CPCM [9, 10].  
The “restricted” formalism was applied in all the calculations. By means of the stationary points 
characterized by IR simulation, the zero-point vibrational energies and thermodynamic parameters 
were obtained [11]. The software used was Gaussian 09 [12] and all the computational work was 
carried out on Intel based × 86-64 workstations. 
 
9.4. In vitro cytotoxic activity 
9.4.1. Growth inhibition assays (ovarian cancer lines) 
Cell growth inhibition assays were carried out using three human ovarian cancer cell lines, A2780, 
A2780-R and SKOV-3. A2780 cells are cisplatin-sensitive whereas A2780-R and SKOV-3 cells are 
cisplatin-resistant. Cell lines were obtained from ATCC (Manassas, VA) and maintained in RPMI 
1640, supplemented with 10% fetal bovine serum (FBS), penicillin (100 Units mL-1), streptomycin 
(100 μg mL-1) and glutamine (2 mM) (complete medium); the pH of the medium was 7.2 and the 
incubation was performed at 37°C in a 5% CO2 atmosphere. Adherent cells were routinely used at 
70% of confluence and passaged every 3 days by treatment with 0.05% trypsin-EDTA (Lonza).  
Pure derivatives were added at serial dilutions and incubated for 3 days. After this time, cells were 
washed with PBS 1X and detached with trypsin. Cells were suspended in physiological solution and 
counted with a Z2 Coulter Counter (Coulter Electronics, Hialeah, FL, USA). The cell number/ml was 
determined as IC50 after 3 days of culture, when untreated cells are in log phase of cell growth [13, 
14]. All stock solutions were diluted in complete medium to give final concentrations. Cisplatin was 
employed as a control for the cisplatin-sensitive A2780, and for the cisplatin-resistant SKOV3. 
Untreated cells were placed in every plate as negative control. The cells were exposed to the 
compounds in 1000 L total volume, for 72 hours.  
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9.4.2. Apoptosis assays 
Annexin V and Dead Cell assays on IB3-1 cells, untreated and treated for 72 h with increasing doses of 
Pd-complexes, were performed with the Muse cell analyzer (Millipore, Billerica, MA, USA) method, 
according to the instructions supplied by the manufacturer. This procedure utilizes Annexin V to detect 
PS (PhosphatidylSerine) on the external membrane of apoptotic cells. A dead cell marker is also used as 
indicator of cell membrane structural integrity. Four populations of cells can be distinguished using this 
assay: live, early apoptotic, late apoptotic and dead cells. Cells were washed with sterile PBS 1X, 
tripsinized, resuspended in the original medium and diluted (1:2) with the one step addition of the Muse 
Annexin V & Dead Cell reagent. After incubation of 20 min at room temperature, samples were 
analyzed, using Triton X 0.01%, as positive control [15]. Data from prepared samples are acquired and 
recorded utilizing the Annexin V and Dead Cell Software Module (Millipore, Billerica, MA, USA). 
9.4.3.  Immunofluorescence microscopy 
Cells were seeded at a density of 2 × 105 cells/mL on coverslip glass (pre-treated with poly-D-Lysine, 
1µg/mL) inserted in 6-well plates. After overnight culture at 37°C and 5% CO2, cells were treated 
with different concentrations of compound 1 (40nM, 80nM, 320nM or 1µM) or cisplatin (10 µM) for 
3, 6, and 12h for γH2AX antibody and for 3, 6, 12 and 24h for cytochrome c antibody. Cells were 
fixed in 4% paraformaldehyde/PBS (20 min, RT), permeabilized with 0.3 % Triton X-100/PBS 
(15min, RT) and blocked in 8% BSA/PBS (1h, RT). Cells were stained with mouse monoclonal anti-
phospho-histone H2AX antibody (1:100 dilution in 1% BSA/PBS, at 4 °C, ON) or with mouse 
monoclonal anti-cytochrome c antibody (1:100 dilution in 1% BSA/PBS, at 4 °C, ON) that were 
obtained respectively from Millipore (Cat. # 05-636; Burlington, MA, US) and Cell signalling 
Technology (Cat. # 12963; Danvers, MA, US), and labelled with secondary antibodies (Alexa Fluor® 
488 dye, 1:1000 dilution, RT, 2h) obtained from Cell signalling Technology (Cat. # 4408; Danvers, 
MA, US). To visualize DNA, cells were stained with DAPI 1mg/µL (1:1000 dilution in PBS, at 4 °C, 
1min). Cells were washed three times with 1 × PBS after all incubations. All the coverslips were 
mounted in fluorSave™ reagent (Cat. # 345789; Millipore: Burlington, MA, US), the cells were 
examined with a Nikon Eclipse Ti fluorescence microscope, and the images were analysed with NIS 
Elements software version 3.0 (Nikon: Shinagawa, Tokyo, Japan). 
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9.4.4.  Mitochondrial membrane potential measurement 
Cells were seeded at a density of 2.5 × 104 cells/mL (compound 1) or 5 × 105 cells/mL (cisplatin) in 
triplicate on 6-well plates. After incubation overnight at 37°C in 5% CO2, cells were treated with 
different concentrations of compound 1 (40nM, 80nM, 320nM or 1µM) or cisplatin (10 µM) for 24, 
48, and 72h. Working staining solution was prepared from the JC-1 powdered dye provided from 
Invitrogen (Cat. # T3168; Waltham, MA, US). in dimethyl sulfoxide (DMSO) at 1 mg/mL, which 
was then added to the cells (10µg/mL according to JC-1 cell staining conditions). Incubation was 
carried out at 37°C in 5% CO2 incubator for 10 minutes. Cells were washed with 1× PBS, examined 
with a Nikon Eclipse Ti fluorescence microscope, and the images were analysed with NIS Elements 
software version 3.0 (Nikon: Shinagawa, Tokyo, Japan). JC-1 exists either as a diffuse green-
fluorescent monomer at depolarized membrane potentials (altered) or as an orange-fluorescent J-
aggregate at hyperpolarized membrane potentials (normal). 
9.4.5. Caspase-3/7 activity detection 
The expression of caspase-3/7 were determined by Caspase-Glo™ 3/7 Assay (Cat. # G8091; 
Promega: Madison, WI, US). Cells were seeded at a density of 105 cells/mL on 6-well plates. After 
incubation overnight at 37°C in 5% CO2, cells were treated with different concentrations of 
compound 1 (40nM, 80nM, 320nM or 1µM) or cisplatin (10 µM) for 24, 48, and 72h. Cells were 
collected by trypsinization and centrifugation. Cell lysis buffer (Tris HCl 1M pH 8, NaCl 5M, 10% 
glycerol, 1% NP-40, EDTA 0.5M) with Sodium orthovanadate 2mM (Cat. # S6508-50G, Sigma-
Aldrich: St. Louis, MO, US), Sodium fluoride 5mM (Cat. # S7920-100G, Sigma-Aldrich: St. Louis, 
MO, US) and EDTA-free protease inhibitors 25x (Cat. # 04693132001, Roche: Basel, Switzerland). 
The cellular protein content was quantified by the Eppendorf BioPhotometer (Hamburg, Germany). 
The assay was performed in 1:1 ratio of Caspase-Glo® 3/7 reagent volume to protein extracts (40 μg) 
in triplicate in 96-well plate. The plate was incubated at RT for 30min. Luminescence was recorded 
using Tecan M1000 PRO instrument (Männedorf, Zürich, Switzerland). 
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9.5. Crystal data 
9.5.1. Data collected at the University of Ferrara (prof. Valerio Bertolasi) 
The crystal data for complexes 41a, 42a, 49d, 60 and 85 were collected at room temperature using a 
Nonius Kappa CCD diffractometer with graphite monochromated Mo-K radiation. The data sets 
were integrated with the Denzo-SMN package [16] and corrected for Lorentz, polarization and 
absorption effects (SORTAV) [17]. The structure was solved by direct methods using the SIR97 [18] 
system of programs and refined using full-matrix least-squares with all non-hydrogen atoms 
anisotropically and hydrogens included on calculated positions, riding on their carrier atoms. In some 
cases, the program SQUEEZE was used to cancel out the effects of the disordered solvent. SQUEEZE 
is part of the PLATON program system which attempts to remove mathematically the effects of 
disordered solvent [19]. All calculations were performed using PLATON [19], SHELXL-97 [20] and 
PARST [21] implemented in WINGX [22] system of programs.   
9.5.2. Data collected at the Elettra Synchrotron of Trieste (dr. Nicola Demitri) 
The crystal data for complexes 4b, 6a, 10d, 11b, 26, 40a, 47b, 48e, 74 and 87 were collected at 100K 
at the XRD1 beamline of the Elettra Synchrotron, Trieste (Italy) [23]. The data sets were integrated 
and corrected for Lorentz and polarization effects with the XDS package [24]. Data have been scaled 
using CCP4 Aimless code [25]. The structures were solved by direct methods using SHELXT 
program [26] and refined using full−matrix least−squares with all non−hydrogen atoms 
anisotropically and hydrogens included on calculated positions, riding on their carrier atoms. 
Geometric restrains on bond lengths and angles (DFIX, DANG) have been used in 7 models for 
disordered fragments (i.e. solvent CH2Cl2 molecule and BF4
- ion). All calculations were performed 
using SHELXL−2017/1 [27]. The Coot program was used for structure building [28]. Pictures were 
prepared using Ortep3 [29] software. 
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9.6. Synthesis of compounds derived from functionalized purine bases 
9.6.1. General procedure for the synthesis of alkyl-functionalized theophylline and 
theobromine (1) 
 
1 g (5.55 mmol) of the starting xanthine (theophylline or theobromine) and 1.15 g (8.33 mmol) of 
K2CO3, were suspended in DMF (20 mL) in a 250 ml flask. To the suspension, 2 equivalents (11.1 
mmol) of the appropriate alkyl halide (benzyl bromide for 1b and 1d and phenyl propargyl chloride 
for 1c) were added and the resulting mixture was vigorously stirred overnight at R.T. The compounds 
were precipitated by addition of H2O (ca. 100 mL).  
7-benzyl-1,3-dimethylxanthine (1b) 
White solid, yield 93 %. 
1H-NMR (400 MHz, CDCl3, T=298K, ppm)  3.43 (s, 3H, N-CH3), 3.60 (s, 3H, N-CH3), 5.52 (s, 
2H, N-CH2), 7.30-7.40 (m, 5H, Ph), 7.58 (s, 1H, NCHN). 
13C{1H}-NMR (CDCl3, T=298K, ppm)  28.0 (N-CH3), 29.8 (N-CH3), 50.3 (N-CH2), 107.0 (C5), 
128.0, 128.7, 129.1, 135.4 (CPh), 140.9 (N-CH-N), 148.9 (C
4), 151.7 (C=O), 155.3 (C=O). 
ESI-MS (CH3CN): m/z Calcd. for C14H15N4O2 [M+H]
+  271.12; found: 271.06.  
Anal. Calcd. for C14H14N4O2: C 62.21, H 5.22, N 20.73. Found: C 62.32, H 5.14, N 20.64. 
 
  
300 
 
7-phenylpropargyl-1,3-dimethylxanthine (1c) 
Pink solid, yield 95 %. 
1H-NMR (400 MHz, CDCl3, T=298K, ppm)  3.45 (s, 3H, N-CH3), 3.63 (s, 3H, N-CH3), 5.42 (s, 
2H, N-CH2), 7.32-7.50 (m, 5H, Ph), 7.94 (s, 1H, NCHN). 
13C{1H}-NMR (CDCl3, T=298K, ppm)  28.0 (N-CH3), 29.8 (N-CH3), 37.4 (N-CH2), 80.5 (≡C-
CH2), 87.6 (≡C-Ph), 106.8 (C5), 121.5, 128.5, 129.2, 131.9 (CPh), 140.6 (N-CH-N), 148.9 (C4), 151.7 
(C=O), 155.3 (C=O). 
ESI-MS (CH3CN): m/z Calcd. for C16H15N4O2 [M+H]
+ 295.12; found: 294.98. 
Anal. Calcd. for C16H14N4O2: C 65.30, H 4.79, N 19.04. Found: C 65.49, H 4.83, N 18.89. 
1-benzyl-3,7-dimethylxanthine (1d) 
White solid, yield 95 %. 
1H-NMR (400 MHz, CDCl3, T=298K, ppm)  3.59 (s, 3H, N-CH3), 4.00 (s, 3H, N-CH3), 5.22 (s, 
2H, N-CH2), 7.25-7.55 (m, 5H, Ph), 7.51 (s, 1H, NCHN).  
13C{1H}-NMR (CDCl3, T=298K, ppm)  29.8 (N-CH3), 33.6 (N-CH3), 44.5 (N-CH2), 107.7 (C5), 
127.5, 128.4, 128.8, 137.3 (CPh), 141.5 (N-CH-N), 148.9 (C
4), 151.6 (C=O), 155.3 (C=O). 
ESI ESI-MS (CH3CN): m/z Calcd. for C14H15N4O2 [M+H]
+ 271.12; found: 271.14. 
Anal. Calcd. for C14H14N4O2: C 62.21, H 5.22, N 20.73. Found: C 62.45, H 5.07, N 20.99. 
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9.6.2. General procedure for the synthesis of the imidazolium salts from caffeine and 
functionalized theophylline and theobromine with BF4 as counterion (2) 
 
1.8 mmol of functionalized xanthine 1a-d (1a = commercial caffeine) was dissolved in ca. 25 mL of 
CH3CN into a 50 mL flask. In the case of incomplete dissolution ultrasounds or moderate heating 
may be useful. One equivalent (1.8 mmol) of Me3OBF4 was added to the clear solution which was 
stirred for 5 min. Na2CO3 (ca. 100 mg) was then added to the mixture which was stirred again for 45 
min. Further addition of 0.6 equivalents (1.1 mmol) of Me3OBF4 and 10 min of additional stirring led 
to virtual completion. The excess of base Na2CO3 and the NaBF4 formed were filtered off and the 
solvent completely removed under reduced pressure. The solid was washed with three aliquots of a 
2:1 mixture of Et2O/CH2Cl2 on a sintered glass filter, dried under vacuum and characterized.  
1,3,7,9-tetramethylxanthinium tetrafluoroborate (2a) 
White solid, yield 97 %. mp = 132-133 °C 
1H-NMR (400 MHz, CD3CN, T=298K, ppm)  3.35 (s, 3H, N-CH3), 3.74 (s, 3H, N-CH3), 4.08 (s, 
6H, 2N-CH3), 8.47 (s, 1H, NCHN).  
13C{1H}-NMR (CD3CN, T=298K, ppm)  28.7 (N-CH3), 31.8 (N-CH3), 36.3 (N-CH3), 37.6 (N-
CH3), 109.1 (C
5), 139.3(N-CH-N), 140.2 (C4), 151.1 (C=O), 154.2 (C=O). 
ESI-MS (CH3CN): m/z Calcd. for C9H13N4O2 [M]
+ 209.10; found: 209.07. 
Anal. Calcd. for C9H13BF4N4O2: C 36.52, H 4.43, N 18.93. Found: C 36.74, H 4.61, N 18.88 
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7-benzyl-1,3,9-trimethylxanthinium tetrafluoroborate (2b) 
White solid, yield 91 %. mp = 251-253 °C 
1H-NMR (400 MHz, CD3CN, T=298K, ppm)  3.33 (s, 3H, N-CH3), 3.73 (s, 3H, N-CH3), 4.06 (s, 
3H, N-CH3), 5.70 (s, 2H, N-CH2), 7.45-7.48 (m, 5H, Ph), 8.56 (s, 1H, NCHN).  
13C{1H}-NMR (CD3CN, T=298K, ppm)  28.8 (N-CH3), 31.8 (N-CH3), 37.9 (N-CH3), 52.7 (N-
CH2), 108.4 (C
5), 129.2, 129.7, 129.8, 133.9 (CPh), 138.9(N-CH-N), 140.6 (C
4), 151.0 (C=O), 154.0 
(C=O). 
ESI-MS (CH3CN): m/z Calcd. for C15H17N4O2 [M]
+ 285.13; found: 285.04. 
Anal. Calcd. for C15H17BF4N4O2: C 48.41, H 4.60, N 15.06. Found: C 48.39, H 4.64, N 15.18. 
7-phenylpropargyl-1,3,9-trimethylxanthinium tetrafluoroborate (2c) 
White solid, yield 92 % (612 mg). mp = 231 °C 
1H-NMR (400 MHz, CD3CN, T=298K, ppm)  3.37 (s, 3H, N-CH3), 3.76 (s, 3H, N-CH3), 4.14 (s, 
3H, N-CH3), 5.57 (s, 2H, N-CH2), 7.42-7.60 (m, 5H, Ph), 8.85 (s, 1H, NCHN). 
13C{1H}-NMR 
(CD3CN, T=298K, ppm)  28.8 (N-CH3), 31.9 (N-CH3), 37.9 (N-CH3), 40.7 (N-CH2), 79.2 (≡C-
CH2), 89.4 (≡C-Ph), 108.3 (C5), 121.6, 129.4, 130.4, 132.5 (CPh), 138.8 (N-CH-N), 140.6 (C4), 151.0 
(C=O), 154.0 (C=O). 
ESI-MS (CH3CN): m/z Calcd. for C17H17N4O2 [M]
+ 309.13; found: 309.02. 
Anal. Calcd. for C17H17BF4N4O2: C 51.54, H 4.33, N 14.14. Found: C 51.73, H 4.28, N 14.31. 
1-benzyl-3,7,9-trimethylxanthinium tetrafluoroborate (2d) 
White solid, yield 94 % (621 mg). mp = 171-172 °C 
1H-NMR (400 MHz, CD3CN, T=298K, ppm)  3.74 (s, 3H, N-CH3), 4.08 (s, 3H, N-CH3), 4.09 (s, 
3H, N-CH3), 5.17 (s, 2H, N-CH2), 7.28-7.42 (m, 5H, Ph), 8.48 (s, 1H, NCHN).  
13C{1H}-NMR (CD3CN, T=298K, ppm)  31.9 (N-CH3), 36.4 (N-CH3), 37.6 (N-CH3), 45.6 (N-
CH2), 109.2 (C
5), 128.3, 128.6, 129.1, 137.1 (CPh), 139.4 (N-CH-N), 140.5 (C
4), 151.0 (C=O), 154.1 
(C=O). 
ESI-MS (CH3CN): m/z Calcd. for C15H17N4O2 [M]
+ 285.13; found: 285.11. 
Anal. Calcd. for C15H17BF4N4O2: C 48.41, H 4.60, N 15.06. Found: C 48.65, H 4.72, N 15.14. 
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9.6.3. Synthesis of the imidazolium salts from caffeine and functionalized theophylline and 
theobromine with chloride as counterion (3) 
 
1,3,7,9-tetramethylxanthinium chloride (3a) 
In a 500 mL flask 0.3562 g (1.203 mmol) of the imidazolium salt 2a was dissolved in ca. 200 mL of 
water. The resulting solution was treated with 503.9 mg (1.203 mmol) of AsPh4Cl and stirred at R.T. 
for 30 min. The precipitated AsPh4BF4 was removed by filtration on a millipore membrane filter and 
the solvent was removed under reduced pressure. 
The white solid was washed with ca. 20 mL of dichloromethane and filtered off on a gooch. 
0.2933 g of 3a was obtained (yield 99%). 
1H-NMR (400 MHz, CD3CN, T = 298K, ppm) : 3.34 (s, 3H, NCH3), 3.75 (s, 3H, NCH3), 4.13 (s, 
3H, NCH3), 4.21 (s, 3H, NCH3), 10.03 (s, 1H, NCHN). 
13C{1H}-NMR (CD3CN, T = 298K, ppm) : 28.6 (CH3, NCH3), 31.8 (CH3, NCH3), 36.2 (CH3, 
NCH3), 37.5 (CH3, NCH3), 108.8 (C, C
5), 140.1 (C, C4), 140.4(CH, N-CH-N), 151.1 (C, C=O), 154.2 
(C, C=O). 
IR (KBr): νC=O = 1719 cm-1, 1675 cm-1, νC-O = 1304 cm-1, 1264 cm-1 
7-benzyl-1,3,9-trimethylxanthinium tetrafluoroborate (3b) 
Compound 3b was prepared in analogues manner as that described for 3a starting from 0.4004 g 
(1.076 mmol) of 2b and 0.4506 g of AsPh4Cl (1.076 mmol). 
0.3434 g (yield 98%) of 3b was obtained. 
1H-NMR (400 MHz, CD3CN, T = 298K, ppm) : 3.33 (s, 3H, NCH3), 3.73 (s, 3H, NCH3), 4.10 (s, 
3H, NCH3), 5.72 (s, 2H, NCH2), 7.44-7.50 (m, 5H, Ph), 8.92 (s, 1H, NCHN). 
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13C{1H}-NMR (CD3CN, T = 298K, ppm) : 28.2 (CH3, NCH3), 31.2 (CH3, NCH3), 37.3 (CH3, 
NCH3), 52.0 (CH2, NCH2), 107.8 (C, C
5), 128.6-133.4 (Ph), 138.6 (CH, NCHN), 140.0 (C, C4), 150.4 
(C, C=O), 153.4 (C, C=O). 
IR (KBr): νC=O = 1717 cm-1, 1671 cm-1, νC-O = 1267 cm-1 
1-benzyl-3,7,9-trimethylxanthinium tetrafluoroborate (3d) 
Compound 3c was prepared in analogues manner as that described for 3a starting from 0.3512 g 
(0.9438 mmol) of 2d and 0.3952 g of AsPh4Cl (0.9438 mmol). 
0.3021 g (yield 99%) of 3d was obtained. 
1H-NMR (400 MHz, CD3CN, T = 298K, ppm) : 3.73 (s, 3H, NCH3), 4.09 (s, 3H, NCH3), 4.10 (s, 
3H, NCH3), 5.16 (s, 2H, NCH2), 7.33-7.39 (m, 5H, Ph), 8.82 (s, 1H, NCHN). 
13C{1H}-NMR (CD3CN, T = 298K, ppm) : 31.3 (CH3, NCH3), 35.8 (CH3, NCH3), 37.0 (CH3, 
NCH3), 45.0 (CH2, NCH2), 108.6 (C, C
5), 127.7-136.5 (Ph), 139.0 (CH, NCHN), 139.8 (C, C4), 150.4 
(C, C=O), 153.5 (C, C=O). 
IR (KBr): νC=O = 1722 cm-1, 1674 cm-1 
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9.6.4. Synthesis of silver bis(purine-based NHC) complexes with BF4 as counterion (4) 
 
Synthesis of 1:1 mixture of 4a and AgBF4 
0.1967 g (0.6644 mmol) of the imidazolium salt 2a was dissolved in 30 mL of anhydrous CH3CN in 
a 100 mL two-necked flask and 0.0924 g (0.3987 mmol) of Ag2O was added under inert atmosphere 
(Ar). The mixture was stirred for 28 h at R.T. in the dark. 
The solution was filtered on millipore membrane filter to remove the Ag2O in excess. The resulting 
clear solution was concentrated under vacuum and the title complex precipitated by addition of 
diethylether. The white complex was filtered off on a gooch, repeatedly washed with diethylether and 
n−pentane and dried under vacuum. 
0.2463 g (yield 92%) of 1:1 mixture of 4a and AgBF4 was obtained. 
1H-NMR (400 MHz, CD3CN, T = 298K, ppm) : 3.33 (s, 6H, 2NCH3), 3.77 (s, 6H, 2NCH3), 4.10 (s, 
6H, 2NCH3), 4.16 (s, 6H, 2NCH3). 
13C{1H}-NMR (CD3CN, T = 298K, ppm) : 28.7 (CH3, NCH3), 32.2 (CH3, NCH3), 38.7 (CH3, 
NCH3), 40.1 (CH3, NCH3), 110.3 (C, C
5), 141.5 (C, C4), 151.8 (C, C=O), 154.6 (C, C=O), 187.4 (C, 
carbene). 
IR (KBr): CO = 1703, 1662 cm-1, BF =1053, 1086 cm-1 
Synthesis of 1:1 mixture of 4b and AgBF4 
The 1:1 mixture of 4b and AgBF4 was prepared in analogues manner as that described for 4a/AgBF4, 
with a reaction time of 24 hours, starting from 0.1564 g of 2b and 0.0584 g of Ag2O. 
0.2077 g (yield 96%) of 1:1 mixture of 4b and AgBF4 was obtained. 
1H-NMR (400 MHz, CD3CN, T = 298K, ppm) : 3.30 (s, 6H, 2NCH3), 3.76 (s, 6H, 2NCH3), 4.08 (s, 
6H, 2NCH3), 5.66 (s, 4H, 2NCH2), 7.28-7.33 (m, 10H, 2Ph). 
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13C{1H}-NMR (CD3CN, T = 298K, ppm) : 27.9 (CH3, NCH3), 31.4 (CH3, NCH3), 39.6 (CH3, 
NCH3), 53.2 (CH2, NCH2), 109.0 (C, C
5), 127.4-136.7 (Ph), 141.0 (C, C4), 150.9 (C, C=O), 153.6 (C, 
C=O), 187.1 (C, carbene). 
IR (KBr): CO = 1711, 1668 cm-1, BF =1046, 1084 cm-1 
Synthesis of 1:1 mixture of 4c and AgBF4 
The 1:1 mixture of 4c and AgBF4 was prepared in analogues manner as that described for 4a/AgBF4, 
with a reaction time of 24 hours, starting from 0.2218 g of 2c and 0.0779 g of Ag2O.  
0.2569 g (yield 91%) of 1:1 mixture of 4c and AgBF4 was obtained. 
1H-NMR (400 MHz, CD3CN, T=298K, ppm) : 3.35 (s, 6H, 2NCH3), 3.70 (s, 6H, 2NCH3), 4.03 (s, 
6H, 2NCH3), 5.40 (s, 4H, 2NCH2), 7.27-7.43 (m, 10H, 2Ph).  
13C{1H}-NMR (CD3CN, T=298K, ppm) : 27.9 (CH3, NCH3), 31.4 (CH3, NCH3), 40.1 (CH2, NCH2), 
40.2 (CH3, NCH3), 82.5 (C, CH2-C≡), 88.7 (C, Ph-C≡), 108.7 (C, C5), 121.3-131.8 (Ph), 140.4 (C, 
C4), 150.7 (C, C=O), 153.5 (C, C=O), 187.1 (C, carbene). 
IR (KBr): C≡C= 2218 cm-1, CO= 1710, 1668 cm-1, BF=1054 cm-1. 
Synthesis of 1:1 mixture of 4d and AgBF4 
The 1:1 mixture of 4d and AgBF4 was prepared in analogues manner as that described for 4a/AgBF4, 
with a reaction time of 24 hours, starting from 0.1505 g of 2d and 0.0562 g of Ag2O. 
0.1801 g (yield 93%) of 1:1 mixture of 4d and AgBF4 was obtained. 
1H-NMR (400 MHz, CD3CN, T = 298K, ppm) : 3.77 (s, 6H, 2NCH3), 4.10 (s, 6H, 2NCH3), 4.15 (s, 
6H, 2NCH3), 5.16 (s, 4H, 2NCH2), 7.28-7.40 (m, 10H, 2Ph). 
13C{1H}-NMR (CD3CN, T = 298K, ppm) : 32.1 (CH3, NCH3), 38.5 (CH3, NCH3), 39.9 (CH3, 
NCH3), 45.3 (CH2, NCH2), 110.2 (C, C
5), 128.0-137.8 (Ph), 141.6 (C, C4), 151.6 (C, C=O), 154.3 (C, 
C=O), 187.5 (C, carbene). 
IR (KBr): CO = 1709, 1665 cm-1, BF =1050 and 1085 cm-1 
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9.6.5. Synthesis of the silver bis(purine-based NHC) complexes with AgCl2 as counterion (5) 
 
Synthesis of the complex 5a 
0.1425 g (0.5824 mmol) of the imidazolium salt 3a was dissolved in 35 mL of anhydrous CH3CN in 
a 100 mL two-necked flask and 0.0742 g (0.3203 mmol) of Ag2O was added under inert atmosphere 
(Ar). The mixture was stirred for 4 h at R.T. in the dark and the solvent was subsequently removed 
under reduced pressure. 
The solid was dissolved in ca. 200 mL of dichloromethane and the resulting mixture was filtered on 
millipore membrane filter to remove the Ag2O in excess. The clear solution was concentrated under 
vacuum and the title complex precipitated by addition of diethylether. 
The white complex was filtered off on a gooch, repeatedly washed with diethylether and n−pentane. 
0.1214 g (yield 60%) of 5a was obtained. 
1H-NMR (400 MHz, CD2Cl2, T = 298K, ppm) : 3.41 (s, 6H, 2NCH3), 3.84 (s, 6H, 2NCH3), 4.17 (s, 
6H, 2NCH3), 4.24 (s, 6H, 2NCH3). 
13C{1H}-NMR (d6-DMSO, T = 298K, ppm) : 28.7 (CH3, NCH3), 31.2 (CH3, NCH3), 32.0 (CH3, 
NCH3), 38.3 (CH3, NCH3), 109.3 (C, C
5), 140.9 (C, C4), 151.0 (C, C=O), 153.7 (C, C=O), 207.0 (C, 
carbene). 
ESI-MS (CH3CN): m/z 525.04 [Ag(NHC)2]
+. 
IR (KBr): νC=O = 1709 cm-1, 1669 cm-1 
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Synthesis of the complex 5b 
Complex 5b was prepared in analogues manner as that described for 5a starting from 0.3434 g (1.071 
mmol) of 3b, and 0.1303 g (0.5620 mmol) of Ag2O. 
0.3069 g (yield 67%) of 5b was obtained. 
1H-NMR (400 MHz, CDCl3, T = 298K, ppm) : 3.31 (s, 6H, 2NCH3), 3.73 (s, 6H, 2NCH3), 4.16 (s, 
6H, 2NCH3), 5.62 (s, 4H, 2NCH2), 7.20-7.41 (m, 10H, 2Ph). 
13C{1H}-NMR (CDCl3, T = 298K, ppm) : 28.8 (CH3, NCH3), 32.0 (CH3, NCH3), 40.1 (CH3, NCH3), 
54.1 (CH2, NCH2), 109.1 (C, C
5), 128.3-135.5 (Ph), 140.3 (C, C4), 150.6 (C, C=O), 153.1 (C, C=O), 
188.1 (C, carbene). 
ESI-MS (CH3CN): m/z 677.11 [Ag(NHC)2]
+. 
IR (KBr): νC=O = 1713 cm-1, 1673 cm-1 
Synthesis of the complex 5d 
Complex 5d was prepared in analogues manner as that described for 5a starting from 0.1341 g (0.4181 
mmol) of 3d, and 0.0509 g (0.2195 mmol) of Ag2O. 
0.1249 g (yield 70%) of 5d was obtained. 
1H-NMR (400 MHz, CDCl3, T = 298K, ppm) : 3.83 (s, 6H, 2NCH3), 4.15 (s, 6H, 2NCH3), 4.19 (s, 
6H, 2NCH3), 5.19 (s, 4H, 2NCH2), 7.29-7.50 (m, 10H, 2Ph). 
13C{1H}-NMR (d6-DMSO, T = 298K, ppm) : 31.2 (CH3, NCH3), 32.1 (CH3, NCH3), 38.3 (CH2, 
NCH2), 109.3 (C, C
5), 127.7-137.3 (Ph), 141.3 (C, C4), 150.9 (C, C=O), 153.5 (C, C=O), 206.9 (C, 
carbene). 
ESI-MS (CH3CN): m/z 677.08 [Ag(NHC)2]
+. 
IR (KBr): νC=O = 1711 cm-1, 1674 cm-1 
 
  
309 
 
 
9.6.6. Synthesis of the mixed purine-based NHC/PPh3 palladium 3-allyl complexes (6) 
 
Synthesis of the complex 6a 
0.0195 g (0.053 mmol) of the [Pd(-Cl)(3-C3H5)]2 dimer and 0.0279 g (0.106 mmol) of PPh3 were 
dissolved in ca. 20 mL of anhydrous CH3CN in a 50 mL two-necked flask under inert atmosphere 
(Ar). The resulting mixture was treated with 0.0388 g (0.048 mmol) of 4a/AgBF4 and stirred at RT 
for ca. 15 min. 
The precipitated AgCl was removed by filtration on a millipore membrane filter. 
Addition of diethylether to the concentrated solution yields the precipitation of the complex 6a as a 
yellow solid which was filtered off on a gooch and washed with n-pentane.  
0.0576 g of 6a was obtained (yield 85%). 
1H-NMR (400 MHz, T=298K, CDCl3, ppm) : 3.16 (d, 1H, J= 13.4 Hz, anti allyl-H trans C), 3.26 
(d, 1H, J= 13.7 Hz, anti allyl-H trans C), 3.27 (m, 1H, anti allyl-H trans P), 3.38 (s, 6H, 2NCH3), 
3.59 (s, 6H, 2NCH3), 3.61 (s, 6H, 2NCH3), 3.68 (m, 1H, anti allyl-H trans P), 3.76 (s, 3H, NCH3), 
3.78 (s, 3H, NCH3), 4.11 (d, 1H, J= 8.4 Hz, syn allyl-H trans C), 4.19 (d, 1H, J= 7.6 Hz, syn allyl-H 
trans C), 4.59 (dd, 1H, JH-H=JH-P= 5.9 Hz, syn allyl-H trans P), 4.80 (dt, 1H, JH-H=JH-P= 6.6 Hz, syn 
allyl-H trans P), 5.71 (m, 1H, central allyl-H), 5.99 (m, 1H, central allyl-H), 7.25-7.53 (m, 30H, 
6Ph). 13C{1H}-NMR (T=298K, CDCl3, ppm) : 28.6 (CH3, NCH3), 31.7 (CH3, NCH3), 36.9 (CH3, 
NCH3), 37.1 (CH3, NCH3), 38.7 (CH3, NCH3), 38.9 (CH3, NCH3), 68.5 (d, CH2, JC-P= 28.5 Hz, allyl 
trans P), 69.3 (d, CH2, JC-P= 27.6 Hz, allyl trans P), 69.4 (d, CH2, JC-P= 1.8 Hz, allyl trans C), 69.4 
(d, CH2, JC-P= 1.7 Hz, allyl trans C), 110.4 (C, C
5), 110.6 (C, C5), 121.4 (d, CH, JC-P= 5.4 Hz, central 
allyl), 122.8 (d, CH, JC-P= 5.1 Hz, central allyl), 129.2-133.2 (Ph), 141.0 (C, C
4), 141.1 (C, C4), 150.4 
310 
 
(C, C=O), 153.0 (C, C=O), 185.8 (d, C, JC-P= 19.7 Hz, carbene), 186.2 (d, C, JC-P= 19.3 Hz, carbene).
 
31P{1H}-NMR (T=298K, CDCl3, ppm) : 25.9, 25.8.  
IR (KBr): CO= 1709, 1668 cm-1, BF=1059 cm-1. 
Anal. Calcd. for C30H32BF4N4O2PPd: C 51.12, H 4.58, N 7.95. Found: C 51.42, H 4.32, N 8.10. 
Synthesis of the complex 6b 
Complex 6b was prepared in analogues manner as that described for 6a starting from 0.0144 g of 
[Pd(-Cl)(3-allyl)]2, 0.0358 g of 4b/AgBF4 and 0.0196 g of PPh3. 
0.0511 g (yield 88%) of 6b was obtained. 
1H-NMR (400 MHz, T=298K, CDCl3, ppm) : 2.38 (m, 1H, anti allyl-H trans P), 2.93 (d, 1H, J= 
13.6 Hz, anti allyl-H trans C), 3.17 (d, 1H, J= 13.4 Hz, anti allyl-H trans C), 3.40 (s, 3H, NCH3), 
3.42 (s, 3H, NCH3), 3.60 (m, 1H, anti allyl-H trans P), 3.62 (s, 3H, NCH3), 3.63 (s, 3H, NCH3), 3.86 
(s, 3H, NCH3), 3.96 (dd, 1H, JH-H = 6.8 Hz, JH-P = 6.8 Hz, syn allyl-H trans P), 4.09 (d, 1H, J= 6.4 Hz, 
syn allyl-H trans C), 4.19 (d, 1H, J= 6.1 Hz, syn allyl-H trans C), 4.70 (dd, 1H, JH-H = 7.7 Hz, JH-P = 
7.7 Hz, syn allyl-H trans P), 4.80 and 5.57 (AB system, 2H, J=14.8 Hz, NCH2), 5.03 and 5.63 (AB 
system, 2H, J=15.0 Hz, NCH2), 5.22 (m, 1H, central allyl-H), 5.97 (m, 1H, central allyl-H), 7.00-
7.60 (m, 40H, 8Ph). 
13C{1H}-NMR (T=298K, CDCl3, ppm) : 28.7 (CH3, NCH3), 28.8 (CH3, NCH3), 31.9 (CH3, NCH3), 
39.3 (CH3, NCH3), 39.5 (CH3, NCH3), 52.4 (CH2, NCH2), 52.7 (CH2, NCH2), 68.6 (d, CH2, JC-P= 1.9 
Hz, allyl trans-C), 68.7 (d, CH2, JC-P= 1.8 Hz, allyl trans-C), 70.1 (d, CH2, JC-P= 27.7 Hz, allyl trans-
P), 70.8 (d, CH2, JC-P= 27.8 Hz, allyl trans-P), 110.1 (C, C
5), 110.3 (C, C5), 121.0 (CH, central allyl), 
122.8 (CH, central allyl), 127.2-135.3 (Ph), 141.1 (C4), 141.3 (C4), 143.7 (Ph), 150.3 (C, C=O), 150.4 
(C, C=O), 152.8 (C, C=O),  152.9 (C, C=O), 187.5 (d, C, JC-P= 18.5 Hz, carbene), 187.8 (d, C, JC-P= 
18.4 Hz, carbene). 31P{1H}-NMR (T=298K, CDCl3, ppm) : 25.6, 26.3 
IR (KBr): CO= 1709, 1668 cm-1, BF=1056 cm-1 
Anal. Calcd. for C36H36BF4N4O2PPd: C 55.37, H 4.65, N 7.17. Found: C 55.12, H 4.80, N 7.38. 
Synthesis of the complex 6c 
Complex 6c was prepared in analogues manner as that described for 6a starting from 0.0160 g of 
[Pd(-Cl)(3-allyl)]2, 0.0418 g of 4c/AgBF4 and 0.0218 g of PPh3. 
0.0559 g (yield 84%) of 6c was obtained. 
1H-NMR (400 MHz, T=298K, CDCl3, ppm) : 2.97 (d, 1H, J= 13.3 Hz, anti allyl-H trans C), 3.20 
(d, 1H, J= 12.8 Hz, anti allyl-H trans C), 3.36 (m, 1H, anti allyl-H trans P), 3.42 (s, 6H, 2NCH3), 
3.61 (s, 3H, NCH3), 3.62 (s, 3H, NCH3), 3.68 (s, 3H, NCH3), 3.76 (m, 1H, anti allyl-H trans P), 3.82 
(s, 3H, NCH3), 4.04 (d, 1H, J= 6.1 Hz, syn allyl-H trans C), 4.22 (d, 1H, J= 6.4 Hz, syn allyl-H trans 
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C), 4.71 (dd, 1H, JH-H = 6.0 Hz, JH-P = 6.8 Hz,, syn allyl-H trans P), 4.82 and 5.28 (AB system, 2H, 
J=17.2 Hz, NCH2), 4.88 and 5.47 (AB system, 2H, J=17.6 Hz, NCH2), 4.89 (m, 1H, syn allyl-H trans 
P), 5.63 (m, 1H, central allyl-H), 6.03 (m, 2H, central allyl-H), 7.15-7.46 (m, 40H, 8Ph). 13C{1H}-
NMR (T=298K, CDCl3, ppm) : 28.7 (CH3, NCH3), 31.8 (CH3, NCH3), 39.4 (CH3, NCH3), 40.0 
(CH2, NCH2), 68.9 (CH2, allyl trans-C), 69.3 (CH2, allyl trans-C), 69.9 (d, CH2, JC-P= 27.5 Hz, allyl 
trans-P), 70.4 (d, CH2, JC-P= 27.6 Hz, allyl trans-P), 81.6 (C, ≡C-CH2), 81.9 (C, ≡C-CH2), 86.5 (C, 
≡C-Ph), 87.4 (C, ≡C-Ph), 109.6 (C, C5), 109.7 (C, C5), 121.4 (d, CH, JC-P= 5.1 Hz, central allyl), 
122.7 (d, CH, JC-P= 5.2 Hz, central allyl), 128.4-134.0 (Ph), 141.2 (C, C
4), 150.4 (C, C=O), 152.6 (C, 
C=O), 152.7 (C, C=O), 187.3 (d, C, JC-P= 18.8 Hz, carbene), 187.7 (d, C, JC-P= 18.5 Hz, carbene).
 
31P{1H}-NMR (T=298K, CDCl3, ppm) : 25.4, 25.9. 
IR (KBr): CO= 1709, 1667 cm-1, BF=1058 cm-1 
Anal. Calcd. for C38H36BF4N4O2PPd: C 56.70, H 4.51, N 6.96. Found: C 56.52, H 4.78, N 7.12. 
Synthesis of the complex 6d 
Complex 6d was prepared in analogues manner as that described for 6a starting from 0.0154 g of 
[Pd(-Cl)(3-allyl)]2, 0.0383 g of 4d/AgBF4 and 0.0210 g of PPh3. 
0.0522 g (yield 84%) of 6d was obtained. 
1H-NMR (400 MHz, T=298K, CDCl3, ppm) : 3.13 (d, 1H, J= 13.4 Hz, anti allyl-H trans C), 3.28 
(d+m, 2H, J= 13.2 Hz, anti allyl-H trans C), 3.29 (m, 1H, anti allyl-H trans P), 3.58 (s, 3H, NCH3), 
3.59 (s, 3H, NCH3), 3.60 (s, 3H, NCH3), 3.62 (s, 3H, NCH3), 3.68 (m, 1H, anti allyl-H trans P), 3.74 
(s, 3H, NCH3), 3.81 (s, 3H, NCH3), 4.13 (d, 1H, J= 7.4 Hz, syn allyl-H trans C), 4.21 (d, 1H, J= 7.8 
Hz, syn allyl-H trans C), 4.58 (dd, 1H, JH-H=JH-P= 5.2 Hz, syn allyl-H trans P), 4.79 (dd, 1H, JH-H = 
5.5 Hz, JH-P = 5.5 Hz, syn allyl-H trans P), 5.15 (s, 4H, 2 NCH2), 5.70 (m, 1H, central allyl-H), 5.99 
(m, 1H, central allyl-H), 7.25-7.47 (m, 40H, 8Ph). 13C{1H}-NMR (T=298K, CDCl3, ppm) : 31.8 
(CH3, NCH3), 36.9 (CH3, NCH3), 37.0 (CH3, NCH3), 38.7 (CH3, NCH3), 38.9 (CH3, NCH3), 45.1 
(CH2, NCH2), 68.3 (d, CH2, JC-P= 28.4 Hz, allyl trans-P), 69.1 (d, CH2, JC-P= 28.1 Hz, allyl trans-P), 
69.2 (d, CH2,  JC-P= 1.7 Hz, allyl trans-C), 69.4 (d, CH2, JC-P= 1.9 Hz, allyl trans-C), 110.7 (C, C
5), 
121.3 (d, CH, JC-P= 5.5 Hz, central allyl), 122.8 (d, CH, JC-P= 5.3 Hz, central allyl), 127.9-136.4 (Ph), 
141.0 (C, C4), 141.1 (C, C4), 150.2 (C, C=O), 152.7 (C, C=O), 186.1 (d, C, JC-P= 19.3 Hz, carbene), 
186.5 (d, C, JC-P= 19.4 Hz, carbene). 
31P{1H}-NMR (T=298K, CDCl3, ppm) : 25.9, 26.0.  
IR (KBr): CO= 1707, 1668 cm-1, BF=1056 cm-1. 
Anal. Calcd. for C36H36BF4N4O2PPd: C 55.37, H 4.65, N 7.17. Found: C 55.22, H 4.58, N 7.42. 
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9.6.7. Synthesis of mixed purine-based NHC/TPPTS palladium 3-allyl complexes (7) 
 
Synthesis of the complex 7a 
0.0571g (0.0999 mmol) of TPPTS (3,3′,3″−phosphinetriyltribenzenesulfonate) was dissolved in 40 
mL of CH3CN and 7 mL of water in a two-necked flask under inert atmosphere (Ar). 
To the resulting solution 0.0239g (0.0653 mmol) of the dimer [Pd(-Cl)(3-allyl)]2 and 0.0352g 
(0.0873 mmol) of 4a/ AgBF4  were added and the final mixture stirred at RT for ca. 1 h. 
The precipitated AgCl was removed by filtration on a millipore membrane filter. 
The solution was dried under vacuum and the residue treated with 5 mL of diethylether and 5 mL of 
CH2Cl2 yielding the complex 7a as brownish solid that was filtered off on a gooch, washed with 
n−pentane and dried under vacuum. 
0.0763g (yield 86%) of 7a was obtained. 
1H-NMR (400 MHz, T = 298K, D2O, ppm) : 3.17 (d, 1H, J = 13.3 Hz, anti allyl-H trans-C), 3.23 (s, 
6H, 2NCH3), 3.29 (d, 1H, J = 13.2 Hz, anti allyl-H trans-C), 3.40 (s, 3H, NCH3), 3.41 (dd = t, 2H, JH-
H = JH-P = 10.0 Hz, 2anti allyl-H trans-P), 3.57 (s, 3H, NCH3), 3.58 (s, 6H, 2NCH3), 3.67 (s, 3H, 
NCH3), 3.84 (s, 3H, NCH3), 4.39 (d, 1H, J = 7.4 Hz, syn allyl-H trans-C), 4.47 (d, 1H, J = 8.1 Hz, syn 
allyl-H trans-C), 4.61 (dd = t, 2H, JH-H = JH-P = 6.1 Hz, 2syn allyl-H trans-P), 5.82 (m, 2H, 2central 
allyl-H), 7.45-7.90 (m, 24H, 6PhSO3Na). 
31P{1H}-NMR (T = 298K, D2O, ppm) : 28.3, 28.5 
13C{1H}-NMR (T = 298K, D2O, ppm) : 28.4 (CH3, NCH3), 31.8 (CH3, NCH3), 36.6 (CH3, NCH3), 
36.8 (CH3, NCH3), 38.3 (CH3, NCH3), 38.4 (CH3, NCH3), 68.2 (d, CH2, JC-P = 28.4 Hz, 2 allyl trans-
P), 69.5 (CH2, allyl trans-C), 69.8 (CH2, allyl trans-C), 111.1 (C, C
5), 111.3 (C, C5), 122.6 (CH, 
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central allyl), 128.3-136.4 and 143.7-143.8 (Ph), 141.5 (C, C4), 141.7 (C, C4), 151.8 (C, C=O), 154.3 
(C, C=O), 185.3 (d, C, JC-P = 20.0 Hz, carbene), 185.4 (d, C, JC-P = 19.9 Hz, carbene). 
IR (KBr): CO = 1705, 1664 cm-1, BF  =1035, 1095 cm-1 
Anal. Calcd. for C30H29BF4N4Na3O11PPdS3: C 35.64, H 2.89, N 5.54. Found: C 35.72, H 2.80, N 
5.52. 
Synthesis of the complex 7b 
Complex 7b was prepared in analogues manner as that described for 7a starting from 0.0153 g of 
[Pd(μ-Cl)(η3-allyl)]2, 0.0475 g of TPPTS and 0.0348 g of 4b/AgBF4. 
0.0708 g (yield 90%) of 7b was obtained. 
1H-NMR (400 MHz, T = 298K, D2O, ppm) : 3.18 (d, 1H, J = 13.8 Hz, anti allyl-H trans-C), 3.27 (d, 
1H, J = 13.3 Hz, anti allyl-H trans-C), 3.41 (dd = t, 2H, JH-H = JH-P = 11.5 Hz, 2anti allyl-H trans-P), 
3.41 (s, 3H, NCH3), 3.57 (s, 3H, NCH3), 3.58 (s, 3H, NCH3), 3.59 (s, 3H, NCH3), 3.67 (s, 3H, NCH3), 
3.84 (s, 3H, NCH3), 4.43 (d, 1H, J = 7.1 Hz, syn allyl-H trans-C), 4.49 (d, 1H, J = 7.0 Hz, syn allyl-
H trans-C), 4.62 (dd, 2H, J = 7.9, J = 5.7 Hz, 2syn allyl-H trans-P), 4.99 and 5.09 (2AB system, 4H, 
J = 15.5 Hz, 2NCH2), 5.86 (m, 2H, 2central allyl-H), 7.27-7.87 (m, 34H, 6PhSO3Na+2Ph). 
31P{1H}-NMR (T = 298K, D2O, ppm) : 28.5, 28.8 
13C{1H}-NMR (T = 298K, D2O, ppm) : 31.9 (CH3, NCH3), 36.7 (CH3, NCH3), 36.9 (CH3, NCH3), 
38.3(CH3, NCH3), 38.5 (CH3, NCH3), 45.2 (CH2, NCH2), 68.2 (d, CH2, JC-P = 28.4 Hz, allyl trans-P), 
68.4 (d, CH2, JC-P = 29.0 Hz, allyl trans-P), 69.5 (CH2, allyl trans-C), 69.6 (CH2, allyl trans-C), 111.1 
(C, C5), 111.2 (C, C5), 122.4 (d, CH, JC-P = 5.2 Hz, central allyl),  and 122.5 (d, CH, JC-P = 5.6 Hz, 
central allyl), 127.2-136.3 (Ph), 141.7 (C, C4), 141.8 (C, C4), 143.7 and 143.8 (Ph), 151.5 (C, C=O), 
153.9 (C, C=O), 186.0 (d, C, JC-P = 19.8 Hz, carbene), 186.1 (d, C, JC-P = 20.0 Hz, carbene). 
IR (KBr): CO = 1706, 1666 cm-1, BF =1036, 1084 cm-1 
Anal. Calcd. for C36H33BF4N4Na3O11PPdS3: C 39.78, H 3.06, N 5.15. Found: C 39.72, H 3.13, N 
5.24. 
Synthesis of the complex 7c 
Complex 7c was prepared in analogues manner as that described for 7a starting from 0.0154 g of 
[Pd(μ-Cl)(η3-allyl)]2, 0.0478 g of TPPTS and 0.0350 g of 4c/AgBF4. 
0.0698 g (yield 88%) of 7c was obtained. 
1H-NMR (400 MHz, T = 298K, D2O, ppm) : 3.03 (d, 1H, J = 13.3 Hz, anti allyl-H trans-C), 3.11 (d, 
1H, J = 13.4 Hz, anti allyl-H trans-C), 3.24 (s, 3H, NCH3), 3.25 (s, 3H, NCH3), 3.28 (m, 2H, 2anti 
allyl-H trans-P), 3.58 (s, 3H, NCH3), 3.62 (s, 3H, NCH3), 3.64 (s, 3H, NCH3), 3.85 (s, 3H, NCH3), 
4.07 (dd = t, 1H, J = 5.4 Hz, syn allyl-H trans-P), 4.33 (d, 1H, J = 7.1 Hz, 2syn allyl-H trans-C), 4.34 
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(d, 1H, J =7.6 Hz, syn allyl-H trans-C), 4.48 (dd = t, 1H, JH-H = JH-P = 4.7 Hz, syn allyl-H trans-P), 
4.93 and 5.25 (AB system, 2H, J = 15.4 Hz, NCH2), 5.17 and 5.35 (AB system, 2H, J = 14.5 Hz, 
NCH2), 5.44 (m, 1H, central allyl-H), 5.78 (m, 1H, central allyl-H), 6.97-7.90 (m, 34H, 
6PhSO3Na+2Ph). 
31P{1H}-NMR (T = 298K, D2O, ppm) : 27.6, 28.1 
13C{1H}-NMR (T = 298K, D2O, ppm) : 28.4 (CH3, NCH3), 31.9 (CH3, NCH3), 38.9 (CH3, NCH3), 
39.0 (CH3, NCH3), 52.4 (CH2, NCH2), 52.6 (CH2, NCH2), 68.9 (d, CH2, JC-P = 28.5 Hz, allyl trans-
P), 69.1 (d, CH2, JC-P = 27.8 Hz, allyl trans-P), 69.8 (CH2, allyl trans-C), 69.9 (CH2, allyl trans-C), 
111.1 (C, C5), 111.4 (C, C5), 122.2 (CH, central allyl), 122.3 (CH, central allyl), 126.6-136.3 and 
143.7 (Ph), 141.8 (C, C4), 151.8 (C, C=O), 154.1 (C, C=O), 187.3 (d, C, JC-P = 19.4 Hz, carbene), 
187.4 (d, C, JC-P = 19.0 Hz, carbene). 
IR (KBr): CO = 1703, 1663 cm-1, BF =1036, 1084 cm-1 
Anal. Calcd. for C36H33BF4N4Na3O11PPdS3: C 39.78, H 3.06, N 5.15. Found: C 39.84, H 3.11, N 
5.20. 
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9.6.8. Synthesis of mixed purine-based NHC/PTA palladium 3-allyl complexes (8) 
 
Synthesis of the complex 8a 
0.0411 g (0.112 mmol) of the dimer [Pd(-Cl)(3-C3H5)]2 and 0.0353 g (0.224 mmol) of PTA (1,3,5-
triaza-7-phosphadamantane) were dissolved in ca. 30 mL of anhydrous CH3CN in a 100 mL two-
necked flask under inert atmosphere (Ar). The resulting mixture was treated with 0.0787 g (0.0975 
mmol) of 4a/AgBF4 and stirred at RT for ca. 1 h.  
The precipitated AgCl was removed by filtration on a millipore membrane filter. 
The solution was dried under vacuum and the residue treated with 2 mL of CH2Cl2.  
Addition of diethylether to the concentrated solution yields the precipitation of the complex 8a as a 
brownish solid which was filtered off on a gooch, washed with n-pentane and dried under vacuum. 
0.0991 g of 8a was obtained (yield 97%). 
1H-NMR (400 MHz, T=298K, D2O, ppm) : 2.88 (d, 2H, J= 13.2 Hz, 2 anti allyl-H trans-C), 3.15 
(m, 2H, 2 anti allyl-H trans-P), 3.32 (s, 3H, NCH3), 3.33 (s, 3H, NCH3), 3.74 (s, 3H, NCH3), 3.77 (s, 
3H, NCH3), 3.80 (s, 3H, NCH3), 3.87 (s, 3H, NCH3), 3.92 (s, 3H, NCH3), 4.05 (s, 3H, NCH3), 4.21 
(s, 12H, 6 NCH2PPTA), 4.38 (d, 2H, J= 7.4 Hz, 2 syn allyl-H trans-C), 4.47 (m, 2H, 2 syn allyl-H 
trans-P), 4.55 (m, 12H, 6 NCH2NPTA), 5.48 (m, 2H, 2 central allyl-H). 
13C{1H}-NMR (T=298K, D2O, 
ppm) : 28.4 (CH3, NCH3), 31.8 (CH3, NCH3), 36.7 (CH3, NCH3), 36.9 (CH3, NCH3), 38.2 (CH3, 
NCH3), 38.4 (CH3, NCH3), 50.3 (CH2, NCH2P, JC-P =13.6 Hz), 62.7 (CH2, allyl trans-C), 62.8 (CH2, 
allyl trans-C), 68.9 (d, CH2, JC-P= 4.8 Hz, allyl trans-P), 69.2 (d, CH2, JC-P= 5.2 Hz, allyl trans-P), 
70.7 (CH2, NCH2N), 70.8 (CH2, NCH2N), 111.2 (C, C
5), 111.4 (C, C5), 121.9 (CH, central allyl), 
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122.0 (CH, central allyl), 141.8 (C, C4), 141.9 (C, C4), 151.8 (C, C=O), 154.5 (C, C=O), 183.9 (C, 
JC-P= 21.2 Hz, carbene). 
31P{1H}-NMR (T=298K, D2O, ppm) : -52.4 
IR (KBr): CO= 1704, 1665 cm-1, BF=1031, 1084 cm-1. 
Anal. Calcd. for C18H29BF4N7O2PPd: C 36.05, H 4.87, N 16.35. Found: C 36.34, H 4.97, N 16.14. 
Synthesis of the complex 8b 
Complex 8b was prepared in analogues manner as that described for 8a starting from 0.0353 g of 
[Pd(-Cl)(3-allyl)]2, 0.0804 g of 4b/AgBF4 and 0.0304 g of PTA. 
0.0925 g (yield 82%) of 8b was obtained. 
1H-NMR (400 MHz, T=298K, D2O, ppm) : 2.76 (m, 2H, 2 anti allyl-H trans-C), 3.06 (m, 2H, 2 anti 
allyl-H trans-P), 3.28 (s, 3H, NCH3), 3.29 (s, 3H, NCH3), 3.72 (s, 6H, 3 NCH2PPTA), 3.75 (s, 6H, 3 
NCH2PPTA), 3.77 (s, 3H, NCH3), 3.80 (s, 3H, NCH3), 3.88 (s, 3H, NCH3), 4.06 (s, 3H, NCH3), 4.27-
4.70 (m, 16 H, 6 NCH2NPTA and 2 syn allyl-H trans-C and 2 syn allyl-H trans-P), 5.07 and 5.64 (AB 
system, 2H, J=15.4 Hz, NCH2), 5.29 and 5.76 (AB system, 2H, J=15.7 Hz, NCH2), 5.36 (m, 2H, 2 
central allyl-H), 6.81-7.36 (m, 10H, 2Ph). 13C{1H}-NMR (T=298K, D2O, ppm) : 28.5 (CH3, NCH3), 
31.9 (CH3, NCH3), 38.6 (CH3, NCH3), 38.9 (CH3, NCH3), 49.9 (d, CH2, J= 13.5 Hz, NCH2P), 50.0 
(d, CH2, J= 13.6 Hz, NCH2P), 52.5 (CH2, NCH2), 52.7 (CH2, NCH2), 62.6 (CH2, allyl trans-C), 63.0 
(CH2, allyl trans-C), 69.4 (d, CH2, JC-P= 26.7 Hz, allyl trans-P), 69.9 (d, CH2, JC-P= 27.8 Hz, allyl 
trans-P), 70.4 (CH2, NCH2NPTA) 70.5 (CH2, NCH2N), 111.1 (C, C
5), 111.4 (C, C5), 121.9 (CH, 
central allyl), 126.9-136.7 (Ph), 141.8 (C, C4), 141.9 (C, C4), 151.8 (C, C=O), 154.2 (C, C=O), 186.0 
(d, C, JC-P= 20.4, carbene), 186.1 (d, C, JC-P= 20.5 Hz, carbene).
 31P{1H}-NMR (T=298K, D2O, ppm) 
: -54.1, -54.0. 
IR (KBr): CO= 1705, 1664 cm-1, BF=1035, 1083 cm-1 
Anal. Calcd. for C24H33BF4N7O2PPd: C 42.66, H 4.92, N 14.51. Found: C 42.82, H 4.78, N 14.22. 
Synthesis of the complex 8d 
Complex 8d was prepared in analogues manner as that described for 8a starting from 0.0352 g of 
[Pd(-Cl)(3-allyl)]2, 0.0800 g of 4d/AgBF4 and 0.0301 g of PTA. 
0.1057 g (yield 94%) of 8d was obtained. 
1H-NMR (400 MHz, T=298K, D2O, ppm) : 2.83 (d, J= 13.8 Hz, 2H, 2 anti allyl-H trans-C), 3.07 
(m, 2H, 2 anti allyl-H trans-P), 3.69 (s, 3H, NCH3), 3.70 (s, 3H, NCH3), 3.73 (s, 3H, NCH3), 3.82 (s, 
3H, NCH3), 3.87 (s, 3H, NCH3), 4.01 (s, 3H, NCH3), 4.15 (s, 6H, 3 NCH2PPTA), 4.27 (s, 6H, 3 
NCH2PPTA), 4.32 (d, J = 6.6 Hz, 2H, 2 syn allyl-H trans-C), 4.45 (m, 2H, 2 syn allyl-H trans-P), 4.50-
4.70 (m, 12H, 6 NCH2PPTA), 5.10 (2s, 4H, 2 N-CH2), 5.42 (m, 2H, 2 central allyl-H), 7.25-7.30 (m, 
10H, 2Ph). 
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13C{1H}-NMR (T=298K, D2O, ppm) : 31.9 (CH3, NCH3), 36.8 (CH3, NCH3), 37.1 (CH3, NCH3), 
38.2 (CH3, NCH3), 38.5 (CH3, NCH3), 45.2 (CH2, NCH2), 50.3 (d, CH2, JC-P= 13.8 Hz, NCH2P), 51.1 
(d, CH2, JC-P= 15.4 Hz, NCH2P), 62.8 (CH2, allyl trans-C), 62.9 (CH2, allyl trans-C), 69.2 (d, CH2, 
JC-P= 27.7 Hz, allyl trans-P), 70.8 (CH2, NCH2N), 71.3 (d, CH2, JC-P= 26.2 Hz, allyl trans-P), 111.4 
(C5), 122.0 (CH, central allyl), 123.0 (CH, central allyl), 127.2-136.2 (Ph), 142.3 (C, C4), 151.6 (C, 
C=O), 154.2 (C, C=O), 184.2 (d, C, JC-P= 19.0 Hz, carbene), 184.3 (d, C, JC-P= 19.8 Hz, carbene). 
31P{1H}-NMR (T=298K, D2O, ppm) : -54.2, -53.1. 
IR (KBr): CO= 1708, 1668 cm-1, BF=1062, 1084 cm-1 
Anal. Calcd. for C24H33BF4N7O2PPd: C 42.66, H 4.92, N 14.51. Found: C 42.52, H 4.99, N 14.32. 
 
  
318 
 
9.6.9. Synthesis of mixed purine-based NHC/DIC palladium 3-allyl complexes (9) 
 
Synthesis of the complex 9a 
0.0173 g (0.047 mmol) of the dimer [Pd(-Cl)(3-C3H5)]2 and 0.0124 g (0.094 mmol) of DIC (2,6-
dimethylphenyl isocyanide) were dissolved in ca. 20 mL of anhydrous CH3CN in a 50 mL two-necked 
flask under inert atmosphere (Ar). The resulting mixture was treated with 0.0344 g (0.043 mmol) of 
4a/AgBF4 and stirred at RT for ca. 15 min. 
The precipitated AgCl was removed by filtration on a millipore membrane filter. 
Addition of diethylether to the concentrated solution yields the precipitation of the complex 9a as a 
brownish solid which was filtered off on a gooch and washed with n-pentane.   
0.0431 g of 9a was obtained (yield 88%). 
1H-NMR (400 MHz, T=298K, CDCl3, ppm) : 2.41 (s, 6H, 2CH3DIC), 3.20 (d, 1H, J= 13.3 Hz, anti 
allyl-H), 3.40 (s, 3H, NCH3), 3.41 (d, 1H, J= 12.7 Hz, anti allyl-H), 3.88 (s, 3H, NCH3), 4.05 (s, 3H, 
NCH3), 4.20 (s, 3H, NCH3), 4.47 (d, 1H, J= 6.4 Hz, syn allyl-H), 4.79 (d, 1H, J= 7.5 Hz, syn allyl-
H), 5.72 (m, 1H, central allyl-H), 7.17-7.31 (m, 3H, PhDIC). 13C{1H}-NMR (T=298K, CDCl3, ppm) 
: 18.7 (CH3, CH3DIC), 28.6 (CH3, NCH3), 32.0 (CH3, NCH3), 37.5 (CH3, NCH3), 39.3 (CH3, NCH3), 
65.0 (CH2, allyl-C), 69.3 (CH2, allyl-C), 110.8 (C, C
5), 122.2 (central allyl), 128.4-135.6 (Ph), 141.4 
(C, C4), 150.6 (C, C=O), 150.7 (C, CNDIC), 153.4 (C, C=O), 181.5 (C, carbene).  
IR (KBr): CN=2175 cm-1, CO= 1706, 1665 cm-1, BF=1056 cm-1. 
Anal. Calcd. for C21H26BF4N5O2Pd: C 43.97, H 4.57, N 12.21. Found: C 44.24, H 4.77, N 12.04. 
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Synthesis of the complex 9b 
Complex 9b was prepared in analogues manner as that described for 9a starting from 0.0180 g of 
[Pd(-Cl)(3-allyl)]2, 0.0428 g of 4b/AgBF4 and 0.128 g of DIC. 
0.0491 g (yield 85%) of 9b was obtained. 
1H-NMR (400 MHz, T=298K, CDCl3, ppm) : 2.36 (s, 6H, 2CH3DIC), 3.42 (s, 3H, NCH3), 3.48 (bd, 
2H, 2anti allyl-H), 3.91 (s, 3H, NCH3), 4.24 (bd, 1H, syn allyl-H), 4.25 (s, 3H, NCH3), 4.67 (d, 1H, 
J= 7.5 Hz, syn allyl-H), 5.65 (s, 2H, NCH2), 5.73 (m, 1H, central allyl-H), 7.16-7.33 (m, 8H, Ph and 
PhDIC). 13C{1H}-NMR (T=298K, CDCl3, ppm) : 18.8 (CH3, CH3DIC), 28.7 (CH3, NCH3), 32.1 (CH3, 
NCH3), 39.9 (CH3, NCH3), 53.0 (CH2, NCH2), 65.5 (CH2, allyl-C), 110.6 (C, C
5), 121.9 (CH, central 
allyl), 127.5-135.9 (Ph), 141.5 (C, C4), 150.5 (C, C=O), 150.7 (C, CNDIC), 153.2 (C, C=O), 183.5 (C, 
carbene). 
IR (KBr): CN=2175 cm-1, CO= 1709, 1670 cm-1, BF=1057 cm-1. 
Anal. Calcd. for C27H30BF4N5O2Pd: C 49.91, H 4.65, N 10.78. Found: C 49.84, H 4.83, N 10.90. 
Synthesis of the complex 9d 
Complex 9d was prepared in analogues manner as that described for 9a starting from 0.0184 g of 
[Pd(-Cl)(3-allyl)]2, 0.0437 g of 4d/AgBF4 and 0.0131 g of DIC. 
0.0543 g (yield 92%) of 9d was obtained. 
1H-NMR (400 MHz, T=298K, CDCl3, ppm) : 2.41 (s, 6H, 2CH3DIC), 3.19 (d, 1H, J= 13.5 Hz, anti 
allyl-H), 3.41 (d, 1H, J= 12.5 Hz, anti allyl-H), 3.86 (s, 3H, NCH3), 4.05 (s, 3H, NCH3), 4.19 (s, 3H, 
NCH3), 4.47 (d, 1H, J= 7.1 Hz, syn allyl-H), 4.78 (d, 1H, J= 7.5 Hz, syn allyl-H), 5.18 (s, 2H, NCH2), 
5.72 (m, 1H, central allyl-H), 7.17-7.49 (m, 8H, Ph and PhDIC). 13C{1H}-NMR (T=298K, CDCl3, 
ppm) : 18.8 (CH3, CH3DIC), 32.0 (CH3, NCH3), 37.5 (CH3, NCH3), 39.3 (CH3, NCH3), 45.2 (CH2, 
NCH2), 64.9 (CH2, allyl-C), 110.9 (C, C
5), 122.2 (CH, central allyl), 127.8-136.3 (Ph), 141.5 (C, C4), 
150.5 (C, C=O), 150.6 (C, CNDIC), 153.2 (C, C=O), 181.8 (C, carbene). 
IR (KBr): CN=2173 cm-1, CO= 1707, 1665 cm-1, BF=1056 cm-1. 
Anal. Calcd. for C27H30BF4N5O2Pd: C 49.91, H 4.65, N 10.78. Found: C 50.04, H 4.51, N 10.95. 
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9.6.10. Synthesis of the Bis(purine-based NHC) palladium 3-allyl complexes (10) 
 
Synthesis of the complex 10a 
0.0156 g (0.086 mmol) of the dimer [Pd(-Cl)(3-C3H5)]2 was dissolved in ca. 20 mL of anhydrous 
CH3CN in a 50 mL two necked flask under inert atmosphere (Ar). 
The resulting mixture was treated with 0.0690 g (0.171 mmol) of 4a/AgBF4, 0.0142 g (0.086 mmol) 
of KI and stirred at RT for ca. 15 min. The precipitated AgCl and AgI were removed by filtration on 
a millipore membrane filter. Addition of diethylether to the concentrated solution yields the 
precipitation of the complex 10a as a white solid which was filtered off on a gooch and washed with 
n-pentane.  
0.0446 g of 10a was obtained (yield 80%). 
1H-NMR (400 MHz, T=298K, CD3CN, ppm) : 2.95 (d, 2H, J= 13.3 Hz, anti allyl-H), 3.30 (s, 6H, 
NCH3), 3.73 (s, 6H, NCH3), 3.93 (s, 6H, NCH3), 4.02 (s, 6H, NCH3), 4.12 (d, 2H, J= 7.4 Hz, syn 
allyl-H), 5.59 (m, 1H, central allyl-H). 13C{1H}-NMR (T=298K, CD3CN, ppm) : 28.4 (CH3, NCH3), 
32.0 (CH3, NCH3), 37.7 (CH3, NCH3), 39.4 (CH3, NCH3), 61.6 (CH2, allyl-C), 110.9 (C, C
5), 121.0 
(CH, central allyl), 141.9 (C, C4), 151.4 (C, C=O), 153.9 (C, C=O), 184.9 (C, carbene). 
IR (KBr): CO= 1706, 1668 cm-1, BF=1053 cm-1. 
Anal. Calcd. for C21H29BF4N8O4Pd: C 38.76, H 4.49, N 17.22. Found: C 38.50, H 4.82, N 17.35. 
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Synthesis of the complex 10b 
Complex 10b was prepared in analogues manner as that described for 10a starting from 0.0157 g of 
[Pd(-Cl)(3-allyl)]2, 0.0822 g of 4b/AgBF4 and 0.0142 g of KI. 
0.0599 g (yield 87%) of 10b was obtained. 
1H-NMR (400 MHz, T=298K, CD3CN, ppm) : 2.79 (d, 2H, J= 13.2 Hz, anti allyl-H), 3.23 (s, 6H, 
NCH3), 3.68 (s, 6H, NCH3), 3.97 (s, 6H, NCH3), 3.97 (bd, 2H, syn allyl-H), 5.39-5.61 (m, 5H, NCH2 
and central allyl-H), 6.94-7.24 (m, 10H, 2Ph). 
13C{1H}-NMR (T=298K, CD3CN, ppm) : 28.3 (CH3, NCH3), 31.9 (CH3, NCH3), 39.6 (CH3, NCH3), 
53.0 (CH2, NCH2), 65.9 (CH2, allyl-C), 110.4 (C, C
5), 121.2 (CH, central allyl), 125.7-137.2 (Ph), 
142.0 (C, C4), 151.2 (C, C=O), 153.2 (C, C=O), 185.3 (C, carbene). 
IR (KBr): CO= 1709, 1664 cm-1, BF=1058 cm-1. 
Anal. Calcd. for C33H37BF4N8O4Pd: C 49.36, H 4.64, N 13.96. Found: C 49.57, H 4.12, N 14.22. 
Synthesis of the complex 10c 
Complex 10c was prepared in analogues manner as that described for 10a starting from 0.0157 g of 
[Pd(-Cl)(3-allyl)]2, 0.0863 g of 4c/AgBF4 and 0.0142 g of KI. 
0.0592g (yield 81%) of 10c was obtained. 
1H-NMR (400 MHz, T=298K, CD3CN, ppm) : 3.02 (s, 6H, NCH3), 3.03 (d, 2H, J= 13.4 Hz, anti 
allyl-H), 3.53 (s, 6H, NCH3), 4.20 (m, 8H,  NCH3 and syn allyl-H), 5.44 (bs, 4H, NCH2), 5.66 (m, 
1H, central allyl-H), 7.16-7.48 (m, 10H, 2Ph). 13C{1H}-NMR (T=298K, CD3CN, ppm) : 28.4 (CH3, 
NCH3), 31.9 (CH3, NCH3), 39.8 (CH3, NCH3), 41.1 (CH2, NCH2), 65.9 (CH2, allyl-C), 83.8 (CH2-
C≡), 84.7 (C, Ph-C≡), 110.4 (C, C5), 121.6 (CH, central allyl), 121.9-131.0 (Ph), 141.7 (C, C4), 150.5 
(C, C=O), 153.4 (C, C=O), 185.5 (C, carbene). 
IR (KBr): CO= 1706, 1667 cm-1, BF=1056 cm-1. 
Anal. Calcd. for C37H37BF4N8O4Pd: C 52.22, H 4.38, N 13.17. Found: C 52.37, H 4.10, N 13.55. 
Synthesis of the complex 10d 
Complex 10d was prepared in analogues manner as that described for 10a starting from 0.0154 g of 
[Pd(-Cl)(3-allyl)]2, 0.0806 g of 4d/AgBF4 and 0.0139 g of KI. 
0.0595 g (yield 88%) of 10d was obtained. 
1H-NMR (400 MHz, T=298K, CD3CN, ppm) : 2.96 (d, 2H, J= 13.3 Hz, anti allyl-H), 3.73 (s, 6H, 
NCH3), 3.93 (s, 6H, NCH3), 4.02 (s, 6H, NCH3), 4.13 (d, 2H, J= 7.4 Hz, 2 syn allyl-H), 5.13 (s, 4H, 
NCH2), 5.59 (m, 1H, central allyl-H), 7.28-7.39 (m, 10H, 2Ph). 
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13C{1H}-NMR (T=298K, CD3CN, ppm) : 31.5 (CH3, NCH3), 37.2 (CH3, NCH3), 38.8 (CH3, NCH3), 
44.6 (CH2, NCH2), 61.1 (CH2, allyl-C), 110.4 (C, C
5), 120.4 (CH, central allyl), 127.4-137.3 (Ph), 
141.5 (C, C4), 150.7 (C, C=O), 153.2 (C, C=O), 184.7 (C, carbene). 
IR (KBr): CO= 1708, 1667 cm-1, BF=1058 cm-1. 
Anal. Calcd. for C33H37BF4N8O4Pd: C 49.36, H 4.64, N 13.96. Found: C 49.61, H 4.17, N 14.05. 
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9.6.11. Synthesis of mixed purine-based NHC/PPh3 pallacyclopentadienyl complexes (11) 
 
Synthesis of the complex 11a 
0.0279 g (0.0713 mmol) of the polymeric precursor [PdC4(COOCH3)4]n was dissolved in 5 mL of 
anhydrous dichloromethane in a 100 mL two necked flask under inert atmosphere (Ar). To this 
solution a mixture constituted by 0.0218 g (0.0310 mmol) of the silver complex 5a and 0.0171 g 
(0.0651 mmol) of PPh3 dissolved in ca. 30 mL of anhydrous dichloromethane, was added.  
The mixture was stirred at R.T. for 1 h and subsequently the precipitated AgCl was removed by 
filtration on a millipore membrane filter. 
Addition of diethylether to the concentrated solution yields the precipitation of the complex 11a as a 
yellow solid which was filtered off on a gooch and washed with n-pentane.  
0.0509 g of 11a was obtained (yield 83%). 
1H-NMR (400 MHz, CDCl3, T=298K, ppm) : 2.53 (s, 3H, OCH3), 3.25 (s, 3H, OCH3), 3.36 (s, 3H, 
NCH3), 3.48 (s, 3H, NCH3), 3.63 (s, 3H, OCH3), 3.65 (s, 3H, OCH3), 3.76 (s, 3H, NCH3), 3.82 (s, 
3H, NCH3), 7.32-7.51 (m, 15H, 3Ph). 
13C{1H}-NMR (CDCl3, T = 298K, ppm) : 28.6 (CH3, NCH3), 31.5 (CH3, NCH3), 36.6 (CH3, NCH3), 
38.2 (CH3, NCH3), 50.0 (CH3, OCH3), 50.8 (CH3, OCH3), 51.2 (CH3, OCH3), 51.3 (CH3, OCH3), 
109.7 (C, C5), 128.3-134.1 (Ph), 140.2 (C, C4), 145.9 (d, C, JC-P = 5.4 Hz, C-COOCH3), 148.8 (d, C, 
JC-P = 7.0 Hz, C-COOCH3), 150.2 (C, C=O), 152.7 (C, C=O), 164.0-166.4 (C, COOCH3), 168.1 (C, 
C-COOCH3), 169.6 (C, C-COOCH3), 174.9 (d, C, JC-P = 4.9 Hz, COOCH3), 175.6 (d, C, JC-P = 5.3 
Hz, COOCH3), 189.1 (d, C, JC-P = 15.8 Hz, carbene). 
31P{1H}-NMR (CDCl3, T = 298K, ppm) : 26.1 
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IR (KBr): νC=O = 1730 cm-1 - 1692 cm-1, νC-O = 1212 cm-1 
Synthesis of the complex 11b 
Complex 11b was prepared in analogues manner as that described for 11a starting from 0.0267 g of 
[PdC4(COOCH3)4]n, 0.0265 g of 5b and 0.0163 g of PPh3. 
0.0552 g (yield 86%) of 11b was obtained. 
1H-NMR (400 MHz, CDCl3, T = 298K, ppm) : 2.56 (s, 3H, OCH3), 3.04 (s, 3H, OCH3), 3.38 (s, 3H, 
NCH3), 3.46 (s, 3H, NCH3), 3.63 (s, 3H, OCH3), 3.64 (s, 3H, OCH3), 3.85 (s, 3H, NCH3), 5.40 and 
5.50 (AB system, 2H, J = 14.2 Hz, NCH2), 7.12-7.52 (m, 20H, 4Ph). 
13C{1H}-NMR (CDCl3, T = 298K, ppm) : 28.7 (CH3, NCH3), 31.8 (CH3, NCH3), 39.0 (CH3, NCH3), 
50.0 (CH3, OCH3), 50.9 (CH3, OCH3), 51.2 (CH3, OCH3), 51.3 (CH3, OCH3), 53.6 (CH2, NCH2), 
109.5 (C, C5), 128.2-134.7 (Ph), 140.9 (C, C4), 148.8 (d, C, JC-P= 5.6 Hz, C-COOCH3), 149.0 (d, C, 
JC-P= 7.3 Hz, C-COOCH3), 150.3 (C, C=O), 152.7 (C, C=O), 164.9-165.1 (C, COOCH3), 166.0 (C, 
C-COOCH3), 166.4 (C, C-COOCH3), 174.5 (d, C, JC-P= 5.2 Hz, COOCH3), 174.9 (d, C, JC-P= 6.4 Hz, 
COOCH3), 189.4 (d, C, JC-P= 15.5 Hz, carbene). 
31P{1H}-NMR (CDCl3, T = 298K, ppm) : 25.1 
IR (KBr): νC=O = 1710 cm-1, 1670 cm-1, νC-O = 1208 cm-1 
Synthesis of the complex 11d 
Complex 11d was prepared in analogues manner as that described for 11a starting from 0.0355 g of 
[PdC4(COOCH3)4]n, 0.0353 g of 5d and 0.0217 g of PPh3. 
0.0729 g (yield 85%) of 11d was obtained. 
1H-NMR (400 MHz, CDCl3, T = 298K, ppm) : 2.53 (s, 3H, OCH3), 3.24 (s, 3H, OCH3), 3.48 (s, 3H, 
NCH3), 3.63 (s, 3H, OCH3), 3.65 (s, 3H, OCH3), 3.80 (s, 6H, 2NCH3), 5.08 and 5.13 (AB system, 
2H, J = 14.5 Hz, NCH2), 7.24-7.50 (m, 20H, 4Ph). 
13C{1H}-NMR (CDCl3, T = 298K, ppm) : 31.6 
(CH3, NCH3), 36.6 (CH3, NCH3), 38.3 (CH3, NCH3), 45.0 (CH2, NCH2), 49.9 (CH3, OCH3), 50.8 
(CH3, OCH3), 51.2 (CH3, OCH3), 51.3 (CH3, OCH3), 109.9 (C, C
5), 128.0-136.5 (Ph), 140.1 (C, C4), 
145.9 (d, C, JC-P = 5.5 Hz, C-COOCH3), 148.8 (d, C, JC-P = 7.1 Hz, C-COOCH3), 150.1 (C, C=O), 
152.5 (C, C=O), 164.1-166.3 (C, COOCH3), 168.1 (C, C-COOCH3), 169.2 (C, C-COOCH3), 174.3 
(d, C, JC-P = 5.5 Hz, COOCH3), 175.6 (d, C, JC-P = 5.5 Hz, COOCH3), 189.4 (d, C, JC-P = 16.0 Hz, 
carbene). 31P{1H}-NMR (CDCl3, T=298K, ppm) : 26.2 
IR (KBr): νC=O = 1699 cm-1, 1674 cm-1, νC-O = 1205 cm-1 
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9.6.12. Synthesis of mixed purine-based NHC/PTA pallacyclopentadienyl complexes (12) 
 
Synthesis of the complex 12a 
0.0578 g (0.148 mmol) of the polymeric precursor [PdC4(COOCH3)4]n was dissolved in 5 mL of 
anhydrous dichloromethane in a 100 mL two-necked flask under inert atmosphere (Ar). To this 
solution a mixture constituted by 0.0452 g (0.0643 mmol) of the silver complex 5a and 0.0212 g 
(0.135 mmol) of PTA (1,3,5-triaza-7-phosphadamantane) dissolved in ca. 25 mL of anhydrous 
dichloromethane, was added. The mixture was stirred at R.T. for 1 h and subsequently the precipitated 
AgCl was removed by filtration on a millipore membrane filter. Addition of diethylether to the 
concentrated solution yields the precipitation of the complex 12a as a brownish solid which was 
filtered off on a gooch and washed with n-pentane. 0.1019 g of 12a was obtained (yield 91%). 
1H-NMR (400 MHz, CDCl3, T = 298K, ppm) : 3.28 (s, 3H, OCH3), 3.42 (s, 3H, NCH3), 3.61 (s, 3H, 
OCH3), 3.68 (s, 3H, OCH3), 3.80 (s, 3H, OCH3), 3.84 (s, 3H, NCH3), 4.00 (d, 6H, J = 2.1 Hz, 
3NCH2P), 4.04 (s, 3H, NCH3), 4.20 (s, 3H, NCH3), 4.49 (s, 6H, 3NCH2N). 
13C{1H}-NMR (CDCl3, T = 298K, ppm) : 28.7 (CH3, NCH3), 32.0 (CH3, NCH3), 37.0 (CH3, NCH3), 
38.9 (CH3, NCH3), 50.9 (CH3, OCH3), 51.1 (d, CH2, JC-P = 10.2 Hz, NCH2P), 51.2 (CH3, OCH3), 51.4 
(CH3, OCH3), 51.6 (CH3, OCH3), 73.1 (d, CH2, JC-P = 6.4 Hz, NCH2N), 110.1 (C, C
5), 140.6 (C, C4), 
164.3-165.0 (C, COOCH3), 165.4 (C, C-COOCH3), 168.7 (C, C-COOCH3), 175.1 (d, C, JC-P = 5.7 
Hz, COOCH3), 177.3 (d, C, JC-P = 5.8 Hz, COOCH3), 186.9 (d, C, JC-P = 18.4 Hz, carbene). 
31P{1H}-NMR (CDCl3, T = 298K, ppm) : -64.8 
IR (KBr): νC=O = 1711 cm-1, 1672 cm-1, νC-O = 1206 cm-1 
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Synthesis of the complex 12b 
Complex 12b was prepared in analogues manner as that described for 12a starting from 0.0290 g of 
[PdC4(COOCH3)4]n, 0.0276 g of 5b and 0.0112 g of PTA (1,3,5-triaza-7-phosphadamantane). 
0.0556 g (yield 90%) of 12b was obtained. 
1H-NMR (400 MHz, CDCl3, T = 298K, ppm) : 3.23 (s, 3H, OCH3), 3.40 (s, 9H, 3NCH2P+NCH3), 
3.53 (s, 3H, OCH3), 3.61 (s, 3H, OCH3), 3.71 (s, 3H, OCH3), 3.78 (s, 3H, NCH3), 4.14 (s, 3H, NCH3), 
4.06 and 4.20 (AB system, 6H, J = 14.8 Hz, 3NCH2N), 5.19 and 6.02 (AB system, 2H, J = 13.4 Hz, 
NCH2), 7.34-7.44 (m, 5H, Ph). 
13C{1H}-NMR (CDCl3, T = 298K, ppm) : 28.8 (CH3, NCH3), 32.2 (CH3, NCH3), 39.3 (CH3, NCH3), 
50.1 (d, CH2, JC-P = 10.0 Hz, NCH2P), 51.0 (CH3, OCH3), 51.3 (CH3, OCH3), 51.4 (CH3, OCH3), 51.6 
(CH3, OCH3), 52.8 (CH2, NCH2), 72.7 (d, CH2, JC-P = 6.5 Hz, NCH2N), 110.1 (C, C
5), 128.6-136.5 
(Ph), 140.6 (C, C4), 164.7-165.2 (C, COOCH3), 166.6 (C, C-COOCH3), 167.7 (C, C-COOCH3), 175.1 
(d, C, JC-P = 5.5 Hz, COOCH3), 177.3 (d, C, JC-P = 5.9 Hz, COOCH3), 188.0 (d, C, JC-P = 17.5 Hz, 
carbene). 31P{1H}-NMR (CDCl3, T=298K, ppm) : -66.7 
IR (KBr): νC=O = 1709 cm-1, 1670 cm-1, νC-O = 1242 cm-1, 1207cm-1 
Synthesis of the complex 12d 
Complex 12d was prepared in analogues manner as that described for 12a starting from 0.0287 g of 
[PdC4(COOCH3)4]n, 0.0286 g of 5d and 0.0105 g of PTA (1,3,5-triaza-7-phosphadamantane). 
0.0564 g (yield 92%) of 12d was obtained. 
1H-NMR (400 MHz, CDCl3, T = 298K, ppm) : 3.24 (s, 3H, OCH3), 3.60 (s, 3H, OCH3), 3.68 (s, 3H, 
OCH3), 3.80 (s, 3H, OCH3), 3.82 (s, 3H, NCH3), 4.00 (d, 6H, J = 2.0 Hz, 3NCH2P), 4.04 (s, 3H, 
NCH3), 4.20 (s, 3H, NCH3), 4.48 (s, 6H, 3NCH2N), 5.18 (s, 2H, NCH2), 7.32-7.50 (m, 5H, Ph). 
13C{1H}-NMR (CDCl3, T = 298K, ppm) : 32.0 (CH3, NCH3), 37.0 (CH3, NCH3), 39.0 (CH3, NCH3), 
45.3 (CH2, NCH2), 50.9 (CH3, OCH3), 51.1 (d, CH2, JC-P = 10.3 Hz, NCH2P), 51.3 (CH3, OCH3), 51.4 
(CH3, OCH3), 51.6 (CH3, OCH3), 73.1 (d, CH2, JC-P = 6.4 Hz, NCH2N), 110.1 (C, C
5), 128.0-136.2 
(Ph), 140.8 (C, C4), 163.6-164.3 (C, COOCH3), 165.4 (C, C-COOCH3), 168.9 (C, C-COOCH3), 175.1 
(d, C, JC-P = 5.5 Hz, COOCH3), 177.3 (d, C, JC-P = 5.7 Hz, COOCH3), 186.0 (d, C, JC-P = 18.7 Hz, 
carbene). 31P{1H}-NMR (CDCl3, T = 298K, ppm) : -64.8 
IR (KBr): νC=O = 1710 cm-1, 1672 cm-1, νC-O = 1243 cm-1, 1207 cm-1 
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9.6.13. Synthesis of mixed purine-based NHC/DIC pallacyclopentadienyl complexes (13) 
 
Synthesis of the complex 13a 
0.0438 g (0.112 mmol) of the polymeric precursor [PdC4(COOCH3)4]n was dissolved in 5 mL of 
anhydrous dichloromethane in a 100 mL two-necked flask under inert atmosphere (Ar). To this 
solution a mixture constituted by 0.0394 g (0.0560 mmol) of the silver complex 5a and 0.0147 g 
(0.112 mmol) of 2,6-dimethylphenyl isocyanide (DIC) dissolved in ca. 25 mL of anhydrous 
dichloromethane, was added. The mixture was stirred at R.T. for 48 h and subsequently the 
precipitated AgCl was removed by filtration on a millipore membrane filter. 
Addition of diethylether to the concentrated solution yields the precipitation of the complex 13a as a 
yellow solid which was filtered off on a gooch and washed with n-pentane.  
0.0731 g of 13a was obtained (yield 89%). 
1H-NMR (400 MHz, CDCl3, T = 298K, ppm) : 2.35 (s, 6H, 2CH3DIC), 3.34 (s, 3H, OCH3), 3.41 (s, 
3H, NCH3), 3.58 (s, 3H, OCH3), 3.61 (s, 3H, OCH3), 3.69 (s, 3H, OCH3), 3.83 (s, 3H, NCH3), 4.14 
(s, 3H, NCH3), 4.30 (s, 3H, NCH3), 7.12 (d, 2H, J= 8.1 Hz, 2H
meta), 7.23 (t, 1H, J= 8.1 Hz, Hpara). 
13C{1H}-NMR (CDCl3, T = 298K, ppm) : 18.5 (CH3, CH3DIC), 28.6 (CH3, NCH3), 32.0 (CH3, 
NCH3), 37.1 (CH3, NCH3), 39.0 (CH3, NCH3), 51.0 (CH3, OCH3), 51.3 (CH3, OCH3), 110.1 (C, C
5), 
128.2-135.1 (PhDIC), 140.6 (C, C4), 145.9 (C, C-COOCH3), 147.7 (C, C-COOCH3), 149.0 (C, CN), 
150.5 (C, C=O), 153.1 (C, C=O), 164.3 (C, COOCH3), 164.5 (C, COOCH3), 164.8 (C, C-COOCH3), 
166.5 (C, C-COOCH3), 174.9 (C, COOCH3), 175.6 (C, COOCH3), 185.8 (C, carbene). 
IR (KBr): νC=N = 2176 cm-1, νC=O = 1710 cm-1, 1670 cm-1, νC-O = 1207 cm-1 
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Synthesis of the complex 13b 
Complex 13b was prepared in analogues manner as that described for 13a starting from 0.0348 g of 
[PdC4(COOCH3)4]n, 0.0381 g of 5b and 0.0117 g of 2,6-dimethylphenyl isocyanide (DIC). 
0.0602 g (yield 84%) of 13b was obtained. 
1H-NMR (400 MHz, CDCl3, T = 298K, ppm) : 2.11 (s, 6H, 2CH3DIC), 3.29 (s, 3H, OCH3), 3.35 (s, 
3H, NCH3), 3.56 (s, 3H, OCH3), 3.66 (s, 3H, OCH3), 3.70 (s, 3H, OCH3), 3.84 (s, 3H, NCH3), 4.33 
(s, 3H, NCH3), 5.60 and 5.94 (AB system, 2H, J = 14.7 Hz, NCH2), 7.04-7.44 (m, 8H, Ph
DIC, PhBn). 
13C{1H}-NMR (CDCl3, T = 298K, ppm) : 18.4 (CH3, CH3DIC), 28.7 (CH3, NCH3), 32.0 (CH3, 
NCH3), 39.3 (CH3, NCH3), 51.0 (CH3, OCH3), 51.1 (CH3, OCH3), 51.3 (CH3, OCH3), 51.4 (CH3, 
OCH3), 53.1 (CH2, NCH2), 109.7 (C, C
5), 128.0-135.9 (Ph), 140.7 (C, C4), 145.7 (C, C-COOCH3), 
148.2 (C, C-COOCH3), 149.1 (C, CN), 150.5 (C, C=O), 152.8 (C, C=O), 163.7 (C, COOCH3), 164.6 
(C, COOCH3), 164.8 (C, C-COOCH3), 166.9 (C, C-COOCH3), 174.9 (C, COOCH3), 175.5 (C, 
COOCH3), 187.4 (C, carbene). 
IR (KBr): νC=N = 2177 cm-1, νC=O = 1710 cm-1, 1670 cm-1, νC-O = 1208 cm-1 
Synthesis of the complex 13d 
Complex 13d was prepared in analogues manner as that described for 13a starting from 0.0313 g of 
[PdC4(COOCH3)4]n, 0.0343 g of 5d and 0.0105 g of 2,6-dimethylphenyl isocyanide (DIC). 
0.0564 g (yield 87%) of 13d was obtained. 
1H-NMR (400 MHz, CDCl3, T = 298K, ppm) : 2.35 (s, 6H, 2CH3DIC), 3.32 (s, 3H, OCH3), 3.57 (s, 
3H, NCH3), 3.65 (s, 3H, OCH3), 3.69 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 4.15 (s, 3H, NCH3), 4.28 
(s, 3H, NCH3), 5.14 and 5.20 (AB system, 2H, J = 13.8 Hz, NCH2), 7.10-7.48 (m, 8H, Ph
DIC, PhBn). 
13C{1H}-NMR (CDCl3, T = 298K, ppm) : 18.6 (CH3, CH3DIC), 32.0 (CH3, NCH3), 37.1 (CH3, 
NCH3), 39.0 (CH3, NCH3), 45.2 (CH2, NCH2), 51.0 (CH3, OCH3), 51.3 (CH3, OCH3), 51.4 (CH3, 
OCH3), 110.2 (C, C
5), 128.0-136.3 (Ph), 140.7 (C, C4), 145.8 (C, C-COOCH3), 147.7 (C, C-
COOCH3), 149.0 (C, CN), 150.4 (C, C=O), 153.0 (C, C=O), 164.2 (C, COOCH3), 164.5 (C, 
COOCH3), 164.8 (C, C-COOCH3), 166.4 (C, C-COOCH3), 174.9 (C, COOCH3), 175.6 (C, 
COOCH3), 186.0 (C, carbene). 
IR (KBr): νC=N = 2178 cm-1, νC=O = 1710 cm-1, 1675 cm-1, νC-O = 1205 cm-1 
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9.6.14. Synthesis of Bis(purine-based NHC) palladacyclopentadienyl complexes (14) 
 
Synthesis of the complex 14a 
0.0182 g (0.0466 mmol) of the polymeric precursor [PdC4(COOCH3)4]n was dissolved in 5 mL of 
anhydrous dichloromethane in a 100 mL two-necked flask under inert atmosphere (Ar). To this 
solution a mixture constituted by 0.0273 g (0.0388 mmol) of the silver complex 5a dissolved in ca. 
25 mL of anhydrous dichloromethane, was added.  
The mixture was stirred at R.T. for 1 h and subsequently the precipitated AgCl was removed by 
filtration on a millipore membrane filter. 
Addition of diethylether to the concentrated solution yields the precipitation of the complex 14a as a 
yellow solid which was filtered off on a gooch and washed with n-pentane.  
0.0213 g of 14a was obtained (yield 70%). 
1H-NMR (400 MHz, CD2Cl2, T = 298K, ppm) : 3.30 (s, 12H, 4 OCH3), 3.36 (s, 12H, 4NCH3), 3.61 
(s, 12H, 4 OCH3), 3.78 (s, 6H, 2NCH3), 3.79 (s, 6H, 2NCH3), 4.11 (s, 6H, 2NCH3), 4.15 (s, 6H, 
2NCH3), 4.32 (s, 6H, 2NCH3), 4.34 (s, 6H, 2NCH3). 
13C{1H}-NMR (CD2Cl2, T = 298K, ppm) : 28.3 (CH3, NCH3), 31.8 (CH3, NCH3), 37.2 (CH3, NCH3), 
37.4 (CH3, NCH3), 39.2 (CH3, NCH3), 39.3 (CH3, NCH3), 50.6 (CH3, OCH3), 51.0 (CH3, OCH3), 
109.8 (C, C5), 140.5 (C, C4), 144.6 (C, C-COOCH3), 150.6 (C, C=O), 153.0 (C, C=O), 164.8 (C, 
COOCH3), 164.9 (C, COOCH3), 167.1 (C, C-COOCH3), 167.2 (C, C-COOCH3), 175.7 (C, 
COOCH3), 175.9 (C, COOCH3), 188.1 (C, carbene), 188.4 (C, carbene). 
IR (KBr): νC=O = 1710 cm-1, 1672 cm-1, νC-O = 1209 cm-1 
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Synthesis of the complex 14b 
Complex 14b was prepared in analogues manner as that described for 14a starting from 0.0194 g of 
[PdC4(COOCH3)4]n and 0.0354 g of 5b. 
0.0363 g (yield 91%) of 14b was obtained. 
1H-NMR (400 MHz, CD2Cl2, T = 298K, ppm) : 3.27 (s, 12H, 4 OCH3), 3.29 (s, 12H, 4NCH3), 3.43 
(s, 6H, 2NCH3), 3.61 (s, 6H, 2 OCH3), 3.63 (s, 6H, 2 OCH3), 3.75 (s, 6H, 2NCH3), 3.79 (s, 6H, 
2NCH3), 4.32 (s, 6H, 2NCH3), 4.98 and 5.40 (AB system, 4H, J = 15.5 Hz, 2NCH2), 5.77 and 5.85 
(AB system, 4H, J = 16.3 Hz, 2NCH2), 6.90-7.33 (m, 20H, 4Ph). 
13C{1H}-NMR (CD2Cl2, T = 298K, ppm) : 28.3 (CH3, NCH3), 31.5 (CH3, NCH3), 31.9 (CH3, NCH3), 
38.4 (CH3, NCH3), 39.4 (CH3, NCH3), 50.6 (CH3, OCH3), 51.0 (CH3, OCH3), 52.7 (CH2, NCH2), 
109.0 (C, C5), 109.5 (C, C5), 125.1-136.7 (Ph), 140.7 (C, C4), 140.8 (C, C4), 145.1 (C, C-COOCH3), 
145.2 (C, C-COOCH3), 150.4 (C, C=O), 150.5 (C, C=O), 152.3 (C, C=O), 164.8 (C, COOCH3), 165.1 
(C, COOCH3), 166.7 (C, C-COOCH3), 167.1 (C, C-COOCH3), 175.4 (C, COOCH3), 188.6 (C, 
carbene), 189.1 (C, carbene). 
IR (KBr): νC=O = 1710 cm-1, 1668 cm-1, νC-O = 1206 cm-1 
Synthesis of the complex 14d 
Complex 14d was prepared in analogues manner as that described for 14a starting from 0.0283 g of 
[PdC4(COOCH3)4]n and 0.0516 g of 5d. 
0.0551 g (yield 80%) of 14d was obtained. 
1H-NMR (400 MHz, CDCl3, T = 298K, ppm) : 3.28 (s, 6H, 2 OCH3), 3.31 (s, 6H, 2 OCH3), 3.62 (s, 
6H, 2 OCH3), 3.64 (s, 6H, 2 OCH3), 3.74 (s, 6H, 2NCH3), 3.78 (s, 6H, 2NCH3), 4.09 (s, 6H, 2NCH3), 
4.13 (s, 6H, 2NCH3), 4.35 (s, 6H, 2NCH3), 4.36 (s, 6H, 2NCH3), 5.14 (m, 8H, 4NCH2), 7.27-7.40 
(m, 20H, 4Ph). 
13C{1H}-NMR (CDCl3, T = 298K, ppm) : 31.9 (CH3, NCH3), 32.0 (CH3, NCH3), 37.4 (CH3, NCH3), 
37.6 (CH3, NCH3), 39.4 (CH3, NCH3), 39.6 (CH3, NCH3), 45.1 (CH2, NCH2), 50.8 (CH3, OCH3), 
51.3 (CH3, OCH3), 109.9 (C, C
5), 127.9-136.3 (Ph), 140.7 (C, C4), 140.8 (C, C4), 145.0 (C, C-
COOCH3), 145.3 (C, C-COOCH3), 150.4 (C, C=O), 152.9 (C, C=O), 165.0 (C, COOCH3), 165.2 (C, 
COOCH3), 166.6 (C, C-COOCH3), 166.9 (C, C-COOCH3), 176.1 (C, COOCH3), 176.2 (C, 
COOCH3), 188.3 (C, carbene), 189.1 (C, carbene). 
IR (KBr): νC=O = 1709 cm-1, 1671 cm-1, νC-O = 1208 cm-1 
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9.6.15. Synthesis of mixed purine-based NHC/PPh3 palladium 2-olefin complexes (15-18) 
               
Synthesis of the complex 15a 
0.0500 g (0.086 mmol) of the precursor [Pd(Me-PyCH2SPh)(2-tmetc)] was dissolved in 10 mL of 
anhydrous dichloromethane in a 50 mL two-necked flask under inert atmosphere (Ar). To this 
solution a mixture constituted by 0.0302 g (0.043 mmol) of the silver complex 5a and 0.0225 g (0.086 
mmol) of PPh3 dissolved in ca. 15 mL of anhydrous dichloromethane, was added.  
The mixture was stirred at R.T. for 1 h and subsequently the precipitated AgCl was removed by 
filtration on a millipore membrane filter. The solvent was removed under reduced pressure and the 
yellow solid was washed with ca. 10 mL of diethylether and filtered off on a gooch. 
0.0641 g of 15a was obtained (yield 80%). 
1H-NMR (400 MHz, CD2Cl2, T=298K, ppm) : 3.35 (s, 3H, NCH3), 3.46 (s, 3H, OCH3), 3.48 (s, 3H, 
NCH3), 3.56 (s, 3H, OCH3), 3.61 (s, 3H, OCH3), 3.62 (s, 3H, OCH3), 3.70 (s, 3H, NCH3), 3.71 (s, 
3H, NCH3), 7.34-7.44 (m, 15H, 3Ph). 
13C{1H}-NMR (CD2Cl2, T=298K, ppm) : 28.2 (CH3, NCH3), 31.4 (CH3, NCH3), 36.5 (CH3, NCH3), 
38.1 (CH3, NCH3), 51.3 (CH3, OCH3), 51.5 (CH3, OCH3), 51.6 (CH3, OCH3), 51.9 (CH3, OCH3), 
110.1 (C, C5), 128.1-134.6 (Ph), 140.2 (C, C4), 150.5 (C, C=O), 152.9 (C, C=O), 169.8-170.4 (C, 
COOCH3), 196.5 (d, C, JC-P = 15.1 Hz, carbene). 
31P{1H}-NMR (CD2Cl2, T=298K, ppm) : 29.4 
IR (KBr): C=O= 1725, 1709, 1694, 1668 cm-1 
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Synthesis of the complex 15b 
Complex 15b was prepared in analogues manner as that described for 15a starting from 0.0377 g of 
[Pd(Me-PyCH2SPh)(2-tmetc)], 0.0170 g of PPh3 and 0.0277 g of 5b. 
0.0473 g (yield 80%) of 15b was obtained. 
1H-NMR (400 MHz, CDCl3, T=298K, ppm) : 3.11 (s, 3H, OCH3), 3.38 (s, 3H, NCH3), 3.41 (s, 3H, 
NCH3), 3.52 (s, 3H, OCH3), 3.64 (s, 3H, OCH3), 3.71 (s, 3H, NCH3), 3.72 (s, 3H, OCH3), 5.25 and 
5.85 (AB system, 2H, J= 13.9 Hz, NCH2), 6.71-7.61 (m, 20H, 4Ph). 
13C{1H}-NMR (CDCl3, T=298K, ppm) : 28.7 (CH3, NCH3), 31.8 (CH3, NCH3), 38.4 (CH3, NCH3), 
51.0 (CH3, OCH3), 52.0 (CH3, OCH3), 52.5 (CH3, OCH3), 52.6 (CH3, OCH3), 53.4 (CH2, NCH2), 
61.9 (C, C=C trans-C), 64.0 (d, C, JC-P = 37.6 Hz, C=C trans-P), 109.4 (C, C
5), 127.9-136.2 (Ph), 
140.7 (C, C4), 150.6 (C, C=O), 152.9 (C, C=O), 169.8-170.4 (C, COOCH3) 198.5 (d, C, JC-P = 14.4 
Hz, carbene). 
31P{1H}-NMR (CDCl3, T=298K, ppm) : 26.9 
IR (KBr): C=O= 1704, 1666 cm-1 
Synthesis of the complex 15d 
Complex 15d was prepared in analogues manner as that described for 15a starting from 0.0500 g of 
[Pd(NSPM)(2-tmetc)], 0.0225 g of PPh3 and 0.0367 g of 5d. 
0.0604 g (yield 77%) of 15d was obtained. 
1H-NMR (400 MHz, CDCl3, T=298K, ppm) : 3.47 (s, 3H, OCH3), 3.53 (s, 3H, NCH3), 3.55 (s, 3H, 
OCH3), 3.65 (s, 3H, OCH3), 3.67 (s, 3H, OCH3), 3.73 (s, 3H, NCH3), 3.74 (s, 3H, NCH3), 5.15 (s, 
2H, NCH2), 7.32-7.46 (m, 20H, 4Ph). 
13C{1H}-NMR (CDCl3, T=298K, ppm) : 31.5 (CH3, NCH3), 36.8 (CH3, NCH3), 38.5 (CH3, NCH3), 
45.0 (CH2, NCH2), 51.5 (CH3, OCH3), 51.9 (CH3, OCH3), 52.1 (CH3, OCH3), 52.5 (CH3, OCH3), 
61.9 (d, C, JC-P = 2.1 Hz, C=C trans-C), 63.8 (d, C, JC-P = 36.9 Hz, C=C trans-P), 110.2 (C, C
5), 127.8-
136.6 (Ph), 140.2 (C, C4), 150.4 (C, C=O), 152.7 (C, C=O), 169.8-170.4 (C, COOCH3),197.4 (d, C, 
JC-P = 15.8 Hz, carbene). 
31P{1H}-NMR (CDCl3, T=298K, ppm) : 29.2 
IR (KBr): C=O= 1706, 1668 cm-1 
Synthesis of the complex 16a 
0.0450 g (0.112 mmol) of the precursor [Pd(Me-PyCH2SPh)(2-fn)] was dissolved in 10 mL of 
anhydrous dichloromethane in a 50 mL two necked flask under inert atmosphere (Ar). To this solution 
a mixture constituted by 0.0396 g (0.056 mmol) of the silver complex 5a and 0.0295 g (0.112 mmol) 
of PPh3 dissolved in ca. 15 mL of anhydrous dichloromethane, was added.  
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The mixture was stirred at R.T. for 1 h and subsequently the precipitated AgCl was removed by 
filtration on a millipore membrane filter.  
Addition of diethylether to the concentrated solution yields the precipitation of the complex 16a as a 
yellow solid which was filtered off on a gooch and washed with n-pentane.  
0.0597 g of 16a was obtained (yield 81%). 
1H-NMR (400 MHz, CDCl3, T=298K, ppm) : 2.90 (dd, JH-H = 9.4 Hz, JH-P = 3.4 Hz, 1H, CH=CH 
trans-P), 3.01 (d, JH-H = 9.4 Hz, 1H, CH=CH trans-C), 3.40 (s, 3H, NCH3), 3.61 (s, 3H, NCH3), 3.69 
(s, 3H, NCH3), 3.78 (s, 3H, NCH3), 7.33-7.42 (m, 15H, 3Ph). 
13C{1H}-NMR (CDCl3, T=298K, ppm) : 22.5 (d, CH, JC-P = 3.4 Hz, CH=CH trans-C), 22.9 (d, CH, 
JC-P = 37.8 Hz, CH=CH trans-P), 28.6 (CH3, NCH3), 31.6 (CH3, NCH3), 37.0 (CH3, NCH3), 38.0 
(CH3, NCH3), 110.2 (C, C
5), 123.2 (d, C, JC-P = 2.6 Hz, CN trans-C), 123.8 (d, C, JC-P = 8.0 Hz, CN 
trans-P), 128.6-134.5 (Ph), 140.3 (C, C4), 150.6 (C, C=O), 152.9 (C, C=O), 198.5 (d, C, JC-P = 11.7 
Hz, carbene).  
31P{1H}-NMR (CDCl3, T=298K, ppm) : 27.9 
IR (KBr): CN= 2191 cm-1, CO= 1807, 1667 cm-1 
Synthesis of the complex 17a 
0.0500 g (0.119 mmol) of the precursor [Pd(Me-PyCH2SPh)(2-ma)] was dissolved in 10 mL of 
anhydrous dichloromethane in a 50 mL two-necked flask under inert atmosphere (Ar). To this 
solution a mixture constituted by 0.0419 g (0.059 mmol) of the silver complex 5a and 0.0312 g (0.119 
mmol) of PPh3 dissolved in ca. 15 mL of anhydrous dichloromethane, was added.  
The mixture was stirred at R.T. for 1 h and subsequently the precipitated AgCl was removed by 
filtration on a millipore membrane filter. Addition of diethylether to the concentrated solution yields 
the precipitation of the complex 17a as a yellow solid which was filtered off on a gooch and washed 
with n-pentane. 0.0594 g of 17a was obtained (yield 74%). 
1H-NMR (400 MHz, CDCl3, T=298K, ppm) : 3.39 (s, 3H, NCH3), 3.60 (s, 3H, NCH3), 3.65 (s, 6H, 
2NCH3), 3.99 (dd, JH-H = 3.9 Hz, JH-P = 2.9 Hz, 1H, CH=CH trans-C), 4.22 (dd, JH-H = 3.9 Hz, JH-P = 
9.8 Hz, 1H, CH=CH trans-P), 7.31-7.41 (m, 15H, 3Ph). 
13C{1H}-NMR (CDCl3, T=298K, ppm) : 28.6 (CH3, NCH3), 31.6 (CH3, NCH3), 36.9 (CH3, NCH3), 
38.0 (CH3, NCH3), 45.6 (CH, CH=CH trans-C), 47.5 (d, CH, JC-P = 27.8 Hz, CH=CH trans-P), 110.2 
(C, C5), 128.6-134.3 (Ph), 140.3 (C, C4), 150.5 (C, C=O), 152.9 (C, C=O), 172.3 (d, C, JC-P = 1.9 Hz,  
C=Oma trans-C), 172.7 (d, C, JC-P = 5.2 Hz, C=O
ma trans-P), 198.4 (d, C, JC-P = 14.5 Hz, carbene).
  
31P{1H}-NMR (CDCl3, T=298K, ppm) : 30.4 
IR (KBr): C=O= 1790, 1722, 1704, 1665 cm-1   C-O= 1224 cm-1    
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Synthesis of the complex 18a 
0.0400 g (0.091 mmol) of the precursor [Pd(TMQ-Me)(2-dmfu)] were dissolved in 10 mL of 
anhydrous dichloromethane in a 50 mL two necked flask under inert atmosphere (Ar) at -40°C. To 
this solution a mixture constituted by 0.0297 g (0.042 mmol) of the silver complex 5a and 0.0238 g 
(0.091mmol) of PPh3 dissolved in ca. 15 mL of anhydrous dichloromethane, was added.  
The mixture was stirred at -40°C for 30 min and subsequently the precipitated AgCl was removed by 
filtration on a millipore membrane filter.  
Addition of diethylether to the concentrated solution yields the precipitation of the complex 18a as a 
brownish solid which was filtered off on a gooch and washed with n-pentane.  
0.0422 g of 18a was obtained (yield 64%). 
1H-NMR (400 MHz, CDCl3, T=298K, ppm) : 3.17 (s, 3H, NCH3), 3.39 (s, 3H, NCH3), 3.54 (s, 3H, 
NCH3), 3.57 (s, 3H, NCH3), 3.97 (dd, JH-H = 9.5 Hz, JH-P = 2.6 Hz, 1H, CH=CH trans-P), 4.08 (d, JH-
H = 9.5 Hz, 1H, CH=CH trans-C), 7.30-7.34 (m, 15H, 3Ph). 
13C{1H}-NMR (CDCl3, T=243K, ppm) : 28.9 (CH3, NCH3), 31.7 (CH3, NCH3), 36.8 (CH3, NCH3), 
37.7 (CH3, OCH3), 38.7 (CH3, NCH3), 50.6 (CH, CH=CH
dmfu), 51.5 (CH, CH=CHdmfu), 110.0 (C, 
C5), 128.4-135.0 (Ph), 140.0 (C, C4), 150.5 (C, C=O), 153.0 (C, C=O), 174.7 (C, C=Odmfu), 198.5 (d, 
C, JC-P = 14.3 Hz, carbene). 
31P{1H}-NMR (CDCl3, T=298K, ppm) : 29.7 
IR (KBr): C=O= 1662 cm-1 
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9.6.16. Synthesis of mixed purine-based NHC/AsPh3 palladium 2-olefin complexes (19-22) 
 
Synthesis of the complex 19a 
0.0500 g (0.086 mmol) of the precursor [Pd(Me-PyCH2SPh)(2-tmetc)] was dissolved in 10 mL of 
anhydrous dichloromethane in a 50 mL two-necked flask under inert atmosphere (Ar). To this 
solution a mixture constituted by 0.0302 g (0.043 mmol) of the silver complex 5a and 0.0263 g (0.086 
mmol) of AsPh3 dissolved in ca. 15 mL of anhydrous dichloromethane, was added.  
The mixture was stirred at R.T. for 1 h and subsequently the precipitated AgCl was removed by 
filtration on a millipore membrane filter. The solvent was removed under reduced pressure and the 
yellow solid was washed with ca. 10 mL of diethylether and filtered off on a gooch. 
0.0626 g of 19a was obtained (yield 83%). 
1H-NMR (400 MHz, CDCl3, T=298K, ppm) : 3.37 (s, 3H, NCH3), 3.47 (s, 3H, OCH3), 3.53 (s, 3H, 
NCH3), 3.58 (s, 3H, OCH3), 3.65 (s, 3H, OCH3), 3.68 (s, 3H, OCH3), 3.75 (s, 3H, NCH3), 3.78 (s, 
3H, NCH3), 7.28-7.42 (m, 15H, 3Ph). 
13C{1H}-NMR (CDCl3, T=298K, ppm) : 28.5 (CH3, NCH3), 31.5 (CH3, NCH3), 36.9 (CH3, NCH3), 
38.5 (CH3, NCH3), 51.6 (CH3, OCH3), 52.0 (CH3, OCH3), 52.1 (CH3, OCH3), 52.5 (CH3, OCH3), 
61.0 (C, C=C), 64.1 (C, C=C), 110.1 (C, C5), 128.7-136.5 (Ph), 140.2 (C, C4), 150.5 (C, C=O), 153.0 
(C, C=O), 169.7 (C, COOCH3), 169.8 (C, COOCH3), 170.0 (C, COOCH3), 170.5 (C, COOCH3), 
197.1 (C, carbene). IR (KBr): C=O= 1707, 1667 cm-1 
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Synthesis of the complex 19b 
Complex 19b was prepared in analogues manner as that described for 19a starting from 0.0430 g of 
[Pd(Me-PyCH2SPh)(2-tmetc)], 0.0226 g of AsPh3 and 0.0316 g of 5b. 
0.0542 g (yield 77%) of 19b was obtained. 
1H-NMR (400 MHz, CDCl3, T=298K, ppm) : 3.08 (s, 3H, OCH3), 3.33 (s, 3H, NCH3), 3.44 (s, 3H, 
NCH3), 3.60 (s, 3H, OCH3), 3.71 (s, 3H, OCH3), 3.75 (s, 3H, NCH3), 3.78 (s, 3H, OCH3), 5.25 and 
5.89 (AB system, 2H, J= 13.6 Hz, NCH2), 6.68-7.74 (m, 20H, 4Ph). 
13C{1H}-NMR (CDCl3, T=298K, ppm) : 28.7 (CH3, NCH3), 31.7 (CH3, NCH3), 38.5 (CH3, NCH3), 
50.9 (CH3, OCH3), 52.0 (CH3, OCH3), 52.1 (CH2, NCH2), 52.2 (CH3, OCH3), 52.6 (CH3, OCH3), 
61.0 (C, C=C), 64.2 (C, C=C), 109.3 (C, C5), 128.0-136.3 (Ph), 140.5 (C, C4), 150.5 (C, C=O), 153.0 
(C, C=O), 169.8 (C, COOCH3), 170.1 (C, COOCH3), 170.2 (C, COOCH3), 170.4 (C, COOCH3), 
198.4 (C, carbene). 
IR (KBr): C=O= 1707, 1670 cm-1 
Synthesis of the complex 19d 
Complex 19d was prepared in analogues manner as that described for 19a starting from 0.0500 g of 
[Pd(NSPM)(2-tmetc)], 0.0263 g of AsPh3 and 0.0367 g of 5d. 
0.0631g (yield 77%) of 19d was obtained. 
1H-NMR (400 MHz, CDCl3, T=298K, ppm) : 3.47 (s, 3H, OCH3), 3.51 (s, 3H, NCH3), 3.58 (s, 3H, 
OCH3), 3.66 (s, 3H, OCH3), 3.69 (s, 3H, OCH3), 3.78 (s, 3H, NCH3), 3.79 (s, 3H, NCH3), 5.14 (s, 
2H, NCH2), 7.26-7.48 (m, 20H, 4Ph). 
13C{1H}-NMR (CDCl3, T=298K, ppm) : 31.5 (CH3, NCH3), 36.9 (CH3, NCH3), 38.6 (CH3, NCH3), 
44.9 (CH2, NCH2), 51.6 (CH3, OCH3), 52.1 (CH3, OCH3), 52.2 (CH3, OCH3), 52.5 (CH3, OCH3), 
61.0 (C, C=C), 64.0 (C, C=C), 110.1 (C, C5), 127.9-136.6 (Ph), 140.1 (C, C4), 150.4 (C, C=O), 152.7 
(C, C=O), 169.7 (C, COOCH3), 169.8 (C, COOCH3), 170.0 (C, COOCH3), 170.4 (C, COOCH3), 
197.2 (C, carbene). 
IR (KBr): C=O= 1708, 1670 cm-1 
Synthesis of the complex 20a 
0.0452 g (0.113 mmol) of the precursor [Pd(Me-PyCH2SPh)(2-fn)] was dissolved in 10 mL of 
anhydrous dichloromethane in a 50 mL two necked flask under inert atmosphere (Ar). To this solution 
a mixture constituted by 0.0397 g (0.056 mmol) of the silver complex 5a and 0.0346 g (0.113 mmol) 
of AsPh3 dissolved in ca. 15 mL of anhydrous dichloromethane, was added.  
The mixture was stirred at R.T. for 1 h and subsequently the precipitated AgCl was removed by 
filtration on a millipore membrane filter.  
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Addition of diethylether to the concentrated solution yields the precipitation of the complex 20a as a 
yellow solid which was filtered off on a gooch and washed with n-pentane.  
0.0582 g of 20a was obtained (yield 74%). 
1H-NMR (400 MHz, CDCl3, T=298K, ppm) : 3.02 (d, JH-H = 9.3 Hz, 1H, CH=CH), 3.16 (d, JH-H = 
9.4 Hz, 1H, CH=CH), 3.40 (s, 3H, NCH3), 3.61 (s, 3H, NCH3), 3.75 (s, 3H, NCH3), 3.84 (s, 3H, 
NCH3), 7.36-7.40 (m, 15H, 3Ph). 
13C{1H}-NMR (CDCl3, T=298K, ppm) : 20.7 (CH, CH=CH), 23.1 (CH, CH=CH), 28.6 (CH3, 
NCH3), 31.6 (CH3, NCH3), 37.1 (CH3, NCH3), 38.2 (CH3, NCH3), 110.2 (C, C
5), 123.1 (C, CN), 
123.3 (C, CN), 129.1-136.1 (Ph), 140.2 (C, C4), 150.5 (C, C=O), 152.9 (C, C=O), 198.0 (C, carbene).   
IR (KBr): CN= 2191 cm-1, C=O= 1708, 1667 cm-1 
Synthesis of the complex 21a 
0.0500 g (0.119 mmol) of the precursor [Pd(Me-PyCH2SPh)(2-ma)] was dissolved in 10 mL of 
anhydrous dichloromethane in a 50 mL two necked flask under inert atmosphere (Ar). To this solution 
a mixture constituted by 0.0419 g (0.059 mmol) of the silver complex 5a and 0.0365 g (0.119 mmol) 
of AsPh3 dissolved in ca. 15 mL of anhydrous dichloromethane, was added.  
The mixture was stirred at R.T. for 1 h and subsequently the precipitated AgCl was removed by 
filtration on a millipore membrane filter.  
Addition of diethylether to the concentrated solution yields the precipitation of the complex 21a as a 
yellow solid which was filtered off on a gooch and washed with n-pentane.  
0.0673 g of 21a was obtained (yield 79%). 
1H-NMR (400 MHz, CDCl3, T=298K, ppm) : 3.39 (s, 3H, NCH3), 3.59 (s, 3H, NCH3), 3.70 (s, 3H, 
NCH3), 3.72 (s, 3H, NCH3), 4.13 (d, J = 3.9 Hz, 1H, CH=CH), 4.33 (d, J = 3.9 Hz, 1H, CH=CH), 
7.32-7.41 (m, 15H, 3Ph). 
13C{1H}-NMR (CDCl3, T=298K, ppm) : 28.6 (CH3, NCH3), 31.6 (CH3, NCH3), 37.1 (CH3, NCH3), 
38.2 (CH3, NCH3), 44.0 (CH, CH=CH), 47.6 (d, CH, CH=CH), 110.2 (C, C
5), 128.8-136.1 (Ph), 140.3 
(C, C4), 150.5 (C, C=O), 152.9 (C, C=O), 172.3 (C, C=Oma), 172.4 (C, C=Oma), 197.9 (C, carbene).  
IR (KBr): C=O= 1788, 1725, 1695 cm-1      C-O=1220 cm-1         
Synthesis of the complex 22a 
0.0400 g (0.091 mmol) of the precursor [Pd(TMQ-Me)(2-dmfu)] was dissolved in 10 mL of 
anhydrous dichloromethane in a 50 mL two necked flask under inert atmosphere (Ar) at -40°C. To 
this solution a mixture constituted by 0.0297 g (0.042 mmol) of the silver complex 5a and 0.0278 g 
(0.091mmol) of AsPh3 dissolved in ca. 15 mL of anhydrous dichloromethane, was added.  
The mixture was stirred at -40°C for 30 min and subsequently the precipitated AgCl was removed by 
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filtration on a millipore membrane filter.  
Addition of diethylether to the concentrated solution yields the precipitation of the complex 18a as a 
brownish solid which was filtered off on a gooch and washed with n-pentane.  
0.0529 g of 18a was obtained (yield 76%). 
1H-NMR (400 MHz, CDCl3, T=298K, ppm) : 3.20 (s, 3H, OCH3), 3.39 (s, 3H, NCH3), 3.56 (s, 6H, 
NCH3+OCH3), 3.71 (s, 3H, NCH3), 3.76 (s, 3H, NCH3), 4.08 (d, J = 10.0 Hz, 1H, CH=CH), 4.22 (d, 
J = 10.0 Hz, 1H, CH=CH), 7.32-7.37 (m, 15H, 3Ph). 
13C{1H}-NMR (CDCl3, T=243K, ppm) : 28.9 (CH3, NCH3), 31.6 (CH3, NCH3), 37.0 (CH3, NCH3), 
37.9 (CH3, NCH3), 45.5 (CH, CH=CH), 48.2 (CH, CH=CH), 50.6 (CH3, OCH3), 51.6 (CH3, OCH3), 
109.9 (C, C5), 128.6-137.0 (Ph), 140.0 (C, C4), 150.5 (C, C=O), 153.1 (C, C=O), 174.7 (C, C=Odmfu), 
174.8 (C, C=Odmfu), 194.5 (C, carbene).  
IR (KBr): C=O= 1709, 1665 cm-1   C-O= 1289 cm-1 
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9.6.17. Synthesis of Bis(purine-based NHC) palladium olefin complexes (23-24) 
  
Synthesis of the complex 23a 
0.0386 g (0.066 mmol) of the precursor [Pd(Me-PyCH2SPh)(2-tmetc)] was dissolved in 25 mL of 
anhydrous dichloromethane in a 100 mL two-necked flask under inert atmosphere (Ar). Subsequently 
0.0466 g (0.066 mmol) of the silver complex 5a, was added. The mixture was stirred at R.T. for 1 h 
and the precipitated AgCl was removed by filtration on a millipore membrane filter. 
The solvent was removed under reduced pressure and the yellow solid was washed with ca. 10 mL 
of diethylether and filtered off on a gooch. 
0.0516 g of 23a was obtained (yield 99%). 
1H-NMR (400 MHz, CDCl3, T=298K, ppm) : 3.39 (s, 6H, 2NCH3), 3.65 (s, 12H, 4 OCH3), 3.80 (s, 
6H, 2NCH3), 4.07 (s, 6H, 2NCH3), 4.34 (s, 6H, 2NCH3). 
13C{1H}-NMR (CDCl3, T=298K, ppm) : 28.5 (CH3, NCH3), 31.8 (CH3, NCH3), 37.2 (CH3, NCH3), 
39.4 (CH3, NCH3), 52.2 (CH3, OCH3), 58.2 (C, C=C), 110.4 (C, C
5), 140.5 (C, C4), 150.7 (C, C=O), 
153.2 (C, C=O), 170.8 (C, COOCH3), 197.0 (C, carbene). 
IR (KBr): C=O= 1706, 1668 cm-1 
Synthesis of the complex 23b 
Complex 23b was prepared in analogues manner as that described for 23a starting from 0.0500 g of 
[Pd(Me-PyCH2SPh)(2-tmetc)] and 0.0735 g of 5b. 0.0722 g (yield 86%) of 23b was obtained. 
1H-NMR (400 MHz, CDCl3, T=298K, ppm) : 3.28 (s, 6H, 2NCH3), 3.43 (s, 6H, 2NCH3), 3.63 (s, 
12H, 4 OCH3), 3.68 (s, 6H, 2NCH3), 5.79 (s, 4H, 2NCH2), 6.88-6.91 and 7.22-7.24 (m, 10H, 2Ph). 
13C{1H}-NMR (CDCl3, T=298K, ppm) : 28.5 (CH3, NCH3), 31.5 (CH3, NCH3), 38.8 (CH3, NCH3), 
52.2 (CH3, OCH3), 52.3 (CH2, NCH2), 58.4 (C, C=C), 109.5 (C, C
5), 125.3-137.3 (Ph), 140.9 (C, C4), 
150.6 (C, C=O), 152.4 (C, C=O), 170.8 (C, COOCH3), 197.4 (C, carbene). 
IR (KBr): C=O= 1708, 1668 cm-1 
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Synthesis of the complex 23d 
Complex 23d was prepared in analogues manner as that described for 23a starting from 0.0500 g of 
[Pd(Me-PyCH2SPh)(2-tmetc)] and 0.0735 g of 5d. 
0.0765 g (yield 95%) of 23d was obtained. 
1H-NMR (400 MHz, CDCl3, T=298K, ppm) : 3.64 (s, 12H, 4 OCH3), 3.77 (s, 6H, 2NCH3), 4.07 (s, 
6H, 2NCH3), 4.31 (s, 6H, 2NCH3), 5.14 (s, 4H, 2NCH2), 7.31-7.35 (m, 10H, 2Ph). 
13C{1H}-NMR (CDCl3, T=298K, ppm) : 31.8 (CH3, NCH3), 37.3 (CH3, NCH3), 39.4 (CH3, NCH3), 
45.0 (CH2, NCH2), 52.2 (CH3, OCH3), 58.3 (C, C=C), 110.4 (C, C
5), 127.8-136.4 (Ph), 140.6 (C, C4), 
150.6 (C, C=O), 153.0 (C, C=O), 170.8 (C, COOCH3), 197.1 (C, carbene). 
IR (KBr): CO= 1707, 1668 cm-1 
Synthesis of the complex 24a 
0.0333 g (0.083 mmol) of the precursor [Pd(Me-PyCH2SPh)(2-fn)] was dissolved in 25 mL of 
anhydrous dichloromethane in a 100 mL two-necked flask under inert atmosphere (Ar). Subsequently 
0.0585 g (0.083 mmol) of the silver complex 5a, was added. The mixture was stirred at R.T. for 1 h 
and the precipitated AgCl was removed by filtration on a millipore membrane filter. 
Addition of diethylether to the concentrated solution yields the precipitation of the complex 24a as a 
yellow solid which was filtered off on a gooch and washed with n-pentane.  
0.0516 g of 24a was obtained (yield 99%). 
1H-NMR (400 MHz, CDCl3, T=298K, ppm) : 2.58 (s, 2H, CH=CH), 3.40 (s, 6H, 2NCH3), 3.82 (s, 
6H, 2NCH3), 4.11 (s, 6H, 2NCH3), 4.31 (s, 6H, 2NCH3). 
13C{1H}-NMR (CDCl3, T=298K, ppm) : 16.3 (CH, CH=CH), 28.6 (CH3, NCH3), 31.9 (CH3, NCH3), 
37.3 (CH3, NCH3), 38.8 (CH3, NCH3), 110.4 (C, C
5), 125.1 (C, CN), 140.5 (C, C4), 150.7 (C, C=O), 
153.1 (C, C=O), 198.3 (C, carbene). 
IR (KBr): CN= 2192 cm-1, CO= 1709, 1666 cm-1 
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9.6.18. Synthesis of Bis(PTA) palladium olefin complexes (25-28) 
                     
Synthesis of the complex 25 
0.0500 g (0.086 mmol) of the precursor [Pd(Me-PyCH2SPh)(2-tmetc)] was dissolved in 25 mL of 
anhydrous dichloromethane in a 100 mL two necked flask under inert atmosphere (Ar). Subsequently 
0.0270 g (0.171 mmol) of PTA (1,3,5-triaza-7-phosphadamantane), was added. The mixture was 
stirred at R.T. for 30 min and the addition of diethylether to the concentrated solution yields the 
precipitation of the complex 25 as a yellow solid which was filtered off on a gooch and washed with 
n-pentane.  
0.0533 g of 25 was obtained (yield 91%). 
1H-NMR (400 MHz, CDCl3, T=298K, ppm) : 3.62 (s, 12H, 4 OCH3), 4.08 and 4.12 (AB system, J= 
12.3 Hz, 12H, 3NCH2P), 4.48 and 4.52 (AB system, J= 13.7 Hz, 12H, 3NCH2N). 
13C{1H}-NMR (CDCl3, T=298K, ppm) : 52.4 (CH3, OCH3), 53.5 (d, CH2, JC-P = 9.2 Hz, NCH2P), 
67.2 (d, JC-P = 3.4 Hz, C=C), 73.5 (d, CH2, JC-P = 6.5 Hz, NCH2N), 168.7 (d, C, JC-P = 11.7 Hz, 
COOCH3). 
31P{1H}-NMR (CDCl3, T=298K, ppm) : -61.0 
IR (KBr): C=O= 1722, 1670 cm-1 
Synthesis of the complex 26                  
0.0500 g (0.125 mmol) of the precursor [Pd(Me-PyCH2SPh)(2-fn)] was dissolved in 25 mL of 
anhydrous dichloromethane in a 100 mL two necked flask under inert atmosphere (Ar). Subsequently 
0.0393 g (0.250 mmol) of PTA (1,3,5-triaza-7-phosphadamantane), was added. The mixture was 
stirred at R.T. for 30 min and the addition of diethylether to the concentrated solution yields the 
precipitation of the complex 26 as a yellow solid which was filtered off on a gooch and washed with 
n-pentane.  
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0.0610 g of 26 was obtained (yield 98%). 
1H-NMR (400 MHz, CDCl3, T=298K, ppm) : 3.00 (s, 2H, CH=CH), 4.19 and 4.23 (AB system, J= 
10.3 Hz, 12H, 3NCH2P), 4.60 and 4.64 (AB system, J= 14.6 Hz, 12H, 3NCH2N). 
13C{1H}-NMR (CDCl3, T=298K, ppm) : 26.9 (CH, CH=CH), 53.6 (d, CH2, JC-P = 7.6 Hz, NCH2P), 
73.5 (d, CH2, JC-P = 6.2 Hz, NCH2N), 121.1 (C, CN). 
31P{1H}-NMR (CDCl3, T=298K, ppm) : -63.7 
IR (KBr): CN= 2199 cm-1 
Synthesis of the complex 27                  
0.0500 g (0.119 mmol) of the precursor [Pd(Me-PyCH2SPh)(2-ma)] was dissolved in 25 mL of 
anhydrous dichloromethane in a 100 mL two necked flask under inert atmosphere (Ar). Subsequently 
0.0374 g (0.238 mmol) of PTA (1,3,5-triaza-7-phosphadamantane), was added. The mixture was 
stirred at R.T. for 30 min and the addition of diethylether to the concentrated solution yields the 
precipitation of the complex 27 as a yellow solid which was filtered off on a gooch and washed with 
n-pentane.  
0.0577 g of 27 was obtained (yield 93%). 
1H-NMR (400 MHz, CDCl3, T=298K, ppm) : 4.16 (m, 14H, 3NCH2P+CH=CH), 4.58 and 4.62 (AB 
system, J= 14.7 Hz, 12H, 3NCH2N). 
13C{1H}-NMR (CDCl3, T=298K, ppm) : 50.8 (CH, CH=CH), 53.4 (d, CH2, JC-P = 8.0 Hz, NCH2P), 
73.4 (d, CH2, JC-P = 6.3 Hz, NCH2N), 170.5 (C, COOCH3). 
31P{1H}-NMR (CDCl3, T=298K, ppm) : -62.2 
IR (KBr): C=O= 1783, 1717, 1637 cm-1 C-O= 1240 cm-1 
Synthesis of the complex 28 
0.0400 g (0.091 mmol) of the precursor [Pd(TMQ-Me)(2-dmfu)] was dissolved in 25 mL of 
anhydrous dichloromethane in a 50 mL two necked flask under inert atmosphere (Ar) at -40°C. To 
this solution 0.0286 g (0.182 mmol) of of PTA (1,3,5-triaza-7-phosphadamantane), was added. The 
mixture was stirred at -40°C for 30 min and the addition of diethylether to the concentrated solution 
yields the precipitation of the complex 28 as a yellow solid which was filtered off on a gooch and 
washed with n-pentane.  
0.0464 g of 28 was obtained (yield 90%). 
1H-NMR (400 MHz, CDCl3, T=298K, ppm) : 3.66 (s, 6H, 2 OCH3), 3.99 (d, J= 5.8 Hz, 2H, 
CH=CH), 4.06 and 4.15 (AB system, J= 15.2 Hz, 12H, 3NCH2P), 4.57 and 4.61 (AB system, J= 20.1 
Hz, 12H, 3NCH2N).
 31P{1H}-NMR (CDCl3, T=298K, ppm) : -61.3 
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13C{1H}-NMR (CDCl3, T=243K, selected peaks ppm) : 51.6 (CH3, OCH3), 53.2 (d, CH2, JC-P = 4.7 
Hz, NCH2P), 73.2 (CH2, NCH2N), 173.1 (C, COOCH3). 
IR (KBr): C=O= 1672, 1632 cm-1 C-O= 1241 cm-1 
9.7. Synthesis of compounds derived from functionalized imidazole and 
benzimidazole 
9.7.1. Synthesis of imidazolium salts with pyridyl or thioether groups (29-30) 
                   
Imidazolium salts 29 and 30 were synthesized according to published procedures [30, 31]. 
9.7.2. Synthesis of imidazolium salts with alkyl and aryl groups (31) 
                         
Synthesis of 31a 
3.647 g (21.0 mmol) of 1-(4-methylbenzyl)-1H-imidazole was dissolved in 50 ml of anhydrous 
CH3CN in a two-necked flask and 3.5 g (34.0 mmol) of NaBr and 3 ml (23.0 mmol) of 1-
(chloromethyl)-4-methylbenzene were added in rapid sequence under inert atmosphere (Ar). The 
resulting mixture was refluxed for 36 h and eventually the residual salts were filtered off and 
repeatedly washed with CH2Cl2 on a gooch. The clear solution was concentrated under vacuum and 
the title compound was precipitated as white powder by addition of diethylether. The compound was 
filtered off on a gooch, repeatedly washed with diethylether and dried under vacuum. 
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6.62 g (yield 88%) of the ligand were obtained. 
1H NMR (CDCl3, T = 298 K, ppm) d: 2.33 (s, 3H, tol-CH3), 5.50 (s, 2H, N-CH2), 7.15 (d, J = 1.6 Hz, 
2H, CH=CHIm), 7.17–7.2 (m, 2H, Ph), 7.33–7.36 (m, 2H, Ph), 10.98 (bt, 1H, NCHN). 
13C{1H}-NMR (CDCl3, T = 298 K, ppm) d: 21.1 (CH3, Ph-CH3), 53.3 (CH2, N-CH2), 121.4 (CH, 
CH=CHIm), 129.0 (CH, Tol o-C), 129.5 (CH, Tol i-C), 130.0 (CH, Tol m-C), 139.6 (CH, Tol p-C), 
137.2 (CH, NCHN). 
Anal. Calc. for C19H21BrN2: C, 63.87; H, 5.92; N, 7.84. Found: C, 63.99; H, 5.87; N, 7.71%. 
Synthesis of 31b-d 
The imidazolium salt 31b (IMes·HCl) was commercial grade product, whereas the compounds 31c 
and 31d were synthesized according to published procedures [32, 31c]. 
9.7.3. Synthesis of imidazolium salts derived from trifluoromethyl benzimidazole (32) 
  
Synthesis of 32a 
A 25 mL Schlenk was charged with 0.0925 g of Me3OBF4 (0.625 mmol) and CH2Cl2 (8 mL). 
Subsequently, a solution constituted by 0.0970 g of 1-(Trifluoromethyl)-1H-benzo[d]imidazole 
(0.521 mmol) and 2 mL of CH2Cl2, was added dropwise. The reaction mixture was stirred at room 
temperature for 4h and the precipitated was filtered off and washed with dichloromethane and 
diethylether. The product was obtained as a white solid (0.1351 mg, 90%).  
1H NMR (CD3CN, T = 298 K, ppm) : 4.19 (s, 3H, NCH3), 7.89–8.05 (m, 4H, ArH), 9.60 (s, 1H, 
NCHN). 
19F{1H}-NMR (CD3CN, T = 298 K, ppm) : -58.7 (CF3), -151.9 (10BF4), -152.0 (11BF4). 
13C{1H}-NMR (CD3CN, T = 298 K, ppm) : 35.5 (CH3, NCH3), 114.1 (q, J = 1.7 Hz, CH), 115.7 
(CH), 118.4 (q, C, J = 268.8 Hz, CF3), 128.4 (C), 129.8 (CH), 130.7 (CH), 133.3 (C), 142.0 (CH, 
NCHN). 
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Anal. Calc. for C9H8BF7N2: C, 37.54; H, 2.80; N, 9.73. Found: C, 37.60; H, 2.78; N, 9.75%. 
Synthesis of 32b 
0.3221 g (0.9044 mmol) of 3-isopropyl-1-(trifluoromethyl)-1H-benzo[d]imidazol-3-ium iodide, 
synthesized according to published procedures [33] was dissolved in 15 mL of anhydrous acetonitrile. 
Subsequently 176.1 mg (0.9044 mmol) of AgBF4, were added and the resulting mixture was stirred 
at R.T. for 30', filtered on millipore membrane filter and concentrated under vacuum. The final 
product precipitated as a pale-yellow solid by addition of diethylether and was filtered off on a gooch. 
270.0 mg of 32b was obtained (yield 93%). 
1H NMR (CD3CN, T = 298 K, ppm) : 1.73 (d, J = 6.7 Hz,6H, CH(CH3)2), 5.12 (d, J = 6.7 Hz, 1H, 
CH(CH3)2), 7.85–8.10 (m, 4H, ArH), 9.57 (s, 1H, NCHN). 
19F{1H}-NMR (CD3CN, T = 298 K, ppm) : -58.7 (CF3), -151.8 (10BF4), -151.9 (11BF4). 
13C{1H}-NMR (CD3CN, T = 298 K, ppm) : 21.7 (CH3, CH3iPr), 54.4 (CH, CH(CH3)2), 114.5 (m, 
CH), 116.0 (CH), 128.8 (C), 129.6 (CH), 130.6 (CH), 132.1 (C), 140.1 (CH, NCHN). 
Anal. Calc. for C11H12BF7N2: C, 41.81; H, 3.83; N, 8.86. Found: C, 41.84; H, 3.80; N, 8.91%. 
Synthesis of 32c 
Imidazolium salt 32c was synthesized according to published procedures [33]. 
9.7.4. Synthesis of imidazolium salts with glucopiranosidic groups (33) 
 
Synthesis of 33a 
Imidazolium salt 33a was synthesized according to published procedures [34]. 
  
346 
 
Synthesis of 33b 
0.9330 g of 1-(2,3,4,6-tetra-O-acetyl--D-glucopyranosyl)imidazole, synthesized according to 
published procedures [34], and 2.8 g (1 mL, 0.02 mol) of methyl iodide were dissolved in 25 mL of 
anhydrous acetonitrile. The mixture was stirred at reflux for 4 h and subsequently the solvent was 
removed under reduced pressure. The brownish solid obtained was dissolved in ca. 3 mL of 
dichloromethane and the addition of diethyleter induced the precipitation of the final product that was 
filtered off on a gooch. 
1.07 g of 33b was obtained (yield 85%). 
1H-NMR (300 MHz, CDCl3, T = 298 K, ppm) : 2.03 (s, 3H, OCH3), 2.07 (s, 3H, OCH3), 2.11 (s, 
3H, OCH3), 2.12 (s, 3H, OCH3), 4.21 (s, 3H, N-CH3), 4.22-4.43 (m, 3H, H
5+ CH2
6), 5.26 (t, 1H, J= 
9.2 Hz, H4), 5.34 (t, 1H, J= 9.2 Hz, H2), 5.48 (t, 1H, J= 9.2 Hz, H3), 6.61 (d, 1H, J= 9.2 Hz, H1), 7.42 
(d, 1H, J= 2.0 Hz, HIm), 7.60 (t, 1H, J= 2.0 Hz, HIm), 10.57 (s, 1H, NCHN). 
13C{1H}-NMR (CDCl3, T = 298 K, ppm) : 20.5 (CH3, OCH3), 20.6 (CH3, OCH3), 20.9 (CH3, OCH3), 
21.1 (CH3, OCH3), 37.7 (CH3, NCH3), 61.1 (CH2, CH2
6), 67.3 (CH, CH4), 71.2 (CH, CH2),  72.4 (CH, 
CH3), 75.0 (CH, CH5), 83.7 (CH, CH1), 119.6 (CH, CHIm), 123.8 (CH, CHIm), 137.7 (CH, NCHN), 
169.4 (C, C=O), 169.5 (C, C=O), 169.9 (C, C=O), 170.5 (C, C=O). 
Synthesis of 33c 
0.405 g (0.608 mmol) of 1-(2,3,4,6-Tetra-O-acetyl--D-glucopyranosyl)-3-(mesityl)imidazolium 
triflate, synthesized according to published procedures [35], was dissolved in 25 mL of methanol. To 
this solution 2g of DOWEX 21K Cl exchange resin was added and the system was stirred for 24h at 
R.T. Subsequently the solvent was removed under vacuum and the solid obtained was dissolved in 
ca. 3 mL of dichloromethane. The addition of diethyleter induced the precipitation of the final product 
that was filtered off on a gooch. 
0.2454 g of 33c was obtained (yield 73%). 
 Anomer (60%): 
1H-NMR (300 MHz, CDCl3, T = 298 K, ppm) : 2.02-2.13 (m, 18H, 4 OCH3 + 2 o-CH3Mes), 2.37 (s, 
3H, p-CH3
Mes), 4.19-4.44 (m, 3H, H5+ CH2
6), 5.27-5.36 (m, 2H, H2+H4), 5.60 (t, 1H, J= 9.3 Hz, H3), 
7.30 (d, 1H, J= 9.3 Hz, H1), 7.66 (d, 1H, J= 2.0 Hz, HIm), 7.84 (t, 1H, J= 2.0 Hz, HIm), 11.12 (s, 1H, 
NCHN).  
13C{1H}-NMR (CDCl3, T = 298 K, ppm) : 17.3 (CH3, o-CH3Mes), 20.4 (CH3, OCH3), 20.5 (CH3, 
OCH3), 20.6 (CH3, OCH3), 20.7 (CH3, OCH3), 21.1 (CH3, p-CH3
Mes), 61.2 (CH2, CH2
6), 67.5 (CH, 
CH4), 71.1 (CH, CH2), 72.4 (CH, CH3), 75.0 (CH, CH5), 83.8 (CH, CH1), 120.0 (CH, CHIm), 123.5 
(CH, CHIm), 129.9 (CH, m-CHMes), 134.3 (C, o-CMes), 139.3 (CH, NCHN), 141.6 (C, i-CMes), 141.8 
(C, p-CMes), 169.2 (C, C=O), 169.7 (C, C=O), 170.1 (C, C=O), 170.4 (C, C=O). 
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 Anomer (40%):  
1H-NMR (300 MHz, CDCl3, T = 298 K, ppm) : 2.02-2.13 (m, 18H, 4 OCH3 + 2 o-CH3Mes), 2.39 (s, 
3H, p-CH3
Mes), 4.19-4.44 (m, 3H, H5+ CH2
6), 5.27-5.36 (m, 2H, H2+H4), 5.60 (t, 1H, J= 9.3 Hz, H3), 
7.30 (d, 1H, J= 9.3 Hz, H1), 7.15 (d, 1H, J= 2.0 Hz, HIm), 7.19 (t, 1H, J= 2.0 Hz, HIm), 8.36 (s, 1H, 
NCHN). 
13C{1H}-NMR (CDCl3, T = 298 K, ppm) : 17.3 (CH3, o-CH3Mes), 20.4 (CH3, OCH3), 20.5 (CH3, 
OCH3), 20.6 (CH3, OCH3), 20.7 (CH3, OCH3), 21.1 (CH3, p-CH3
Mes), 61.2 (CH2, CH2
6), 67.5 (CH, 
CH4), 71.1 (CH, CH2), 72.4 (CH, CH3), 75.0 (CH, CH5), 83.8 (CH, CH1), 121.1 (CH, CHIm), 122.3 
(CH, CHIm), 130.2 (CH, m-CHMes), 133.6 (CH, NCHN), 134.3 (C, o-CMes), 141.6 (C, i-CMes), 141.8 
(C, p-CMes), 169.2 (C, C=O), 169.7 (C, C=O), 170.1 (C, C=O), 170.4 (C, C=O). 
9.7.5. Synthesis of bis-imidazolium salts (34): 
 
Imidazolium salts 34a-f were synthesized according to published procedures [36]. 
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9.7.6. Synthesis of silver complexes bearing NHC with pyridyl and thioether groups (35-36) 
                   
Complexes 35a-b and 36a-b were synthesized according to published procedures [30, 31]. 
 
9.7.7. Synthesis of silver complexes bearing NHC with alkyl and aryl groups (37) 
 
Synthesis of 37a 
0.400 g (1.12 mmol) of 31a was dissolved in 30 ml of anhydrous CH2Cl2 in a two-necked flask and 
0.1557 g (0.672 mmol) of Ag2O was added under inert atmosphere (Ar). 
The mixture was stirred overnight at RT in the dark. The solution was filtered on millipore membrane 
filter, concentrated under vacuum and the title complex precipitated by addition of diethylether. 
The white complex was filtered off on a gooch, repeatedly washed with diethylether and n-pentane 
and dried under vacuum. 
0.4893 g (yield 94%) of complex 37a was obtained. 
1H-NMR (CDCl3, T = 298 K, ppm) d: 2.35 (s, 6H, tol-CH3), 5.25 (s, 4H, N-CH2), 6.90 (s, 2H, CH=CH 
Im), 7.16–7.17 (m, 8H, tol-H). 
13C{1H}NMR (CDCl3, T = 298 K, ppm) d: 21.1 (CH3, Ph-CH3), 55.5 (CH2, N-CH2), 121.2 (CH, 
CH=CHIm), 127.8 (CH, Tol o-C), 129.7 (CH, Tol m-C), 132.3 (CH, Tol i-C), 138.5 (CH, Tol p-C), 
180.8 (C, carbene). 
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Anal. Calc. for C19H20AgBrN2: C, 49.17; H, 4.34; N, 6.04. Found: C, 49.33; H, 4.19, N, 6.21%. 
Synthesis of 37b-d 
Complexes 37b, 37c and 37d were synthesized according to published procedures [32, 31c]. 
9.7.8. Synthesis of silver complexes from imidazolium salts with glucopiranosidic group (38) 
 
Synthesis of the complex 38a 
0.2020 g (0.377 mmol) of 33a was dissolved in 25 ml of anhydrous CH2Cl2 in a two-necked flask 
and 0.0524 g (0.226 mmol) of Ag2O was added under inert atmosphere (Ar). 
The mixture was stirred for 5 hours at RT in the dark and subsequently transferred in a 250 mL flask 
with the addition of ca. 150 mL of CH2Cl2. The solution was filtered on millipore membrane filter, 
concentrated under vacuum and the title complex precipitated by addition of diethylether. 
The pale-yellow complex was filtered off on a gooch, repeatedly washed with diethylether and n-
pentane and dried under vacuum. 
0.2159 g of 38a was obtained (yield 89%). 
1H-NMR (300 MHz, CDCl3, T = 298 K, ppm) : 0.96 (t, 3H, J= 7.3 Hz, CH34’), 1.33 (m, 2H, CH23’), 
1.79 (m, 2H, CH2
2’), 1.96 (s, 3H, OCH3), 2.02 (s, 3H, OCH3), 2.08 (s, 3H, OCH3), 2.11 (s, 3H, OCH3), 
4.11-4.37 (m, 5H, H5+CH2
1’+CH2
6), 5.21-5.29 (m, 2H, H2+H4), 5.44 (t, 1H, J= 9.3 Hz, H3), 6.62 (d, 
1H, J= 9.3 Hz, H1), 7.04 (d, 1H, J= 1.8 Hz, HIm), 7.25 (d, 1H, J= 1.8 Hz, HIm). 
13C{1H}-NMR (CDCl3, T = 298 K, ppm) : 13.6 (CH3, CH34’), 19.5 (CH2, CH23’), 20.4 (CH3, OCH3), 
20.5 (CH3, OCH3), 20.6 (CH3, OCH3), 20.7 (CH3, OCH3), 33.2 (CH2, CH2
2’), 55.3 (CH2, CH2
1’), 61.6 
(CH2, CH2
6), 67.7 (CH, CH4), 71.0 (CH, CH2), 72.5 (CH, CH3), 74.9 (CH, CH5), 87.5 (CH, CH1), 
118.4 (CH, CHIm), 121.9 (CH, CHIm), 169.1 (C, C=O), 169.5 (C, C=O), 169.6 (C, C=O), 170.5 (C, 
C=O), 179.9 (C, carbene). IR(KBr): νC=O = 1754cm-1, νC-O = 1230 cm-1. 
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Synthesis of the complex 38b 
Complex 38b was prepared in analogues manner as that described for 38a starting from 0.2020 g of 
33b and 0.0524 g of Ag2O. 
0.1878 g (yield 78%) of 38b was obtained. 
1H-NMR (300 MHz, CDCl3, T = 298 K, ppm) : 1.99 (s, 3H, OCH3), 2.03 (s, 3H, OCH3), 2.09 (s, 
3H, OCH3), 2.11 (s, 3H, OCH3), 3.91 (s, 3H, NCH3), 4.16-4.38 (m, 3H, H
5+CH2
6), 5.16 (t, 1H, J= 9.3 
Hz, H4), 5.25 (t, 1H, J= 9.3 Hz, H2), 5.38 (t, 1H, J= 9.3 Hz, H3), 6.12 (d, 1H, J= 9.2 Hz, H1), 7.01 (d, 
1H, J= 1.8 Hz, HIm), 7.24 (d, 1H, J= 1.8 Hz, HIm). 
13C{1H}-NMR (CDCl3, T = 298 K, ppm) : 20.5 (CH3, OCH3), 20.6 (CH3, OCH3), 20.7 (CH3, OCH3), 
20.8 (CH3, OCH3), 39.1 (CH3, NCH3), 61.5 (CH2, CH2
6), 67.8 (CH, CH4), 70.8 (CH, CH2), 72.9 (CH, 
CH3), 74.4 (CH, CH5), 86.5 (CH, CH1), 118.1 (CH, CHIm), 122.7 (CH, CHIm), 169.4 (C, C=O), 169.5 
(C, C=O), 169.6 (C, C=O), 170.5 (C, C=O), 185.8 (C, carbene). 
IR(KBr): νC=O = 1752cm-1, νC-O = 1228 cm-1. 
Synthesis of the complex 38c 
Complex 38c was prepared in analogues manner as that described for 38a starting from 0.1073 g of 
33c and 0.0270 g of Ag2O. 
0.0661 g (yield 52%) of 38c was obtained. 
1H-NMR (300 MHz, CDCl3, T = 298 K, ppm) : 1.92 (s, 3H, p-CH3Mes), 1.98 (s, 3H, o-CH3Mes), 2.02 
(s, 3H, o-CH3
Mes), 2.05 (s, 3H, OCH3), 2.11 (s, 3H, OCH3), 2.15 (s, 3H, OCH3), 2.35 (s, 3H, OCH3), 
4.07 (m, 1H, H5), 4.21-4.42 (m, 2H, CH2
6), 5.25-5.37 (m, 2H, H2+H4), 5.45 (t, 1H, J= 9.4 Hz, H3), 
5.77 (d, 1H, J= 9.3 Hz, H1), 6.99 (m, 2H, m-CHMes), 7.02 (t, 1H, J= 1.9 Hz, HIm), 7.44 (t, 1H, J= 1.9 
Hz, HIm). 
13C{1H}-NMR (CDCl3, T = 298 K, ppm) : 17.3 (CH3, p-CH3Me), 20.4 (CH3, o-CH3Mes), 20.5 (CH3, 
OCH3), 20.6 (CH3, OCH3), 20.8 (CH3, OCH3), 21.1 (CH3, OCH3), 61.5 (CH2, CH2
6), 67.6 (CH, CH4), 
71.1 (CH, CH2), 72.3 (CH, CH3), 75.1 (CH, CH5), 87.8 (CH, CH1), 118.5 (CH, CHIm), 124.0 (CH, 
CHIm), 129.6-140.0 (Ph), 169.0 (C, C=O), 169.4 (C, C=O), 169.6 (C, C=O), 170.5 (C, C=O), 180.4 
(C, carbene). 
IR(KBr): νC=O = 1754cm-1, νC-O = 1231 cm-1. 
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9.7.9. Synthesis of silver complexes with chelating bis(NHC) (39) 
 
Synthesis of the complex 39a 
0.2693 g (0.549 mmol) of the imidazolium salt 34a was dissolved in 35 mL of anhydrous methanol 
in a 100 mL two necked flask and 0.1655 g (0.7140 mmol) of Ag2O was added under inert atmosphere 
(Ar). The mixture was stirred for 2 h at R.T. in the dark and the resulting mixture was filtered on 
millipore membrane filter to eliminate the Ag2O in excess. The solvent was removed under vacuum 
and the brownish solid obtained was suspended in ca. 3 mL of dichloromethane. The product was 
precipitated by addition of diethylether and filtered off on a gooch. 
0.2445 g of 39a was obtained (yield 63%). 
1H-NMR (300 MHz, d6-DMSO, T = 298 K, ppm) : 5.18 (s, 4H, 2CH2Ph), 7.05 (s, 2H, 2CHIm), 7.04-
7.23 (m, 10H, 2Ph), 7.54 (s, 2H, 2CHIm), 7.93 (s, 2H, NCH2N). 
13C{1H}-NMR (d6-DMSO, T = 298 K, ppm) : 54.9 (CH2, CH2Ph), 63.4 (CH2, NCH2N), 123.0 (CH, 
CHIm), 123.5 (CH, CHIm), 127.5-137.1 (Ph), 182.6 (C, carbene). 
Synthesis of the complex 39b 
Complex 39b was prepared in analogues manner as that described for 39a starting from 0.252 g of 
34b and 0.150 g of Ag2O. 
0.212 g (yield 59%) of 39b was obtained. 
1H-NMR (300 MHz, d6-DMSO, T = 298 K, ppm) : 4.65 (s, 4H, NCH2CH2N), 5.17 (s, 4H, 2CH2Ph), 
6.98-7.26 (m, 10H, 2Ph), 7.45 (d, 2H, J= 1.8 Hz, 2CHIm), 7.48 (d, 2H, J= 1.8 Hz, 2CHIm).  
13C{1H}-NMR (d6-DMSO, T = 298 K, ppm) : 51.5 (CH2, NCH2CH2N), 54.5 (CH2, CH2Ph), 122.9 
(CH, CHIm), 123.3 (CH, CHIm), 127.4-137.5 (Ph), 180.8 (C, carbene). 
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Synthesis of 39c-f 
Complexes 39c-f were synthesized according to published procedures [37]. 
9.7.10. Synthesis of palladacyclopentadienyl complexes with chelating bis(NHC) ligands (40) 
 
Synthesis of the complex 40a 
0.0391 g (0.100 mmol) of the polymeric precursor [PdC4(COOCH3)4]n was dissolved in 10 mL of 
anhydrous dichloromethane in a 50 mL two necked flask under inert atmosphere (Ar). To this solution 
was added a mixture constituted by 0.0705 g (0.100 mmol) of the silver complex 39a dissolved in ca. 
15 mL of anhydrous dichloromethane.  
The mixture was stirred at R.T. for 1 h and subsequently the precipitated AgBr was removed by 
filtration on a millipore membrane filter. 
Addition of diethylether to the concentrated solution yields the precipitation of the complex 40a as a 
brownish solid which was filtered off on a gooch and washed with n-pentane.  
0.0654 g of 40a was obtained (yield 90%). 
1H-NMR (400 MHz, CDCl3, T = 298K, ppm) : 3.44 (s, 6H, 2 OCH3), 3.69 (s, 6H, 2 OCH3), 4.98 
and 5.60 (AB system, 4H, J = 15.0 Hz, 2 -CH2Ph), 6.00 and 6.49 (AB system, 2H, J = 13.6 Hz, 
NCH2N), 6.65 (d, 2H, J = 1.8 Hz, 2 CHIm), 6.99 (d, 4H, J = 7.1 Hz, 4 Ph
orto), 7.16-7.26 (m, 6H, 4 
Phmeta + 2 Ph
para), 7.32 (d, 2H, J = 1.8 Hz, 2 CHIm). 
13C{1H}-NMR (CDCl3, T = 298K, ppm) : 50.7 (CH3, OCH3), 51.3 (CH3, OCH3), 54.5 (CH2, CH2Ph), 
65.5 (CH2, NCH2N), 119.4 (CH, CHIm), 122.6 (CH, CHIm), 127.8-136.4 (Ph), 145.7 (C, C-COOCH3), 
166.5 (C, COOCH3), 169.7 (C, C-COOCH3), 177.5 (C, COOCH3), 179.7 (C, carbene). 
IR (KBr): νC=O = 1733 cm-1, 1686 cm-1, νC-O = 1194 cm-1, 1159 cm-1 
Synthesis of 40b 
Complex 40b was prepared in analogues manner as that described for 40a starting from 0.0385 g of 
[PdC4(COOCH3)4]n and 0.0707 g of 39b. 
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0.0707 g of 40b was obtained (yield 97%). 
1H-NMR (400 MHz, CDCl3, T = 298K, ppm) : 3.32 (s, 6H, 2 OCH3), 3.58 (s, 6H, 2 OCH3), 4.35 
(m, 2H, NCH2CH2N), 5.02 and 5.07 (AB system, 4H, J = 15.4 Hz, 2CH2Ph), 5.33 (m, 2H, 
NCH2CH2N), 6.56 (d, 2H, J = 1.9 Hz, 2 CHIm), 6.86 (d, 4H, J = 8.1 Hz, 4 Ph
orto), 6.93 (d, 2H, J = 1.9 
Hz, 2 CHIm), 7.10-7.15 (m, 6H, 4 Ph
meta
 + 2 Ph
para). 
13C{1H}-NMR (CDCl3, T = 298K, ppm) : 48.2 (CH2, NCH2CH2N), 50.7 (CH3, OCH3), 51.1 (CH3, 
OCH3), 54.4 (CH2, CH2Ph), 120.5 (CH, CHIm), 121.9 (CH, CHIm), 128.0-136.2 (Ph), 144.8 (C, C-
COOCH3), 165.9 (C, COOCH3), 169.9 (C, C-COOCH3), 177.4 (C, COOCH3), 178.9 (C, carbene). 
IR (KBr): νC=O = 1691 cm-1, νC-O = 1202 cm-1 
9.7.11. Synthesis of bis(NHC) palladacyclopentadienyl complexes (41) 
 
Complexes 41a-c were synthesized according to published procedures [38]. 
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9.7.12. Synthesis of palladacyclopentadienyl complexes bearing hemi-labile NHCs (42-43) 
                 
Complexes 42a-b and 43 were synthesized according to published procedures [38]. 
9.7.13. Synthesis of mixed NHC/PPh3 and NHC/DIC palladacyclopentadienyl complexes (44-
46) 
             
Synthesis of complexes 44 and 46 
Complexes 44 and 46 were synthesized according to published procedures [38]. 
Synthesis of the complex 45a 
0.0308 g (0.0789 mmol) of the polymeric precursor [PdC4(COOCH3)4]n was dissolved in 10 mL of 
anhydrous dichloromethane in a 50 mL two-necked flask under inert atmosphere (Ar). To this 
solution was added a mixture constituted by 0.0505 g (0.0789 mmol) of the silver complex 38a and 
0.0207 g (0.0789 mmol) of PPh3 dissolved in ca. 15 mL of anhydrous dichloromethane.  
The mixture was stirred at R.T. for 30 min and subsequently the precipitated AgBr was removed by 
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filtration on a millipore membrane filter. 
Addition of n-hexane to the concentrated solution yields the precipitation of the complex 45a as a 
yellow solid which was filtered off on a gooch.  
0.0758 g of 45a was obtained (yield 87%). 
Anomer 1 () 
1H-NMR (300 MHz, CD2Cl2, T = 298 K, ppm selected peaks) : 0.80-0.86 (m, 3H, CH34’), 0.97-1.04 
(m, 2H, 2CH2
3’), 1.10-1.31 (m, 2H, 2CH2
2’), 2.04 (s, 6H, 2 OCH3), 2.07 (s, 3H, OCH3), 2.09 (s, 3H, 
OCH3), 2.58 (s, 3H, OCH3), 3.18 (s, 3H, OCH3), 3.57 (s, 3H, OCH3), 3.58 (s, 3H, OCH3), 6.15 (d, 
2H, J= 8.8 Hz, H1), 6.71 (d, 1H, J= 2.1 Hz, HIm), 7.25 (d, 1H, J= 2.1 Hz, HIm), 7.25-7.75 (m, 15H, 
3Ph).  
31P{1H}-NMR (CD2Cl2, T = 298 K, ppm) : 24.4. 
13C{1H}-NMR (CDCl3, T = 233 K, ppm selected peaks) : 14.0 (CH3, CH34’), 20.3 (CH2, CH23’), 
20.9-21.4 (CH3, OCH3), 30.4 (CH2, CH2
2’), 50.7 (CH2, CH2
1’), 51.2-52.1 (CH3, OCH3), 85.8 (CH, 
CH1), 169.5-171.4 (C, C=O), 174.2 (d, JC-P= 19.5 Hz, C, carbene). 
Anomer 2 () 
1H-NMR (300 MHz, CD2Cl2, T = 298 K, ppm selected peaks) : 0.80-0.86 (m, 3H, CH34’), 0.97-1.04 
(m, 2H, 2CH2
3’), 1.10-1.31 (m, 2H, 2CH2
2’), 1.94 (s, 3H, OCH3), 1.97 (s, 3H, OCH3), 2.04 (s, 3H, 
OCH3), 2.08 (s, 3H, OCH3), 2.56 (s, 3H, OCH3), 3.17 (s, 3H, OCH3), 3.56 (s, 3H, OCH3), 3.61 (s, 
3H, OCH3), 6.24 (d, 2H, J= 8.8 Hz, H
1), 6.76 (d, 1H, J= 2.1 Hz, HIm), 7.17 (d, 1H, J= 2.1 Hz, HIm), 
7.25-7.75 (m, 15H, 3Ph). 
31P{1H}-NMR (CD2Cl2, T = 298 K, ppm) : 25.2. 
13C{1H}-NMR (CDCl3, T = 233 K, ppm selected peaks) : 14.0 (CH3, CH34’), 20.4 (CH2, CH23’), 
20.9-21.4 (CH3, OCH3), 30.4 (CH2, CH2
2’), 50.9 (CH2, CH2
1’), 51.2-52.1 (CH3, OCH3), 85.9 (CH, 
CH1), 169.5-171.4 (C, C=O), 175.4 (d, JC-P= 19.8 Hz, C, carbene). 
IR(KBr): νC=O = 1753 cm-1, 1714 cm-1 νC-O = 1229 cm-1 
Synthesis of the complex 45b 
Complex 45b was prepared in analogues manner as that described for 45a starting from 0.0309 g of 
[PdC4(COOCH3)4]n, 0.0510 g of 38b and 0.0207 g of PPh3. 
0.0707 g (yield 84%) of 45b was obtained. 
Anomer 1 () 
1H-NMR (300 MHz, CDCl3, T = 298 K, ppm selected peaks) : 1.98 (s, 3H, OCH3), 2.04 (s, 3H, 
OCH3), 2.08 (s, 3H, OCH3), 2.13 (s, 3H, OCH3), 2.61 (s, 3H, OCH3), 3.03 (s, 3H, NCH3), 3.17 (s, 
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3H, OCH3), 3.62 (s, 3H, OCH3), 3.63 (s, 3H, OCH3), 6.12 (d, 2H, J= 8.9 Hz, H
1), 6.54 (d, 1H, J= 2.1 
Hz, HIm), 7.12 (d, 1H, J= 2.1 Hz, HIm), 6.98-7.47 (m, 15H, 3Ph).  
31P{1H}-NMR (CDCl3, T = 298 K, ppm) : 24.4. 
13C{1H}-NMR (CDCl3, T = 233 K, ppm selected peaks) : 20.6-21.4 (CH3, OCH3), 37.1 (CH3, 
NCH3), 50.7 (CH3, OCH3), 51.2 (CH3, OCH3), 51.7 (CH3, OCH3), 51.8 (CH3, OCH3), 85.9 (CH, 
CH1), 169.9-171.4 (C, C=O), 181.7 (d, JC-P= 19.7 Hz, C, carbene). 
Anomer 2 () 
1H-NMR (300 MHz, CDCl3, T = 298 K, ppm selected peaks) : 1.99 (s, 3H, OCH3), 2.03 (s, 3H, 
OCH3), 2.05 (s, 3H, OCH3), 2.07 (s, 3H, OCH3), 2.60 (s, 3H, OCH3), 2.97 (s, 3H, NCH3), 3.19 (s, 
3H, OCH3), 3.60 (s, 3H, OCH3), 3.61 (s, 3H, OCH3), 6.30 (d, 2H, J= 8.8 Hz, H
1), 6.60 (d, 1H, J= 2.1 
Hz, HIm), 7.08 (d, 1H, J= 2.1 Hz, HIm), 6.98-7.47 (m, 15H, 3Ph). 
31P{1H}-NMR (CDCl3, T = 298 K, ppm) : 25.3. 
13C{1H}-NMR (CDCl3, T = 233 K, ppm selected peaks) : 20.6-21.4 (CH3, OCH3), 37.1 (CH3, 
NCH3), 51.0 (CH3, OCH3), 51.7 (CH3, OCH3), 51.8 (CH3, OCH3), 51.9 (CH3, OCH3), 85.9 (CH, 
CH1), 169.9-171.4 (C, C=O), 185.1 (d, JC-P= 19.7 Hz, C, carbene). 
IR(KBr): νC=O = 1753 cm-1, 1714 cm-1 νC-O = 1228 cm-1. 
Synthesis of the complex 45c 
Complex 45c was prepared in analogues manner as that described for 45a starting from 0.0323 g of 
[PdC4(COOCH3)4]n, 0.0546 g of 38c and 0.0217 g of PPh3. 
0.0894 g (yield 92%) of 45c was obtained. 
Anomer 1 () 
1H-NMR (300 MHz, CDCl3, T = 298 K, ppm selected peaks) : 1.61-2.42 (m, 21H, 4 OCH3 + 
3CH3
Mes), 2.86-3.73 (m, 12H, 4 OCH3), 5.87 (d, 2H, J= 8.9 Hz, H
1), 6.81-7.78 (m, 17H, 3Ph+2HIm). 
31P{1H}-NMR (CDCl3, T = 298 K, ppm) : 22.9. 
13C{1H}-NMR (CDCl3, T = 233 K, ppm selected peaks) : 20.8-21.4 (CH3, OCH3), 51.4-52.4 (CH3, 
OCH3), 169.3-171.3 (C, C=O), 182.1 (d, JC-P= 17.0 Hz, C, carbene). 
Anomer 2 () 
1H-NMR (300 MHz, CDCl3, T = 298 K, ppm selected peaks) : 1.61-2.42 (m, 21H, 4 OCH3 + 
3CH3
Mes), 2.86-3.73 (m, 12H, 4 OCH3), 6.09 (d, 2H, J= 8.8 Hz, H
1), 6.81-7.78 (m, 17H, 3Ph+2HIm). 
31P{1H}-NMR (CDCl3, T = 298 K, ppm) : 22.7. 
13C{1H}-NMR (CDCl3, T = 233 K, ppm selected peaks) : 20.8-21.4 (CH3, OCH3), 51.4-52.4 (CH3, 
OCH3), 169.3-171.3 (C, C=O), 183.6 (d, JC-P= 16.2 Hz, C, carbene). 
IR(KBr): νC=O = 1753 cm-1, 1714 cm-1 νC-O = 1229 cm-1. 
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9.7.14. Synthesis of the unexpected products of halogen addition (47) 
 
Synthesis of complex 47a 
To 0.0958 g (0.170 mmol) of complex 42a dissolved in ca. 20 ml of anhydrous CH2Cl2 in a two-
necked 100 ml flask, 0.0517 g (0.204 mmol) of I2 dissolved in a small quantity of anhydrous CH2Cl2 
was added under inert atmosphere (Ar). The reaction mixture was stirred for 3 days at R.T. and 
evaporated to small volume under vacuum. Addition of diethyl ether induces the precipitation of the 
orange complex 47a which was filtered off on a gooch, repeatedly washed with diethyl ether and 
finally dried under vacuum. 0.1274 g (yield 92%) of the complex 47a was obtained.  
1H NMR (CDCl3, T = 298 K, ppm),  δ: 3.66 (s, 3H, OCH3), 3.71 (s, 3H, NCH3), 3.76 (s, 3H, OCH3), 
3.82 (s,3H, OCH3), 3.93 (s, 3H, OCH3), 5.06 (d, J = 14.4 Hz, 1H, NCH2), 6.48 (d, J = 14.4 Hz, 1H, 
NCH2), 6.76 (bs,1H, CH=CH Im), 7.38 (m, 1H, 5-Pyr), 7.42 (bs, 1H, CH=CH Im), 7.59 (d, J = 7.7 
Hz, 1H, 3-Pyr), 7.83 (t, J =7.7, 1H, 4-Pyr), 8.84 (d, J = 4.9 Hz, 1H, 6-Pyr ). 
13C{1H} NMR (CDCl3, T = 298 K, ppm), δ: 36.9 (CH3, NCH3), 51.8 (CH3, OCH3), 52.4 (CH3, 
OCH3), 53.3 (CH3, OCH3), 54.1 (CH3, OCH3), 54.7 (CH2, NCH2), 118.1 (C, C=C), 122.3 (CH, 
CH=CH Im), 125.9 (CH,5-Pyr), 126.1 (CH, CH=CH Im), 126.8 (CH, 3-Pyr), 132.3 (C, C=C), 138.7 
(CH, 4-Pyr), 139.8 (C, NCN),151.7 (C, 2-Pyr), 154.8 (CH, 6-Pyr), 156.5 (C, C=C), 162.4 (C, C=C), 
162.7 (C, C=O), 165.4 (C, C=O),165.9 (C, C=O), 171.6 (C, C=O). 
IR (KBr pellets): νc=o : 1717 cm-1 , νc-o : 1241 cm-1 
Synthesis of complex 47b 
Complex 47b was obtained according to the above described protocols using the appropriate starting 
complex (42b) and I2. The yield, color, reaction time and, where necessary, some supplementary 
information will be reported under the title.  
Reaction time: 28 days. Temperature: R.T. Yield 93%. Color: orange. 
358 
 
1H NMR (CDCl3, T = 298 K, ppm), δ: 2.04 (s, 3H, o-mesytil-CH3), 2.34 (s,3H, o-mesityl-CH3), 2.39 
(s, 3H, p-mesityl-CH3),  3.25 (s, 3H, OCH3), 3.68 (s, 3H, OCH3), 3.73 (s, 3H, OCH3), 3.93 (s, 3H, 
OCH3),  5.13 (d, J = 14.4 Hz, 1H, NCH2), 6.57 (d, J = 14.4 Hz, 1H, NCH2), 6.92 (s, 1H, m-mesityl-
H), 7.01 (s, 1H, m-mesityl-H), 7.23 (d, J = 2.1 Hz, 1H, CH=CH Im), 7.39 (d, J = 2.1 Hz, 1H, CH=CH 
Im),  7.45 (ddd, 1H, J = 7.7, 5.4, 1.6 Im, 5-Pyr), 7.63 (d, J = 7.7 Hz, 1H, 3-Pyr), 7.90 (td, J = 7.7, 1.6 
Hz, 1H, 4-Pyr), 8.97 (ddd, J = 5.4, 1.6, 0.7 Hz, 1H, 6-Pyr ). 
13C{1H } NMR (CDCl3, T = 298 K, ppm) δ: 17.8 (CH3, o-mesityl-CH3), 20.6 (CH3, o-mesityl-CH3), 
21.8 (CH3, p-mesityl-CH3), 51.2 (CH3, OCH3), 51.2 (CH3, OCH3), 52.9 (CH3, OCH3), 53.5 (CH3, 
OCH3), 56.3 (CH2, NCH2), 116.2 (C, Pd-C-C, C=C), 123.6 (CH, CH=CH Im), 125.7 (CH,5-Pyr), 
125.9 (CH, CH=CH Im), 127.3 (CH, 3-Pyr), 129.2 (CH, m-mesityl), 130.1 (CH, m-mesityl), 130.7 
(C, i-mesityl), 131.4 (C, Pd-C-I), 135.3 (C, o-mesityl), 137.0 (C, o-mesityl), 140.4 (C, p-mesityl), 
138.9 (CH, 4-Pyr), 142.2 (C, NCN), 150.7 (C, 2-Pyr), 155.1 (CH, 6-Pyr), 159.8 (C, C=O), 161.4 (C, 
C=C), 164.6 (C, C=O), 165.3 (C, C=O), 171.7 (C, C=O),  181.4 (C, C=C). 
IR (KBr pellets):νc=o : 1723 cm-1 , νc-o : 1225 cm-1 
9.7.15. Synthesis of palladium 3-allyl complexes with chelating bis(NHC) ligands (48) 
     
Synthesis of the complex 48a 
0.0527 g (0.1137 mmol) of the precursor [Pd(Me-PyCH2SPh)(3-C3H5)]ClO4 was dissolved in 15 
mL of anhydrous dichloromethane in a 50 mL two-necked flask under inert atmosphere (Ar). 
Subsequently was added 0.0802 g (0.181 mmol) of the silver complex 39a, previously dissolved in 
ca. 5 mL of CH2Cl2. The mixture was stirred at R.T. for 15 min and the precipitated AgBr was 
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removed by filtration on a millipore membrane filter. 
The solvent was reduced under vacuum and the white solid was precipitated by addition of 
diethylether and filtered off on a gooch. 
0.0651 g of 48a was obtained (brownish solid, yield 98%). 
1H NMR (300 MHz, CDCl3, T=298 K, ppm)  : 2.79 (d, J=13.3 Hz, 2H, 2 anti allyl-H), 4.05 (d, J = 
7.6 Hz , (2H, 2 syn allyl-H), 5.26 (m, 1H, central-allyl-H), 5.29 (s, 2H, 2NCH2), 6.24-6.61 (AB 
system, J= 13.1 Hz, 2H, NCH2N), 6.90 (d, J =1.9 Hz, 2H, CH=CH
Im), 7.11-7.38 (10H, Ar-H), 7.89 
(d, J=1.9 Hz, 2H, CH=CHIm). 
13C{1H} NMR (CD2Cl2, T=298 K, ppm)  : 55.1 (CH2, NCH2), 58.9 (CH2, allyl- CH2), 63.0 (CH2, 
NCH2N), 119.7 (CH, central allyl),  120.6 (CH, CH=CH
Im), 123.1 (CH, CH=CHIm), 127.2-135.7 (Ar-
C), 176.1 (C, carbene). 
IR [KBr Pellet]: ClO = 1088, ClO = 620, cm-1. 
Synthesis of the complex 48b 
Complex 48b was prepared in analogues manner as that described for 48a starting from 0.0512 g 
(0.1105 mmol) of [[Pd(Me-PyCH2SPh)(3-C3H5)]ClO4 and 0.0793 g (0.1105 mmol) of 39b. 
0.0641 g (yield 98%) of 48b was obtained. 
1H NMR (300 MHz, CDCl3, T=298 K, ppm)  : 2.62 (d, J=15.8 Hz, 2H, 2 anti allyl-H), 3.81 (d, J = 
7.3 Hz, 2H, 2 syn allyl-H), 4.84-5.27 (9H, 2NCH2, NCH2CH2N,central allyl-H), 6.94-7.42 (14H, Ar-
H, 2CH=CHIm) 
13C{1H} NMR (CDCl3, T=298 K, ppm)  : 48.6 (CH2, NCH2CH2N), 55.0 (CH2, NCH2), 58.5 (CH2, 
allyl CH2), 122.1 (CH, central allyl), 124.2 (CH, CH=CH
Im), 126.9 (CH, CH=CHIm), 128.4-135.9 
(Ar-C), 174.7 (C, carbene). 
IR [KBr Pellet]: ClO = 1093, ClO = 620, cm-1. 
Synthesis of the complex 48c 
Complex 48c was prepared in analogues manner as that described for 48a starting from 0.0515 g 
(0.1112 mmol) of [[Pd(Me-PyCH2SPh)(3-C3H5)]ClO4 and 0.0845 g (0.1112 mmol) of 39c. 
0.0605 g (yield 86%) of 48c was obtained. 
Most abundant isomer (ca. 60%):  
1H NMR (300 MHz, CDCl3, T=298 K, ppm)  : 1.87 (d, J=13.8 Hz, 2H, 2 anti allyl-H), 1.91 (s, 6H, 
2 o-aryl-CH3), 1.96 (s, 6H, 2 o-aryl-CH3), 2.35 (s, 6H, 2 p-aryl-CH3), 2.94 (d, J=7.5 Hz, 2H, 2 syn 
allyl-H), 4.68 (m, 1H, central allyl-H), 6.33-6.84 (AB system, J= 13.2 Hz, 2H, NCH2N), 6.85-8.16 
(8H, Ar-H, 2CH=CHIm). 
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13C{1H} NMR (CDCl3, T=298 K, ppm)  : 17.7 (CH3, o-mesityl-CH3), 21.1 (CH3, p-mesityl-CH3), 
58.6 (CH2, allyl CH2), 62.9 (CH2, NCH2N), 118.8 (CH, central allyl),  121.7 (CH, CH=CH
Im), 123.3 
(CH, CH=CHIm), 129.0-139.6 (Ar-C), 176.1 (C, carbene). 
Less abundant isomer (ca. 40%):  
1H NMR (300 MHz, CDCl3, T=298 K, ppm)  : 1.37 (s, 6H, 2 o-aryl-CH3), 1.66 (s, 6H, 2 o-aryl-
CH3), 1.68 (d, J=13.6 Hz, 2H, 2 anti allyl-H), 2.36 (d, J=7.4 Hz, 2H, 2 syn allyl-H), 2.47 (s, 6H, 2 p-
aryl-CH3), 4.68 (m, 1H, central allyl-H) 6.33-6.84 (AB system, J= 13.7 Hz, 2H, NCH2N), 6.85-8.16 
(8H, Ar-H, 2CH=CHIm). 
13C{1H} NMR (CDCl3, T=298 K, ppm)  : 17.7 (CH3, o-mesityl-CH3), 21.1 (CH3, p-mesityl-CH3), 
58.6 (CH2, allyl CH2), 62.9 (CH2, NCH2N), 118.8 (CH, central allyl),  121.7 (CH, CH=CH
Im), 123.3 
(CH, CH=CHIm), 129.0-139.6 (Ar-C), 176.1 (C, carbene). 
IR [KBr Pellet]: ClO = 1096, ClO = 623, cm-1. 
Synthesis of the complex 48d 
Complex 48d was prepared in analogues manner as that described for 48a starting from 0.0361 g 
(0.0779 mmol) of [Pd(Me-PyCH2SPh)(3-C3H5)]ClO4 and 0.0603 g (0.0779 mmol) of 39d. 
0.0465 g (yield 92%) of 49d was obtained. 
Most abundant isomer (ca. 70%):  
1H NMR (300 MHz, CDCl3, T=298 K, ppm)  : 1.65 (d, J=13.5 Hz, 2H, 2 anti allyl-H), 1.91 (s, 6H, 
2 o-aryl-CH3), 1.94 (s, 6H, 2 o-aryl-CH3), 2.33 (s, 6H, 2 p-aryl-CH3), 3.22 (d, J=7.5 Hz, 2H, 2 syn 
allyl-H), 4.66 (m, 1H, central allyl-H), 5.00 (m, 4H, NCH2CH2N), 6.91-6.93 (4H, Ar-H), 6.96 (d, 
J=1.9 Hz, 2H, CH=CHIm), 7.59 (d, J=1.9 Hz, 2H, CH=CHIm). 
13C{1H} NMR (CDCl3, T=298 K, ppm)  : 17.5 (CH3, mesityl-CH3), 18.0 (CH3, mesityl-CH3), 18.3 
(CH3, mesityl-CH3), 21.0 (CH3, mesityl-CH3), 49.5 (CH2, NCH2CH2N), 59.3 (CH2, allyl CH2), 118.4 
(CH, central allyl),  123.5 (CH, CH=CHIm), 123.6 (CH, CH=CHIm), 128.9-139.3 (Ar-C), 174.7 (C, 
carbene). 
Less abundant isomer (ca. 30%):  
1H NMR (300 MHz, CDCl3, T=298 K, ppm)  : 1.65 (d, J=13.5 Hz, 2H, 2 anti allyl-H), 1.69 (s,  
12H, 2 o-aryl-CH3), 2.43 (s, 6H, 2 p-aryl-CH3), 3.22 (d, J=7.5 Hz, 2H, 2 syn allyl-H), 4.81 (s, 4H, 
NCH2CH2N), 5.02 (m, 1H, central allyl-H), 6.86 (d, J=1.9 Hz, 2H, CH=CH
Im),   6.91-6.93 (4H, Ar-
H), 7.91 (d, J=1.9 Hz, 2H, CH=CHIm). 
13C{1H} NMR (CDCl3, T=298 K, ppm)  : 17.5 (CH3, mesityl-CH3), 18.0 (CH3, mesityl-CH3), 18.3 
(CH3, mesityl-CH3), 21.0 (CH3, mesityl-CH3), 49.5 (CH2, NCH2CH2N), 59.3 (CH2, allyl CH2), 118.4 
(CH, central allyl),  123.5 (CH, CH=CHIm), 123.6 (CH, CH=CHIm), 128.9-139.3 (Ar-C), 174.7 (C, 
carbene). 
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Synthesis of the complex 48e 
Complex 48e was prepared in analogues manner as that described for 48a starting from 0.0436 g 
(0.0913 mmol) of [[Pd(Me-PyCH2SPh)(3-2-MeC3H4)]ClO4 and 0.0694 g (0.0913 mmol) of 39c. 
0.0491 g (yield 83%) of 48e was obtained. 
Most abundant isomer (ca. 52%):  
1H NMR (300 MHz, CDCl3, T=298 K, ppm)  : 1.18 (s, 3H, allyl-CH3), 1.80 (s, 2H, 2 anti allyl-H), 
1.86 (s, 6H, 2 o-aryl-CH3), 1.97 (s, 6H, 2 o-aryl-CH3), 2.37 (s, 6H, 2 p-aryl-CH3), 2.52 (s, 2H, 2 syn 
allyl-H), 6.51-6.73 (AB system, J= 13.2 Hz, 2H, NCH2N), 6.85-8.15 (8H, Ar-H, 2CH=CH
Im). 
13C{1H} NMR (CDCl3, T=298 K, ppm)  : 17.7 (CH3, o-Mesityl-CH3), 17.8 (CH3, o-Mesityl-CH3), 
21.1 (CH3, p-Mesityl-CH3), 23.7 (CH3, allyl CH3), 58.0 (CH2, allyl CH2), 63.1 (CH2, NCH2N),  121.7 
(CH, CH=CHIm), 123.3 (CH, CH=CHIm), 128.9-139.6 (Ar-C), 132.7 (C, central allyl-C), 176.7 (C, 
carbene). 
Less abundant isomer (ca. 48%):  
1H NMR (300 MHz, CDCl3, T=298 K, ppm)  : 1.37 (s, 6H, 2 o-aryl-CH3),  1.51 (s, 3H, allyl-CH3), 
1.67 (s, 6H, 2 o-aryl-CH3), 1.81 (s, 2H, 2 anti allyl-H), 2.39 (s, 2H, 2 syn allyl-H), 2.47 (s, 6H, 2 p-
aryl-CH3), 6.86-6.96 (AB system, J= 13.6 Hz, 2H, NCH2N), 6.85-8.15 (8H, Ar-H, 2CH=CH
Im). 
13C{1H} NMR (CDCl3, T=298 K, ppm)  : 17.0 (CH3, o-Mesityl-CH3), 17.3 (CH3, o-Mesityl-CH3), 
21.3 (CH3, p-Mesityl-CH3), 23.7 (CH3, allyl CH3), 58.0 (CH2, allyl CH2), 63.1 (CH2, NCH2N),  121.7 
(CH, CH=CHIm), 123.3 (CH, CH=CHIm), 128.9-139.6 (Ar-C), 132.7 (C, central allyl-C), 176.7 (C, 
carbene). 
Synthesis of the complex 48f 
Complex 48f was prepared in analogues manner as that described for 48a starting from 0.1603 g 
(0.3270 mmol) of [Pd(Me-PyCH2SPh)(3-1,1-dimethylC3H3)]ClO4 and 0.2485 g (0.3270 mmol) of 
39c. 
The mixture of 48f and the Pd(I) dimer 87 was dissolved in a CH2Cl2/Et2O mixture (30 mL : 67 mL) 
and set at 5°C overnight. The Pd(I) dimer 87 was filtered in a gooch and, from the resulting solution, 
the solvent was reduced under vacuum and the brownish solid (compound 48f) was precipitated by 
addition of diethylether. 
0.1224 g of 48f was obtained. 
Equimolar mixture of the two atropoisomers  
1H NMR (300 MHz, CDCl3, T=298 K, ppm)  : 0.55 (s, 6H, 2 allyl-CH3),  1.27 (s, 6H, 2 allyl-CH3), 
1.50 (d, J=12.0 Hz , 2H, 2 anti allyl-H), 1.96 (s, 6H, 2 o-aryl-CH3), 1.99 (s, 12H, 4 o-aryl-CH3), 2.04 
(s, 6H, 2 o-aryl-CH3), 2.36 (s, 12H, 4 p-aryl-CH3), 2.63 (d, J=6.4 Hz , 2H, 2 syn allyl-H), 4.54 (m, 
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2H, 2 central allyl-H), 6.22-6.76 (AB system, J= 11.6 Hz, 4H, 2NCH2N), 6.80-8.05 (16H, Ar-H, 
4CH=CHIm).  
13C{1H} NMR (CDCl3, T=298 K, ppm)  : 15.3 (CH3, allyl CH3), 17.8 (CH3, o-Mesityl-CH3), 18.0 
(CH3, o-Mesityl-CH3), 18.2 (CH3, o-Mesityl-CH3), 18.3 (CH3, o-Mesityl-CH3), 19.7 (CH3, allyl 
CH3), 21.0 (CH3, p-Mesityl-CH3), 22.6 (CH3, allyl CH3), 26.2 (CH3, p-Mesityl-CH3), 31.6 (CH3, allyl 
CH3), 46.6 (CH2, allyl CH2), 62.9 (CH2, NCH2N), 111.7 (CH, central allyl-CH),  122.2-123.3 (CH, 
CH=CHIm), 128.9-139.5 (Ar-C), 177.0 (C, carbene), 179.0 (C, carbene). 
IR [KBr Pellet]: ClO = 1085, ClO = 620, cm-1. 
Synthesis of the complex 48g 
Complex 48g was prepared in analogues manner as that described for 48a starting from 0.0361 g 
(0.0779 mmol) of [[Pd(Me-PyCH2SPh)(3-C3H5)]ClO4 and 0.0603 g (0.0779 mmol) of 39e. 
0.0480 g (yield 90%) of 48g was obtained. 
1H NMR (300 MHz, CD3CN, T=298 K, ppm)  : 2.92 (d, J= 13.3 Hz,2H, 2 anti allyl-H), 3.79 (s,  6H, 
2 NCH3), 4.27 (d, J=7.4 Hz, 2H, 2 syn allyl-H), 5.36 (m, 1H, central allyl-H), 5.85-6.04 (m, 4H, 
NCH2N), 7.18 (d, J= 1.9 Hz, 2H, CH=CH
Im ), 7.39 (d, J= 1.9 Hz, 2H, CH=CHIm). 
13C{1H} NMR (CD3CN, T=298 K, ppm)  : 38.2 (CH3, NCH3), 58.4 (CH2, allyl-CH2), 62.9 (CH2, 
NCH2N), 119.6 (CH, central allyl), 121.6 (CH, CH=CH
Im), 122.1 (CH, CH=CHIm), 175.8 (C, 
carbene).  
IR [KBr Pellet]: ClO = 1081, ClO = 623, cm-1. 
Synthesis of the complex 48h 
Complex 48h was prepared in analogues manner as that described for 48a starting from 0.0720 g 
(0.156 mmol) of [[Pd(Me-PyCH2SPh)(3-C3H5)]ClO4 and 0.0880 g (0.156 mmol) of 39f. 
0.0655 g (yield 96%) of 48h was obtained. 
1H NMR (300 MHz, CD2Cl2, T=298 K, ppm)  : 2.77 (d, J= 13.4 Hz, 2H, 2 anti allyl-H), 3.69 (s,  6H, 
2 NCH3), 4.08 (d, J=7.4 Hz, 2H, 2 syn allyl-H), 4.69 (m, 4H, NCH2N),  5.40 (m, 1H, central allyl-
H), 7.08 (d, J= 1.9 Hz, 2H, CH=CHIm ), 7.24 (d, J= 1.9 Hz, 2H, CH=CHIm). 
13C{1H} NMR (CD2Cl2, T=298 K, ppm)  : 38.7 (CH3, NCH3), 48.3 (NCH2CH2N), 58.2 (CH2, allyl-
CH2), 119.0 (CH, central allyl), 122.8 (CH, CH=CH
Im), 122.9 (CH, CH=CHIm), 174.6 (C, carbene). 
IR [KBr Pellet]: ClO = 1090, ClO = 623, cm-1. 
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9.7.16. Synthesis of bis(NHC) palladium 3-allyl complexes (49) 
 
Synthesis of the complex 49a 
0.0406 g (0.0904 mmol) of the precursor [Pd(Me-PyCH2SPh)(3-C3H5)] was dissolved in 10 mL of 
anhydrous dichloromethane in a 50 mL two-necked flask under inert atmosphere (Ar). Subsequently 
was added 0.0839 g (0.181 mmol) of the silver complex 37a, previously dissolved in ca. 5 mL of 
CH2Cl2. The mixture was stirred at R.T. for 15 min and the precipitated AgBr was removed by 
filtration on a millipore membrane filter. 
The solvent was removed under reduced pressure and the white solid was washed with ca. 5 mL of 
diethylether and filtered off on a gooch. 
0.0578 g of 49a was obtained (yield 80%). 
1H NMR (400 MHz, CDCl3, T=298 K, ppm)  : 2.30 (s, 12H, 4CH3Tol), 2.51 (d, J = 13.3 Hz, 2H, 2 
anti allyl-H), 3.73 (d, J = 7.3 Hz , 2H, 2 syn allyl-H), 5.12 (AB system, J = 15.5 Hz, J= 34.6 Hz, 8H, 
4NCH2), 5.13 (m, 1H, central-allyl-H), 6.86 (d, J = 7.9 Hz, 8H, m-Ph), 6.89 (s, 4H, 2CH=CH
Im), 7.10 
(d, J = 7.9 Hz, 8H, o-Ph).  
13C{1H} NMR (CDCl3, T=298 K, ppm)  : 21.1 (CH3, CH3Tol), 54.3 (CH2, NCH2), 61.0 (CH2, allyl- 
CH2), 119.3 (CH, central allyl), 122.8 (CH, CH=CH
Im), 126.8-138.0 (Ar-C), 177.2 (C, carbene).  
IR [KBr Pellet]: ClO = 1090, ClO = 620, cm-1. 
Synthesis of the complex 49b 
Complex 49b was prepared in analogues manner as that described for 49a starting from 0.0362 g 
(0.0781 mmol) of [[Pd(Me-PyCH2SPh)(3-C3H5)]ClO4 and 0.0586 g (0.156 mmol) of 37d. 
0.0400 g (yield 83%) of 49b was obtained. 
1H NMR (400 MHz, CDCl3, T=298 K, ppm)  : 2.32 (s, 6H, 2CH3Tol), 2.66 (d, J = 13.2 Hz, 2H, 2 
anti allyl-H), 3.71 (s, 6H, 2NCH3), 3.87 (d, J = 7.5 Hz , 2H, 2 syn allyl-H), 5.08 (s, 4H, 2NCH2), 5.30 
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(m, 1H, central-allyl-H), 6.77-7.12 (10H, Ar-H), 6.87 (d, J = 1.9 Hz, 2H, CH=CHIm), 7.10 (d, J = 1.9 
Hz, 2H, CH=CHIm).  
13C{1H} NMR (CDCl3, T=298 K, ppm)  : 21.1 (CH3, CH3Tol), 38.3 (CH3, NCH3), 54.1 (CH2, NCH2), 
60.2 (CH2, allyl-CH2), 119.3 (CH, central allyl), 122.1 (CH, CH=CH
Im), 123.9 (CH, CH=CHIm), 
126.7-138.0 (Ar-C), 176.8 (C, carbene).  
IR [KBr Pellet]: ClO = 1090, ClO = 623, cm-1. 
Synthesis of the complexes 49c and 49d 
Complexes 49c and 49d were synthesized according to published procedures [31c]. 
9.7.17. Synthesis of palladium 3-allyl complexes bearing hemi-labile NHCs (50-55) 
                 
Synthesis of the complex 50 
0.0501 g (0.137 mmol) of the dimer [Pd(-Cl)(3-C3H5)]2 was dissolved in ca. 10 ml of anhydrous 
CH2Cl2 in a two-necked flask and 0.1274 g (0.2739 mmol) of the silver complex 35b was added 
under inert atmosphere (Ar) and the mixture was stirred at RT for ca. 30 m. The precipitated AgBr 
was removed by filtration on a millipore membrane filter and 0.067 g (0.55 mmol) of NaClO4·H2O 
dissolved in ca. 10 ml of methanol (CH2Cl2/MeOH≈ 3/1) was added to the clear solution. The mixture 
was stirred for ca. 15 min, dried under vacuum and treated with CH2Cl2 and activated carbon. The 
inorganic salts were filtered off on a Celite filter and repeatedly washed with CH2Cl2, whereas the 
resulting solution was concentrated under vacuum. Addition of diethylether to the concentrated 
solution yields the precipitation of the complex 50 as a white solid which was filtered off on a gooch 
and washed with n-pentane. 0.1313 g of 50 was obtained (yield 91%). 
1H NMR (CDCl3, T=298 K, ppm)  : 1.93 (d, J = 12.3 1H, anti allyl-H trans-N), 1.97 (s, 3H, o-aryl-
CH3), 1.99 (s, 3H, o-aryl-CH3), 2.39 (s, 3H, p-aryl-CH3), 2.91 (d, J = 6.9 Hz, 1H, syn allyl-H trans-
N), 3.44 (d, J = 13.7 Hz , 1H, anti allyl-H trans-C), 4.29 (d, J = 7.7 Hz, 1H, syn allyl-H trans-C), 5.40 
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(m, 1H, central-allyl-H), 5.47, 5.82 (AB system, J = 15.2 Hz, 2H, CH2N), 6.94 (d, J = 1.9 Hz, 1H, 
CH=CHIm), 7.01 (bs, 2H, m-aryl-H),7.46 (ddd, J = 7.7, 5.4, 1.4 Hz, 1H , 5-Pyr); 7.92 (d, J = 1.9 Hz, 
1H, CH=CHIm), 8.02 (td, J = 7.7, 1.7 Hz, 1H, 4-Pyr), 8,19 (d, J = 7.7 Hz, 1H, 3-Pyr); 8.79 (d, J = 5.4 
Hz, 1H, 6- Pyr).  
13C{1H} NMR (CDCl3, T=298 K, ppm)  : 17.7 (CH3, o-mesityl-CH3), 17.9 (CH3, o-mesityl-CH3), 
21.1 (CH3, p-mesityl-CH3), 47.9 (CH2, allyl trans-N), 54.7 (CH2, CH2-Pyr), 74.1 (CH2, allyl trans-
C), 120.3 (CH, central allyl), 121.7 (CH, CH=CHIm), 123.6 (CH, CH=CHIm), 125.3 (CH, 5-Pyr), 
127.4 (CH, 3-Pyr), 129.0 (CH, m-mesityl), 129.2 (CH, m-mesityl), 134.8 (C, o-mesityl), 135.2 (C, o-
mesityl), 135.9 (C, i-mesityl), 139.7 (C, p-mesityl), 140.5 (CH, 4-Pyr), 153.8 (C, 2-Pyr), 155.6 (CH, 
6-Pyr), 176.4 (C, carbene).  
IR [KBr Pellet]: ClO = 1090, ClO = 620, cm-1. 
Synthesis of the complex 51 
Complex 51 was prepared in analogues manner as that described for 50 starting from 0.0534 g of 
[Pd(-Cl)(3-2MeC3H4)]2, 0.1261 g of 35b and 0.0759 g of NaClO4·H2O. 
0.1299 g (yield 89%) of 51 was obtained. 
1H NMR (CDCl3, T=298 K, ppm)  : 1.83 (s, 3H, allyl-CH3), 1.92 (d, J = 2.1 Hz, 1H, anti allyl-H 
trans-N), 1.96 (s, 3H, o-aryl-CH3), 1.99 (s, 3H, o-aryl-CH3), 2.39 (s, 3H, p-aryl-CH3), 2.56 (t, J = 2.6 
Hz, 1H, syn allyl-H trans-N), 3.29 (s, 1H, anti allyl-H trans-C), 4.01 (d, J = 3.0 Hz, 1H, syn allyl-H 
trans-C), 5.52, 5.80 (AB system, J = 15.3 Hz, 2H, CH2N), 6.93 (d, J = 1.8 Hz, 1H, CH=CH
Im), 7.01 
(bs, 2H, m-aryl-H), 7.44 (ddd, J = 7.7, 5.3, 1.5 Hz, 1H , 5-Pyr); 7.92 (d, J = 1.8 Hz, 1H, CH=CHIm), 
8.01 (td, J = 7.7, 1.7 Hz, 1H, 4-Pyr), 8,19 (d, J = 7.7 Hz, 1H, 3-Pyr); 8.76 (d, J = 5.3 Hz, 1H, 6- Pyr).  
13C{1H} NMR (CDCl3, T=298 K, ppm)  : 17.8 (CH3, o-mesityl-CH3), 17.8 (CH3, o-mesityl-CH3), 
23.9 (CH3, allyl-CH3), 21.1 (CH3, p-mesityl-CH3), 48.1 (CH2, allyl trans-N), 54.8 (CH2, CH2-Pyr), 
72.0 (CH2, allyl trans-C), 121.6 (CH, CH=CH
Im), 123.7 (CH, CH=CHIm), 125.2 (CH, 5-Pyr), 127.4 
(CH, 3-Pyr), 129.0 (CH, m-mesityl), 129.1 (CH, m-mesityl), 134.9 (C, o-mesityl), 135.3 (C, o-
mesityl), 135.3 (C, central allyl), 136.1 (C, i-mesityl), 139.6 (C, p-mesityl), 140.5 (CH, 4-Pyr), 153.9 
(C, 2-Pyr), 155.6 (CH, 6-Pyr), 176.8 (C, NHC).  
IR [KBr Pellet]: ClO = 1093, ClO = 620, cm-1. 
Synthesis of the complex 52 
Complex 52 was prepared in analogues manner as that described for 50 starting from 0.0505 g of 
[Pd(-Cl)(3-1,1-dimethylC3H3)]2, 0.1113 g of 35b and 0.0672 g of NaClO4·H2O. 
0.1159 g (yield 88%) of 52 was obtained. 
1H NMR (CDCl3, T=298 K, ppm)  : 1.35 (s, 3H, anti allyl-CH3), 1.75 (s, 3H, syn allyl-CH3),1.93 
366 
 
(dd, J = 12.7, 3.3 Hz, 1H, anti allyl-H trans-N), 1.97 (s, 3H, o-aryl-CH3), 1.98 (s, 3H, o-aryl-CH3), 
2.38 (s, 3H, p-aryl-CH3), 2.91 (dd, J = 7.5 , 3.3 Hz, 1H, syn allyl-H trans-N), 4.91 (dd, J = 12.7 , 7.5 
Hz, 1H, central-allyl-H), 5.48, (d, J = 15.1 Hz, 1H, CH2N), 5.78, (d, J = 15.1 Hz, 1H, CH2N), 6.93 
(d, J = 1.9 Hz, 1H, CH=CH Im), 7.02 (bs, 2H, m-aryl-H),7.57 (ddd, J = 7.7, 5.4, 1.6 Hz, 1H , 5-Pyr); 
7.91 (d, J = 1.9 Hz, 1H, CH=CH Im), 8.03   8,18 (d, J = 7.7 Hz, 1H, 3-Pyr); 8.45 (d, J = 5.4 Hz, 1H, 
6- Pyr).  
13C{1H} NMR (CDCl3, T=298 K, ppm)  : 17.7 (CH3, o-mesityl-CH3), 17.9 (  o-mesityl-CH3), 20.4 
(CH3, anti allyl-CH3), 21.1 (CH3, p-mesityl-CH3), 25.5 (CH3, syn allyl-CH3), 40.7 (CH2, allyl trans-
N), 54.7 (CH2, CH2-Pyr), 104.1 (C, allyl trans-C), 109.9 (CH, central allyl), 121.9 (CH, CH=CH Im), 
123.6 (CH, CH=CH Im), 125.7 (CH, 5-Pyr), 127.2 (CH, 3-Pyr), 128.9 (CH, m-mesityl), 129.0 (CH, 
m-mesityl), 134.9 (C, o-mesityl), 135.1 (C, o-mesityl), 136.0 (C, i-mesityl), 139.5 (C, p-mesityl), 
140.4 (CH, 4-Pyr), 150.5 (C, 2-Pyr), 154.1 (CH, 6-Pyr), 177.2 (C, NHC). 
Synthesis of the complex 53 
Complex 53 was synthesized according to published procedures [31c]. 
Synthesis of the complex 54 
Complex 54 was prepared in analogues manner as that described for 50 starting from 0.0500 g of 
[Pd(-Cl)(3-C3H5)]2, 0.1357 g of 36d and 0.1040 g of NaClO4·H2O. 
0.1407 g (yield 93%) of 54 was obtained. 
1H NMR (CDCl3, T = 298 K, ppm) d: 1.94 (s, 3H, o-aryl-CH3), 2.04 (s, 3H, o-aryl-CH3), 2.40 (s, 3H, 
p-aryl-CH3), 2.43 (d, J = 15.9 Hz, 1H, anti allyl-H trans-S), 3.00 (d, J = 6.9 Hz, 1H, syn allyl-H trans-
S), 3.09 (d, J = 13.7 1H, anti allyl-H trans-C), 4.40 (d, J = 7.6 Hz, 1H, syn allyl-H trans-C), 5.40 (m, 
1H, central-allyl-H), 5.73, 5.88 (AB system, J = 13.6 Hz, 2H, CH2S), 7.03 (bs, 2H, m-aryl-H), 7.05 
(d, J = 1.9 Hz, 1H, CH=CHIm), 7.37–7.47 (m, 3H, Ph), 7.54–7.60 (m, 2H, Ph), 7.84 (d, J = 1.9 Hz, 
1H, CH=CHIm). 
13C{1H} NMR (CDCl3, T = 298 K, ppm) d: 17.6 (CH3, o-mesityl-CH3), 17.8 (CH3, o-mesityl-CH3), 
21.1 (CH3, p-mesityl-CH3), 59.0 (CH2, CH2-S), 59.2 (CH2, allyl trans-S), 69.9 (CH2, allyl trans-C), 
118.4 (CH, central allyl), 121.6 (CH, CH=CHIm), 123.5 (CH, CH=CHIm), 129.0 (CH, m-mesityl), 
129.2 (CH, m-mesityl), 130.1 (CH, o-Ph), 130.3 (C, i-Ph), 130.5 (CH, p-Ph), 132.1 (CH, m-Ph), 135.3 
(C, o-mesityl), 135.7 (C, o-mesityl), 136.6 (C, i-Ph), 139.9 (C, p-mesityl), 180.7 (C, NHC). 
IR [KBr Pellet]: ClO = 1085, ClO = 620, cm-1. 
Anal. Calc. for C22H25N2PdS: C, 57.95; H, 5.53; N, 6.14. Found: C, 58.12; H, 5.44, N, 6.02%. 
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Synthesis of the complex 55 
Complex 55 was prepared in analogues manner as that described for 50 starting from 0.0503 g of 
[Pd(-Cl)(3-C3H5)]2, 0.1081 g of 36b and 0.0772 g of NaClO4·H2O. 
0.0931 g (yield 96%) of 55 was obtained. 
1H NMR (CD2Cl2, T = 298 K, ppm) : 3.33 (d, J = 13.6 Hz, 1H, anti allyl-H trans-C), 3.43 (d, J = 
12.5 Hz, 1H, anti allyl-H trans-S), 3.93 (s, 3H, NCH3), 4.62 (dd, J = 7.6 , J = 2.2, 1H, syn allyl-H 
trans-S), 4.73 (dt, J = 7.0, 1.9 Hz, 1H, syn allyl-H trans-C), 5.33, 5.43 (AB system, J= 12.9 Hz, 2H, 
CH2S), 5.62 (m, 1H, central-allyl -H), 7.23 (d, J = 1.9 Hz, 1H, CH=CH Im), 7.46 (d, J = 1.9 Hz, 1H, 
CH=CH Im), 7.43-751 (m, 3H, SPh-H ), 7.57-7.61 (m, 2H, SPh-H). 
9.7.18. Synthesis of mixed NHC/Cl palladium 3-allyl complexes (56-58) 
                    
Synthesis of the complex 56a 
0.0243 g (0.0664 mmol) of the dimer [Pd(-Cl)(3-C3H5)]2 was dissolved in ca. 25 mL of anhydrous 
dichloromethane in a 50 mL two necked flask under inert atmosphere (Ar). The resulting mixture was 
treated with 0.0853 g (0.133 mmol) of the silver complex 38a and stirred at RT for ca. 30 min. 
The precipitated AgBr was removed by filtration on a millipore membrane filter. 
Addition of diethylether to the concentrated solution yields the precipitation of the complex 56a as a 
brownish solid which was filtered off on a gooch and washed with n-pentane.  
0.0703 g of 56a was obtained (yield 76%). 
( Anomer +  Anomer) 1H-NMR (300 MHz, CD2Cl2, T = 298 K, ppm) : 0.95-1.00 (m, 6H, 2CH34’), 
1.33-1.42 (m, 4H, 2CH2
3’), 1.79-1.88 (m, 4H, 2CH2
2’), 1.95 (s, 3H, OCH3), 1.97 (s, 3H, OCH3), 2.03 
(s, 3H, OCH3), 2.04 (s, 3H, OCH3), 2.07 (s, 3H, OCH3), 2.08 (s, 3H, OCH3), 2.09 (s, 3H, OCH3), 
2.10 (s, 3H, OCH3), 2.45 (d, 2H, J= 12.1 Hz, 2anti allyl-H trans-Cl), 3.32 (d, 1H, J= 12.2 Hz, anti 
allyl-H trans-C), 3.36 (d, 1H, J= 12.2 Hz, anti allyl-H trans-C), 3.48 (d, 2H, J= 6.7 Hz, 2syn allyl-H 
trans-Cl), 4.02 (m, 2H, 2H5), 4.15-4.32 (m, 10H, 2syn allyl-H trans-C+2CH2
1’+2CH2
6), 5.22 (t, 2H, 
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J= 9.7 Hz, 2H3), 5.38-5.48 (m, 6H, 2central allyl-H +2H2+2H4), 6.15 (d, 1H, J= 8.5 Hz, H1), 6.20 (d, 
1H, J= 8.5 Hz, H1), 7.05 (d, 1H, J= 2.1 Hz, HIm), 7.07 (d, 1H, J= 2.1 Hz, HIm), 7.24 (d, 2H, J= 2.1 Hz, 
2HIm). 
( Anomer +  Anomer) 13C{1H}-NMR (CD2Cl2, T = 298 K, ppm) : 13.4 (CH3, CH34’), 13.5 (CH3, 
CH3
4’), 19.6 (CH2, CH2
3’), 19.7 (CH2, CH2
3’), 20.2 (CH3, OCH3), 20.3 (CH3, OCH3), 20.4 (CH3, 
OCH3), 20.5 (CH3, OCH3), 32.7 (CH2, CH2
2’), 32.8 (CH2, CH2
2’), 48.9 (CH2, allyl trans-Cl), 49.3 
(CH2, allyl trans-Cl), 51.0 (CH2, CH2
1’), 51.1 (CH2, CH2
1’), 61.8 (CH2, CH2
6), 61.9 (CH2, CH2
6), 67.9 
(CH, CH4), 68.0 (CH, CH4), 70.0 (CH, CH2), 70.1 (CH, CH2), 72.0 (CH2, allyl trans-C), 72.4 (CH2, 
allyl trans-C), 72.8 (CH, CH3), 72.9 (CH, CH3), 74.6 (CH, CH5), 74.7 (CH, CH5), 86.7 (CH, CH1), 
86.8 (CH, CH1), 115.1 (CH, central allyl), 118.0 (CH, CHIm), 118.1 (CH, CHIm), 122.0 (CH, CHIm), 
122.1 (CH, CHIm), 169.2 (C, C=O), 169.5 (C, C=O), 169.6 (C, C=O), 170.3 (C, C=O), 182.7 (C, 
carbene), 183.0 (C, carbene). 
IR(KBr): νC=O = 1754cm-1, νC-O = 1231 cm-1. 
Synthesis of the complex 56b 
Complex 56b was prepared in analogues manner as that described for 56a starting from 0.0243 g of 
[Pd(-Cl)(3-allyl)]2 and 0.0860 g of 38b. 
0.0566 g (yield 72%) of 56b was obtained. 
( Anomer +  Anomer) 1H-NMR (300 MHz, CDCl3, T = 298 K, ppm) : 1.97 (s, 3H, OCH3), 1.98 
(s, 3H, OCH3), 2.03 (s, 3H, OCH3), 2.04 (s, 3H, OCH3), 2.07 (s, 3H, OCH3), 2.08 (s, 3H, OCH3), 
2.09 (s, 3H, OCH3), 2.11 (s, 3H, OCH3), 2.45 (d, 2H, J= 13.2 Hz, anti allyl-H trans-Cl), 2.48 (d, 2H, 
J= 13.2 Hz, anti allyl-H trans-Cl), 3.38 (d, 1H, J= 13.4 Hz, anti allyl-H trans-C), 3.42 (d, 1H, J= 13.4 
Hz, anti allyl-H trans-C), 3.48 (d, 2H, J= 5.4 Hz, 2syn allyl-H trans-Cl), 3.83 (s, 3H, NCH3), 3.88 (s, 
3H, NCH3), 3.98 (m, 2H, 2H
5), 4.14-4.30 (m, 4H, 2CH2
6), 4.38 (d, 1H, J= 5.3 Hz, syn allyl-H trans-
C), 4.41 (d, 1H, J= 5.3 Hz, syn allyl-H trans-C), 5.20 (t, 2H, J= 9.7 Hz, 2H3), 5.41-5.44 (m, 6H, 
2central allyl-H +2H2+2H4), 6.18 (d, 1H, J= 8.6 Hz, H1), 6.24 (d, 1H, J= 8.6 Hz, H1), 6.96 (d, 1H, J= 
2.1 Hz, HIm), 6.98 (d, 1H, J= 2.1 Hz, HIm), 7.20 (d, 2H, J= 2.1 Hz, 2HIm). 
( Anomer +  Anomer) 13C{1H}-NMR (CDCl3, T = 298 K, ppm) : 20.4 (CH3, OCH3), 20.5 (CH3, 
OCH3), 20.6 (CH3, OCH3), 20.7 (CH3, OCH3), 38.5 (CH3, NCH3), 48.8 (CH2, allyl trans-Cl), 49.1 
(CH2, allyl trans-Cl), 61.8 (CH2, CH2
6), 61.9 (CH2, CH2
6), 68.0 (CH, CH4), 68.1 (CH, CH4), 69.9 
(CH, CH2), 70.0 (CH, CH2), 73.0 (CH, CH3), 73.1 (CH, CH3), 73.4 (CH2, allyl trans-C), 73.8 (CH2, 
allyl trans-C), 74.6 (CH, CH5), 74.7 (CH, CH5), 86.4 (CH, CH1), 86.5 (CH, CH1), 115.2 (CH, central 
allyl), 118.3 (CH, CHIm), 118.4 (CH, CHIm), 123.2 (CH, CHIm), 123.4 (CH, CHIm), 169.4 (C, C=O), 
169.5 (C, C=O), 169.7 (C, C=O), 170.5 (C, C=O), 183.1 (C, carbene), 183.6 (C, carbene). 
IR(KBr): νC=O = 1752 cm-1, νC-O = 1230 cm-1. 
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Synthesis of the complex 56c 
Complex 56c was prepared in analogues manner as that described for 56a starting from 0.0112 g of 
[Pd(-Cl)(3-allyl)]2 and 0.0400 g of 38c. 
0.0290 g (yield 68%) of 56c was obtained. 
 Anomer (60%):  
1H-NMR (300 MHz, CDCl3, T = 298 K, ppm selected peaks) : 1.46 (d, 1H, J= 12.0 Hz, anti allyl-H 
trans-C), 1.89-2.84 (21H, 3CH3
Mes+4OCH3), 2.95-3.10 (m, 2H, 3.32 (d, 3H, anti allyl-H trans-Cl + 
syn allyl-H trans-C + anti allyl-H trans-Cl), 4.26 (d, 1H, J= 3.2 Hz, syn allyl-H trans-C), 5.12 (m, 
1H, central allyl-H), 6.94-6.99 (m, 3H, Ph+HIm), 7.40 (d, 1H, J= 1.9 Hz, HIm). 
13C{1H}-NMR (CDCl3, T = 298 K, ppm selected peaks) : 17.4 (CH3, p-CH3Mes), 18.8 (CH3, m-
CH3
Mes),  20.3-21.1 (CH3, OCH3), 49.5 (CH2, allyl trans-Cl), 74.5 (CH2, allyl trans-C), 86.1 (CH, 
CH1), 114.8 (CH, central allyl), 128.6-139.3 (Ph), 168.9-170.5 (C, C=O), 183.0 (C, carbene). 
 Anomer (40%):  
1H-NMR (300 MHz, CDCl3, T = 298 K, ppm selected peaks) : 1.46 (d, 1H, J= 12.0 Hz, anti allyl-H 
trans-C), 1.89-2.84 (21H, 3CH3
Mes+4OCH3), 2.95-3.10 (m, 2H, 3.32 (d, 3H, anti allyl-H trans-Cl + 
syn allyl-H trans-C + anti allyl-H trans-Cl), 4.22 (d, 1H, J= 3.0 Hz, syn allyl-H trans-C), 4.87 (m, 
1H, central allyl-H), 6.94-6.99 (m, 3H, Ph+HIm), 7.42 (d, 1H, J= 1.9 Hz, HIm). 
13C{1H}-NMR (CDCl3, T = 298 K, ppm selected peaks) : 17.6 (CH3, p-CH3Mes), 18.5 (CH3, m-
CH3
Mes), 20.3-21.1 (CH3, OCH3), 49.5 (CH2, allyl trans-Cl), 74.6 (CH2, allyl trans-C), 86.4 (CH, 
CH1), 114.8 (CH, central allyl), 128.6-139.3 (Ph), 168.9-170.5 (C, C=O), 183.1 (C, carbene). 
IR(KBr): νC=O = 1752 cm-1, νC-O = 1230 cm-1. 
Synthesis of complexes 57 
0.0802 g (0.220 mmol) of the dimer [Pd(-Cl)(3-C3H5)]2 was dissolved in ca. 20 mL of anhydrous 
dichloromethane in a 50 mL two necked flask under inert atmosphere (Ar). The resulting mixture was 
treated with 0.1963 g (0.440 mmol) of the silver complex 37b and stirred at RT for ca. 30 min. 
The precipitated AgCl was removed by filtration on a millipore membrane filter. 
Addition of a diethylether/n-pentane mixture (1:1) to the concentrated solution yields the precipitation 
of the complex 57 as a white solid which was filtered off on a gooch and washed with n-pentane.  
0.1807 g of 57 was obtained (yield 85%). 
1H NMR (CDCl3, T=298 K, ppm) δ: 1.82 (d, J= 12Hz, 1H, anti allyl-H trans-Cl), 2.21 (s, 6H, o-m-
mesityl-CH3), 2.24 (s, 6H, o-m-mesityl-CH3), 2.34 (s, 6H, p- m-mesityl-CH3), 2.83 (d, J = 13.4, 1H, 
anti allyl-H trans-C),  3.21 (d,  J = 7.4 Hz,1H, syn allyl-H trans-Cl), 3.89 (dd, J = 7.5, 2.2 Hz,1H, syn 
allyl-H trans-C), 4.87 (m, 1H, CH central allyl),  6.99 (s, 4H, m-mesityl-H), 7.11 (s, 2H, CH=CHIm). 
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Synthesis of complexes 58 
Complex 58 was prepared in analogues manner as that described for 57 starting from 0.0803 g of 
[Pd(-Cl)(3-2-Me-C3H4)]2 and 0.1826 g of 37b. 
0.1877 g (yield 92%) of 58 was obtained. 
1H NMR (CDCl3, T=298 K, ppm) : 1.36 (s, 3H, allyl-CH3), 1.86 (s,1H, anti allyl-H trans-Cl), 2.21 
(s, 6H, o- m-mesityl -CH3), 2.26 (s, 6H, o- m-mesityl -CH3), 2.34 (s, 6H, p- m-mesityl -CH3), 2.71 
(s, 1H, syn allyl-H trans-Cl), 2.96 (dd, J = 3.0, 1.0 Hz, 1H, anti allyl-H trans-C), 2.96 (d, J = 3.0 
Hz,1H, syn allyl-H trans-C), 6.98 (s, 2H, m-mesityl -H), 7.00 (s, 2H, m-mesityl-H), 7.11 (s, 2H, 
CH=CH Im). 
9.7.19. Synthesis of mixed NHC/PPh3 palladium 3-allyl complexes (59-75) 
                
Synthesis of complex 59 
0.0502 g (0.137 mmol) of the dimer [Pd(-Cl)(3-C3H5)]2 was dissolved in ca. 10 ml of anhydrous 
CH2Cl2 and 0.1269 g (0.274 mmol) of the silver complex 37a dissolved in ca. 7 ml of CH2Cl2 was 
added and the mixture was stirred at RT for ca. 30 min in a 50 mL two necked flask under inert 
atmosphere (Ar). 
The precipitated AgBr was removed by filtration on a millipore membrane filter and 0.0718 g (0.274 
mmol) of PPh3 was added to the clear solution which was left aside for ca. 15 min. The resulting 
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mixture was treated with 0.0800 g (0.570 mmol) of NaClO4·H2O dissolved in ca. 8 ml of methanol 
(CH2Cl2/MeOH≈ 2/1). and further stirred for ca. 15 min, dried under vacuum and treated with CH2Cl2 
and activated carbon. The inorganic salts were filtered off on a Celite filter and repeatedly washed 
with CH2Cl2, whereas the resulting solution was concentrated under vacuum. Addition of diethylether 
to the concentrated solution yields the precipitation of the complex 59 as a white solid which was 
filtered off on a gooch and washed with n-pentane. 0.1865 g of 59 was obtained (yield 87%). 
1H NMR (CDCl3, T = 298 K, ppm, selected peaks) : 2.30 (s, 6H, tol-CH3), 2.61 (dd, J = 13.3, 10.5 
Hz, 1H, anti allyl-H trans-P), 2.85 (d, J = 13.4 Hz, 1H, anti allyl-H trans-C), 3.99 (m, 2H, syn allyl-
H trans-C, syn allyl-H trans-P), 4.59, 4.64 (AB system, J = 15.3 Hz, 2H, NCH2), 4.68, 4.84 (AB 
system, J = 14.8 Hz, 2H, NCH2), 5.37 (m, 1H, central-allyl-H), 6.80–6.85 (m, 4H, tol o-H), 7.02–7.17 
(m, 12H, CH=CHIm, PPh), 7.41–7.57 (m, 9H, tol m-H, PPh). 
13C{1H} NMR (CDCl3, T = 298 K, ppm selected peaks) : 21.1 (CH3, tol-CH3), 54.4 (CH3, NCH2), 
54.5 (CH2, NCH2), 67.9 (d, CH2, JCP = 29.5 Hz, CH2 allyl trans-P), 68.8 (CH2, allyl trans-C), 121.2 
(d, CH, JCP = 5.1 Hz, central allyl), 123.2 (CH, CH=CH
Im), 123.6 (CH, CH=CHIm), 176.1 (d, C, JCP 
= 19.0 Hz, carbene). 
31P{1H} NMR (CDCl3, T = 298 K) : 25.8. 
IR [KBr Pellet]: ClO = 1090, ClO = 618, cm-1. 
Anal. Calc. for C40H40N2PPd: C, 70.02; H, 5.88; N, 4.08. Found: C, 69.97; H, 5.91; N, 3.87%. 
Synthesis of the complex 60 
Complex 60 was prepared in analogues manner as that described for 59 starting from 0.0538 g of 
[Pd(-Cl)(3-2-MeC3H4)]2, 0.1270 g of the silver complex 37a, 0.0719 g of PPh3 and 0.080 g of 
NaClO4·H2O.  
0.1980 g (yield 91%) of 60 was obtained. 
1H NMR (CDCl3, T=298 K, ppm, selected peaks)  : 1.69 (s, 3H, allyl-CH3), 2.28 (s, 3H, tol-CH3), 
2.30 (s, 3H, tol-CH3), 2.65 (dd, J = 10.1, 1.4 Hz, 1H, anti allyl-H trans-P), 2.88 (s, 1H, anti allyl-H 
trans-C), 3.70 (s, 1H, syn allyl-H trans-C), 3.97 (bt, 1H, syn allyl-H trans-P), 4.49, 4.83 (AB system, 
J = 15.1 Hz, 2H, NCH2), 4.78, 4.94 (AB system, J = 14.8 Hz, 2H, NCH2), 6.74-6.90 (m, 4H, tol o-
H), 7.00-7.15 (m, 12 H, CH=CH Im, PPh), 7.40-7.57 (m, 9H, tol m-H, PPh).  
13C{1H} NMR (CDCl3, T=298 K, ppm selected peaks)  : 21.0 (CH3, tol-CH3), 21.1 (CH3, tol-CH3), 
54.3 (CH3, NCH2), 54.5 (CH2, NCH2), 66.8 (d, CH2, JCP = 31.2 Hz, CH2 allyl trans-P), 68.5 (CH2, 
allyl trans-C), 123.1 (CH, CH=CH Im), 123.7 (CH, CH=CH Im), 135.8 (d, C, JCP = 4.9 Hz, central 
allyl), 176.6 (d, C, JCP = 18.5 Hz, carbene). 
31P{1H} NMR (CDCl3, T = 298 K)  : 27.5.  
IR [KBr Pellet]: ClO = 1093, ClO = 620, cm-1. 
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Synthesis of complex 61 
Complex 61 was synthesized according to published procedures [39a]. 
Synthesis of complex 62 
Complex 62 was prepared in analogues manner as that described for 59 starting from 0.0197 g of 
[Pd(-Cl)(3-2-MeC3H4)]2, 0.0457 g of the silver complex 37b, 0.0262 g of PPh3 and 0.0281 g of 
NaClO4·H2O.  
0.0726 g (yield 88%) of 62 was obtained. 
1H NMR (CD2Cl2, T=233 K, ppm)  : 1.12 (s, 3H, allyl-CH3), 1.48 (s, 3H, p-mesityl -CH3), 1.85 
(s,1H, anti allyl-H trans-C), 1.88 (s, 3H, p-mesityl -CH3), 2.11 (s, 3H, o-mesityl -CH3), 2.16 (s, 3H, 
o-mesityl -CH3), 2.40 (d, JHP = 10.1 Hz, 1H, anti allyl-H trans-P), 2.40 (s, 3H, o-mesityl -CH3), 2.43 
(s, 3H, o-mesityl -CH3), 3.02 (bt, 1H, syn allyl-H trans-C), 3.82 (bt, 1H, anti allyl-H trans-P), 6.83-
7.50 (m, 19 H, m-mesityl, CH=CH Im, PPh3).  
31P{1H} NMR (CDCl3, T = 298 K)  : 28.8. 
13C{1H} NMR (CD2Cl2, T=298 K, ppm)  : 18.0 (bs, CH3, p-mesityl-CH3), 18.5 (bs,CH3, o-mesityl-
CH3, p-mesityl-CH3), 20.8 (CH3, o-mesityl-CH3), 21.4 (CH3, allyl-CH3), 68.0 (d, CH2, JCP = 31.6 Hz,  
allyl trans-P), 72.4 (CH2, allyl trans-C), 125.1 (CH, m-mesityl), 128.8. (CH, CH=CH Im), 129.7 (CH, 
m-mesityl), 135.0 (C, o-mesityl), 135.5 (C, i-mesityl), 136.0 (d, JCP = 4.6 Hz, C, central allyl), 139.9 
(C, p-mesityl), 179.9 (d, C, JCP = 14.4 Hz, NHC).  
Synthesis of complex 63 
Complex 63 was prepared in analogues manner as that described for 59 starting from 0.0502 g of 
[Pd(-Cl)(3-C3H5)]2, 0.0986 g of the silver complex 37c, 0.0718 g of PPh3 and 0.080 g of 
NaClO4·H2O.  
0.1752 g (yield 94%) of 63 was obtained. 
Most abundant isomer (ca. 55%):  
1H NMR (CDCl3, T=298 K, ppm, selected peaks)  : 3.08 (d, J = 13.4 Hz, 1H, anti allyl-H trans-C), 
3.31 (dd, J = 13.2, 9.6 Hz, 1H, anti allyl-H trans-P), 3.32 (s, 3H, NCH3), 3.95-4.00 (m, 2H, syn allyl-
H trans-P, syn allyl-H trans-C, partially overlapped), 4.60 (bs, 5.84, 2H, NCH2), 5.28 (m, 1H, central-
allyl-H).  
13C{1H} NMR (CDCl3, T=298 K, ppm selected peaks)  : 38.1 (CH3, NCH3), 54.3 (CH2, NCH2), 
67.4 (d, CH2, JCP = 30.0 Hz, CH2 allyl trans-P), 69.1 (CH2, allyl trans-C), 121.0 (d, CH, JCP = 5.0 Hz, 
central allyl), 123.1 (CH, CH=CHIm), 123.4 (CH, CH=CHIm), 176.4 (d, C, JCP = 19.5 Hz, carbene). 
31P{1H} NMR (CDCl3, T = 298 K) : 26.1.  
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Less abundant isomer (ca. 45%):  
1H NMR (CDCl3, T=298 K, ppm, selected peaks)  : 2.51 (dd, J = 13.2, 10.2 Hz, 1H, anti allyl-H 
trans-P), 2.84 (d, J = 13.5 Hz, 1H, anti allyl-H trans-C), 3.95-4.00 (m, 1H, syn allyl-H trans-C, 
partially overlapped), 3.98 (dd, 6.9, 6.8 Hz, 1H, syn allyl-H trans-P), 4.68, 4.80 (AB system, J = 15.0 
Hz, 2H, NCH2), 5.82 (m, 1H, central-allyl-H).  
13C{1H} NMR (CDCl3, T=298 K, ppm selected peaks)  : 38.0 (CH3, NCH3), 54.3 (CH2, NCH2), 
67.0 (d, CH2, JCP = 30.0 Hz, CH2 allyl trans-P), 68.9 (CH2, allyl trans-C), 121.7 (d, CH, JCP = 5.2 Hz, 
central allyl), 124.0 (CH, CH=CHIm), 124.2 (CH, CH=CHIm), 176.1 (d, C, JCP = 19.3 Hz, carbene). 
31P{1H} NMR (CDCl3, T = 298 K) : 25.7.  
IR [KBr Pellet]: ClO = 1090, ClO = 623, cm-1. 
Synthesis of the complex 64 
0.0801 g (0.170 mmol) of the complex [Pd(Me-PyCH2SPh)(3-C3H5)]ClO4 was dissolved in ca. 30 
ml of anhydrous CH2Cl2.   
The resulting mixture was treated with 0.0624 g (0.170 mmol) of the silver complex 35a and 0.0454 
g (0.170 mmol) of PPh3 dissolved in ca. 60 ml of anhydrous CH2Cl2, further stirred for ca. 30 min 
and the precipitated AgBr was removed by filtration on a millipore membrane filter. 
Addition of diethylether to the concentrated solution yields the precipitation of the complex 64 as a 
white solid which was filtered off on a gooch and washed with n-pentane.  
0.1141 g of 64 was obtained (yield 96%). 
Most abundant isomer (ca. 52%):  
1H NMR (CD2Cl2, T=233 K, ppm, selected peaks)  : 2.44 (dd, JHH = 13.1 Hz, JHP = 10.9 Hz, 1H, 
anti allyl-H trans-P), 2.86 (d,1H, JHH = 13.1 Hz anti allyl-H trans-C), 3.25 (s, 3H, NCH3), 4.01 (dd, 
JHH = 7.9 Hz, JHP = 7.9 Hz, 1H, syn allyl-H trans-P), 4.09 (d, 1H, JHH = 7.9 Hz, syn allyl-H trans-C), 
4.75, 4.81 (AB system, J = 15.5 Hz, 2H, NCH2), 6.98 (d, J = 1.8 Hz, 1H, CH=CH Im), 7.18 (d, J = 
1.8 Hz, 1H, CH=CH Im), 8.36 (d, J = 4.8 Hz, 1H, 6- Pyr).  
13C{1H} NMR (CD2Cl2, T=233 K, ppm selected peaks) : 37.7 (CH3, NCH3), 55.6 (CH2, NCH2), 
66.8 (d, CH2, JCP = 29.9 Hz, CH2 allyl trans-P), 68.3 (CH2, allyl trans-C), 123.6 (CH, CH=CH Im), 
124.0 (CH, CH=CH Im), 121.2 (d, CH, JCP = 4.9 Hz, central allyl), 137.1 (CH, 4-Pyr), 149.6 (C, 2-
Pyr), 154.7 (CH, 6-Pyr), 176.2 (d, C, JCP = 14.5 Hz, NHC).  
31P{1H} NMR (CDCl3, T = 298 K)  : 26.2. 
Less abundant isomer (ca. 48%):  
1H NMR (CD2Cl2, T=233 K, ppm, selected peaks)  : 2.86 (d,1H, JHH = 13.1 Hz anti allyl-H trans-
C), 3.09 (dd, JHH = 13.1 Hz, JHP = 10.9 Hz, 1H, anti allyl-H trans-P), 3.16 (s, 3H, NCH3), 4.03 (d, 
1H, JHH = 7.9 Hz, syn allyl-H trans-C), 4.26 (dd, JHH = 7.9 Hz, JHP = 7.9 Hz, 1H, syn allyl-H trans-
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P), 4.73 (s, 2H, NCH2), 7.02 (d, J = 1.8 Hz, 1H, CH=CH Im), 7.13 (d, J = 1.8 Hz, 1H, CH=CH Im), 
8.40 (d, J = 4.9 Hz, 1H, 6- Pyr).  
13C{1H} NMR (CD2Cl2, T=233 K, ppm selected peaks) : 37.8 (CH3, NCH3), 55.7 (CH2, NCH2), 
66.5 (d, CH2, JCP = 30.3 Hz, CH2 allyl trans-P), 68.4 (CH2, allyl trans-C), 123.4 (CH, CH=CH Im), 
123.7 (CH, CH=CH Im), 121.1 (d, CH, JCP = 5.3 Hz, central allyl), 137.3 (CH, 4-Pyr), 149.4 (C, 2-
Pyr), 155.0 (CH, 6-Pyr), 176.3 (d, C, JCP = 14.5 Hz, NHC).  
31P{1H} NMR (CD2Cl2, T = 233 K)  : 25.7. 
Synthesis of the complex 65 
0.0639 g (0.122 mmol) of the complex 50 was dissolved in ca. 15 ml of anhydrous CH2Cl2 and the 
resulting mixture was treated with 0.0319 g (0.122 mmol) of PPh3 and further stirred for ca. 10 min. 
Addition of diethylether to the concentrated solution yields the precipitation of the complex 65 as a 
white solid which was filtered off on a gooch and washed with n-pentane.  
0.0936 g of 65 was obtained (yield 98%). 
Most abundant isomer (ca. 61%):  
1H NMR (CD2Cl2, T=233 K, ppm, selected peaks)  : 1.45 (s, 3H, o-aryl-CH3), 1.90 (s, 3H, o-aryl-
CH3), 2.25 (dd, JHH = 13.3 Hz, JHP = 10.9 Hz, 1H, anti allyl-H trans-P), 2.33 (s, 3H, p-aryl-CH3), 2.71 
(d,1H, JHH = 13.3 Hz anti allyl-H trans-C), 3.39 (d, 1H, JHH = 7.2 Hz, syn allyl-H trans-C), 3.77 (dd, 
JHH = 7.2 Hz, JHP = 7.2 Hz, 1H, syn allyl-H trans-P), 4.41, 4.46 (AB system, J = 15.7 Hz, 2H, NCH2), 
4.92 (m, CH, central allyl), 7.76 ( td, J = 7.7, 1.6 Hz, 4- Pyr),8.56 (d, J = 4.5 Hz, 1H, 6- Pyr).  
13C{1H} NMR (CD2Cl2, T=233 K, ppm selected peaks)  : 17.8 (CH3, o-mesityl-CH3), 17.9 (o-
mesityl-CH3), 20.4 (CH3, anti allyl-CH3), 21.1 (CH3, p-mesityl-CH3), 55.6 (CH2, NCH2), 66.9 (d, 
CH2, JCP = 30.0 Hz, CH2 allyl trans-P), 71.7 (CH2, allyl trans-C), 120.7 (CH, central allyl), 121.9 
(CH, CH=CH Im), 123.6 (CH, 3-Pyr), 124.5 (CH, 5-Pyr), 125.1 (CH, CH=CH Im), 137.4 (CH, 4-
Pyr), 149.7 (C, 2-Pyr), 155.5 (CH, 6-Pyr), 178.9 (d, C, JCP = 19.6 Hz, NHC).  
31P{1H} NMR (CD2Cl2, T = 233 K)  : 23.4. 
Less abundant isomer (ca. 39%):  
1H NMR (CD2Cl2, T=233 K, ppm, selected peaks)  : 1.37 (s, 3H, o-aryl-CH3), 1.90 (s, 3H, o-aryl-
CH3), 2.15 (d,1H, JHH = 13.4 Hz anti allyl-H trans-C), 2.22 (dd, JHH = 13.4 Hz, JHP = 10.9 Hz, 1H, 
anti allyl-H trans-P), 2.32 (s, 3H, p-aryl-CH3), 3.69 (d, 1H, JHH = 7.3 Hz, syn allyl-H trans-C), 3.94 
(dd, JHH = 7.3 Hz, JHP = 7.3 Hz, 1H, syn allyl-H trans-P), 4.59, 4.80 (AB system, J = 15.5 Hz, 2H, 
NCH2), 4.92 (m, CH, central allyl), 7.76 ( td, J = 7.7, 1.6 Hz, 4- Pyr), 8.55 (d, J = 4.5 Hz, 1H, 6- Pyr). 
13C{1H} NMR (CD2Cl2, T=233 K, ppm selected peaks)  :  18.1 (CH3, o-mesityl-CH3), 18.1 (o-
mesityl-CH3), 20.4 (CH3, anti allyl-CH3), 21.1 (CH3, p-mesityl-CH3), 56.0 (CH2, NCH2), 68.0 (CH2, 
allyl trans-C),  69.4 (d, CH2, JCP = 29.3 Hz, CH2 allyl trans-P), 120.5 (CH, central allyl), 122.0 (CH, 
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CH=CH Im), 123.8 (CH, 3-Pyr), 124.1 (CH, 5-Pyr), 125.4 (CH, CH=CH Im), 137.7 (CH, 4-Pyr), 
149.5 (C, 2-Pyr), 155.7 (CH, 6-Pyr), 178.9 (d, C, JCP = 19.6 Hz, NHC).  
31P{1H} NMR (CD2Cl2, T = 233 K)  : 24.0. 
Synthesis of the complex 66 
Complex 66 was prepared in analogues manner as that described for 65 starting from 0.0640 g of the 
complex 55 and 0.0373 g of PPh3. 
0.0947 g (yield 96%) of 66 was obtained. 
Most abundant isomer (ca. 57%):  
1H NMR (CD2Cl2, T=233 K, ppm, selected peaks)  :  2.93 (d,1H, JHH = 13.6 Hz anti allyl-H trans-
C), 3.06 (dd, JHH = 13.6 Hz, JHP = 9.7 Hz, 1H, anti allyl-H trans-P),3.27 (s,3H, NCH3), 3.77 (dd, JHH 
= 8,1 Hz, JHP = 8.1 Hz, 1H, syn allyl-H trans-P), 4.05 (d, 1H, JHH = 8.1 Hz, syn allyl-H trans-C), 4.32, 
(d, J = 14.1 Hz, 1H, NCH2), 4.79, (d, J = 14.1 Hz, 1H, NCH2), 5.46 (m, CH, central allyl), 6.96, 7.01 
(AB system, J = 1.9 Hz, 2H, CH=CH Im).  
13C{1H} NMR (CD2Cl2, T=233 K, ppm selected peaks)  :  38.0 (CH3, NCH3), 55.3 (CH2, NCH2), 
67.1 (d, CH2, JCP = 29.1 Hz, CH2 allyl trans-P), 68.6 (CH2, allyl trans-C), 121.2 (d, JCP = 4.9 Hz, CH, 
central allyl), 122.2 (CH, CH=CH Im), 124.1 (CH, CH=CH Im), 176.3 (d, C, JCP = 18.8 Hz, NHC).  
31P{1H} NMR (CD2Cl2, T = 233 K)  : 26.3. 
Less abundant isomer (ca. 43%):  
1H NMR (CD2Cl2, T=233 K, ppm, selected peaks)  : 2.57 (dd, JHH = 13.6 Hz, JHP = 10.7 Hz, 1H, 
anti allyl-H trans-P), 2.93 (d,1H, JHH = 13.6 Hz anti allyl-H trans-C), 3.14 (s,3H, NCH3), 4.02 (d, 
1H, JHH = 8.1 Hz, syn allyl-H trans-C), 4.18 (dd, JHH = 8,1 Hz, JHP = 8.1 Hz, 1H, syn allyl-H trans-
P), 4.47, (d, J = 14.2 Hz, 1H, NCH2), 4.86, (d, J = 14.2 Hz, 1H, NCH2), 5.64 (m, CH, central allyl), 
6.99, 7.00 (AB system, J = 1.9 Hz, 2H, CH=CH Im). 
13C{1H} NMR (CD2Cl2, T=233 K, ppm selected peaks)  : 38.1 (CH3, N-CH3), 55.1 (CH2, NCH2), 
67.0 (d, CH2, JCP = 29.6 Hz, CH2 allyl trans-P), 68.1 (CH2, allyl trans-C), 121.1 (d, JCP = 5.0 Hz, CH, 
central allyl), 122.2 (CH, CH=CH Im), 124.3 (CH, CH=CH Im), 176.4 (d, C, JCP = 17.3 Hz, NHC).  
31P{1H} NMR (CD2Cl2, T = 233 K)  : 26.0. 
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Synthesis of the complex 67 
Complex 67 was prepared in analogues manner as that described for 65 starting from 0.0640 g of the 
complex 54 and 0.0302 g of PPh3. 
0.0765 g (yield 85%) of 67 was obtained. 
Most abundant isomer (ca. 75%):  
1H NMR (CD2Cl2, T=233 K, ppm, selected peaks)  : 1.42 (s, 3H, o-aryl-CH3), 1.71 (s, 3H, o-aryl-
CH3), 1.84 (dd, JHH = 13.3 Hz, JHP = 10.1 Hz, 1H, anti allyl-H trans-P), 2.28 (s, 3H, p-aryl-CH3), 2.76 
(d,1H, JHH = 13.3 Hz anti allyl-H trans-C), 3.16 (dd, JHH = 7.2 Hz, JHP = 7.2 Hz, 1H, syn allyl-H 
trans-P), 3.34 (d, J = 13.6 Hz, 1H, NCH2), 3.45 (d, 1H, JHH = 7.2 Hz, syn allyl-H trans-C), 4.67 (d, J 
= 13.6 Hz, 1H, NCH2), 5.00 (m, CH, central allyl), 6.78 (d, J = 1.9 Hz, 1H, CH=CH Im), 6.92 (d, J = 
1.9 Hz, 1H, CH=CH Im).  
13C{1H} NMR (CD2Cl2, T=233 K, ppm selected peaks)  : 17.8 (CH3, o-mesityl-CH3), 18.3 (o-
mesityl-CH3), 21.1 (CH3, p-mesityl-CH3), 56.1 (CH2, NCH2), 67.0 (d, CH2, JCP = 29.5 Hz, CH2 allyl 
trans-P), 71.3 (CH2, allyl trans-C), 120.4 (d, CH, JCP = 4.8 Hz, central allyl), 121.9 (CH, CH=CH 
Im), 126.3 (CH, CH=CH Im), 177.4 (d, C, JCP = 17.2 Hz, NHC).  
31P{1H} NMR (CD2Cl2, T = 233 K)  : 24.5. 
Less abundant isomer (ca. 25%):  
1H NMR (CD2Cl2, T=233 K, ppm, selected peaks)  : 1.42 (s, 3H, o-aryl-CH3), 1.80 (s, 3H, o-aryl-
CH3), 1.94 (dd, JHH = 13.8 Hz, JHP = 9.6 Hz, 1H, anti allyl-H trans-P), 2.09 (d,1H, JHH = 13.8 Hz anti 
allyl-H trans-C),  2.30 (s, 3H, p-aryl-CH3), 3.55 (dd, JHH = 6.7 Hz, JHP = 6.7 Hz, 1H, syn allyl-H 
trans-P), 3.69 (d, J = 13.9 Hz, 1H, NCH2), 3.80 (d, 1H, JHH = 6.7 Hz, syn allyl-H trans-C), 4.74 (m, 
CH, central allyl), 4.94 (d, J = 13.9 Hz, 1H, NCH2), 6.73 (d, J = 1.9 Hz, 1H, CH=CH Im), 6.97 (d, J 
= 1.9 Hz, 1H, CH=CH Im).  
13C{1H} NMR (CD2Cl2, T=233 K, ppm selected peaks)  : 17.9 (CH3, o-mesityl-CH3), 18.4 (o-
mesityl-CH3), 21.1 (CH3, p-mesityl-CH3), 56.4 (CH2, NCH2), 67.8 (CH2, allyl trans-C), 69.6 (d, CH2, 
JCP = 28.7 Hz, CH2 allyl trans-P), 120.6 (d, CH, JCP = 4.6 Hz, central allyl), 122.0 (CH, CH=CH Im), 
126.3 (CH, CH=CH Im), 177.4 (d, C, JCP = 17.2 Hz, NHC).  
31P{1H} NMR (CD2Cl2, T = 233 K)  : 25.3. 
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Synthesis of the complex 68 
Complex 68 was prepared in analogues manner as that described for 65 starting from 0.0858 g of the 
complex 53 and 0.0455 g of PPh3. 
0.1270 g (yield 97%) of 68 was obtained. 
Most abundant isomer (ca. 67%):  
1H NMR (CD2Cl2, T=233 K, ppm, selected peaks)  : 1.51 (s, 3H, o-aryl-CH3), 1.94 (s, 6H, o-aryl-
CH3), 1.94. (s, 3H, SCH3), 2.33 (s, 3H, p-aryl-CH3), 2.38 (dd, JHH = 13.4 Hz, JHP = 9.5 Hz, 1H, anti 
allyl-H trans-P), 2.94 (d,1H, JHH = 13.4 Hz,  anti allyl-H trans-C), 3.43 (d, J = 13.8 Hz, 1H, NCH2),  
3.54 (d, 1H, JHH = 6.9 Hz, syn allyl-H trans-C), 4.25 (dd, JHH = 6.9 Hz, JHP = 6.9 Hz, 1H, syn allyl-H 
trans-P), 4.32 (d, J = 13.8 Hz, 1H, NCH2), 5.54 (m, CH, central allyl), 6.83 (d, J = 1.9 Hz, 1H, CH=CH 
Im), 7.00 (d, J = 1.9 Hz, 1H, CH=CH Im).  
13C{1H} NMR (CD2Cl2, T=233 K, ppm selected peaks)  :  14.2 ( CH3, SCH3), 17.8 (CH3, o-mesityl-
CH3), 18.1 (o-mesityl-CH3), 21.1 (CH3, p-mesityl-CH3), 53.2 (CH2, NCH2), 67.7 (d, CH2, JCP = 30.1 
Hz, CH2 allyl trans-P), 71.8 (CH2, allyl trans-C), 120.7 (d, CH, JCP = 4.7 Hz, central allyl), 122.6 
(CH, CH=CH Im), 126.0 (CH, CH=CH Im), 178.0 (d, C, JCP = 17.5 Hz, NHC).  
31P{1H} NMR (CD2Cl2, T = 233 K)  : 24.3 
Less abundant isomer (ca. 33%):  
1H NMR (CD2Cl2, T=233 K, ppm, selected peaks)  : 1.43 (s, 3H, o-aryl-CH3), 1.94 (s, 3H, SCH3),  
2.00 (s, 3H, o-aryl-CH3), 2.33 (s, 3H, p-aryl-CH3) 2.36 (d,1H, JHH = 13.4 Hz,  anti allyl-H trans-C), 
3.04 (dd, JHH = 13.4 Hz, JHP = 9.5 Hz, 1H, anti allyl-H trans-P), 4.03 (d, 1H, JHH = 6.9 Hz, syn allyl-
H trans-C), 4.12 (dd, JHH = 6.9 Hz, JHP = 6.9 Hz, 1H, syn allyl-H trans-P), 3.71 (d, J = 13.8 Hz, 1H, 
NCH2), 4.45 (d, J = 13.8 Hz, 1H, NCH2), 4.93 (m, CH, central allyl), 6.77 (d, J = 1.9 Hz, 1H, CH=CH 
Im), 7.03 (d, J = 1.9 Hz, 1H, CH=CH Im).  
13C{1H} NMR (CD2Cl2, T=233 K, ppm selected peaks)  :  14.2 ( CH3, SCH3), 18.1 (CH3, o-mesityl-
CH3), 18.3 (o-mesityl-CH3), 21.1 (CH3, p-mesityl-CH3), 53.4 (CH2, NCH2), 67.5 (CH2, allyl trans-
C), 67.4 (d, CH2, JCP = 29.2 Hz, CH2 allyl trans-P), 120.4 (d, CH, JCP = 4.6 Hz, central allyl), 122.8 
(CH, CH=CH Im), 125.9 (CH, CH=CH Im), 178.6 (d, C, JCP = 17.5 Hz, NHC).  
31P{1H} NMR (CD2Cl2, T = 233 K)  : 24.8. 
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Synthesis of the complex 69a 
0.0365 g (0.0525 mmol) of the allyl complex 56a and 0.0138 g (0.0525 mmol) of PPh3 were dissolved 
in ca. 25 ml of anhydrous CH2Cl2 and stirred at RT for ca. 30 min in a 50 mL two necked flask under 
inert atmosphere (Ar).  
The resulting mixture was treated with 0.0155 g (0.127 mmol) of NaClO4·H2O dissolved in ca. 4 ml 
of methanol (CH2Cl2/MeOH≈ 3/1). and further stirred for ca. 20 min, dried under vacuum and treated 
with CH2Cl2 and activated carbon. The inorganic salts were filtered off on a Celite filter and 
repeatedly washed with CH2Cl2, whereas the resulting solution was concentrated under vacuum. 
Addition of diethylether to the concentrated solution yields the precipitation of the complex 69a as a 
white solid which was filtered off on a gooch and washed with n-pentane.  
0.0423 g of 69a was obtained (yield 83%). 
2 Exo isomers ( Anomer +  Anomer) () 
1H-NMR (300 MHz, CD2Cl2, T = 298 K, ppm) : 0.79-0.89 (m, 6H, 2CH34’), 1.05-1.49 (m, 8H, 
2CH2
3’+2CH2
2’), 1.89 (s, 3H, OCH3), 1.94 (s, 3H, OCH3), 1.98 (s, 3H, OCH3), 2.01 (s, 3H, OCH3), 
2.02 (s, 3H, OCH3), 2.03 (s, 3H, OCH3), 2.05 (s, 3H, OCH3), 2.07 (s, 3H, OCH3),), 3.65 (d, 2H, J= 
12.7 Hz, 2anti allyl-H trans-C), 3.01-3.42 (m, 4H, 2anti allyl-H trans-P+2H5), 3.82 (d, 1H, J= 3.9 
Hz, syn allyl-H trans-C), 3.86 (d, 1H, J= 3.9 Hz, syn allyl-H trans-C), 4.30-4.41 (m, 2H, 2syn allyl-
H trans-P), 5.03-5.77 (m, 12H, 2CH2
6 + 2H3 + 2H2 + 2H4 + 2H1), 5.93 (m, 2H, 2central allyl-H), 6.93 
(d, 1H, J= 2.1 Hz, HIm), 6.98 (d, 1H, J= 2.1 Hz, HIm), 7.13-7.58 (m, 32H, 6Ph+2HIm).  
31P{1H}-NMR (CD2Cl2, T = 298 K, ppm) : 25.6, 25.5.  
13C{1H}-NMR (CDCl3, T = 298 K, ppm selected peaks) : 13.6 (CH3, CH34’), 13.7 (CH3, CH34’), 19.5 
(CH2, CH2
3’), 19.6 (CH2, CH2
3’), 20.4-20.7 (CH3, OCH3), 31.4 (CH2, CH2
2’), 31.5 (CH2, CH2
2’), 50.5 
(CH2, CH2
1’), 51.0 (CH2, CH2
1’), 60.4 (CH2, CH2
6), 60.7 (CH2, CH2
6), 67.2 (CH, CH4), 67.3 (CH, 
CH4), 68.3 (d, CH2, JC-P = 29.6 Hz, allyl trans-P), 68.4 (d, CH2, JC-P  = 27.7 Hz, allyl trans-P), 69.3 
(CH2, allyl trans-C), 69.7 (CH2, allyl trans-C), 86.4 (CH, CH
1), 86.5 (CH, CH1), 119.3 (CH, CHIm), 
119.4 (CH, CHIm), 122.0 (d, CH, JC-P  = 5.3 Hz,  central allyl), 122.4 (d, CH, JC-P  = 4.8 Hz,  central 
allyl), 123.0 (CH, CHIm), 123.2 (CH, CHIm), 129.2-133.4 (Ph), 169.1 (C, C=O), 169.2 (C, C=O), 
169.4 (C, C=O), 169.5 (C, C=O), 169.6 (C, C=O), 169.7 (C, C=O), 170.1 (C, C=O), 170.2 (C, C=O), 
179.7 (d, JC-P = 19.1 Hz, C, carbene), 179.9 (d, JC-P= 15.1 Hz, C, carbene). 
2 Endo isomers ( Anomer +  Anomer) () 
1H-NMR (300 MHz, CD2Cl2, T = 298 K, ppm) : 0.79-0.89 (m, 6H, 2CH34’), 1.05-1.49 (m, 8H, 
2CH2
3’+2CH2
2’), 1.43 (s, 3H, OCH3), 1.45 (s, 3H, OCH3), 1.94 (s, 3H, OCH3), 1.98 (s, 3H, OCH3), 
2.00 (s, 3H, OCH3), 2.10 (s, 3H, OCH3), 2.11 (s, 3H, OCH3), 2.12 (s, 3H, OCH3), 2.84 (d, 2H, J= 
12.7 Hz, 2anti allyl-H trans-C), 3.01-3.42 (m, 4H, 2anti allyl-H trans-P+2H5), 3.65 (d, 1H, J= 3.9 
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Hz, syn allyl-H trans-C), 3.73 (d, 1H, J= 3.9 Hz, syn allyl-H trans-C), 4.12-4.16 (m, 2H, 2syn allyl-
H trans-P), 5.03-5.77 (m, 12H, 2CH2
6+ 2H3+ 2H2 +2H4+ 2H1), 5.93 (m, 2H, 2central allyl-H), 7.03 
(d, 1H, J= 2.1 Hz, HIm), 7.08 (d, 1H, J= 2.1 Hz, HIm), 7.13-7.58 (m, 32H, 6Ph+2HIm). 
31P{1H}-NMR (CD2Cl2, T = 298 K, ppm) : 25.2, 25.4. 
13C{1H}-NMR (CDCl3, T = 298 K, ppm selected peaks) : 13.5 (CH3, CH34’), 13.6 (CH3, CH34’), 19.6 
(CH2, CH2
3’), 19.7 (CH2, CH2
3’), 20.1-20.9 (CH3, OCH3), 31.6 (CH2, CH2
2’), 31.7 (CH2, CH2
2’), 51.0 
(CH2, CH2
1’), 51.1 (CH2, CH2
1’), 62.2 (CH2, CH2
6), 62.4 (CH2, CH2
6), 67.6 (CH, CH4), 67.8 (CH, 
CH4), 68.3 (d, CH2, JC-P = 29.6 Hz, allyl trans-P), 68.4 (d, CH2, JC-P  = 27.7 Hz, allyl trans-P), 68.8 
(CH2, allyl trans-C), 69.0 (CH2, allyl trans-C), 86.0 (CH, CH
1), 86.1 (CH, CH1), 119.9 (CH, CHIm), 
119.9 (CH, CHIm), 121.7 (d, CH, JC-P  = 5.8 Hz,  central allyl), 122.6 (CH, CH
Im), 122.8 (CH, CHIm), 
129.2-133.4 (Ph), 169.2 (C, C=O), 169.2 (C, C=O), 169.3 (C, C=O), 169.3 (C, C=O), 169.9 (C, C=O), 
170.0 (C, C=O), 170.3 (C, C=O), 170.4 (C, C=O), 180.1 (d, JC-P = 18.0 Hz, C, carbene), 181.1 (d, JC-
P = 19.2 Hz, C, carbene). 
IR(KBr): νC=O = 1754 cm-1, νC-O = 1231 cm-1. 
Synthesis of the complex 69b 
Complex 69b was prepared in analogues manner as that described for 69a starting from 0.0442 g of 
56b, 0.0196 g of PPh3 and 0.0236 g of NaClO4.  
0.0519 g (yield 85%) of 69b was obtained. 
2 Exo isomers ( Anomer +  Anomer) () 
1H-NMR (300 MHz, CDCl3, T = 298 K, ppm) : 1.95 (s, 3H, OCH3), 1.98 (s, 3H, OCH3), 2.00 (s, 
3H, OCH3), 2.02 (s, 3H, OCH3), 2.03 (s, 3H, OCH3), 2.04 (s, 3H, OCH3), 2.05 (s, 3H, OCH3), 2.06 
(s, 3H, OCH3), 3.05 (s, 3H, NCH3), 3.31 (s, 3H, NCH3), 3.17 (d, 2H, J= 12.7 Hz, 2anti allyl-H trans-
C), 3.39 (m, 2H, 2anti allyl-H trans-P), 3.59-3.92 (m, 4H, 2syn allyl-H trans-C+2H5), 4.01-4.58 (m, 
2H, 2syn allyl-H trans-P), 4.01-4.58 (m, 2H, 2syn allyl-H trans-P), 5.04-5.54 (m, 10H, 
2CH2
6+2H3+2H2+2H4), 5.74 (d, 2H, J= 8.6 Hz, H1), 5.92 (m, 2H, 2central allyl-H), 6.82 (d, 1H, J= 
2.1 Hz, HIm), 6.85 (d, 1H, J= 2.1 Hz, HIm), 7.20-7.53 (m, 32H, 6Ph+2HIm).  
31P{1H}-NMR (CDCl3, T = 298 K, ppm) : 26.0, 25.6.  
13C{1H}-NMR (CDCl3, T = 298 K, ppm selected peaks) : 20.0 (CH3, OCH3), 20.4 (CH3, OCH3), 
20.5 (CH3, OCH3), 20.7 (CH3, OCH3), 20.7 (CH3, OCH3), 20.8 (CH3, OCH3), 20.8 (CH3, OCH3), 
20.9 (CH3, OCH3), 37.6 (CH3, NCH3), 38.0 (CH3, NCH3), 69.7 (d, CH2, JC-P  = 38.8 Hz, allyl trans-
P), 60.2 (CH2, CH2
6), 60.5 (CH2, CH2
6), 74.1 (CH2, allyl trans-C), 86.5 (CH, CH
1), 86.6 (CH, CH1), 
118.9 (CH, CHIm), 119.0 (CH, CHIm), 122.2 (CH, central allyl), 124.9 (CH, CHIm), 125.0 (CH, CHIm), 
129.2-133.4 (Ph), 169.1 (C, C=O), 169.2 (C, C=O), 169.4 (C, C=O), 169.5 (C, C=O), 169.8 (C, C=O), 
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169.9 (C, C=O), 170.1 (C, C=O), 170.2 (C, C=O), 180.4 (d, JC-P= 19.5 Hz, C, carbene), 181.0 (d, JC-
P= 19.5 Hz, C, carbene). 
2 Endo isomers ( Anomer +  Anomer) () 
1H-NMR (300 MHz, CDCl3, T = 298 K, ppm) : 1.98 (s, 3H, OCH3), 1.99 (s, 3H, OCH3), 2.07 (s, 
3H, OCH3), 2.09 (s, 3H, OCH3), 2.10 (s, 3H, OCH3), 2.11 (s, 3H, OCH3), 2.12 (s, 3H, OCH3), 2.19 
(s, 3H, OCH3), 2.95 (d, 2H, J= 12.7 Hz, 2anti allyl-H trans-C), 2.99 (s, 3H, NCH3), 3.23 (s, 3H, 
NCH3),   3.39 (m, 2H, 2anti allyl-H trans-P), 3.59-3.92 (m, 4H, 2syn allyl-H trans-C+2H
5), 4.01-4.58 
(m, 2H, 2syn allyl-H trans-P), 5.04-5.54 (m, 10H, 2CH2
6+2H3+2H2+2H4), 5.76 (d, 2H, J= 8.6 Hz, 
H1), 5.92 (m, 2H, 2central allyl-H), 6.95 (d, 1H, J= 2.1 Hz, HIm), 6.98 (d, 1H, J= 2.1 Hz, HIm), 7.20-
7.53 (m, 32H, 6Ph+2HIm). 
31P{1H}-NMR (CDCl3, T = 298 K, ppm) : 25.4, 25.1. 
13C{1H}-NMR (CDCl3, T = 298 K, ppm selected peaks) : 20.4 (CH3, OCH3), 20.5 (CH3, OCH3), 
20.6 (CH3, OCH3), 20.7 (CH3, OCH3), 37.5 (CH3, NCH3), 37.8 (CH3, NCH3), 60.2 (CH2, CH2
6), 60.5 
(CH2, CH2
6), 73.0 (CH, CH3), 69.3 (d, CH2, JC-P  = 27.4 Hz, allyl trans-P), 74.2 (CH2, allyl trans-C), 
86.0 (CH, CH1), 86.2 (CH, CH1), 121.8 (CH, CHIm), 121.9 (CH, CHIm), 122.1 (CH, central allyl), 
122.6 (CH, CHIm), 122.7 (CH, CHIm), 129.2-133.4 (Ph), 169.0 (C, C=O), 169.3 (C, C=O), 169.4 (C, 
C=O), 169.7 (C, C=O), 169.8 (C, C=O), 169.9 (C, C=O), 170.3 (C, C=O), 170.4 (C, C=O), 180.2 (d, 
JC-P= 19.5 Hz, C, carbene), 181.1 (d, JC-P= 19.5 Hz, C, carbene). 
IR(KBr): νC=O = 1752 cm-1, νC-O = 1231 cm-1. 
Synthesis of the complex 69c 
Complex 69c was prepared in analogues manner as that described for 69a starting from 0.0369 g of 
56c, 0.0143 g of PPh3 and 0.0150 g of NaClO4.  
0.0488 g (yield 88%) of 69c was obtained. 
2 Exo isomers ( Anomer +  Anomer) () 
1H-NMR (300 MHz, CDCl3, T = 298 K, ppm selected peaks) : 1.28 (s, 3H, p-CH3Mes), 1.76 (s, 3H, 
OCH3), 1.90 (s, 6H, 2 o-CH3
Mes), 2.03 (s, 3H, OCH3), 2.07 (s, 3H, OCH3), 2.37 (s, 3H, OCH3),  
2.84 (d, 2H, J= 12.7 Hz, 2anti allyl-H trans-C), 3.32 (d, 2H, J= 7.4 Hz, 2syn allyl-H trans-C), 3.60 
(m, 2H, 2anti allyl-H trans-P), 4.40 (m, 2H, 2 syn allyl-H trans-P), 5.11 (m, 2H, 2central allyl-H), 
6.62-7.62 (m, 34H, 6Ph+4HIm).  
31P{1H}-NMR (CDCl3, T = 298 K, ppm) : 23.0, 22.3.  
13C{1H}-NMR (CDCl3, T = 298 K, ppm selected peaks) : 16.6-17.6 (CH3, CH3Mes),  20.5-21.1 (CH3, 
OCH3), 71.5 (d, CH2, JC-P  = 28.4 Hz, allyl trans-P), 74.2 (CH2, allyl trans-C), 86.4 (CH, CH
1), 119.7 
(CH, CHIm), 120.0 (CH, CHIm), 122.8 (d, CH, JC-P  = 3.2 Hz,  central allyl), 126.4 (CH, CH
Im), 126.6 
(CH, CHIm), 128.9-140.2 (Ph), 169.3-170.4 (C, C=O), 181.8 (d, JC-P= 14.7 Hz, C, carbene). 
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2 Endo isomers ( Anomer +  Anomer) () 
1H-NMR (300 MHz, CDCl3, T = 298 K, ppm selected peaks) : 1.09 (s, 3H, p-CH3Mes), 1.77 (s, 3H, 
OCH3), 1.90 (s, 6H, 2 o-CH3
Mes), 2.06 (s, 3H, OCH3), 2.09 (s, 3H, OCH3), 2.34 (s, 3H, OCH3),  
2.84 (d, 2H, J= 12.7 Hz, 2anti allyl-H trans-C), 3.32 (d, 2H, J= 7.4 Hz, 2syn allyl-H trans-C), 3.60 
(m, 2H, 2anti allyl-H trans-P), 4.32 (m, 2H, 2 syn allyl-H trans-P), 6.06 (m, 2H, 2central allyl-H), 
6.62-7.62 (m, 34H, 6Ph+4HIm). 
31P{1H}-NMR (CDCl3, T = 298 K, ppm) : 21.8, 21.8. 
13C{1H}-NMR (CDCl3, T = 298 K, ppm selected peaks) : 16.6-17.6 (CH3, CH3Mes),  20.5-21.1 (CH3, 
OCH3), 71.5 (d, CH2, JC-P  = 28.4 Hz, allyl trans-P), 74.1 (CH2, allyl trans-C), 86.5 (CH, CH
1), 119.7 
(CH, CHIm), 120.0 (CH, CHIm), 120.8 (d, CH, JC-P  = 5.3 Hz, central allyl), 126.4 (CH, CH
Im), 126.6 
(CH, CHIm), 128.9-140.2 (Ph), 169.3-170.4 (C, C=O), 181.8 (d, JC-P= 14.7 Hz, C, carbene). 
IR(KBr): νC=O = 1752 cm-1, νC-O = 1230 cm-1. 
Synthesis of the complex 70 
0.0394 g (0.137 mmol) of the imidazolium salt 32a was dissolved in 15 mL of anhydrous CH3CN in 
a 50 mL two-necked flask and 0.0174 g (0.075 mmol) of Ag2O was added under inert atmosphere 
(Ar). The mixture was stirred for 7 h at R.T. in the dark. The resulting mixture was treated with 0.0358 
g (0.137 mmol) of PPh3 and 0.0250 g (0.068 mmol) of the precursor [Pd(-Cl)(3-C3H5)]2 and further 
stirred at R.T. for 1h. The precipitated AgCl was removed by filtration on a millipore membrane filter. 
The solution was dried under vacuum and the residue treated with 1 mL of CH2Cl2.  
Addition of diethylether/n-hexane (1:1) to the concentrated solution yields the precipitation of the 
complex 70 as a white solid which was filtered off on a gooch, washed with n-pentane and dried 
under vacuum. 
0.0702 g of 70 was obtained (yield 74%). 
Most abundant isomer (ca. 52%):  
1H NMR (CDCl3, T=298 K, ppm, selected peaks)  : 3.38 (d, J = 13.4 Hz, 1H, anti allyl-H trans-C), 
3.63 (s, CH3, NCH3), 3.86 (dd, J = 13.3, 9.6 Hz, 1H, anti allyl-H trans-P), 4.16 (d, J= 7.8 Hz, 1H, syn 
allyl-H trans-C), 4.54 (dd, J = 6.4, 6.4 Hz,  1H, syn allyl-H trans-P), 5.61 (m, 1H, central-allyl-H), 
7.20-7.51 (m, 19H, ArH).  
13C{1H} NMR (CDCl3, T=298 K, ppm selected peaks)  : 36.6 (CH3, NCH3), 69.3 (d, CH2, JCP = 2.3 
Hz, CH2 allyl trans-C), 70.6 (d, CH2, JCP = 26.6 Hz, allyl trans-P), 111.6-134.8 (Ar-C), 125.4 (d, CH, 
JCP = 4.9 Hz, central allyl), 192.9 (m, C, carbene).  
31P{1H} NMR (CDCl3, T = 298 K) : 26.6 
19F{1H} NMR (CDCl3, T = 298 K) : -54.6 (CF3), -152.7 (10BF4), -152.8 (11BF4). 
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Less abundant isomer (ca. 48%):  
1H NMR (CDCl3, T=298 K, ppm, selected peaks)  : 3.04 (d, J = 13.2 Hz, 1H, anti allyl-H trans-C), 
3.14 (dd, J = 13.2, 9.5 Hz, 1H, anti allyl-H trans-P), 3.79 (s, CH3, NCH3), 4.11 (d, J= 7.0 Hz, 1H, syn 
allyl-H trans-C), 4.85 (dd, J = 6.2, 6.2 Hz,  1H, syn allyl-H trans-P), 6.19 (m, 1H, central-allyl-H), 
7.20-7.51 (m, 19H, ArH). 
13C{1H} NMR (CDCl3, T=298 K, ppm selected peaks)  : 36.7 (CH3, NCH3), 68.9 (d, CH2, JCP = 2.3 
Hz, CH2 allyl trans-C), 70.0 (d, CH2, JCP = 27.7 Hz, allyl trans-P), 111.6-134.8 (Ar-C), 121.3 (d, CH, 
JCP = 5.2 Hz, central allyl), 192.2 (m, C, carbene). 
31P{1H} NMR (CDCl3, T = 298 K) : 25.1 (q, JP-F =3.1 Hz) 
19F{1H} NMR (CDCl3, T = 298 K) : -55.2 (d, JF-P =3.1 Hz, CF3), -152.7 (10BF4), -152.8 (11BF4). 
IR [neat]: 2980,       cm-1. 
Anal. Calc. for C30H27BF7N2PPd: C, 51.72; H, 3.91; N, 4.02. Found: C, 51.84; H, 4.01; N, 3.76%. 
Synthesis of the complex 71 
Complex 71 was prepared in analogues manner as that described for 70 starting from 0.0414 g of 32a, 
0.0199 g of Ag2O, 0.0377 g of PPh3 and 0.0283 g of the precursor [Pd(-Cl)(3-2-MeC3H4)]2.  
0.0715 g (yield 70%) of 71 was obtained (pale-yellow solid). 
Most abundant isomer (ca. 60%):  
1H NMR (CDCl3, T=298 K, ppm, selected peaks)  : 2.02 (s, 3H, allyl-CH3), 3.29 (s, 1H, anti allyl-
H trans-C), 3.66 (d, J = 21.3 Hz, 1H, anti allyl-H trans-P), 3.82 (s, 3H, NCH3), 3.89 (s, 1H, syn allyl-
H trans-C), 4.32 (bs, 1H, syn allyl-H trans-P), 7.20-7.54 (m, 19H, ArH).  
13C{1H} NMR (CDCl3, T=298 K, ppm selected peaks)  : 23.4 (CH3, allyl-CH3), 36.8 (CH3, NCH3), 
68.9 (CH2, allyl trans-C), 69.3 (d, CH2, JCP = 28.3 Hz, CH2 allyl trans-P), 111.2-134.6 (Ar-C), 136.5 
(d, C, JCP = 5.0 Hz, central allyl), 193.2 (m, C, carbene).  
31P{1H} NMR (CDCl3, T = 298 K) : 27.4 (q, JP-F=1.0 Hz) 
19F{1H} NMR (CDCl3, T = 298 K) : -54.4 (d, JF-P=1.0 Hz, CF3), -152.8 (10BF4), -152.9 (11BF4). 
Less abundant isomer (ca. 40%):  
1H NMR (CDCl3, T=298 K, ppm, selected peaks)  : 2.18 (s, 3H, allyl-CH3), 3.04 (s, 1H, anti allyl-
H trans-C), 3.05 (d, J = 12.3 Hz, 1H, anti allyl-H trans-P), 3.68 (s, 3H, NCH3), 3.80 (s, 1H, syn allyl-
H trans-C), 4.55 (bs, H, syn allyl-H trans-P), 7.20-7.54 (m, 19H, ArH).  
13C{1H} NMR (CDCl3, T=298 K, ppm selected peaks)  : 23.9 (CH3, allyl-CH3), 37.0 (CH3, NCH3), 
68.2 (d, CH2, JCP = 26.9 Hz, CH2 allyl trans-P), 68.4 (CH2, allyl trans-C), 111.2-134.6 (Ar-C), 137.5 
(d, C, JCP = 5.0 Hz, central allyl), 193.0 (m, C, carbene). 
31P{1H} NMR (CDCl3, T = 298 K) : 26.8 (q, JP-F=2.4 Hz) 
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19F{1H} NMR (CDCl3, T = 298 K) : -54.9 (d, JF-P=2.4 Hz, CF3), -152.8 (10BF4), -152.9 (11BF4). 
IR [neat]: 2977,       cm-1. 
Anal. Calc. for C31H29BF7N2PPd: C, 52.38; H, 4.11; N, 3.94. Found: C, 52.20; H, 4.02; N, 3.80%. 
Synthesis of the complex 72 
Complex 72 was prepared in analogues manner as that described for 70 starting from 0.0321 g of 
32b, 0.0129 g of Ag2O, 0.0266 g of PPh3 and 0.0186 g of the precursor [Pd(-Cl)(3-C3H5)]2.  
0.0634 g (yield 86%) of 72 was obtained (white solid). 
Most abundant isomer (ca. 60%):  
1H NMR (CDCl3, T=298 K, ppm, selected peaks)  : 1.14 (d, J= 7.0 Hz, 3H, CH3i-Pr), 1.73 (d, J= 7.0 
Hz, 3H, CH3
i-Pr), 3.69 (d, J = 13.4 Hz, 1H, anti allyl-H trans-C), 3.75 (dd, J = 13.4, 9.7 Hz, 1H, anti 
allyl-H trans-P), 3.97 (d, J= 7.3 Hz, 1H, syn allyl-H trans-C), 4.50 (dd, J = 6.5, 6.5 Hz,  1H, syn allyl-
H trans-P), 5.48 (hept, J= 7.0 Hz, 1H, CH(CH3)2), 5.64 (m, 1H, central-allyl-H), 7.15-7.71 (m, 19H, 
ArH).  
13C{1H} NMR (CDCl3, T=298 K, ppm selected peaks)  : 19.4 (CH3, CH3i-Pr), 19.4 (CH3, CH3i-Pr),  
58.7 (CH, CH(CH3)2), 69.0 (d, CH2, JCP = 13.3 Hz, CH2 allyl trans-P), 71.7 (d, CH2, JCP = 1.5 Hz, 
allyl trans-C), 112.5-133.3 (Ar-C), 119.0 (apt d, C, JCP = 265.7 Hz, NCF3), 121.1 (d, CH, JCP = 5.4 
Hz, central allyl), 190.5 (m, C, carbene).  
31P{1H} NMR (CDCl3, T = 298 K) : 24.4 (q, JP-F=3.2 Hz) 
19F{1H} NMR (CDCl3, T = 298 K) : -55.1 (d, JF-P=3.2 Hz, CF3), -153.0 (10BF4), -153.1 (11BF4). 
Less abundant isomer (ca. 40%):  
1H NMR (CDCl3, T=298 K, ppm, selected peaks)  : 1.09 (d, J= 7.0 Hz, 3H, CH3i-Pr), 1.68 (d, J= 7.0 
Hz, 3H, CH3
i-Pr), 2.91 (d, J = 13.2 Hz, 1H, anti allyl-H trans-C), 3.15 (dd, J = 13.4, 9.5 Hz, 1H, anti 
allyl-H trans-P), 4.11 (d, J= 7.3 Hz, 1H, syn allyl-H trans-C), 4.68 (dd, J = 6.2, 6.2 Hz,  1H, syn allyl-
H trans-P), 5.13 (hept, J= 7.0 Hz, 1H, CH(CH3)2), 6.31 (m, 1H, central-allyl-H), 7.15-7.71 (m, 19H, 
ArH). 
13C{1H} NMR (CDCl3, T=298 K, ppm selected peaks)  : 21.0 (CH3, CH3i-Pr), 21.4 (CH3, CH3i-Pr),   
58.3 (CH, CH(CH3)2), 68.7 (d, CH2, JCP = 13.9 Hz, CH2 allyl trans-P), 69.6 (d, CH2, JCP = 1.8 Hz, 
allyl trans-C), 112.5-133.3 (Ar-C), 119.1 (apt d, C, JCP = 265.8 Hz, NCF3),  123.4 (d, CH, JCP = 5.3 
Hz, central allyl), 191.5 (m, C, carbene). 
31P{1H} NMR (CDCl3, T = 298 K) : 24.2 (q, JP-F=5.0 Hz) 
19F{1H} NMR (CDCl3, T = 298 K) : -55.6 (d, JF-P=5.0 Hz, CF3), -153.0 (10BF4), -153.1 (11BF4). 
IR [neat]: 2972,        cm-1. 
Anal. Calc. for C32H31BF7N2PPd: C, 53.03; H, 4.31; N, 3.87. Found: C, 53.15; H, 4.22; N, 3.97%. 
384 
 
Synthesis of the complex 73 
Complex 73 was prepared in analogues manner as that described for 70 starting from 0.0400 g of 
32b, 0.0162 g of Ag2O, 0.0332 g of PPh3 and 0.0249 g of the precursor [Pd(-Cl)(3-2-MeC3H4)]2.  
0.0765 g (yield 82%) of 73 was obtained (brownish solid). 
Most abundant isomer (ca. 65%):  
1H NMR (CDCl3, T=298 K, ppm, selected peaks)  : 1.15 (d, J= 6.9 Hz, 3H, CH3i-Pr), 1.71 (d, J= 6.8 
Hz, 3H, CH3
i-Pr), 1.97 (s, 3H, allyl-CH3), 3.61 (s, 1H, anti allyl-H trans-C), 3.66 (s, 1H, syn allyl-H 
trans-C), 3.22 (d, J = 9.5, 1H, anti allyl-H trans-P), 4.24 (dd, J = 3.9, 3.9 Hz,  1H, syn allyl-H trans-
P), 5.50 (hept, J= 6.8 Hz, 1H, CH(CH3)2), 7.13-7.74 (m, 19H, ArH).  
13C{1H} NMR (CDCl3, T=298 K, ppm selected peaks)  : 19.4 (CH3, CH3i-Pr), 21.3 (CH3, CH3i-Pr), 
23.5 (CH3, allyl-CH3), 58.7 (CH, CH(CH3)2), 67.6 (d, CH2, JCP = 28.1 Hz, CH2 allyl trans-P), 71.2 
(CH2, allyl trans-C), 112.5-133.6 (Ar-C), 136.4 (d, C, JCP = 5.1 Hz, central allyl), 191.6 (m, C, 
carbene).  
31P{1H} NMR (CDCl3, T = 298 K) : 26.0 (q, JP-F=3.8 Hz) 
19F{1H} NMR (CDCl3, T = 298 K) : -55.0 (d, JF-P=3.8 Hz, CF3), -153.2 (10BF4), -153.3 (11BF4). 
Less abundant isomer (ca. 35%):  
1H NMR (CDCl3, T=298 K, ppm, selected peaks)  : 1.08 (d, J= 7.0 Hz, 3H, CH3i-Pr), 1.68 (d, J= 7.1 
Hz, 3H, CH3
i-Pr), 2.15 (s, 3H, allyl-CH3), 2.99 (s, 1H, anti allyl-H trans-C), 3.07 (d, J = 9.6, 1H, anti 
allyl-H trans-P), 3.73 (s, 1H, syn allyl-H trans-C), 4.37 (dd, J = 4.0, 4.0 Hz,  1H, syn allyl-H trans-
P), 4.98 (hept, J= 7.2 Hz, 1H, CH(CH3)2), 7.13-7.74 (m, 19H, ArH). 
13C{1H} NMR (CDCl3, T=298 K, ppm selected peaks)  : 19.3 (CH3, CH3i-Pr), 20.9 (CH3, CH3i-Pr), 
23.8 (CH3, allyl-CH3), 58.5 (CH, CH(CH3)2), 67.9 (d, CH2, JCP = 25.7 Hz, CH2 allyl trans-P), 68.9 
(CH2, allyl trans-C), 112.5-133.6 (Ar-C), 137.4 (d, C, JCP = 5.0 Hz, central allyl), 191.8 (m, C, 
carbene). 
31P{1H} NMR (CDCl3, T = 298 K) : 25.6 (q, JP-F=4.5 Hz) 
19F{1H} NMR (CDCl3, T = 298 K) : -55.3 (d, JF-P=4.5 Hz, CF3), -153.2 (10BF4), -153.3 (11BF4). 
IR [neat]: 2986,       cm-1. 
Anal. Calc. for C33H33BF7N2PPd: C, 53.65; H, 4.50; N, 3.79. Found: C, 53.80; H, 4.32; N, 3.94%. 
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Synthesis of the complex 74 
Complex 74 was prepared in analogues manner as that described for 70 starting from 0.0404 g of 32c, 
0.0154 g of Ag2O, 0.0303 g of PPh3 and 0.0211 g of the precursor [Pd(-Cl)(3-C3H5)]2.  
0.0801 g (yield 91%) of 74 was obtained (white solid). 
Most abundant isomer (ca. 58%):  
1H NMR (CDCl3, T=298 K, ppm, selected peaks)  : 3.00 (d, J = 13.1 Hz, 1H, anti allyl-H trans-C), 
3.48 (m, 1H, anti allyl-H trans-P), 3.61 (d, J= 7.2 Hz, 1H, syn allyl-H trans-C), 5.10 (dd, J = 6.7, 6.7 
Hz,  1H, syn allyl-H trans-P), 5.70 (m, 1H, central-allyl-H), 6.77-7.74 (m, 24H, ArH).  
13C{1H} NMR (CDCl3, T=298 K, ppm selected peaks)  : 68.4 (d, CH2, JCP = 1.8 Hz, CH2 allyl trans-
C), 72.3 (d, CH2, JCP = 27.1 Hz, allyl trans-P), 112.2-135.9 (Ar-C), 126.4 (d, CH, JCP = 5.8 Hz, central 
allyl), 192.8 (m, C, carbene).  
31P{1H} NMR (CDCl3, T = 298 K) : 24.4 (q, JP-F =2.5 Hz) 
19F{1H} NMR (CDCl3, T = 298 K) : -55.2 (d, JF-P =2.5 Hz, CF3), -153.8 (10BF4), -153.9 (11BF4). 
Less abundant isomer (ca. 42%):  
1H NMR (CDCl3, T=298 K, ppm, selected peaks)  : 2.55 (d, J = 13.4 Hz, 1H, anti allyl-H trans-C), 
3.37 (m, 1H, anti allyl-H trans-P), 4.04 (d, J= 7.2 Hz, 1H, syn allyl-H trans-C), 4.86 (dd, J = 7.0, 7.0 
Hz,  1H, syn allyl-H trans-P), 5.70 (m, 1H, central-allyl-H), 6.77-7.74 (m, 24H, ArH).  
13C{1H} NMR (CDCl3, T=298 K, ppm selected peaks)  : 69.1 (d, CH2, JCP = 2.1 Hz, CH2 allyl trans-
C), 71.8 (d, CH2, JCP = 27.4 Hz, allyl trans-P), 112.2-135.9 (Ar-C), 126.2 (d, CH, JCP = 5.5 Hz, central 
allyl), 192.6 (m, C, carbene). 
31P{1H} NMR (CDCl3, T = 298 K) : 24.8 
19F{1H} NMR (CDCl3, T = 298 K) : -54.5, -153.8 (10BF4), -153.9 (11BF4). 
IR [neat]: 2970,        cm-1. 
Anal. Calc. for C35H29BF7N2PPd: C, 55.40; H, 3.85; N, 3.69. Found: C, 55.25; H, 4.02; N, 3.77%. 
Synthesis of the complex 75 
Complex 75 was prepared in analogues manner as that described for 70 starting from 0.0443 g of 32c, 
0.0169 g of Ag2O, 0.0332 g of PPh3 and 0.0249 g of the precursor [Pd(-Cl)(3-2-MeC3H4)]2.  
0.0821 g (yield 84%) of 75 was obtained (white solid). 
Most abundant isomer (ca. 65%):  
1H NMR (CDCl3, T=298 K, ppm, selected peaks)  : 1.66 (s, 3H, allyl-CH3), 2.94 (s, 1H, anti allyl-
H trans-C), 3.20 (d, J = 9.6 Hz, 1H, anti allyl-H trans-P), 3.37 (s, 1H, syn allyl-H trans-C), 4.65 (bs, 
1H, syn allyl-H trans-P), 6.80-7.74 (m, 19H, ArH).  
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13C{1H} NMR (CDCl3, T=298 K, ppm selected peaks)  : 23.0 (CH3, allyl-CH3), 68.7 (CH2, allyl 
trans-C), 70.1 (d, CH2, JCP = 28.5 Hz, CH2 allyl trans-P), 112.2-136.0 (Ar-C), 137.6 (d, C, JCP = 5.0 
Hz, central allyl), 193.3 (m, C, carbene).  
31P{1H} NMR (CDCl3, T = 298 K) : 25.3 (q, JP-F=3.1 Hz) 
19F{1H} NMR (CDCl3, T = 298 K) : -54.9 (d, JF-P=3.1 Hz, CF3), -153.9 (10BF4), -154.0 (11BF4). 
Less abundant isomer (ca. 35%):  
1H NMR (CDCl3, T=298 K, ppm, selected peaks)  : 2.04 (s, 3H, allyl-CH3), 2.47 (s, 1H, anti allyl-
H trans-C), 3.28 (d, J = 9.6 Hz, 1H, anti allyl-H trans-P), 3.72 (s, 1H, syn allyl-H trans-C), 4.61 (bs, 
1H, syn allyl-H trans-P), 6.80-7.74 (m, 19H, ArH). 
13C{1H} NMR (CDCl3, T=298 K, ppm selected peaks)  : 23.1 (CH3, allyl-CH3), 68.7 (CH2, allyl 
trans-C), 68.7 (d, CH2, JCP = 28.7 Hz, CH2 allyl trans-P), 112.2-136.0 (Ar-C), 136.6 (d, C, JCP = 5.0 
Hz, central allyl), 193.1 (m, C, carbene). 
31P{1H} NMR (CDCl3, T = 298 K) : 26.6 (q, JP-F=2.0 Hz) 
19F{1H} NMR (CDCl3, T = 298 K) : -54.3 (d, JF-P=2.0 Hz, CF3), -153.9 (10BF4), -154.0 (11BF4). 
IR [neat]: 2973,        cm-1. 
Anal. Calc. for C36H31BF7N2PPd: C, 55.95; H, 4.04; N, 3.62. Found: C, 55.83; H, 4.14; N, 3.79%. 
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9.7.20. Synthesis of mixed NHC/PTA palladium 3-allyl complexes (76-84) 
       
Synthesis of the complex 76 
0.0508 g (0.104 mmol) of the complex 57 was dissolved in ca. 6 mL of anhydrous CH2Cl2 and 0.0164 
g (0.104 mmol) of PTA dissolved in ca. 6 ml of CH2Cl2 was added and the mixture was stirred at RT 
for ca. 10 min in a 50 mL two necked flask under inert atmosphere (Ar). 
The resulting mixture was treated with 0.0282 g (0.208 mmol) of NaClO4·H2O dissolved in ca. 4 ml 
of methanol (CH2Cl2/MeOH≈ 2/1). and further stirred for ca. 10 min, dried under vacuum and treated 
with CH2Cl2 and activated carbon. The inorganic salts were filtered off on a Celite filter and 
repeatedly washed with CH2Cl2, whereas the resulting solution was concentrated under vacuum. 
Addition of diethylether to the concentrated solution yields the precipitation of the complex 76 as a 
white solid which was filtered off on a gooch and washed with n-pentane. 0.0558 g of 76 was obtained 
(yield 75%). 
1H NMR (CD2Cl2, T=298 K, ppm)  : 2.13 (s, 3H, o-mesityl -CH3), 2.18 (dd, JHH = 14.0 Hz, JHP = 
9.4 Hz, 1H, anti allyl-H trans-P), 2.17 (s, 3H, o-mesityl -CH3), 2.37 (d,1H, JHH = 14.0 Hz anti allyl-
H trans-C), 2.40 (s, 3H, p-mesityl -CH3), 3.64 (m, 1H, allyl-H trans-C), 3.76 (m, 6H, NCH2N), 4.12 
(m, 1H, anti allyl-H trans-P), 4.44 (m, 6H, PCH2N), 7.11 (s, 2H, m-mesityl -H), 7.14 (s, 2H, m-
mesityl-H), 7.39 (s, 2H, CH=CH Im). 
13C{1H} NMR (CD2Cl2, T=298 K, ppm)  : 18.6 (CH3, o-mesityl-CH3), 18.8 (CH3, o-mesityl-CH3),  
20.7 (CH3, p-mesityl-CH3), 52.5 (d, CH2, JCP = 11.4 Hz, NCH2N), 60.4  (CH2, allyl trans-C), 70.9 (d, 
CH2, JCP = 27.5 Hz,  allyl trans-P),  72.9 (d, CH2, JCP = 7.4 Hz, PCH2N), 120.7 (d, CH, JCP = 4.5 Hz, 
central allyl), 124.8. (CH, CH=CH Im), 129.8 (CH, m-mesityl), 130.0 (CH, m-mesityl), 134.2 (C, o-
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mesityl), 134.7 (C, o-mesityl), 135.3 (C, i-mesityl), 140.1 (C, p-mesityl), 178.3 (d, C, JCP = 16.4 Hz, 
NHC).  
31P{1H} NMR (CDCl3, T = 298 K)  : -59.7. 
Synthesis of the complex 77 
Complex 77 was prepared in analogues manner as that described for 76 starting from 0.0504 g of 58, 
0.0158 g of PTA and 0.0282 g of NaClO4·H2O. 
0.0536 g (yield 75%) of 77 was obtained (white solid). 
1H NMR (CD2Cl2, T=298 K, ppm)  : 1.25 (s, 3H, allyl-CH3), 2.16 (s, 3H, o-mesityl -CH3), 2.22 (s, 
3H, o-mesityl -CH3), 2.30 (d,1H, JHP = 1.2 Hz anti allyl-H trans-C), 2.31 (d, JHP = 9.7 Hz, 1H, anti 
allyl-H trans-P), 2.40 (s, 3H, p-mesityl -CH3), 3.64 (ddt, 1H, JHP = 3.2 Hz, JHH = 3.2 Hz, JHH = 1.2 
Hz, syn allyl-H trans-C), 3.76 (m, 6H, NCH2N), 3.85 (dd, 1H,  JHP = 5.1 Hz, JHH = 3.2 Hz, anti allyl-
H trans-P), 4.45 (m, 6H, PCH2N), 7.13 (s, 2H, m-mesityl -H), 7.16 (s, 2H, m-mesityl-H), 7.37 (s, 2H, 
CH=CH Im).  
13C{1H} NMR (CD2Cl2, T=298 K, ppm)  : 18.7 (CH3, o-mesityl-CH3), 20.7 (CH3, p-mesityl-CH3), 
22.5 (CH3, allyl-CH3),  52.8 (CH2, NCH2N), 60.4 (CH2, allyl trans-C), 70.9 (d, CH2, JCP = 29.2 Hz,  
allyl trans-P),  72.9 (d, CH2, JCP = 7.1 Hz, PCH2N), 124.8. (CH, CH=CH Im), 129.9 (CH, m-mesityl), 
130.0 (CH, m-mesityl), 134.3 (C, o-mesityl), 134.6 (C, i-mesityl), 135.5 (C, o-mesityl), 136.0 (d, C, 
JCP = 4.5 Hz, central allyl), 140.1 (C, p-mesityl), 178.7 (d, C, JCP = 15.7 Hz, NHC). 
31P{1H} NMR (CDCl3, T = 298 K) : -59.5. 
Synthesis of the complex 78 
0.0714 g (0.170 mmol) of the complex [Pd(Me-Im-CH2Pyr)(3-C3H5)]ClO4, previously synthetized 
in analogues manner as that described for 50, was dissolved in ca. 20 mL of anhydrous CH2Cl2.   
The resulting mixture was treated with 0.0267 g (0.170 mmol) of PTA dissolved and further stirred 
for ca. 30 min. 
Addition of diethylether to the concentrated solution yields the precipitation of the complex 78 as a 
white solid which was filtered off on a gooch and washed with n-pentane.  
0.0952 g of 78 was obtained (yield 97%). 
Most abundant isomer (ca. 52%):  
1H NMR (CD2Cl2, T=233 K, ppm, selected peaks) δ: 2.91 (dd, JHH = 13.9 Hz, JHP = 9.8 Hz, 1H, anti 
allyl-H trans-P), 2.64 (d,1H, JHH = 13.9 Hz anti allyl-H trans-C), 3.71 (s, 3H, NCH3), 3.9-4.17 (m, 
8H, syn allyl-H trans-P, syn allyl-H trans-C, NCH2N), 4.46- 4.58 (m, 6H, PCH2N), 5.01, 5.10 (AB 
system, J = 15.4 Hz, 2H, NCH2), 7.16-7.34 (m, 4H, CH=CH Im, 3-pyr, 5-pyr), 7.78 (td  J = 7.7, 1.8 
Hz, 1H, 4-pyr), 8. 57 (d, J = 4.8 Hz, 1H, 6- Pyr). 
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31P{1H} NMR (CDCl3, T = 233 K) δ: -55.8. 
Less abundant isomer (ca. 48%):  
1H NMR (CD2Cl2, T=233 K, ppm, selected peaks) δ: 2.58 (dd, JHH = 13.9 Hz, JHP = 9.8 Hz, 1H, anti 
allyl-H trans-P), 2.69 (d,1H, JHH = 13.9 Hz anti allyl-H trans-C), 3.55 (s, 3H, NCH3), 3.9-4.17 (m, 
8H, syn allyl-H trans-P, syn allyl-H trans-C, NCH2N), 4.46- 4.58 (m, 6H, PCH2N), 5.21, 5.30 (AB 
system, J = 15.8 Hz, 2H, NCH2), 7.16-7.34 (m, 4H, CH=CH Im, 3-pyr, 5-pyr), 7.79 (td  J = 7.7, 1.8 
Hz, 1H, 4-pyr),  8. 57 (d, J = 4.8 Hz, 1H, 6- Pyr).  
31P{1H} NMR (CDCl3, T = 233 K) δ: -55.9. 
IR (KBr pellet, cm-1): 1095 (stretching ClO), 621 (bending ClO) 
Synthesis of the complex 79 
0.0432 g (0.150 mmol) of the imidazolium salt 32a was dissolved in 20 mL of anhydrous CH3CN in 
a 50 mL two-necked flask and 0.0191 g (0.082 mmol) of Ag2O was added under inert atmosphere 
(Ar). The mixture was stirred for 7 h at R.T. in the dark. 
The resulting mixture was treated with 0.0236 g (0.150 mmol) of PTA (1,3,5-triaza-7-
phosphadamantane) and 0.0274 g (0.075 mmol) of the precursor [Pd(-Cl)(3-C3H5)]2 and further 
stirred at R.T. for 1h. The precipitated AgCl was removed by filtration on a millipore membrane filter. 
The solution was dried under vacuum and the residue treated with 1 mL of CH2Cl2.  
Addition of diethylether to the concentrated solution yields the precipitation of the complex 79 as a 
brownish solid which was filtered off on a gooch, washed with n-pentane and dried under vacuum. 
0.0785 g of 79 was obtained (yield 88%). 
Equimolar mixture of the two isomers 
1H NMR (CD3CN, T=298 K, ppm, selected peaks)  : 2.85-3.27 (m, 4H, 2 anti allyl-H trans-C, 2 anti 
allyl-H trans-P), 3.84 (s, 3H, NCH3), 4.03 (s, 3H, NCH3), 4.22-4.69 (m, 28H, 2 syn allyl-H trans-C, 
2 syn allyl-H trans-P, 6 NCH2N, 6 NCH2P), 5.45 (m, 2H, 2 central-allyl-H), 7.51-7.82 (m, 8H, ArH).  
13C{1H} NMR (CD3CN, T=298 K, ppm selected peaks)  : 37.2 (CH3, NCH3), 37.5 (CH3, NCH3), 
52.7 (d, CH2, J= 12.6 Hz, NCH2P), 52.7 (d, CH2, J= 12.6 Hz, NCH2P), 62.5 (CH2, allyl trans-C), 62.6 
(CH2, allyl trans-C), 71.3 (d, CH2, JCP = 26.5 Hz, CH2 allyl trans-P), 71.9 (d, CH2, JCP = 26.7 Hz, 
CH2 allyl trans-P), 73.3 (d, CH2, J= 7.0 Hz, NCH2N), 73.3 (d, CH2, J= 7.0 Hz, NCH2N), 122.5 (d, C, 
JCP = 4.9 Hz, central allyl), 122.5 (d, C, JCP = 4.9 Hz, central allyl), 191.4 (m, C, carbene). 191.6 (m, 
C, carbene). 
31P{1H} NMR (CD3CN, T = 298 K) : -57.2, -57.2 
19F{1H} NMR (CD3CN, T = 298 K) : -55.8 (CF3), -56.2 (CF3), -151.8 (10BF4), -151.9 (11BF4). 
IR [neat]:        cm-1. 
Anal. Calc. for C18H24BF7N5PPd: C, 36.54; H, 4.09; N, 11.84. Found: C, 36.73; H, 4.18; N, 11.61%. 
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Synthesis of the complex 80 
Complex 80 was prepared in analogues manner as that described for 79 starting from 0.0401 g of 32a, 
0.0194 g of Ag2O, 0.0219 g of PTA (1,3,5-triaza-7-phosphadamantane) and 0.0275 g of the precursor 
[Pd(-Cl)(3-2-MeC3H4)]2.  
0.0791 g (yield 94%) of 80 was obtained (white solid). 
Equimolar mixture of the two isomers  
1H NMR (CD3CN, T=298 K, ppm, selected peaks)  : 1.80 (s, 3H, allyl-CH3), 1.86 (s, 3H, allyl-CH3), 
2.72-3.06 (m, 4H, 2 anti allyl-H trans-C, 2 anti allyl-H trans-P), 3.82 (s, 3H, NCH3), 3.89 (s, 3H, 
NCH3), 4.08-4.67 (m, 28H, 2 syn allyl-H trans-C, 2 syn allyl-H trans-P, 6 NCH2N, 6 NCH2P), 7.52-
7.79 (m, 8H, ArH).  
13C{1H} NMR (CD3CN, T=298 K, ppm selected peaks)  : 23.6 (CH3, allyl-CH3), 24.1 (CH3, allyl-
CH3), 37.5 (CH3, NCH3), 37.6 (CH3, NCH3), 52.8 (d, CH2, J= 12.7 Hz, NCH2P), 52.8 (d, CH2, J= 
12.7 Hz, NCH2P), 61.9 (CH2, allyl trans-C), 62.1 (CH2, allyl trans-C), 70.1 (d, CH2, JCP = 26.5 Hz, 
CH2 allyl trans-P), 71.0 (d, CH2, JCP = 27.2 Hz, CH2 allyl trans-P), 73.4 (d, CH2, J= 8.7 Hz, NCH2N), 
73.4 (d, CH2, J= 8.7 Hz, NCH2N), 137.2 (d, C, JCP = 5.0 Hz, central allyl), 137.4 (d, C, JCP = 4.8 Hz, 
central allyl), 191.6 (m, C, carbene), 191.7 (m, C, carbene).  
31P{1H} NMR (CD3CN, T = 298 K) : -56.8 (q, JP-F = 4.1 Hz), -56.9 (q, JP-F = 4.4 Hz), 
19F{1H} NMR (CD3CN, T = 298 K) : -55.5 (d, JF-P = 3.0 Hz, CF3), -56.1 (d, JF-P = 3.4 Hz, CF3), -
151.7 (10BF4), -151.8 (
11BF4). 
IR [neat]:        cm-1. 
Anal. Calc. for C19H26BF7N5PPd: C, 37.68; H, 4.33; N, 11.56. Found: C, 37.53; H, 4.28; N, 11.80%. 
Synthesis of the complex 81 
Complex 81 was prepared in analogues manner as that described for 79 starting from 0.0400 g of 
32b, 0.0161 g of Ag2O, 0.0199 g of PTA (1,3,5-triaza-7-phosphadamantane) and 0.0231 g of the 
precursor [Pd(-Cl)(3-C3H5)]2. 0.0552 g (yield 71%) of 81 was obtained (brownish solid). 
Equimolar mixture of the two isomers 
1H NMR (CD3CN, T=298 K, ppm, selected peaks)  : 1.57 (d, J= 7.0 Hz, 3H, CH3i-Pr), 1.64 (d, J= 7.0 
Hz, 3H, CH3
i-Pr), 1.71 (d, J= 7.0 Hz, 3H, CH3
i-Pr), 1.83 (d, J= 7.0 Hz, 3H, CH3
i-Pr), 2.86-3.12 (m, 4H, 
2 anti allyl-H trans-C, 2 anti allyl-H trans-P), 4.25-4.70 (m, 28H, 2 syn allyl-H trans-C, 2 syn allyl-
H trans-P, 6 NCH2N, 6 NCH2P), 4.84 (hept, J= 7.0 Hz, 1H, CH(CH3)2), 5.08 (hept, J= 7.0 Hz, 1H, 
CH(CH3)2), 5.46 (m, 1H, central-allyl-H), 5.48 (m, 1H, central-allyl-H), 7.55-7.97 (m, 8H, ArH).   
13C{1H} NMR (CD3CN, T=298 K, ppm selected peaks)  : 21.0 (CH3, CH3i-Pr), 21.2 (CH3, CH3i-Pr),  
52.9 (d, CH2, J= 12.7 Hz, NCH2P), 57.7 (CH, CH(CH3)2), 58.3 (CH, CH(CH3)2), 62.0 (CH2, allyl 
trans-C), 62.6 (CH2, allyl trans-C), 71.1 (d, CH2, JCP = 24.9 Hz, CH2 allyl trans-P), 72.0 (d, CH2, JCP 
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= 25.7 Hz, CH2 allyl trans-P), 73.3 (d, CH2, J= 7.3 Hz, NCH2N), 122.2 (d, CH, JCP = 5.3 Hz, central 
allyl), 122.3 (d, CH, JCP = 4.6 Hz, central allyl), 190.9 (m, C, carbene), 191.0 (m, C, carbene).  
31P{1H} NMR (CD3CN, T = 298 K) : -57.4 (m) 
19F{1H} NMR (CD3CN, T = 298 K) : -55.8 (d, JF-P=5.0 Hz, CF3), -56.3 (d, JF-P=5.8 Hz, CF3), -151.7 
(10BF4), -151.8 (
11BF4). 
IR [neat]:        cm-1. 
Anal. Calc. for C20H28BF7N5PPd: C, 38.77; H, 4.55; N, 11.30. Found: C, 38.93; H, 4.38; N, 11.14%. 
Synthesis of the complex 82 
Complex 82 was prepared in analogues manner as that described for 79 starting from 0.0408 g of 
32b, 0.0165 g of Ag2O, 0.0202 g of PTA (1,3,5-triaza-7-phosphadamantane) and 0.0254 g of the 
precursor [Pd(-Cl)(3-2-MeC3H4)]2.  
0.0752 g (yield 92%) of 82 was obtained (pale-yellow solid). 
Equimolar mixture of the two isomers 
1H NMR (CD3CN, T=298 K, ppm, selected peaks)  : 1.57 (d, J= 7.4 Hz, 3H, CH3i-Pr), 1.60 (d, J= 7.4 
Hz, 3H, CH3
i-Pr), 1.73 (d, J= 7.1 Hz, 3H, CH3
i-Pr), 1.79 (d, J= 7.1 Hz, 3H, CH3
i-Pr), 1.79 (s, 3H, allyl-
CH3), 1.85 (s, 3H, allyl-CH3), 2.75-3.09 (m, 4H, 2 anti allyl-H trans-C, 2 anti allyl-H trans-P), 4.07-
4.69 (m, 28H, 2 syn allyl-H trans-C, 2 syn allyl-H trans-P, 6 NCH2N, 6 NCH2P), 4.77 (hept, J= 7.1 
Hz, 1H, CH(CH3)2), 5.09 (hept, J= 7.4 Hz, 1H, CH(CH3)2), 7.54-7.95 (m, 8H, ArH).  
13C{1H} NMR (CD3CN, T=298 K, ppm selected peaks)  : 20.9 (CH3, CH3i-Pr), 21.0 (CH3, CH3i-Pr),  
21.1 (CH3, CH3
i-Pr), 21.2 (CH3, CH3
i-Pr), 23.6 (CH3, allyl-CH3), 23.8 (CH3, allyl-CH3), 53.0 (d, CH2, 
J= 12.7 Hz, NCH2P), 53.0 (d, CH2, J= 12.7 Hz, NCH2P), 58.2 (CH, CH(CH3)2), 58.4 (CH, CH(CH3)2), 
61.7 (CH2, allyl trans-C), 62.1 (CH2, allyl trans-C), 70.2 (d, CH2, JCP = 26.6 Hz, CH2 allyl trans-P), 
71.1 (d, CH2, JCP = 27.4 Hz, CH2 allyl trans-P), 73.4 (d, CH2, J= 7.1 Hz, NCH2N), 73.4 (d, CH2, J= 
7.1 Hz, NCH2N), 137.0 (d, C, JCP = 4.7 Hz, central allyl), 137.3 (d, C, JCP = 4.6 Hz, central allyl), 
190.9 (m, C, carbene). 191.0 (m, C, carbene).  
31P{1H} NMR (CD3CN, T = 298 K) : -57.6 (q, JP-F = 4.1 Hz), -57.7 (q, JP-F = 4.4 Hz), 
19F{1H} NMR (CD3CN, T = 298 K) : -55.6 (d, JF-P = 4.1 Hz, CF3), -56.2 (d, JF-P =4.4 Hz, CF3), -
151.7 (10BF4), -151.8 (
11BF4). 
IR [neat]:        cm-1. 
Anal. Calc. for C21H30BF7N5PPd: C, 39.80; H, 4.77; N, 11.05. Found: C, 39.91; H, 4.93; N, 10.89%. 
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Synthesis of the complex 83 
Complex 83 was prepared in analogues manner as that described for 79 starting from 0.0404 g of 32c, 
0.0160 g of Ag2O, 0.0181 g of PTA (1,3,5-triaza-7-phosphadamantane) and 0.0211 g of the precursor 
[Pd(-Cl)(3-C3H5)]2.  
0.0542 g (yield 75%) of 83 was obtained (white solid). 
Most abundant isomer (ca. 60%):  
1H NMR (CD3CN, T=298 K, ppm, selected peaks)  : 2.73 (d, J= 13.2 Hz, 1H, anti allyl-H trans-C), 
3.12 (m, 1H, anti allyl-H trans-P), 3.81-4.71 (m, 14H, syn allyl-H trans-C, syn allyl-H trans-P, 3 
NCH2N, 3 NCH2P), 5.21 (m, 2H, 2 central-allyl-H), 7.43-7.91 (m, 9H, ArH).  
13C{1H} NMR (CD3CN, T=298 K, ppm selected peaks)  : 52.7 (d, CH2, J= 12.4 Hz, NCH2P), 61.4 
(CH2, CH2 allyl trans-C), 73.1 (d, CH2, J= 7.4 Hz, NCH2N), 73.5 (CH2, allyl trans-P), 122.3 (d, CH, 
JCP = 5.0 Hz, central allyl), 192.0 (m, C, carbene).  
31P{1H} NMR (CD3CN, T = 298 K) : -57.2 (q, JP-F= 2.9 Hz) 
19F{1H} NMR (CD3CN, T = 298 K) : -56.4 (d, JF-P= 2.9 Hz, CF3), -151.9 (10BF4), -152.0 (11BF4). 
Less abundant isomer (ca. 40%):  
1H NMR (CD3CN, T=298 K, ppm, selected peaks)  : 2.56 (d, J= 13.6 Hz, 1H, anti allyl-H trans-C), 
2.93 (m, 1H, anti allyl-H trans-P), 3.81-4.71 (m, 14H, syn allyl-H trans-C, syn allyl-H trans-P, 3 
NCH2N, 3 NCH2P), 5.40 (m, 2H, 2 central-allyl-H), 7.43-7.91 (m, 9H, ArH).  
13C{1H} NMR (CD3CN, T=298 K, ppm selected peaks)  : 52.8 (d, CH2, J= 11.4 Hz, NCH2P),  61.8 
(CH2, CH2 allyl trans-C), 73.8 (CH2, allyl trans-P), 73.1 (d, CH2, J= 7.4 Hz, NCH2N), 122.1 (d, CH, 
JCP = 4.8 Hz, central allyl), 192.3 (m, C, carbene).  
31P{1H} NMR (CD3CN, T = 298 K) : -57.4 
19F{1H} NMR (CD3CN, T = 298 K) : -56.0 (CF3), -151.9 (10BF4), -152.0 (11BF4). 
IR [neat]:        cm-1. 
Anal. Calc. for C23H26BF7N5PPd: C, 42.26; H, 4.01; N, 10.71. Found: C, 42.35; H, 3.93; N, 10.59%. 
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Synthesis of the complex 84 
Complex 84 was prepared in analogues manner as that described for 79 starting from 0.0185 g of 32c, 
0.0071 g of Ag2O, 0.0083 g of PTA (1,3,5-triaza-7-phosphadamantane) and 0.0104 g of the precursor 
[Pd(-Cl)(3-2-MeC3H4)]2.  
0.0282 g (yield 80%) of 84 was obtained (white solid). 
Most abundant isomer (ca. 58%):  
1H NMR (CD3CN, T=298 K, ppm, selected peaks)  : 1.48 (s, 3H, allyl-CH3), 2.59 (s, 1H, allyl-H 
trans-C), 2.96 (d, J= 8.8 Hz, 1H, allyl-H trans-P), 3.83-4.65 (m, 14H, syn allyl-H trans-C, syn allyl-
H trans-P, 3 NCH2N, 3 NCH2P), 7.38-7.88 (m, 9H, ArH). 
13C{1H} NMR (CD3CN, T=298 K, ppm selected peaks)  : 23.3 (CH3, allyl-CH3), 52.9 (d, CH2, J= 
12.8 Hz, NCH2P), 61.4 (CH2, allyl trans-C), 72.0 (d, CH2, JCP = 25.9 Hz, CH2 allyl trans-P), 73.2 (d, 
CH2, J= 7.5 Hz, NCH2N), 137.3 (d, C, JCP = 4.6 Hz, central allyl), 192.9 (m, C, carbene).  
31P{1H} NMR (CD3CN, T = 298 K) : -57.5 (q, JP-F = 3.9 Hz). 
19F{1H} NMR (CD3CN, T = 298 K) : -56.2 (d, JF-P = 3.9 Hz, CF3), -151.8 (10BF4), -151.9 (11BF4). 
Less abundant isomer (ca. 42%):  
1H NMR (CD3CN, T=298 K, ppm, selected peaks)  : 1.79 (s, 3H, allyl-CH3), 2.42 (s, 1H, allyl-H 
trans-C), 2.79 (d, J= 8.4 Hz, 1H,  allyl-H trans-P), 3.83-4.65 (m, 14H, syn allyl-H trans-C, syn allyl-
H trans-P, 3 NCH2N, 3 NCH2P), 7.38-7.88 (m, 9H, ArH).  
13C{1H} NMR (CD3CN, T=298 K, ppm selected peaks)  : 23.4 (CH3, allyl-CH3), 52.9 (d, CH2, J= 
12.6 Hz, NCH2P), 61.3 (CH2, allyl trans-C), 72.1 (d, CH2, JCP = 27.0 Hz, CH2 allyl trans-P), 73.2 (d, 
CH2, J= 7.5 Hz, NCH2N), 137.0 (d, C, JCP = 4.8 Hz, central allyl), 193.2 (m, C, carbene).  
31P{1H} NMR (CD3CN, T = 298 K) : -57.1 (q, JP-F = 2.9 Hz). 
19F{1H} NMR (CD3CN, T = 298 K) : -55.7 (d, JF-P = 2.9 Hz, CF3), -151.8 (10BF4), -151.9 (11BF4). 
IR [neat]:         cm-1. 
Anal. Calc. for C24H28BF7N5PPd: C, 43.17; H, 4.23; N, 10.49. Found: C, 43.25; H, 4.03; N, 10.20%. 
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9.7.21. Synthesis of mixed NHC/DIC and DIC/PPh3 palladium 3-allyl complexes (85-86) 
                    
The mixed NHC/DIC (85) and DIC/PPh3 (86) complexes were synthesized according to published 
procedures [39]. 
9.7.22. Synthesis of the Pd(I) dimer (87) 
 
 
Compound 87 was synthesized according to the procedure described for compound 48f (see section 
6.7.15). 0.0354 g of 87 was obtained.  
1H NMR (300 MHz, d6-DMSO, T=298 K, ppm)  : 1.26 (s, 12H, 4 o-aryl-CH3), 1.59 (s, 12H, 4 o-
aryl-CH3), 2.43 (s, 12H, 4 p-aryl-CH3), 6.51 and 7.23 (AB system, J= 13.6 Hz, 4H, 2NCH2N), 6.95-
7.07 (8H, Ar-H), 7.45-8.03 (8H, CHIm). 
13C{1H} NMR (d6-DMSO, T=298 K, ppm)  : 16.8 (CH3, o-Mesityl-CH3), 17.2 (CH3, o-Mesityl-
CH3), 21.2 (CH3, p-Mesityl-CH3), 64.0 (CH2, NCH2N), 122.6-125.1 (CH, CH=CH
Im), 129.6-139.3 
(Ar-C), 182.8 (C, carbene). 
Anal. Calc. for C50H56Cl2N8O8Pd2 : C, 50.86; H, 4.78; N, 9.49. Found: C, 51.02; H, 4.70; N, 9.57%. 
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1. Crystallographic data and Selected bond distances/angles for 4b (Tables S1-S2) 
 
Table S1.  Crystallographic data for 4b 
Compound 4b 
Formula [Ag(C15H16N4O2)2]
+· BF4
- 
M 763.31 
Space group C2/c 
Crystal system Monoclinic 
a/Å 24.619(5) 
b/Å 8.689(2) 
c/Å 14.402(3) 
β/° 101.07(3) 
V/Å3 3023.5(11) 
Z 4 
T/K 100(2) 
Dc/g cm
-3 1.677 
F(000) 1552 
μ(0.7Å)/cm-1 7.05 
Measured Reflections 26696 
Unique Reflections 4161 
Rint 0.0345 
Obs. Refl.ns [I2σ(I)] 3881 
θmin- θmax/° 1.66 – 29.08 
hkl ranges -34,34; -12,12; -19,19 
R(F2) (Obs.Refl.ns) 0.0342 
wR(F2) (All Refl.ns) 0.0366 
No. Variables 245 
Goodness of fit 1.094 
Δρmax; Δρmin /e Å-3 0.56; -2.18 
CCDC Deposition N. 1551527 
 
Table S2.  Selected bond distances and angles (Å and degrees) for 4b. 
 
Distances (Å) Angles  (°) 
Ag-C8 2.0975(23) C8-Ag-C8_$1 176.69(10) 
$1 = -x+1, y, -z+3/2 
 
 
 
  
401 
 
 
2. Crystallographic data and Selected bond distances/angles for 6a and 10d  (Tables S3-S4) 
 
Table S3.  Crystallographic data for 6a and 10d. 
Compound 10d 6a 
Formula PdC33H37N8O4·BF4 PdC30H32N4O2P·BF4·0.5CH2Cl2 
M 802.91 747.24 
Space group P21/c P21/n 
Crystal system Monoclinic Monoclinic 
a/Å 8.200(2) 8.818(2) 
b/Å 13.605(3) 15.614(3) 
c/Å 30.666(6) 23.329(5) 
β/° 96.85(3) 94.90(3) 
V/Å3 3396.7(12) 3200.3(11) 
T/K 100 100 
Dc/g cm
-3 1.570 1.551 
F(000) 1640 1516 
μ(0.7Å)/cm-1 5.88 7.31 
Measured Reflections 77120 38281 
Unique Reflections 6783 8782 
Rint 0.0311 0.0304 
Obs. Refl.ns [I2σ(I)] 6042 8453 
θmin- θmax/° 1.32 – 25.77 1.55 – 29.08 
hkl ranges -10,10; -16,16; -14,38 -11,11; -21,21; -32,32 
R(F2) (Obs.Refl.ns) 0.1325 0.0276 
wR(F2) (All Refl.ns) 0.3219 0.0714 
No. Variables 407 449 
Goodness of fit 1.139 1.000 
Δρmax; Δρmin /e Å-3 3.95; -4.43 1.20; -0.90 
CCDC Deposition N. 1825947 1825948 
 
Table S4.  Selected bond distances and angles (Å and degrees) for 6a and 10d. 
8d  4a 
Distances (Å) Angles  (°)  Distances (Å) Angles  (°) 
Pd_1-C19_2 2.1653(184) C19_2-Pd_1-C20_2 68.64(58)  Pd_1-C19_2 2.1776(20) C19_2-Pd_1-
C20_2 
67.50(8) 
Pd_1-C20_2 2.1467(125) C8_3-Pd_1-C8_4          98.14(51)  Pd_1-C20_2 2.1543(16) P_4-Pd_1-C8_3         95.17(4) 
Pd_1-C8_3 2. 0298(123) C8_3-Pd_1-C20_2          98.97(47)  Pd_1-C8_3 2.0354(15) C8_3-Pd_1-
C20_2          
94.62(7) 
Pd_1-C8_4 2. 0294(120) C8_4-Pd_1-C19_2          94.38(58)  Pd_1-P_4 2.3041(6) P_4-Pd_1-C19_2          102.80(6) 
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3. Crystallographic data and Selected bond distances/angles for 11b (Tables S5-S6) 
 
Table S5.  Crystallographic data for 11b. 
Compound 1 
  
Formula PdC45H43N4O10P·0.65H2O 
M 948.91 
Space group C2/c 
Crystal system Monoclinic 
a/Å 24.468(5) 
b/Å 13.682(3) 
c/Å 26.059(5) 
β/° 90.05(3) 
V/Å3 8724(3) 
Z 8 
T/K 100 
Dc/g cm
-3 1.445 
F(000) 3908 
μ(0.7Å)/cm-1 0.50 
Measured Reflections 78925 
Unique Reflections 12211 
Rint 0.0406 
Obs. Refl.ns [I2σ(I)] 10282 
θmin- θmax/° 1.54 – 29.08 
hkl ranges -33,33; -18,18; -36,36  
R(F2) (Obs.Refl.ns) 0.0373 
wR(F2) (All Refl.ns) 0.1029 
No. Variables 577 
Goodness of fit 1.035 
Δρmax; Δρmin /e Å-3 0.75; -2.47 
 
Table S6.  Selected bond distances and angles (Å and degrees) for 11b. 
 
11b 
Distances (Å) Angles  (°) 
Pd_1-C1_3 2.0757(17) C1_3-Pd_1-C4_3 80.08(7) 
Pd_1-C4_3 2.0647(18) C1_3-Pd_1-P_2          95.81(5) 
Pd_1-P_2 2.3367(8) P_2-Pd_1-C8_4          92.83(5) 
Pd_1-C8_4 2.0379(17) C8_4-Pd_1-C4_3          91.21(7) 
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4. Crystallographic data and Selected bond distances/angles for 47b (Tables S7-S8) 
 
Table S7.  Crystallographic data for 47b and 47bsolv. 
 Orthorhombic 47b 
[PdC30H31I2N3O8] 
Monoclinic 47b·¾CH2Cl2 
[PdC30H31I2N3O8·0.75CH2Cl2] 
Chemical Formula PdC30H31I2N3O8 PdC30.75H32.5Cl1.5I2N3O8 
Formula weight 921.78 g/mol 985.47 g/mol 
Temperature 100(2) K 100(2) K 
Wavelength 0.700 Å 0.700 Å 
Crystal system  Orthorhombic Monoclinic 
Space Group  P bca P 21/c 
Unit cell dimensions a = 19.777(4) Å a = 10.929(2) Å 
 b = 15.975(3) Å b = 15.041(3) Å 
 c = 20.563(4) Å c = 21.431(4) Å 
 α = 90° α = 90° 
 β = 90° β = 94.00(3)° 
  = 90°  = 90° 
Volume 6497(2) Å3 3514.3(12) Å3 
Z  8 4 
Density (calculated) 1.885 g·cm-3 1.863 g·cm-3 
Absorption coefficient 2.392 mm-1 2.322 mm-1 
F(000)  3584 1918 
Crystal size 0.08 x 0.02 x 0.02 mm3 0.08 x 0.02 x 0.02 mm3 
Crystal habit Dark yellow thin rods Dark yellow thin rods 
Theta range  
for data collection 
1.89° to 27.04° 1.63° to 27.42° 
Index ranges -25 ≤ h ≤ 25, 
-19 ≤ k ≤ 19, 
-26 ≤ l ≤ 26 
-14 ≤ h ≤ 14, 
-19 ≤ k ≤ 19, 
-28 ≤ l ≤ 28 
Reflections collected 82101 52503 
Independent reflections 7229, 6011 data with I>2(I) 8252, 7003 data with I>2(I) 
Data multiplicity  
(max resltn) 
10.54 (10.42) 2.57 (2.49) 
I/(I) (max resltn) 25.88 (15.89) 10.89 (6.67) 
Rmerge (max resltn) 0.047 (0.104) 0.053 (0.101) 
Data completeness  
(max resltn) 
97% (95%) 99% (99%) 
Refinement method  Full-matrix least-squares 
on F2 
Full-matrix least-squares 
on F2 
Data / restraints / 
parameters  
7229/36/456 8252/6/443 
Goodness-of-fit on F2 1.047 1.045 
Δ/σmax 0.001 0.003 
Final R indices [I>2(I)] R1 = 0.0426, wR2 = 0.1080 R1 = 0.0623, wR2 = 0.1666 
R indices (all data) R1 = 0.0525, wR2 = 0.1157 R1 = 0.0715, wR2 = 0.1755 
Largest diff. peak and hole 2.487 and -1.424 eÅ-3 2.352 and -1.955 eÅ-3 
R.M.S. deviation  
from mean 
 0.157 eÅ-3  0.217 eÅ-3 
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Table S8.  Selected bond distances and angles (Å and degrees) for 47b and 47bsolv. 
 
47b  47bsolv 
Distances (Å) Angles  (°)  Distances (Å) Angles (°) 
Pd-I1 2.614(1) I1-Pd-I2 165.75(2)  Pd-I1 2.628(1) I1-Pd-I2 163.65(3) 
Pd-I2 2.601(1) I1-Pd-N1          86.03(10)  Pd-I2 2.610(1) I1-Pd-N1          86.15(17) 
Pd-N1 2.113(4) I2-Pd-N1          88.54(10)  Pd-N1 2.131(6) I2-Pd-N1          90.49(16) 
Pd-C13 1.988(4) C13-Pd-
N1 
174.52(15)  Pd-C13 1.993(7) C13-Pd-
N1 
172.92(25) 
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5. Crystallographic data and Selected bond distances/angles for 48e, 74, 87 (Tables S9-S10) 
Table S9.  Crystallographic data for for 48e, 74 and 87. 
Compound 48e  87 74 
    
Formula PdC29H35N4·ClO4·CHCl3 Pd2C50H56N8·2ClO4·3CHCl3 PdC35H29N2F3P·BF4 
M 764.83 1538.83 758.78 
Space group P21/c P21/n Cc 
Crystal system Monoclinic Monoclinic Monoclinic 
a/Å 16.774(3) 12.180(2) 10.329(2) 
b/Å 14.074(3) 15.906(3) 19.223(4) 
c/Å 15.262(3) 33.211(7) 16.587(3) 
β/° 113.44(3) 93.15(3) 105.00(3) 
V/Å3 3305.8(13) 6424(2) 3181.2(12) 
Z 4 4 4 
T/K 100 100 100 
Dc/g cm
-3 1.537 1.591 1.584 
F(000) 1560 3104 1528 
μ(0.7Å)/cm-1 6.31 7.29 4.85 
Measured 
Reflections 
23773 126769 31018 
Unique Reflections 9846 26232 12600 
Rint 0.0358 0.0477 0.0198 
Obs. Refl.ns 
[I2σ(I)] 
8856 20246 12447 
θmin- θmax/° 1.71 – 21.85 1.24 – 21.85 1.85 – 30.01 
hkl ranges -23,23; -20,20; -21,21 -19,19; -25,25; -53,53 -16,16; -30,30; -26,26  
R(F2) (Obs.Refl.ns) 0.0590 0.0532 0.0211 
wR(F2) (All Refl.ns) 0.1482 0.1558 0.0563 
No. Variables 395 826 461 
Goodness of fit 1.049 1.042 1.064 
Δρmax; Δρmin /e Å-3 6.81; -3.09 1.31; -1.69 0.64; -1.08 
 
Table S10.  Selected bond distances and angles (Å and degrees) for 48e, 74 and 87. 
48e  87 
Distances (Å) Angles  (°)  Distances (Å) Angles  (°) 
Pd_1-C19_3 2.1710(36) C19_3-Pd_1-C20_3 67.40(14)  Pd_1-C2_3 2.0831(26) C2_3-Pd_1-C12_4 170.41(10) 
Pd_1-C20_3 2.1703(34) C2_2-Pd_1-C12_2          86.89(12)  Pd_1-C12_4 2.0783(25) C2_3-Pd_1-Pd_2          103.08(8) 
Pd_1-C2_2 2.0387(31) C2_2-Pd_1-C20_3          103.05(13)  Pd_2-C2_4 2.0894(26) C12_4-Pd_1-Pd_2          86.14(7) 
Pd_1-C12_2 2.0422(30) C12_2-Pd_1-C19_3          102.11(13)  Pd_2-C12_3 2.0909(25) C2_4-Pd_2-C12_3 171.66(10) 
     Pd_1-Pd_2 3.1624(5) C2_4-Pd_2-Pd_1          101.73(8) 
       C12_3-Pd_2-Pd_1          86.45(7) 
 
74 
Distances (Å) Angles  (°) 
Pd_1-C19_2 2.1694(21) C19_2-Pd_1-C20_2 68.03(9) 
Pd_1-C20_2 2.1812(20) P_4-Pd_1-C8_3         100.36(5) 
Pd_1-C8_3 2.0350(20) C8_3-Pd_1-C20_2          96.44(8) 
Pd_1-P_4 2.3044(6) P_4-Pd_1-C19_2          95.26(6) 
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6. Crystallographic data and Selected bond distances/angles for 42a (Tables S11-S12). 
Table S11.  Crystallographic data for for 42a. 
Formula C22H23N3O8Pd 
M 563.83 
Space group P21/n 
Crystal system Monoclinic 
a/Å 12.2088(2) 
b/Å 10.1565(2) 
c/Å 18.8943(4) 
β/° 97.2508(8) 
U/Å3 2324.13(8) 
T/K 295 
Dc/g cm
-3 1.611 
F(000) 1144 
μ(Mo-Kα)/cm-1 8.51 
Measured Reflections 21222 
Unique Reflections 6763 
Rint 0.0369 
Obs. Refl.ns [I2σ(I)] 5020 
θmin- θmax/° 3.54 – 30.00 
hkl ranges -17,17;-
14,14;-19,26 
R(F2) (Obs.Refl.ns) 0.0352 
wR(F2) (All Refl.ns) 0.0953 
No. Variables 312 
Goodness of fit 1.021 
Δρmax; Δρmin /e Å-3 0.68; -0.84 
CCDC Deposition N. 1059980 
 
Table S12.  Selected bond distances and angles (Å and degrees) for 42a. 
Distances 42a 
 
Pd1–C1 2.027(2) 
 
Pd1–N3 2.140(2) 
 
Pd1–C11 2.013(2) 
 
Pd1–C14 2.072(2) 
 
C11–C12 1.338(3) 
 
C12–C13 1.475(3) 
 
C13–C14 1.349(3) 
 
Angles 
C1–Pd1–N3 83.94(8) 
 
C1–Pd1–C11 95.01(9) 
 
C1–Pd1–C14 173.91(9) 
 
N3–Pd1–C11 175.40(8) 
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Distances 42a 
 
N3–Pd1–C14 101.88(8) 
 
C11–Pd1–C14 79.32(9) 
 
 
7. Crystallographic data and Selected bond distances/angles for 60 (Tables S13-S14). 
Table S13.  Crystallographic data for for 60. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S14.  Selected bond distances and angles (Å and degrees) for 60. 
Distances  Angles  
Pd1-C1 2.047(3) C1-Pd1-P1 94.42(7) 
Pd1-P1 2.3042(6) C1-Pd1-C20 166.93(12) 
Pd1-C20 2.157(3) C1-Pd1-C21 131.07(12) 
Pd1-C21 2.173(3) C1-Pd1-C22 100.05(14) 
Pd1-C22 2.179(3) P1-Pd1-C20 98.60(10) 
C1-N1 1.342(4) P1-Pd1-C21 130.63(9) 
C1-N2 1.350(4) P1-Pd1-C22 165.23(12) 
C20-C21 1.391(5) C20-Pd1-C21 37.48(14) 
C21-C22 1.400(5) C20-Pd1-C22 66.89(15) 
C21-C23 1.514(6) C21-Pd1-C22 37.52(14) 
  N1-C1-N2 104.2(2) 
  C20-C21-C22 117.8(4) 
 
Formula (C41H42N2PPd)
+•(ClO4)- 
Space group P-1 
Crystal system Triclinic 
a/Å 10.8829(2) 
b/Å 11.2739(4) 
c/Å 17.4886(6) 
α/° 74.597(2) 
β/° 85.914(2) 
γ/° 67.153(2) 
U/Å3 1905.1(1) 
T/K 295 
Dc/g cm
-3 1.394 
F(000) 824 
μ(Mo-Kα)/mm-1 0.642 
Measured Reflections 22736 
Unique Reflections 10937 
Rint 0.0490 
Obs. Refl.ns [I2σ(I)] 8272 
θmin- θmax/° 2.72 – 30.00 
hkl ranges -15,15;-14,15; -24,22  
R(F2) (Obs.Refl.ns) 0.0462 
wR(F2) (All Refl.ns) 0.1278 
No. Variables 478 
Goodness of fit 1.036 
Δρmax; Δρmin /e Å-3 1.174; -0.740 
